imatinib mesylate has been researched along with Gastrointestinal Stromal Neoplasm in 1892 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 579 (30.60) | 29.6817 |
| 2010's | 1001 (52.91) | 24.3611 |
| 2020's | 312 (16.49) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, J; Teng, L | 1 |
| Cai, Y; Cao, WT; Deng, YH; Ding, MM; Hu, HB; Ling, JY; Shi, LS; Wang, H; Wang, HM; Xie, XY; Yang, ZF; Zhang, JW; Zhao, YD | 1 |
| Donmez, T; Gul, MO; Ozkara, S; Subasi, IE; Sunamak, O | 1 |
| Zhou, YB | 1 |
| Cao, H; Feng, F; Fu, Y; Gao, ZD; Hu, JB; Jie, ZG; Kou, YW; Li, Y; Liu, HJ; Liu, HL; Qian, HR; Qiu, HB; Shen, KT; Sun, XF; Tao, KX; Wu, XJ; Wu, XY; Xu, H; Yang, WC; Zhai, G; Zhang, B; Zhang, J; Zhang, P; Zhou, YB; Zou, XM | 1 |
| Alconchel, F; Fernández, JÁ; Gómez, B; Martínez, J; Ramírez, P | 1 |
| Hashikura, Y; Hirota, S; Kihara, T; Kimura, N; Kitajima, K; Ohkouchi, M; Ohkubo, S; Takahashi, T; Watabe, T; Yuan, J | 1 |
| Doki, Y; Eguchi, H; Fujimoto, M; Hirota, S; Ishida, T; Kurokawa, Y; Makino, T; Naka, T; Nakajima, K; Nishida, T; Saito, T; Serada, S; Takahashi, T; Tanaka, K; Teranishi, R; Yamamoto, K; Yamasaki, M; Yamashita, K | 1 |
| Badalamenti, G; Bauer, S; Blay, JY; Brunello, A; Casali, PG; De Pas, T; Dei Tos, AP; Desar, IME; Falkenhorst, J; Fiocco, M; Fumagalli, E; Gasperoni, S; Gelderblom, H; Gennatas, S; Grignani, G; Gronchi, A; Hindi, N; Hohenberger, P; IJzerman, NS; Italiano, A; Joensuu, H; Jones, RL; Le Cesne, A; Martin-Broto, J; Mir, O; Nannini, M; Napolitano, A; Pantaleo, MA; Reichardt, P; Rutkowski, P; Sbaraglia, M; Silletta, M; Spalato Ceruso, M; Steeghs, N; Tonini, G; van Houdt, WJ; Vincenzi, B | 1 |
| Arribas, J; Barretina, J; Carles, J; de Álava, E; Demetri, GD; Esteve, A; Fletcher, JA; García-Valverde, A; Gómez-Peregrina, D; Gut, M; Maurel, J; Olivares-Rivas, I; Pilco-Janeta, DF; Rosell, J; Rubió-Casadevall, J; Sayols, S; Serrano, C; Valverde, C | 1 |
| Akçakaya, P; Bränström, R; Caramuta, S; Gangaev, A; Huang, WK; Larsson, C; Lui, WO; Shi, H; Yeh, CN; Zeljic, K | 1 |
| Adesunkanmi, AO; Lawal, AO; Mustapha, B; Ndegbu, CU; Odunafolabi, TA; Olasehinde, O; Olorunsola, IS | 1 |
| Mu, J; Sun, H; Sun, P; Sun, X; Zhao, Z | 1 |
| Hong, R; Jung, Y; Kim, SJ; Lee, J | 1 |
| Bruns, CJ; Fuchs, HF; Ghadimi, M; Schmidt, T | 1 |
| Arima, J; Inomata, Y; Lee, SW; Shima, T; Takabe, K; Taniguchi, K; Tokumaru, Y; Uchiyama, K; Yoshida, K | 1 |
| Cai, Z; Shen, C; Wang, Q; Yang, H; Yin, X; Zhang, B | 1 |
| Chen, H; Chen, W; Du, H; Hu, F; Ning, L; Shan, G; Xu, G | 1 |
| Bang, YH; Kang, S; Kang, YK; Kim, HD; Lee, HE; Ryu, MH | 1 |
| Devine, C; Ganeshan, D; Segaran, N; Wang, MX | 1 |
| Cai, K; Chen, J; Du, X; Guo, L; Huang, L; Jiang, J; Jiang, X; Li, H; Lin, G; Liu, T; Peng, H; Tang, J; Ye, Y; Zhang, W | 1 |
| Chiguchi, G; Cho, H; Kataoka, M; Katayanagi, S; Kikuchi, H; Maruyama, T; Nabeshima, K; Sato, S; Takahashi, T | 1 |
| Huang, PH; Jones, RL; Napolitano, A; Smith, MJ; Thway, K | 1 |
| Kesselheim, AS; Rome, BN; Sarpatwari, A; Walsh, BS | 1 |
| Antonescu, CR; Berger, MF; Biniakewitz, MD; Chen, Y; Chi, P; Crago, AM; D'Angelo, SP; Dickson, MA; Gounder, MM; Hwang, S; Kelly, CM; Keohan, ML; Lee, CJ; Martindale, M; Movva, S; Nacev, BA; Nguyen, B; Phelan, HT; Qin, LX; Rosenbaum, E; Schultz, ND; Singer, S; Tap, WD; Thornton, KA; Ulaner, G; Warda, S; Yeh, R; Yoon, S | 1 |
| Iede, K; Ikenaga, M; Koh, M; Matsuyama, J; Nakashima, S; Sekiguchi, N; Tanida, T; Tsuda, Y; Ueda, M; Yamada, T | 1 |
| Akamaru, Y; Eguchi, S; Hama, N; Harada, S; Ikeshima, R; Munakata, K; Ohashi, H; Ota, H; Shibata, K; Shimaoka, T; Takiuchi, D; Wada, N | 1 |
| Hanyu, T; Ichikawa, H; Ishikawa, T; Koyama, Y; Moro, K; Nagahashi, M; Obata, Y; Sakata, J; Shimada, Y; Takizawa, K; Toshikawa, C; Tsuchida, J; Uchida, H; Umezu, H; Wakai, T | 1 |
| Aoki, T; Fujishima, F; Imoto, H; Kamei, T; Kawana, T; Morikawa, T; Onuma, S; Sasaki, H; Sugisawa, N; Tanaka, N; Tsuchiya, T; Unno, M; Yamamura, A | 1 |
| Akamaru, Y; Eguchi, S; Hama, N; Harada, S; Ikeshima, R; Munakata, K; Ota, H; Shibata, K; Shimaoka, T; Takiuchi, D; Wada, N | 1 |
| Funahashi, K; Ikeda, Y; Kagami, S; Kaneko, T; Kurihara, A; Mitsuda, A; Miura, Y; Nagashima, Y; Tochigi, N; Ushigome, M; Yoshino, S; Yoshino, Y | 1 |
| Ando, T; Atsuta, K; Hayashi, M; Isobe, K; Mihara, Y; Nakayama, T | 1 |
| Bauer, S; Serrano, C | 1 |
| Bruland, ØS; Fauske, L; Hompland, I; Wærstad, PH | 1 |
| Doki, Y; Eguchi, H; Kurokawa, Y; Makino, T; Nakajima, K; Saito, T; Sekiguchi, N; Takahashi, T; Tanaka, K; Yamamoto, K; Yamashita, K | 1 |
| Antonescu, CR; Berger, MF; Biniakewitz, MD; Camacho, N; Chen, Y; Chi, P; Crago, AM; D'Angelo, SP; Dickson, MA; Francis, JH; Gounder, MM; Hwang, S; Kelly, CM; Keohan, ML; Lee, CJ; Martindale, M; Movva, S; Nacev, BA; Phelan, HT; Qin, LX; Rosenbaum, E; Singer, S; Tap, WD; Thornton, KA | 1 |
| Hirai, T; Ishikawa, T; Kanda, T; Maekawa, K; Matsuki, A; Saito, Y; Yamaguchi, Y; Yamamura, M | 1 |
| Doki, Y; Eguchi, H; Hirota, S; Kawabata, R; Kurokawa, Y; Makino, T; Motoori, M; Nakajima, K; Nishida, T; Nishikawa, K; Omori, T; Saito, T; Takahashi, T; Tanaka, K; Teranishi, R; Ushimaru, Y; Yamamoto, K; Yamashita, K | 1 |
| Basaran, A; Kurt, F; Ozlu, O; Yazar, BC | 1 |
| Antonescu, CR; Chang, JC; Chi, P; Dermawan, JK; Singer, S; Tap, WD; Untch, BR; Vanderbilt, CM | 1 |
| Cao, J; Chen, C; Gao, J; Hu, C; Jiang, Z; Liu, F; Liu, J; Liu, Q; Qi, S; Qi, Z; Wang, A; Wang, L; Wang, W; Wu, H; Yu, K | 1 |
| Heinrich, MC; Kent, JD; Khosroyani, HM; Klug, LR | 1 |
| den Hollander, D; Desar, IME; Dirkson, AR; Gelderblom, H; Husson, O; Kraaij, W; Oosten, A; Reyners, AKL; Steeghs, N; van der Graaf, WTA; van Oortmerssen, G; Verberne, S | 1 |
| Dok I, Y; Eguchi, H; Ikenaga, N; Kurokawa, Y; Makino, T; Nakajima, K; Saito, T; Takahashi, T; Tanaka, K; Yamamoto, K; Yamasaki, M; Yamashita, K | 1 |
| Cao, H; Huang, C; Huang, P; Li, Q; Ma, X; Ni, B; Shen, Y; Tu, L; Wang, M; Xia, X; Yang, L; Zhang, Z; Zhao, E; Zhao, W; Zhu, C; Zhuang, C | 1 |
| Clancy, C; Connelly, TM; Hu, S; Kessler, H; Steele, SR | 1 |
| Burge, M; Chantrill, L; Desai, J; Foo, T; Goldstein, D; Karapetis, CS; Nagrial, A; Pavlakis, N; Price, TJ; Roy, AC; Segelov, E; Shapiro, J; Tebbutt, N; Yip, D; Zalcberg, J | 1 |
| Cen, Y; Chen, Y; Gong, J; Li, L; Lian, N; Liu, R; Shen, X; Shen, Y; Wan, Q; Wu, X; Wu, Y; Xia, L; Xiao, H; Xu, X; Zhao, R | 1 |
| Ikushima, H; Koseki, M; Matsushita, K; Mizuno, H; Nagai, K; Ota, H; Takahashi, H; Yamashita, S | 1 |
| Borruso, L; D'Jamirze, A; Kotecha, K; Mittal, A; Samra, JS; Sharma, V | 1 |
| Ahr, K; Senchak, J; von Mehren, M | 1 |
| Artigas-Raventós, V; Asencio-Pascual, JM; Cantín-Blázquez, S; Fernández-Hernández, JA; García-Granero, E; García-Somacarrera, E; González-López, JA; Mendiola, M; Serrano, C; Varo-Pérez, E | 1 |
| Hwang, HS; Jeong, YJ; Nam, KH; Oh, SJ; Park, YE | 1 |
| Åhlen, J; Bränström, R; Haglund de Flon, F; Jalmsell, L; Karlsson, F; Linder-Stragliotto, C; Papakonstantinou, A; Renberg, S; Zhang, Y | 1 |
| Blay, JY; Italiano, A; Jespers, P; Kasper, B; Kyriazoglou, A; Litière, S; Mir, O; Nzokirantevye, A; Papai, Z; Schöffski, P; Vandecavaye, V; Zaffaroni, F | 1 |
| DeMatteo, RP; Schaefer, IM; Serrano, C | 1 |
| Bauer, S; Berhanu, G; Brandt, U; Gelderblom, H; Grignani, G; Heinrich, MC; Italiano, A; Pantaleo, MA; Reichardt, P; Reyners, AKL; Schöffski, P; Stark, D; Stefanelli, T; Valverde, C | 1 |
| Ali, AA; Amankulor, NM; Duensing, A; Kaczorowski, A; Lee, DM; Liu, C; Liu, L; Patil, SS; Presutti, LD; Rao, AV; Rausch, JL; Schneider, F; Shuda, M; Sun, A; Trent, PT | 1 |
| Hirano, H; Honma, Y; Imaizumi, J; Inoue, M; Kanemitsu, Y; Moritani, K; Shoji, H; Takamizawa, Y; Tsukamoto, S | 1 |
| Hergan, K; Janata, F; Slavicek, J; Zandieh, S | 1 |
| Fairweather, M; Li, GZ; Raut, CP; Wang, J | 1 |
| Cho, H; Hirota, S; Kagimura, T; Kitagawa, Y; Komatsu, Y; Kondo, M; Kurokawa, Y; Nakahara, Y; Nishida, T; Ozaka, M; Sato, S | 1 |
| Bang, YH; Kang, YK; Kim, HD; Lee, HE; Ryu, MH | 1 |
| Cai, S; Cao, H; Deng, Y; Dong, J; Huang, Z; Li, J; Shen, L; Wu, X; Zhang, J; Zhou, Y | 1 |
| Doi, T; Honma, Y; Iwagami, S; Komatsu, Y; Kurokawa, Y; Naito, Y; Nishida, T; Sawaki, A; Takahashi, T | 1 |
| Amaadour, L; Arifi, S; Benbrahim, Z; Berrad, S; Mellas, N; Oualla, K | 1 |
| Gao, Z; Jiang, K; Shen, Z; Wang, C; Ye, Y | 1 |
| Italiano, A | 1 |
| Alves, GV; DE-Antoni, NM; Everling, EM; Grezzana-Filho, TJM; Isbert, BBM; Marchet, D | 1 |
| Killock, D | 1 |
| Chen, X; Gong, Z; Ju, RH; Qu, H; Ren, Y; Shao, S; Xu, Z; Zhang, F | 1 |
| Carter, M; Colwell, B; Gaston, D; Rasmussen, S; Stueck, A | 1 |
| Abad-Santos, F; Borobia, AM; Chien, YH; Gagno, S; Hempel, G; Pena, MÁ; Posocco, B; Würthwein, G; Zubiaur, P | 1 |
| Goggin, C; Huang, P; Jones, RL; Mahalingam, P; Napolitano, A; Smith, MJ; Stansfeld, A; Thway, K | 1 |
| Luvira, V; Pairojkul, C; Wannasri, T | 1 |
| DeMatteo, RP; Do, KJ; Etherington, MS; Hanna, AN; Liu, M; Medina, BD; Rossi, F; Tieniber, AD; Vitiello, GA | 1 |
| Bachet, JB; Mas, L | 1 |
| Chen, W; Cheng, X; Wu, T | 1 |
| He, X; Mu, M; Yin, Y; Zhang, H | 1 |
| Chang, CF; Chen, JS; Chou, WC; Huang, WK; Wang, SY; Wu, CE; Yeh, CN | 1 |
| Chen, Y; Dong, X; Huang, T; Mi, D; Shi, S; Wang, Q; Xiao, H; Zhang, H; Zhang, R | 1 |
| Chang, Z; Chen, Y; Guo, Y; He, C; He, Y; Li, B; Li, J; Li, N; Pan, Y; Pei, H; Yang, M; Yu, L; Zhang, C; Zhang, D; Zhang, Q; Zhao, Y; Zhao, ZJ | 1 |
| Chen, QY; Huang, CM; Li, JT; Li, P; Wang, FH; Xie, JW; Zheng, CH; Zheng, HL | 1 |
| Hassan, S; Liu, J; Ni, M; Ren, X; Wang, L; Xu, G; Yang, J; Zhu, T; Zou, X | 1 |
| Ahn, JB; Cheong, C; Kang, J; Kim, NK; Lee, KY; Min, BS | 1 |
| Aglietta, M; Basiricò, M; Berrino, E; Cerviere, I; D'Ambrosio, L; Donini, C; Ferrone, S; Fiorino, E; Galvagno, F; Giraudo, L; Grignani, G; Leuci, V; Marchiò, C; Massa, A; Merlini, A; Mesiano, G; Pignochino, Y; Pisacane, A; Proment, A; Rotolo, R; Sangiolo, D; Vitali, L | 1 |
| Andrew, N; Dangoor, A; Garcia-Petit, C; Wong, NACS | 1 |
| Bozic, B; Jaros, D; Sebesta, C | 1 |
| Fan, Y; Tian, X; Wang, C; Yu, B; Zhang, L; Zhang, X | 1 |
| Borsatti, R; Buonadonna, A; Buzzo, M; Cecchin, E; Dalle Fratte, C; De Mattia, E; Foltran, L; Gagno, S; Guardascione, M; Polesel, J; Posocco, B; Puglisi, F; Roncato, R; Toffoli, G; Zanchetta, M | 1 |
| Feng, Z; Gao, L; Huang, Y; Li, M; Ma, F; Mi, L; Sui, S; Wang, Q; Yu, W | 1 |
| Aoyama, T; Atsumi, Y; Higuchi, A; Kano, K; Kato, A; Kawabe, T; Kazama, K; Murata, M; Nakazono, M; Numata, M; Rino, Y; Saeki, H; Sawazaki, S; Takahashi, A; Tamagawa, H; Tanaka, S; Yukawa, N | 1 |
| Alfagih, A; AlJassim, A; Alqahtani, N; Alshamsan, B; Asmis, T | 1 |
| Ferro, S; Giantin, M; Romanelli, G; Treggiari, E | 1 |
| Al-Horani, RA | 1 |
| Bleckman, RF; den Hollander, D; Desar, IME; Gelderblom, H; Ijzerman, NS; Jansen-Werkhoven, TM; Mohammadi, M; Oosten, AW; Reyners, AKL; Steeghs, N | 1 |
| Attolou, SGR; Dossou, FM; Gangbo, F; Gbessi, DG; Gbetchedji, PP; Gnangnon, FHR; Imorou Souaïbou, Y; Kpossou, AR; Laleye, MC; Lawani, I; Mehinto, DK; Sehonou, J; Seidou, F | 1 |
| Charlab, R; Doros, L; Fashoyin-Aje, LA; Kumar, V; Lemery, SJ; Mushti, SL; Pazdur, R; Spehalski, EI; Tang, S; Theoret, MR; Thompson, M; Thompson, MD; Zhao, H | 1 |
| Bian, Y; Cui, Z; Gao, Z; He, Z; Li, B; Li, C; Li, F; Li, X; Li, Z; Liu, Z; Sun, H; Wang, L; Wang, N; Wang, Z; Xu, H; Xu, Z; Yang, L; Yang, Y; Zhang, D | 1 |
| Chiba, S; Hoshino, I; Kano, M; Kurosaki, T; Kuwayama, N; Nabeya, Y; Soda, H; Suitou, H; Takayama, W; Tonooka, T | 1 |
| Chen, LT; Higashi, T; Huang, RY; Ichinose, Y; Nishida, T; Tsai, HJ; Yang, YH | 1 |
| Heinrich, MC; Khosroyani, HM; Klug, LR | 1 |
| Kohyama, M; Komo, T; Sasaki, M; Sugiyama, Y; Takahashi, S; Tazaki, T | 1 |
| Constantinidou, A; Jones, RL; Kucharczyk, MA; Sargsyan, A | 1 |
| Hirota, S; Ishikawa, T; Kanda, T; Matsumoto, Y; Saijo, Y; Sasaki, K | 1 |
| Ding, P; Guo, H; Liu, Y; Lowe, S; Meng, L; Sun, C; Tian, Y; Wu, H; Wu, J; Yang, P; Zhao, Q | 1 |
| Li, C; Liu, W; Mei, Y; Ni, Z; Wang, L; Xu, W; Zhu, Z | 1 |
| Dykhoff, H; Grotz, TE; Ho, TP; Okuno, SH; Robinson, SI; Sangaralingham, LR; Siontis, BL | 1 |
| Boye, K; Füzesi, L; Golas, M; Gorunova, L; Gunawan, B; Heim, S; Hompland, I; Hølmebakk, T; Langer, C; Micci, F; Panagopoulos, I; Sander, B | 1 |
| Bian, Y; Cui, Z; Gao, Z; He, Z; Li, B; Li, C; Li, F; Li, Z; Liu, Z; Sun, H; Wang, L; Wang, N; Xu, H; Xu, Z; Yang, L; Zhang, D | 1 |
| Blum, A; Brandstetter, S; Buchstaller, HP; Busch, M; Dorsch, D; Esdar, C; Glaser, N; Grädler, U; Linde, N; Petersson, C; Ruff, A; Schieferstein, H; Sherbetjian, E | 1 |
| Aljanabi, I; Janssen, G; Wood, D | 1 |
| Imoto, H; Kamei, T; Kawana, T; Morikawa, T; Ohnuma, S; Okamoto, K; Saijo, F; Sasaki, H; Soeta, T; Tanaka, N; Tsuchiya, T; Unno, M; Yamamura, A; Yamazaki, Y | 1 |
| Ii, Y; Irie, T; Ishiyama, S; Kawaguchi, M; Kawai, M; Kobari, A; Momose, H; Okazawa, Y; Sakamoto, K; Sugimoto, K; Takahashi, H; Takahashi, M; Takahashi, R; Tomiki, Y; Tsukamoto, R | 1 |
| Hata, T; Hiraki, M; Ikeshima, R; Katsura, Y; Katsuyama, S; Kawai, K; Masuzawa, T; Murata, K; Nakata, K; Ohmura, Y; Shinke, G; Sugimura, K; Takeda, Y | 1 |
| Hasegawa, K; Hayakawa, T; Isogai, J; Kaneko, J; Maejima, K; Okamoto, S; Takatsuno, Y | 1 |
| Akita, H; Fujii, Y; Hara, H; Haraguchi, N; Hasegawa, S; Kanemura, T; Matsuda, C; Matsui, Y; Miyata, H; Nishimura, J; Omori, T; Oue, M; Shinno, N; Wada, H; Yasui, M | 1 |
| Doki, Y; Eguchi, H; Fujimoto, M; Hirota, S; Kazuno, H; Kurokawa, Y; Makino, T; Naka, T; Nakajima, K; Nishida, T; Obata, Y; Ohkubo, S; Saito, T; Saito, Y; Serada, S; Takahashi, T; Tanaka, K; Teranishi, R; Yamamoto, K; Yamashita, K | 1 |
| Feng, J; Li, R; Liu, HR | 1 |
| Aghmesheh, M; Daly, D; Gandy, R; Goldstein, D; Symons, R | 1 |
| Del Prado, P; Feng, WA; Mazraani, M; Zeineddin, S | 1 |
| Fan, X; Li, L; Li, R; Li, Y; Liu, F; Pan, Q; Shi, J; Wang, Q | 1 |
| Beck, MY; Kang, YK; Kim, HD; Kim, HJ; Park, YS; Ryu, MH | 1 |
| Chen, H; He, X; Shen, C; Tang, Y; Yan, J; Zou, Y | 1 |
| Doi, T; Naito, Y; Nishida, T | 2 |
| Ding, J; Fang, H; He, W; Jiang, G; Klooster, I; Ou, WB; Pilco-Janeta, DF; Serrano, C; Song, L; Wang, X; Xu, L; Yang, W; Yu, J | 1 |
| Cao, B; Li, J; Wang, B; Weng, Z; Xu, Z; Zhao, Y; Zhou, X | 1 |
| Antonescu, CR; DeMatteo, RP; Do, K; Etherington, MS; Hanna, A; Liu, M; Param, NJ; Rossi, F; Tieniber, A; Vitiello, GA; Wang, L; Zeng, S; Zhang, JQ | 1 |
| Doki, Y; Eguchi, H; Hayashi, Y; Hirota, S; Koh, M; Kurokawa, Y; Makino, T; Motoori, M; Nakajima, K; Nishida, T; Nishigaki, T; Omori, T; Saito, T; Takahashi, T; Takehara, T; Tanaka, K; Teranishi, R; Yamamoto, K; Yamashita, K | 1 |
| Duyster, J; Follo, M; Illert, AL; Jilg, S; Jolic, M; Jost, PJ; Peschel, C; Philipp, U; Rassner, M; Scherer, F; von Bubnoff, N; Waldeck, S; Wehrle, J | 1 |
| Bauer, S; Cameron, S; Eriksson, M; Hall, KS; Hohenberger, P; Joensuu, H; Jost, PJ; Kallio, R; Lindner, LH; Nilsson, B; Pesonen, T; Reichardt, A; Reichardt, P; Schütte, J; Sihto, H; Wardelmann, E | 1 |
| Hotko, YS; Rosul, MV; Varga, LL; Zhero, SV | 1 |
| Bleckman, RF; Bonenkamp, HJJ; Gelderblom, H; IJzerman, NS; Mathijssen, RHJ; Mohammadi, M; Reyners, AKL; Roets, E; Steeghs, N; van Etten, B | 1 |
| Bleckman, RF; Desar, IME; Gelderblom, H; Hollander, DD; IJzerman, NS; Mohammadi, M; Oosten, AW; Reyners, AKL; Steeghs, N | 1 |
| Hu, K; Shu, M; Wang, X; Zhang, H | 1 |
| Bauer, S; Bialick, S; George, S; Gómez-Peregrina, D; Grassian, A; Heinrich, MC; Jones, RL; Kang, YK; Mir, O; Newberry, K; Pantaleo, MA; Rutkowski, P; Schöffski, P; Serrano, C; Shi, H; Tap, WD; Trent, JC; von Mehren, M | 1 |
| Boisguérin, P; de Santa Barbara, P; Dekkar, S; Deshayes, S; Faure, S; Ruiz-Demoulin, S; Serrano, C; Trenquier, E | 1 |
| Dutta, PK; Mandal, C | 1 |
| Call, J; Evans, D; Garland, M; Hughes, TJ; Kaur, S; Knox, P; Lim, PT; Luedke, M; Rothschild, S; Scherzer, NJ; Tordella, C; Trent, J; Wojtkowiak, J | 1 |
| Kang, YK; Kim, HD; Ryu, MH; Yoo, C | 1 |
| Fu, Q; Jiang, X; Kong, Y; Liu, H; Peng, H; Rexiti, K; Wei, X; Xiao, P | 1 |
| Bai, R; Cao, X; Fan, Z; Li, S; Liang, N; Liu, A; Sun, J; Tian, J; Wang, M; Xiao, K; Yu, Y; Zhang, L; Zhang, S; Zhao, H; Zhao, S; Zhou, L | 1 |
| Friedlaender, A; Mechahougui, H; Michael, M | 1 |
| Aasen, T; Angelini, S; Benuzzi, E; Coschina, E; Di Vito, A; Gorini, F; Hrelia, P; Monesmith, S; Morroni, F; Ravegnini, G; Serrano, C | 1 |
| Cote, GM; George, S; Venkataraman, V | 1 |
| Buonadonna, A; Canil, G; Cecchin, E; Dalle Fratte, C; Gagno, S; Guardascione, M; Orleni, M; Posocco, B; Roncato, R; Toffoli, G; Zanchetta, M | 1 |
| Cho, H; Hirota, S; Honda, H; Im, SA; Ishikawa, T; Kang, HJ; Kang, YK; Kong, SH; Kurokawa, Y; Kwon, OK; Lee, KH; Masuzawa, T; Matsumoto, S; Nabeshima, K; Nishida, T; Park, YS; Ryu, SW; Shimokawa, T; Yang, HK; Yook, JH | 1 |
| Brinch, CM; Krarup-Hansen, A; Penninga, L; Preisler, L; Smith, HG | 1 |
| Hao, CY; Jia, WW; Li, CP; Liu, DN; Wang, HY; Wu, JH | 1 |
| Biesemans, M; Dudzik, D; Macioszek, S; Markuszewski, MJ; Schöffski, P; Wozniak, A | 1 |
| DeMatteo, RP; Do, K; Etherington, MS; Hanna, AN; Liu, M; Loo, JK; Param, N; Rossi, F; Tieniber, AD; Wang, L; Zeng, S | 1 |
| Antonescu, CR; Chi, P; Dermawan, JK; Gao, Z; Jadeja, B; Kelly, C; Singer, S; Smith, S; Tap, WD | 1 |
| Hao, Y; Jia, J; Jiang, Q; Li, C; Liu, W; Lou, Z; Ma, X; Tao, K; Wang, T; Zeng, X; Zhang, P; Zhang, R; Zhao, F | 1 |
| Jones, RL; Symcox, M | 1 |
| Attia, S; Bauer, S; Becker, C; Blay, JY; Boye, K; Chi, P; Druta, M; Gelderblom, H; George, S; Goldstein, D; Harrow, B; Heinrich, MC; Jones, RL; Kang, YK; Le Cesne, A; Razak, AA; Reichmann, W; Ruiz-Soto, R; Rutkowski, P; Sanchez, C; Serrano, C; Sherman, ML; Siontis, BL; Somaiah, N; Steeghs, N; Trent, J; von Mehren, M; Zalcberg, JR | 1 |
| Boye, K; Hovig, E; Khelik, K; Meza-Zepeda, LA; Myklebost, O; Nakken, S; Namløs, HM; Vodák, D | 1 |
| Kebbati, Z; Khettab, M; Zidane, H | 1 |
| Cao, X; Fan, Z; Kazi, JU; Li, S; Liu, A; Ma, L; Nasimian, A; Sun, J; Tian, J; Wang, M; Xiao, K; Xu, S; Yu, Y; Zhang, L; Zhang, S; Zhao, H; Zhao, S | 1 |
| Aploks, K; Da Dong, X; Dong, M; Gu, KW; Miller, K; Murdande, S; Rahimi-Ardabily, A; Zhang, B | 1 |
| Chen, W; Chen, X; Lin, J; Sun, X; Yan, J | 1 |
| Hartemink, KJ; Ijzerman, N; Kerst, M; Koenen, AM; Roets, E; Schrage, YM; Steeghs, N; van Coevorden, F; van de Wal, D; van der Burg, SJC; van der Graaf, WTA; van Houdt, WJ; van Sandick, JW; Veenhof, XAAFA | 1 |
| Feng, YD; Qiu, C; Yang, X | 1 |
| Cao, H; Chen, HM; Chen, JJ; Jin, JZ; Li, XB; Lin, J; Qiu, QX; Wang, XY; Xie, ZH; Yan, ZB; Zhang, QW; Zhang, RY; Zhao, YX; Zhou, Y | 1 |
| Costa E Silva, M; Dienstmann, R; Gil Ferreira, C; Lopes David, BB; Nazareth Aguiar Junior, P; Serrano, C | 1 |
| Maki, RG | 2 |
| Bajt, M; Grgic, D; Moric, T; Pavlek, G; Petrovic, I; Puz, P; Romic, I; Romic, M | 1 |
| Barysauskas, CM; Demetri, GD; Fletcher, JA; George, S; Kuang, Y; Leal, A; Mariño-Enríquez, A; Morgan, JA; Paweletz, CP; Phallen, J; Serrano, C; Triplett, O; Velculescu, VE; Wagner, AJ | 1 |
| Bonvalot, S; Casali, P; Gronchi, A; Hohenberger, P; Litiere, S; Olungu, C; Rutkowski, P; Stoeckle, E; van Coevorden, F; Wardelmann, E | 1 |
| Cho, H; Horiguchi, S; Oguri, Y; Onoyama, H; Oohinata, R | 1 |
| Doi, T; Komatsu, Y; Kurokawa, Y; Naito, Y; Nishida, T; Ohkubo, S; Ozaka, M; Sawaki, A; Takahashi, T | 1 |
| Barone, C; Bauer, S; Castellana, R; Crippa, S; Delgado Perez, JR; Fumagalli, E; Le Cesne, A; Melichar, B; Papai, Z; Prausova, J; Pustowka, A; Quiering, C; Reichardt, P; Schlemmer, M | 1 |
| Gao, XD; Shen, KT; Sun, XF | 1 |
| Beck, M; Chae, H; Kang, YK; Ma, J; Ryu, MH | 1 |
| Carney, D; Chase, A; Clark, CE; Oprea-Ilies, G; Turner, J | 1 |
| Gao, J; Liu, W; Shuai, X; Tao, K; Wang, S; Zeng, X; Zhang, P | 1 |
| Adegoke, OO; Egbo, OH; Ogun, GO; Rahman, A | 1 |
| Aickara, DJ; McBride, J; Morrison, B; Romanelli, P | 1 |
| Buonadonna, A; Buzzo, M; Casetta, B; Gagno, S; Guardascione, M; Iacuzzi, V; Marangon, E; Montico, M; Poetto, AS; Posocco, B; Toffoli, G; Zanchetta, M | 1 |
| Achour, H; Bauer, S; Blay, JY; Choucair, K; Gelderblom, H; George, S; Heinrich, MC; Mehren, MV; Nemunaitis, J; Ruiz-Soto, R; Schöffski, P; Zalcberg, J | 1 |
| Du, J; Han, Q; Liu, Y; Wang, R; Wang, S; Wang, SY; Xu, HT; Yang, P | 1 |
| Chong, TH; Dong, Z; Guan, B; Peng, J; Sun, P; Wang, C; Yang, J | 1 |
| Chai, L; Chen, J; Fletcher, JA; Huang, M; Li, X; Mariño-Enríquez, A; Ou, WB; Qiu, H; Quan, Y; Wu, Y; Yang, W; Zhu, C; Zhu, J | 1 |
| Baek, Y; Bao, K; Choi, HS; Coll, JL; Hu, S; I, H; Jo, MJ; Kang, H; Nomura, S; Park, GK; Rubin, BP; Stiles, WR | 1 |
| Doki, Y; Fujimoto, M; Hirota, S; Ishida, T; Koh, M; Kurokawa, Y; Makino, T; Miyazaki, Y; Mori, M; Naka, T; Nakagawa, F; Nakajima, K; Nishida, T; Nishigaki, T; Obata, Y; Ohkawara, T; Ohkubo, S; Saito, Y; Serada, S; Sugase, T; Takahashi, T; Tanaka, K; Yamasaki, M | 1 |
| Hirano, H; Hirota, S; Iwamoto, H; Katayanagi, S; Katsumata, K; Kawachi, S; Makuuchi, Y; Osakabe, H; Sumi, T; Tsuchida, A; Yokoyama, T | 1 |
| Androulakis, N; Aravantinos, G; Avgerinos, A; Boukovinas, I; Christodoulou, C; Kosmidis, P; Kotsakis, A; Kousidou, O; Michalaki, V; Papandreou, C; Sidiropoulou, V | 1 |
| Chapman, TP; Kennedy, J; Satsangi, J | 1 |
| Aida, A; Aigul, G; Elena, S; Firyuza, B; Ilmira, N; Ilshat, M; Natalia, A; Pavel, D; Refat, K; Sergei, B; Vera, G | 1 |
| Han, Y; McLeod, HL; Nelson, RS; Tao, K; Wang, Y; Xiang, H; Yuan, Y; Zhang, M; Zhang, P; Zhou, H | 1 |
| Ma, Z; Mu, J; Sun, P | 1 |
| Hu, Z; Li, X; Su, N; Sun, Q; Wang, W | 1 |
| Lei, C; Wang, HJ; Yu, Z; Zeng, XY | 1 |
| Astolfi, A; Indio, V; Nannini, M; Pantaleo, MA; Urbini, M | 1 |
| Fan, J; Huang, B; Li, Y; Luo, D; Nie, X; Shi, H; Wang, Z; Yang, M; Zhang, J; Zhang, P | 1 |
| Lee, S; Muguruma, K; Ohira, M; Takahashi, R; Tamura, T; Tanaka, H; Toyokawa, T; Yashiro, M; Yoshii, M | 1 |
| Amano, H; Fujimori, M; Nakahara, M; Nakatsuka, H; Nishidate, T; Noriyuki, T; Ohdan, H; Okuda, H; Takemasa, I; Yano, T | 1 |
| Ding, H; Gao, K; Hang, C; Jia, Y; Lao, X; Yan, Z; Yu, X; Yu, Y | 1 |
| Hakim, N; Rehman, H; Saif, MW; Seetharamu, N; Sugarman, R | 1 |
| Ahadi, M; Chou, A; Gill, AJ; Guminski, A; Pulvers, J | 1 |
| Cai, Z; Fu, W; Pu, L; Shen, C; Wang, J; Wang, Y; Yin, X; Yin, Y; Zhang, B | 1 |
| Aimone, P; Benson, C; Brandt, U; Doi, T; Gelderblom, H; George, S; Hertle, S; Jones, RL; Le Cesne, A; Leahy, M; Renouf, DJ; Schӧffski, P; Valverde Morales, C | 1 |
| Kashu, N; Kataoka, N; Makimoto, S; Shono, Y; Takami, T; Tomita, M; Yamaguchi, T; Yasuda, K; Yoshitake, H | 1 |
| Hazama, S; Iida, M; Kanekiyo, S; Matsui, H; Matsukuma, S; Nagano, H; Nishida, Y; Shindo, Y; Suzuki, N; Takeda, S; Tokumitsu, Y; Tomochika, S; Ueno, T; Yoshino, S | 1 |
| Aoki, T; Imoto, H; Kamei, T; Karasawa, H; Kohyama, A; Motoi, F; Musha, H; Naitoh, T; Ohnuma, S; Ono, T; Suzuki, H; Tanaka, N; Unno, M; Watanabe, K; Yamamura, A | 1 |
| Akami, T; Hatakeyama, T; Komiyama, S; Mazaki, T; Ogino, S; Sakai, K; Tamai, H; Ueda, Y | 1 |
| Enomoto, M; Ishizaki, T; Katsumata, K; Mazaki, J; Nagakawa, Y; Sakurai, T; Tsuchida, A; Wada, T | 1 |
| Aida, T; Miyazawa, K; Miyoshi, T; Ogasawara, T; Sato, S; Shiobara, M; Suda, K; Wakatsuki, K; Yamazaki, K; Yoshioka, S | 1 |
| Guan, W; Shi, X; Tao, T; Wang, F; Wang, M; Wang, X; Xia, X; Yu, H | 1 |
| Fang, Y; Fu, M; Gao, XD; Hou, YY; Qin, J; Qin, XY; Shen, KT; Shu, P; Sun, XF; Sun, YH; Xue, AW | 1 |
| Agha, A; Ali, AA; Debiec-Rychter, M; Dhillon, HS; Duensing, A; Gebreyohannes, YK; Lee, DM; Makielski, KR; Mehalek, KR; Patil, SS; Rausch, JL; Schöffski, P; Tolstov, Y; Wellens, J; Wozniak, A | 1 |
| Hasegawa, M; Ieta, K; Ishida-Yamamoto, A; Ishikawa, O; Shibusawa, K; Shimizu, A; Tamura, A | 1 |
| Blay, JY; Bonvalot, S; Broto, JM; Casali, PG; Duffaud, F; Fumagalli, E; Gelderblom, HJ; Goldstein, D; Gronchi, A; Hohenberger, P; Italiano, A; Judson, IR; Kopp, HG; Kotasek, D; Le Cesne, A; Litière, S; Marréaud, S; Penel, N; Poveda Velasco, A; Rutkowski, P; Smithers, M; van Coevorden, F; Wardelmann, E; Zaffaroni, F | 1 |
| Almquist, M; Nordenström, E | 1 |
| Devi, BMP | 1 |
| Arab, JP; Barrera, F; Benítez, C; Briceño, E; Cortinez, LI; Dib, M; Fernandes, E; Garrido, M; Guerra, JF; Inzunza, M; Martínez, JA; Rivas, V; Riveros, S; Torres, J | 1 |
| Chen, W; Dong, Y; Huang, J; Jiang, S; Li, J; Li, Z; Liu, H; Sun, L; Wang, G; Wang, X; Yu, S | 1 |
| Cai, GQ; Liao, GQ; Liu, HL; Liu, S; Liu, WH; Qi, J; Ren, F; Shi, W | 1 |
| Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
| Khuri, FR | 1 |
| Awale, L; Deo, KB; Gautam, S; Pandit, N; Pradhan, A; Yadav, TN | 1 |
| Hou, Y; Jiang, Q; Li, J; Lin, Q; Liu, J; Lu, W; Ma, L; Tao, P; Tong, H; Wang, J; Xue, R; Zhang, G; Zhang, Y | 1 |
| Acharya, MR; Goel, M; Nadkarni, S; Parray, A; Patel, S; Patkar, S; Shah, A | 1 |
| Accurso, V; Badalamenti, G; Bronte, E; Di Lisi, D; Macaione, F; Novo, G; Novo, S; Rinaldi, G; Russo, A; Siragusa, S | 1 |
| Adachi, S; Akagi, K; Andou, H; Douno, K; Hirota, M; Imamura, H; Iwazawa, T; Kawase, T; Nagase, H; Noguchi, K; Noura, S; Oshima, K; Taguchi, T; Tamura, Y; Tanida, T | 1 |
| Fujimoto, Y; Okada, T; Ueno, T; Uraoka, M; Yamamura, M | 1 |
| Akita, H; Amagasa, H; Ami, K; Ando, M; Chong, JM; Fukuda, A; Ganno, H; Iida, S; Imai, K; Kajiyama, D; Kawaguchi, M; Maeda, F; Motoyama, K; Tokito, F; Yamada, A | 1 |
| Akamatsu, H; Furukawa, K; Imasato, M; Kado, T; Kishi, K; Mikamori, M; Ohtsuka, M; Saito, T; Suzuki, Y; Tanemura, M | 1 |
| Beijnen, JH; Groenland, SL; Huitema, ADR; Lucas, L; Nuijen, B; Roosendaal, J; Rosing, H; Steeghs, N; Venekamp, N | 1 |
| Alassani, F; Bagny, A; Darré, T; Djiwa, T; Napo-Koura, G; Tchangaï, B; Tchaou, M | 1 |
| Bränström, R; Chen, Z; Cui, HL; Gao, J; Huang, WK; Larsson, C; Li, S; Lui, WO; Shi, H; Yeh, CN; Yuan, J | 1 |
| Al-Batran, SE; Alvegård, T; Bauer, S; Cameron, S; Eriksson, M; Hermes, B; Hohenberger, P; Jaakkola, P; Joensuu, H; Jost, PJ; Junnila, J; Kallio, R; Lindner, LH; Nilsson, B; Reichardt, A; Reichardt, P; Schütte, J; Sundby Hall, K; Wardelmann, E | 1 |
| Ali, N; Benson, C; Blay, JY; Cousin, S; Dileo, P; Gelderblom, H; Italiano, A; Kasper, B; Kopeckova, K; LeCesne, A; Litiere, S; Marreaud, S; Menge, F; Mir, O; Nzokirantevye, A; Papai, Z; Schöffski, P; Vanden Bempt, I; Wardelmann, E; Wozniak, A; Zaffaroni, F | 1 |
| Huang, W; Li, J; Li, X; Qiu, F; Wu, X; Yao, G; Zhang, J; Zhu, S | 1 |
| Gennatas, S; Huang, P; Jones, RL; Smrke, A | 1 |
| Aydin, E; Erdogan, O; Rencuzogullari, A; Teke, Z | 1 |
| Anwei, X; Jiaxin, L; Kuntang, S; Lei, R; Peiyun, Z; Shanshan, S; Wei, Y; Xiaodong, G; Yingyong, H; Yong, F; Zheng, T; Zhengwen, X | 1 |
| Dhillon, S | 1 |
| Albert, M; Laurini Zanola, M; Monson, J; Rodríguez Goñi, P; Viola Malet, M; Wright, J | 1 |
| Audevard, D; Bédane, C; Bourgaux, M; Delauménie, S; Marcaillou, M | 1 |
| Beck, MY; Kang, YK; Kim, EJ; Lee, MW; Lee, WJ; Park, SR; Ryu, MH | 1 |
| George, S; Serrano, C | 1 |
| Cescon, M; Del Gaudio, M; Nannini, M; Pantaleo, MA; Ravaioli, M | 1 |
| Gheysen, M; Lehnert, S; Schöffski, P; Vanden Bempt, I; Vander Borght, S; Vanslembrouck, R | 1 |
| Comandini, D; Damiani, A; Damiano, G; Grassi, M; Martelli, V; Prelaj, A; Rebuzzi, SE | 1 |
| Li, J; Li, Y; Liu, X; Shen, L; Wu, X; Zhang, B; Zhang, X; Zhou, Y | 1 |
| Hu, B; Li, Y; Ye, L | 1 |
| Christopher, WO; D Anderson, C; J Wynn, J; M Earl, T; Orr, WS; Pham, VL; W Cassell, M | 1 |
| Benítez, C; Dib, M; Garrido, M; Inzunza, M; Martínez, JA | 1 |
| Beijnen, JH; Groenland, SL; Huitema, ADR; IJzerman, NS; Kerst, M; Koenen, AM; Rosing, H; Steeghs, N; van der Graaf, WTA | 1 |
| Abood, G; Baker, MS; Eguia, E; Knab, L; Lutfi, W; Patel, DJ; Sweigert, P | 1 |
| Chen, M; He, Z; Wang, N; Xu, H; Xu, K; Xu, Z; Yang, L; Zhang, D | 1 |
| Keung, EZ; Raut, CP; Rutkowski, P | 1 |
| Cho, WC; Kang, YK; Ku, JL; Na, YS; Ryu, MH; Shin, YK | 1 |
| Copur, MS; Cushman-Vokoun, AM; Delaney, A; Lauer, S; Padussis, J; Talmon, GA; Wedel, W | 1 |
| Anadkat, MJ; Chen, DY; Lewis, HA; Picus, J; Rosman, IS | 1 |
| Bylina, E; Cybulska-Stopa, B; Głuszek, S; Hudziec, P; Jankowski, M; Klimczak, A; Koseła-Paterczyk, H; Las-Jankowska, M; Olesiński, T; Osuch, C; Rutkowski, P; Streb, J; Świtaj, T; Ziętek, M; Łopacka-Szatan, K | 1 |
| Chandan, VS; Lee, S; Lee, W; Li, X | 1 |
| He, YL; Zhang, XH | 1 |
| Lin, TY; Qian, HR | 1 |
| Dong, Z; Li, J | 1 |
| Gao, XD; Shen, KT; Sun, JY | 1 |
| Bai, X; Li, Y; Lin, G; Zhou, W | 1 |
| Amirnasr, A; Sleijfer, S; Wiemer, EAC | 1 |
| Brosens, LAA; Gertsen, EC; Ruurda, JP; van Boxel, GI; van Hillegersberg, R | 1 |
| Banerjee, S; Kumar, A; Lopez, N; Murphy, JD; Sicklick, JK; Tang, CM; Yebra, M; Yoon, H; Zhao, B | 1 |
| Dong, F; Lu, LJ; Min, J; Xu, XP | 1 |
| Callegaro, D; Gladdy, R; Gronchi, A; Keung, EZ; Kim, T; Le Pechoux, C; Martin-Broto, J; Raut, CP; Swallow, C | 1 |
| Kouyama, M; Nakamitsu, A; Sasaki, M; Shimbara, K; Sugiyama, Y; Takahashi, S; Tazaki, T | 1 |
| Ikeda, T; Ito, T; Koike, K; Kubota, H; Takayanagi, Y | 1 |
| Kim, BJ; Kim, HJ; Kim, HS; Kim, JG; Park, JM; Park, JY | 1 |
| Antonescu, CR; Balachandran, VP; Cavnar, MJ; Curtin, C; DeMatteo, RP; Gönen, M; Seier, K; Singer, S; Tap, WD | 1 |
| Gomes, A; Mankoski, R; Miller, A; Nellesen, D; Norregaard, C; Proudman, D; Sullivan, E | 1 |
| Adam, J; Blay, JY; Boilève, A; Brahmi, M; Chamseddine, A; Dufresne, A; Dumont, S; Faron, M; Haddad, V; Honoré, C; Karanian, M; Le Cesne, A; Meeus, P; Mir, O; Nassif, E; Rouleau, E | 1 |
| Gelderblom, H; Mohammadi, M | 1 |
| Abe, O; Amemiya, S; Baba, A; Fujita, N; Gonoi, W; Hagiwara, A; Kawahara, T; Kurokawa, M; Kurokawa, R; Nakai, Y; Ota, Y; Yamaguchi, H | 1 |
| Attia, S; Bojanini, L; Gonzalez-Estrada, A; Heagney, H | 1 |
| Aggarwal, A; Aggarwal, M; Arora, S; Rathi, AK; Singh, K | 1 |
| Adashek, JJ; Chantharasamee, J; Chmielowski, B; Dry, S; Eckardt, MA; Eilber, FC; Singh, AS; Wong, K | 1 |
| Chi, P; Gutierrez Sainz, L; Kelly, CM | 1 |
| Bellotto, O; Bunka, D; Meneghello, A; Poetto, AS; Polo, F; Posocco, B; Tartaggia, S; Toffoli, G; Zanchetta, M | 1 |
| Amaya, K; Hayashi, H; Hirose, A; Kaji, M; Maeda, K; Nakura, M; Shimizu, K; Tsukada, T; Watanabe, T | 1 |
| Goto, A; Inaba, K; Inukai, M; Kikuchi, K; Matsuo, K; Nakamura, K; Shibasaki, S; Suda, K; Suzuki, K; Tanaka, T; Tsuru, Y; Uyama, I | 1 |
| Ge, HJ; Shen, WW; Shi, XQ; Song, LJ | 1 |
| Blay, JY; Casali, PG; Duffaud, F; Fumagalli, E; Gelderblom, H; Goldstein, D; Gronchi, A; Hartmann, JT; Hohenberger, P; Italiano, A; Judson, IR; Kotasek, D; Le Cesne, A; Litière, S; Marréaud, S; Martin-Broto, J; Penel, N; Rutkowski, P; Velasco, AP; Wardelmann, E; Zalcberg, JR | 1 |
| Araki, K; Harimoto, N; Hoshino, T; Ishii, N; Kakizaki, S; Kudo, T; Masuda, T; Naganuma, A; Ogawa, T; Ogawa, Y; Shirabe, K; Suzuki, Y; Tateno, K; Tateyama, Y; Uehara, S; Yasuoka, H | 1 |
| Pink, D; Reichardt, P | 1 |
| Fernández, JA; Ferreras, D; Ferri, B; Frutos, MD; Martínez, J; Olivares, V; Ruiz-Manzanera, JJ | 1 |
| Eriksson, M; Joensuu, H | 1 |
| Akamaru, Y; Doki, Y; Eguchi, H; Kimura, Y; Koh, M; Kurokawa, Y; Makino, T; Miyazaki, Y; Motoori, M; Nakajima, K; Nishida, T; Takahashi, T; Tanaka, K; Wada, N; Yamasaki, M | 1 |
| Hazama, S; Iida, M; Ioka, T; Kanesada, K; Kimura, S; Matsui, H; Matsukuma, S; Nagano, H; Shindo, Y; Suzuki, N; Takeda, S; Tokumitsu, Y; Tomochika, S; Watanabe, Y; Yoshida, S | 1 |
| Liao, MJ; Lu, T; Wu, YQ; Yang, QB | 1 |
| Adachi, S; Hirota, M; Imamura, H; Inada, M; Kawase, T; Nakamatsu, D; Nishida, T; Osugi, N; Sugimoto, A; Yamamoto, M | 1 |
| Bowler, TG; DeMatteo, RP; Etherington, MS; Hanna, A; Levin, L; Liu, M; Medina, BD; Param, NJ; Rossi, F; Vitiello, GA | 1 |
| Butt, ZA; Howard, D; Ng, WL; Osman, K | 1 |
| Cao, H; Jia, X; Lee, JC; Liu, X; Lu, X; Pang, Y; Shen, Y; Tu, L; Wang, Y | 1 |
| Dolezel, P; Havlasek, J; Kikalova, K; Melichar, B; Mlejnek, P; Pastvova, N; Studentova, H; Zemankova, A | 1 |
| Demirağ, G; Yılmaz, A; Yilmaz, H | 1 |
| Fukuoka, T; Iseki, Y; Lee, S; Matsuzuka, S; Miki, Y; Muguruma, K; Nagahara, H; Ohira, M; Shibutani, M; Tamura, T; Tanaka, H; Toyokawa, T; Yoshii, M | 1 |
| Chen, K; Chen, W; Hu, L; Lu, X; Luan, X; Mao, J; Tang, Y; Zhang, J; Zhang, S; Zhang, X; Zheng, X | 1 |
| Carandina, S; Clementi, M; De Leonardis, M; Pessia, B; Sista, F; Vicentini, R | 1 |
| Al Hallak, MN; Al-Share, B; Alloghbi, A; Azmi, A; Kim, SH; Mohammad, RM; Philip, PA; Shields, AF; Uddin, H | 1 |
| Baia, M; Bastiaannet, E; Desar, IME; Farag, S; Gelderblom, H; Gronchi, A; Hohenberger, P; IJzerman, NS; Jones, RL; Martin-Broto, J; Mohammadi, M; Oosten, AW; Reyners, AKL; Rutkowski, P; Schöffski, P; Schrage, Y; Steeghs, N; van Sandick, JW; Vassos, N | 1 |
| Largaespada, DA | 1 |
| Akiyoshi, T; Emoto, S; Fukunaga, Y; Konishi, T; Mukai, T; Nagasaki, T; Yamaguchi, T | 1 |
| Babu, R; Patil, S; Shah, PA; Uthaiah, SB | 1 |
| Billingsley, KG; Corless, CL; Heinrich, MC; Mayo, SC; Sheppard, BC; Sutton, TL; Walker, BS | 2 |
| Ando, S; Fujiwara, Y; Kamei, R; Kitamura, Y; Matsui, H; Nagano, H; Sakamoto, K; Yamamoto, T; Yoshino, S | 1 |
| Massarweh, NN; Roland, CL; Voss, RK | 1 |
| Li, J; Luo, Y; Wang, G; Zhuo, N | 1 |
| Chiang, YJ; Feig, BW; Massarweh, NN; Roland, CL; Somaiah, N; Voss, RK | 1 |
| Bertucci, F; Blay, JY; Bouché, O; Callejo, A; Chevalier, T; Collard, O; Duffaud, F; Faouzi, S; Isambert, N; Le Cesne, A; Mir, O; Penel, N; Terrier, P | 1 |
| Ikeda, M; Inoue, M; Kajikawa, R; Kajiwara, R; Miyamoto, K; Ohmori, I; Sadamoto, S; Sawada, H; Shishida, M; Takahashi, T; Toyota, K; Watanabe, A | 1 |
| Ali Abuderman, AW; M Aldakheel, F | 1 |
| Al-Bahrani, B; Al-Maqrashi, Z; Al-Moundhri, M; Al-Sawafi, Y; Burney, IA; Kumar, S; Lakhtakia, R; Mehdi, I; Qureshi, A; Taqi, KM | 1 |
| Alcantar, O; Bollag, G; Burton, EA; Carias, H; Chan, K; Chugh, R; Ewing, T; Habets, G; Ibrahim, PN; Inokuchi, K; Lin, J; Marimuthu, A; Matusow, B; Michelson, G; Nespi, M; Patnaik, A; Rezaei, H; Sanftner, L; Severson, PL; Shellooe, R; Shields, AF; Spevak, W; Tap, WD; Tinoco, G; Trent, JC; Tsai, J; Tsang, G; Tsiatis, AC; Wagner, AJ; Wu, G; Zhang, C; Zhang, Y | 1 |
| Mei, X; Qianyi, W; Rui, Z; Xiaoding, S; Xiaoting, W; Yong, W; Yutao, W | 1 |
| Cao, H; Feng, F; Hu, J; Lin, G; Liu, Q; Tao, K; Xia, L; Xiong, Z; Yang, W; Ye, Y; Zhang, B; Zhang, P; Zhao, Y | 1 |
| Che, K; Gupta, A; Ma, S; Pobbati, AV; Rubin, BP | 1 |
| Arkhiri, PP; Filonenko, DA; Kolobanova, ES; Meshcheryakov, AA; Nered, SN; Nikulin, MP; Stilidi, IS; Yugay, VV | 1 |
| Antonescu, CR; Chi, P; Torrence, D; Xie, Z; Zhang, L | 1 |
| Aubry, S; Braunstein, C; Chaigneau, L; Delroeux, D; Hubert, P; Kalbacher, E; Marie, B; Meynard, G; Mihai, I; Sirveaux, F | 1 |
| Baek, EJ; Kim, JO; Kim, KH; Ko, BJ; Ko, HJ; Park, B; Park, SG; So, MK | 1 |
| Andes, R; Brackert, SR; Chmielowski, B; Chow, W; DeMatteo, R; Douek, M; Eilber, FC; Glaspy, JA; Hagopian, A; Hecht, JR; Rosen, L; Sauer, L; Singh, AS; Wainberg, ZA; Wang, X | 1 |
| Doki, Y; Eguchi, H; Ishida, T; Kimura, Y; Kurokawa, Y; Makino, T; Miyazaki, Y; Motoori, M; Nakahara, Y; Nakajima, K; Nishida, T; Ohnishi, H; Saito, T; Sato, S; Takahashi, T; Takeno, A; Tanaka, K; Tsuboyama, T; Yamamoto, K; Yamasaki, M; Yamashita, K | 1 |
| Liu, Y; Sun, W; Wang, H; Ye, S; Zhu, G | 1 |
| Kubo, N; Takeuchi, N | 1 |
| Corless, CL; Demetri, GD; Heinrich, MC | 1 |
| Al-Batran, SE; Bauer, S; Cameron, S; Eriksson, M; Hartmann, JT; Hohenberger, P; Joensuu, H; Junnila, J; Kallio, R; Nilsson, B; Pink, D; Reichardt, A; Reichardt, P; Schlemmer, M; Sihto, H; Sundby Hall, K; Vehtari, A; Wardelmann, E | 1 |
| Eriksson, M; Hall, KS; Joensuu, H; Nilsson, B; Pulkka, OP; Reichardt, P; Sarlomo-Rikala, M; Sihto, H; Vehtari, A; Wardelmann, E | 1 |
| Fancellu, A; Hao, SL; Jiang, LX; Liu, XC; Ma, C; Nin, JY; Porcu, A; Wu, GC; Zheng, HT | 1 |
| Cubedo, R; García Del Muro, X; López-Guerrero, JA; Martín-Broto, J; Martínez, V; Poveda, A; Romero, I; Serrano, C; Valverde, C | 1 |
| Han, X; Lin, G; Qiu, H; Xu, J | 1 |
| Chang, J; Draexler, K; Madin-Warburton, M; Ngai, C; Pitcher, A; Tamoschus, D | 1 |
| Blay, JY; Casali, PG; Fumagalli, E; Gronchi, A; Grünwald, V; Hogendoorn, P; Italiano, A; Judson, IR; Kerst, JM; Kotasek, D; Le Cesne, A; Leyvraz, S; Lindner, LH; Litière, S; Marreaud, S; Pousa, AL; Reichardt, P; Rutkowski, P; Schöffski, P; Sleijfer, S; van der Graaf, W; Verweij, J; Zalcberg, J | 1 |
| Baniak, N; Lee, L; Young, S; Yu, D; Zhou, C | 1 |
| Friberg, LE; Krishnan, SM; Mathijssen, R; Ruggiero, A; Schiavon, G; Schindler, E | 1 |
| Diepstraten, J; Gelderblom, H; Kouwen, S; Posthuma, WF; Swen, JJ; van Lammeren, D; Verboom, MC; Visser, L; Wilms, EB | 1 |
| Chen, J; Chen, Z; Shen, C; Tang, S; Yang, J; Yao, Y; Yin, X; Yin, Y; Zhang, B | 1 |
| Mori, M; Nakashima, Y; Nishida, T; Takahashi, T; Tsujinaka, T; Yasui, M | 1 |
| Kykalos, S; Machairas, N; Sotiropoulos, GC; Stamopoulos, P | 1 |
| Bertucci, F; Blay, JY; Bompas, E; Bonvalot, S; Bouché, O; Delhorme, JB; Duffaud, F; Gagniere, J; Isambert, N; Meeus, P; Salas, S; Stoeckle, E; Toulmonde, M | 1 |
| Beslija, S; Ceric, T; Hasic, A; Ibisevic, N; Iljazovic, E; Keskic, L; Kopric, D; Kozaric, M; Kugic, A; Kurtovic, S; Kurtovic-Kozaric, A; Pasic, A; Todorovic Barbuscia, J; Vranic, S | 1 |
| An, ZM; Li, F; Mei, JG; Song, P; Tang, YM; Wang, LP; Yu, YP; Zhai, YP; Zhou, XG | 1 |
| Antonescu, C; Balachandran, VP; Bertagnolli, MM; DeMatteo, RP; Fairweather, M; Li, GZ; Raut, CP; Singer, S; Tap, W | 1 |
| Demetter, P; Erneux, C; Hagué, P; Hockman, SC; Manganiello, VC; Vandenberghe, P; Vanderwinden, JM | 1 |
| Carles, J; García-Valverde, A; George, S; Morales-Barrera, R; Olivares, D; Serrano, C; Suárez, C; Valverde, C | 1 |
| Cho, H; Doki, Y; Hahn, S; Hirota, S; Honda, H; Im, SA; Ishikawa, T; Kang, YK; Kong, SH; Kurokawa, Y; Kwon, OK; Lee, HJ; Lee, KH; Masuzawa, T; Matsumoto, S; Nabeshima, K; Nishida, T; Park, SR; Ryu, MH; Shimokawa, T; Yang, HK; Yook, JH | 1 |
| Li, J; Li, X; Lu, Y; Mao, F; Wang, M; Xu, Q; Zheng, X; Zhu, J | 1 |
| Barger, J; Kurtz, J; Ryan, K | 1 |
| Chen, XM; Huang, M; Qiu, HB; Sun, XW; Wang, XD; Yang, LF; Yuan, XH; Zhou, XJ; Zhou, ZW; Zhuang, W | 1 |
| Agud Fernández, M; Díaz Pedroche, C; Gómez-Martín, C; López López, F | 1 |
| Burger, D; Colbers, A; Desar, IME; Gelderblom, H; Kweekel, DM; Lubberman, FJE; van der Graaf, WTA; van Erp, N; Wilmer, CM | 1 |
| Beets, GL; Farag, S; Steeghs, N; van Akkooi, ACJ; van Boven, HH; van der Kolk, LE; Wilmink, JW | 1 |
| Lin, G; Liu, Q; Zhong, G; Zhou, W | 1 |
| Cao, Z; Chen, W; Eilers, G; Fletcher, JA; He, Q; Kuang, Y; Li, HL; Meng, F; Ou, WB; Qiu, HB; Sheng, Q; Tu, Y; Wang, Y; Wu, Y; Zhang, R; Zhu, M | 1 |
| Bonkobara, M; Kobayashi, M; Kurita, S; Kuroki, S; Miyamoto, R; Tamura, K; Tani, H | 1 |
| Felisiak-Golabek, A; Kowalik, A; Lasota, J; Miettinen, M; Wang, ZF; Zięba, S | 1 |
| Diller, A; Laborie, MV; Seculini Patiño, CE; Tabares, AH | 1 |
| Adenis, A; Barone, C; Bauer, S; Blay, JY; Bouché, O; Camozzi, M; Castellana, R; Comandone, A; Crippa, S; Del Muro, XG; Fumagalli, E; Grignani, G; Italiano, A; Joensuu, H; Le Cesne, A; Martin-Broto, J; Pousa, AL; Valverde, C; Weiss, C | 1 |
| Emoto, S; Hata, K; Kaneko, M; Kawai, K; Kiyomatsu, T; Murono, K; Nishikawa, T; Nozawa, H; Otani, K; Sasaki, K; Tanaka, T; Watanabe, T | 1 |
| Cheng, KS; Yang, CY | 1 |
| Qiu, H; Sun, X; Zhou, Z | 1 |
| Cao, H; Zhao, W | 1 |
| Chen, G; Chu, X; Cui, G; Cui, Q; Dai, Y; Guo, H; Han, G; Hou, Q; Hui, X; Jiang, L; Li, L; Li, Y; Lin, H; Lu, C; Lun, Z; Luo, W; Su, Y; Sun, Z; Wang, A; Wei, Z; Xia, L; Yang, D; Yao, L; Zhang, H; Zhou, Y | 1 |
| Boonstra, PA; Desar, I; Farag, S; Gelderblom, H; Geus-Oei, LF; Grunhagen, D; Reyners, AKL; Steeghs, N; van Coevorden, F; van der Graaf, WT | 1 |
| Binia, S; Diumenjo, M; Fader, E; García, B; Ibarra, J; Sola, A | 1 |
| Bovée, JVMG; Gelderblom, H; Guchelaar, HJ; Kloth, JSL; Mathijssen, RHJ; Reyners, AKL; Sleijfer, S; Steeghs, N; Swen, JJ; van der Straaten, T; Verboom, MC | 1 |
| Aguilar, JG; Antonescu, CR; Balachandran, VP; Cavnar, MJ; DeMatteo, RP; Guillem, JG; Keohan, M; Nash, GM; Paty, PB; Singer, S; Tap, WD; Temple, L; Wang, L; Weiser, MR | 1 |
| Abid, MB; de Mel, S; Ng, SY; Poon, KS; Poon, LM; Wang, S | 1 |
| Benson, C; Chou, AJ; Magnan, H; Rutkowski, P | 1 |
| Babić, N; Bohnec, S; Budimir, I; Hrabar, D; Nikolić, M; Pavić, I | 1 |
| Fan, LQ; Hao, YJ; Jia, N; Li, B; Li, Y; Liang, H; Liang, XB; Liu, Y; Ma, ZX; Shi, YN; Tan, BB; Wang, D; Wang, LL; Wang, LP; Wang, ZH; Zhang, L; Zhang, ZD; Zhao, Q; Zhao, XF | 1 |
| Alabed, YZ | 1 |
| Decristoforo, C; Fricker, G; Niedermoser, S; Prause, M; Riester, S; Schirrmacher, R; Seibold, U; Taguchi, T; Wängler, B; Wängler, C | 1 |
| Ehmke, N; Gopakumar, H; Harrison, S; Sharma, NR; Zelt, C | 1 |
| Chen, Y; Cui, Y; Huang, Y; Wang, Y; Wu, X; Xia, L; Zhao, R; Zhou, Y; Zhuang, W | 1 |
| Boichuk, S; Dunaev, P; Galembikova, A; Gusev, O; Khaiboullina, S; Shagimardanova, E; Valeeva, E | 1 |
| Ehrchen, J; Metze, D; Mühl, S | 1 |
| Al Asad, O; Alawin, I; Nawgiri, R; Saraireh, H; Tayyem, O | 1 |
| Huang, ML; Li, C; Liu, WT; Sah, BK; Shi, HP; Wang, ZQ; Yan, M; Zheng, YN; Zhu, ZG; Zhu, ZL | 1 |
| Jeon, YK; Jung, M; Kim, WH; Park, SH; Won, JK; Yang, HK | 1 |
| Antonescu, CR; Balachandran, VP; Bowler, TG; Cross, JR; DeMatteo, RP; Liu, M; Loo, JK; Medina, BD; Moral, AJ; Param, NJ; Rossi, F; Vitiello, GA; Zeng, S; Zhang, JQ; Zhao, JN | 1 |
| Jiang, T; Piao, D; Wang, W; Zhang, Z | 1 |
| Chishima, T; Eilber, FC; Elliott, I; Endo, I; Hiroshima, Y; Hoffman, RM; Igarashi, K; Kawaguchi, K; Kiyuna, T; Li, Y; Matsuyama, R; Miyake, K; Miyake, M; Momiyama, M; Murakami, T; Nelson, SD; Russell, T; Singh, A; Zhang, Z | 1 |
| Doki, Y; Kurokawa, Y; Makino, T; Miyazaki, Y; Mori, M; Nakajima, K; Saito, Y; Takahashi, T; Takiguchi, S; Tanaka, K; Yamasaki, M | 1 |
| Fujikawa, Y; Hasuo, K; Jin, Y; Kakazu, A; Koumori, K; Masuda, M; Mikayama, Y; Watanabe, T | 1 |
| Iwamatsu, K; Kimura, A; Kogure, N; Kuwano, H; Nakazawa, N; Ogata, K; Suzuki, M; Ubukata, Y; Yanai, M; Yanoma, T | 1 |
| Akabori, H; Iida, H; Kaida, S; Kitamura, N; Miyake, T; Mori, T; Shimizu, T; Sonoda, H; Takebayashi, K; Tani, M; Terada, Y; Ueki, T; Yamaguchi, T | 1 |
| Hiraki, Y; Imamoto, H; Imano, M; Iwama, M; Kato, H; Kimura, Y; Shinkai, M; Shiraishi, O; Tanaka, Y; Yasuda, A; Yasuda, T | 1 |
| Fukumoto, K; Hirajima, S; Kobayashi, H; Takagi, T | 1 |
| Aoyama, T; Cho, H; Hayashi, T; Kano, K; Maezawa, Y; Masuda, M; Ogata, T; Oshima, T; Rino, Y; Sato, T; Yamada, T; Yoshikawa, T; Yukawa, N | 1 |
| Daito, K; Hida, J; Kawamura, J; Okuno, K; Tokoro, T; Ueda, K; Ushijima, H; Yoshioka, Y | 1 |
| Ahmadou, I; Bah, A; Dembélé, BT; Diakité, I; Diallo, G; Dicko, MY; Kanté, L; Konaté, M; Koné, T; Togo, A; Traoré, A; Yoro Sidibé, B | 1 |
| Cabezas–Palacios, MN; Fernández–Ruiz, M; Rodríguez–Zarco, E; Tato–Varela, S | 1 |
| Bjerkehagen, B; Boye, K; Bruland, ØS; Hall, KS; Hompland, I; Hølmebakk, T; Stoldt, S | 1 |
| Büttner, R; Eriksson, M; Hartmann, W; Huss, S; Ihle, MA; Jeske, W; Joensuu, H; Merkelbach-Bruse, S; Reichardt, P; Schildhaus, HU; Sihto, H; Sundby Hall, K; Wardelmann, E | 1 |
| Antonescu, CR; Balachandran, V; Beckman, MJ; DeMatteo, RP; Loo, JK; Maltbaek, JH; Medina, BD; Moral, JA; Param, NJ; Rossi, F; Santamaria-Barria, J; Seifert, AM; Vitiello, GA; Zeng, S; Zhang, JQ; Zhao, JN | 1 |
| Chen, YB; Feng, XY; Guo, J; Liu, XC; Ma, MZ; Qiu, HB; Sun, XW; Zhou, ZG; Zhou, ZW | 1 |
| Feng, JX; He, JP | 1 |
| Astolfi, A; Biasco, G; Brandi, G; Castellani, G; do Valle, IF; Fiorentino, M; Gatto, L; Heinrich, MC; Indio, V; Nannini, M; Pantaleo, MA; Patterson, J; Remondini, D; Santini, D; Saponara, M; Tarantino, G; Urbini, M; von Mehren, M | 1 |
| Fu, Y; Liang, J; Lin, L; Wei, X; Xu, W | 1 |
| Bertagnolli, MM; Cavnar, MJ; DeMatteo, RP; Fairweather, M; Li, GZ; Raut, CP | 1 |
| Bylina, E; Czarnecka, AM; Klimczak, A; Lugowska, I; Osuch, C; Rutkowski, P; Streb, J; Teterycz, P | 1 |
| Doki, Y; Fujimoto, M; Hanasaki, K; Hiramatsu, K; Hirota, S; Kishimoto, T; Kurokawa, Y; Makino, T; Miyazaki, Y; Mori, M; Naka, T; Nakajima, K; Nishida, T; Ohkawara, T; Saito, Y; Serada, S; Sugase, T; Takahashi, T; Tanaka, K; Yamasaki, M | 1 |
| Chijimatsu, H; Hayashi, H; Kijima, T; Kondo, J; Morita, K; Nagashima, Y; Sakata, K; Setoguchi, M | 1 |
| Ishigame, T; Kase, K; Kenjo, A; Kimura, T; Kofunato, Y; Marubashi, S; Muto, M; Okada, R; Sato, N; Shimura, T; Watanabe, J | 1 |
| Bonenkamp, JJ; de Wilt, JHW; Lemmens, V; Tielen, R; van der Graaf, WTA; Verhoeven, RHA | 1 |
| Boichuk, S; Dunaev, P; Galembikova, A; Mustafin, I; Valeeva, E | 1 |
| Baker, LH; Bolejack, V; Chow, WA; Choy, E; Chugh, R; D'Amato, G; Forscher, CA; Ganjoo, KN; Loeb, DM; Okuno, S; Patel, S; Priebat, DA; Reinke, DK; Rushing, DA; Samuels, B; Schuetze, SM; Staddon, AP; Thomas, DG; von Mehren, M | 1 |
| Bylina, E; Klimczak, A; Lugowska, I; Rutkowski, P; Szamotulska, K; Teterycz, P | 1 |
| Ainsua-Enrich, E; Arango, D; Arribas, J; Bazzocco, S; García-Valverde, A; Macaya, I; Martin, M; Navinés-Ferrer, A; Rodrigues, P; Sayós, J; Serrano, C; Serrano-Candelas, E | 1 |
| Reichardt, P | 3 |
| do Carmo, LL; Mendonça, LG; Yung, AA | 1 |
| Dong, P; Li, F; Liu, S; Lv, W; Pan, L; Shu, Y; Yang, Z | 1 |
| Gronchi, A; Tattersall, HL | 1 |
| Gao, J; Li, J; Li, Y; Shen, L; Wu, X; Xu, W | 1 |
| Chen, WS; Chen, YJ; Juan, CK; Yang, CS | 1 |
| Feng, L; Ren, S; Tang, J; Wang, P; Wang, Y; Xu, L; Xu, M; Zhang, M; Zhao, R; Zheng, X | 1 |
| Kato, Y; Kimura, K; Kouno, H; Otsuji, H; Seita, K; Yoneyama, F | 1 |
| Akabane, H; Funakoshi, T; Inagaki, M; Kenno, S; Nakano, S; Sato, K; Yanagida, N | 1 |
| Fu, YY; Hu, HJ; Li, FY | 1 |
| Ali, NS; Aloma, A; Aslam, MH; Hachem, H; Inayat, F; Saif, MW; Song, F | 1 |
| Antonescu, CR; Chi, P; D'Angelo, SP; DeMatteo, RP; Dickson, MA; Francis, JH; Gounder, MM; Heinemann, MH; Hwang, S; Kelly, CM; Keohan, ML; Mcfadyen, C; Qin, LX; Shoushtari, AN; Singer, S; Sjoberg, A; Tap, WD | 1 |
| Gong, JF; Ji, JF; Li, J; Li, XT; Li, ZY; Shen, L; Sun, YS; Tang, L | 1 |
| Cai, W; Cao, J; Chen, H; Chen, Z; He, F; Hu, H; Li, W; Wang, Q; Wei, F; Wei, J; Yang, P; Yang, Z; Zhang, T; Zhong, J | 1 |
| Arribas, J; Carles, J; Díaz-Beveridge, R; Durán, J; Estival, A; García-Del-Muro, X; Hernández-Losa, J; Hindi, N; Jiménez, L; Landolfi, S; Lavernia, J; Manzano, A; Martínez-Marín, V; Pajares, I; Pericay, C; Rubió-Casadevall, J; Safont, MJ; Sebio, A; Serrano, C; Valverde, C; Vicente-Baz, D; Vivancos, A | 1 |
| Åhlén, J; Akçakaya, P; Berglund, E; Bränström, R; Gangaev, A; Ghaderi, M; Hajeri, P; Huang, WK; Larsson, C; Lee, L; Lui, WO; Zeljic, K | 1 |
| Canbay, A; Franck, C; Franke, S; Haybaeck, J; Rosania, R; Venerito, M | 1 |
| Cowie, F; Grosset, DG; Watson-Fargie, T; White, J | 1 |
| Abe, M; Asakawa, T; Chen, P; Guo, S; Ji, J; Tan, S; Yu, D; Zhou, Y; Zong, L | 1 |
| Aparicio, T; Arsène, D; Bertucci, F; Bisot-Locard, S; Blay, JY; Bouché, O; Bourges, O; Cesne, AL; Chabaud, S; Chaigneau, L; Collard, O; Duffaud, F; Isambert, N; Italiano, A; Lecomte, T; Manfredi, S; Priou, F; Remy, S; Rios, M; Sambuc, R | 1 |
| Angelini, S; Astolfi, A; Biasco, G; Brandi, G; Gatto, L; Genovese, C; Hrelia, P; Ianni, M; Indio, V; Nannini, M; Pantaleo, MA; Ravegnini, G; Saponara, M; Simeon, V; Trino, S; Urbini, M | 1 |
| Bannon, AE; Fleming, WH; Fletcher, JA; Heinrich, MC; Javidi-Sharifi, N; Klug, LR; Musil, LS; Town, A; Tyner, JW; VanSlyke, JK | 1 |
| Guan, RY; Jiang, FQ; Jiang, NY; Piao, D; Zhang, Z; Zhu, YK | 1 |
| Gao, Y; Jing, X; Liu, B; Meng, X; Yu, J | 1 |
| Berner, JM; Bjerkehagen, B; Boye, K; Bruland, ØS; Hall, KS; Hompland, I; Hølmebakk, T; Poulsen, JP; Revheim, ME; Stoldt, S; Wiedswang, AM | 1 |
| Chen, L; Chen, M; He, Z; Li, Q; Qian, Y; Sun, L; Sun, X; Wang, L; Wang, Y; Xu, H; Xu, J; Xu, K; Xu, Z; Yang, L; Zhang, D; Zhang, Q | 1 |
| Boichuk, S; Dunaev, P; Galembikova, A; Khromova, N; Kopnin, P; Micheeva, E; Novikova, M; Valeeva, E | 1 |
| Araujo, DM; DeMatteo, RP; Espat, NJ; Maki, RG; Purkayastha, DD; Raut, CP; Trent, J; Williams, TF | 1 |
| Aguayo-González, Á; Avila-Rojo, JA; Baquerizo-Burgos, JE; Coronel, MFC; Cuevas-Ramos, D; Gomez-Perez, FJ; Gómez-Sámano, MÁ; Gulias-Herrero, A; Molina-Botello, D; Palacios-Báez, L; Villanueva-Martinez, F; Wong-Campoverde, BD; Zentella-Dehesa, A | 1 |
| Emoto, S; Hata, K; Hiyoshi, M; Kaneko, M; Kawai, K; Murono, K; Nishikawa, T; Nozawa, H; Sasaki, K; Shuno, Y; Sonoda, H; Tanaka, T | 1 |
| Bi, X; Cai, J; Chen, Q; Huang, Z; Li, C; Li, Z; Yang, H; Zhang, Y; Zhao, H; Zhao, J; Zhou, J | 1 |
| Eilers, G; Ni, N; Nie, Z; Ou, WB; Pei, Y; Tu, Y; Wu, D; Wu, Y; Zuo, R | 1 |
| Gao, J; Li, J; Li, Y; Pan, F; Qi, C; Shen, L | 1 |
| Lin, G; Qiu, H; Wu, X; Xu, J; Zhou, J | 1 |
| Bjerkehagen, B; Boye, K; Hompland, I; Hølmebakk, T; Stoldt, S | 1 |
| Kou, Y; Wang, Q; Yang, R | 1 |
| Brown, JB; Burgess, MA; Chennat, J; Pai, RK; Zureikat, AH | 1 |
| Jordan, K; Kordic, G; Ondecker, J | 1 |
| Haq, MI; Nixon, J; Stanley, AJ | 1 |
| Andersen, JL; Armstrong, SA; Bradner, JE; Chipashvili, O; Demetri, GD; Hagan, T; Hemming, ML; Lawlor, MA; Raut, CP; Scott, TG; Sicinska, E | 1 |
| Cao, LL; Chen, QY; Dai, Y; Huang, CM; Huang, ZN; Li, P; Lin, JL; Lin, JX; Lin, M; Lu, J; Tu, RH; Wang, JB; Xie, JW; Zheng, CH; Zheng, HL | 1 |
| Baek, D; Christensen, P; Jung, M; Karakas, C; Ro, JY | 1 |
| Boonstra, PA; Gietema, JA; Reyners, AKL; Schuuring, E; Ter Elst, A; Tibbesma, M | 1 |
| Bai, M; Chen, C; Hu, C; Hu, Z; Jiang, Z; Liu, F; Liu, J; Liu, Q; Lu, T; Qi, S; Qi, Z; Tang, J; Wang, A; Wang, B; Wang, L; Wang, W; Wu, H; Wu, J; Yan, H | 1 |
| Amano, S; Goto, A; Hanai, T; Inaba, K; Inoue, S; Kadoya, S; Kato, Y; Kikuchi, K; Matsuo, K; Nakamura, K; Nakauchi, M; Shibasaki, S; Sugioka, A; Tomatsu, M; Uyama, I | 1 |
| Deguchi, S; Hirakawa, K; Hori, T; Iimori, N; Ishikawa, T; Masuda, G; Nakao, S; Nakata, B; Ohira, M; Sakimura, C; Tendo, M | 1 |
| Fujimoto, T; Hattori, A; Hattori, T; Katsube, T; Kishibe, S; Naritaka, Y; Satake, M; Shimakawa, T; Shiozawa, S; Usui, T; Yamaguchi, K; Yoshimatsu, K | 1 |
| Furuke, H; Ikeda, E; Ikeda, J; Imura, K; Komatsu, S; Kumano, T; Mizuno, A; Nanishi, K; Shimomura, K; Shioaki, Y; Takashina, K; Tanaka, S; Taniguchi, F | 1 |
| Beck, M; Chae, H; Kang, YK; Kim, BS; Kim, CW; Kim, JH; Kim, KH; Na, H; Ryu, MH; Yoo, C; Yoo, MW; Yook, JH | 1 |
| Gelderblom, H; Guchelaar, HJ; Kloth, JSL; Mathijssen, RHJ; Reyners, AKL; Sleijfer, S; Steeghs, N; Swen, JJ; Verboom, MC | 1 |
| Cui, Y; Huang, Y; Li, Z; Song, Y; Wang, Y; Wu, X; Xia, L; Yi, M; Zhao, R; Zhou, Y; Zhuang, W | 1 |
| Li, K; Shou, CH; Tjhoi, WEH; Yang, WL; Yu, JR | 1 |
| Bernardes, AM; Campanati, RG; Nolasco, F; Rodrigues, JBSR; Sanches, SRA; Savassi-Rocha, PR | 1 |
| Altimari, A; Astolfi, A; Casadio, R; Castellucci, P; Ceccarelli, C; De Leo, A; Di Scioscio, V; Fanti, S; Gatto, L; Gruppioni, E; Indio, V; Martelli, PL; Nannini, M; Pantaleo, MA; Pession, A; Ravegnini, G; Santini, D; Saponara, M; Tarantino, G; Urbini, M | 1 |
| Napolitano, A; Vincenzi, B | 1 |
| Bauer, S; Czaplinski, JT; Demetri, GD; Eilers, G; Fletcher, JA; George, S; Heinrich, MC; Ketzer, J; Mannan, AM; Mariño-Enríquez, A; McKinley, A; Presnell, A; Raut, CP; Rubin, BP; Serrano, C; Sicinska, E; Tao, DL; Yu, C; Zhu, M | 1 |
| Bartolomei, MS; Chung, K; Ingles, SA; Krapp, C; Li, K; McGinnis, LK; Nowak, RA; Paulson, RJ; Salem, W | 1 |
| He, X; Li, J; Luo, S; Mao, Y; Shen, Y; Wang, L; Wu, X; Yang, L; Zhang, H; Zhang, J; Zhou, Y | 1 |
| Chen, M; He, Z; Huang, X; Li, F; Li, Z; Qian, Y; Song, S; Sun, L; Wang, Y; Xu, H; Xu, K; Xu, Z; Yang, L; Zhang, D; Zhang, Q | 1 |
| Bauer, S; Falkenhorst, J; Hamacher, R; Treckmann, J | 1 |
| Goto, T; Ishida, R; Ku, Y; Miyashita, M; Muramatsu, S; Sendo, H; Tsukamoto, Y; Yamazaki, T; Yasuda, T | 1 |
| Akita, H; Asanuma, H; Hamamoto, Y; Ishida, T; Jinzaki, M; Kameyama, K; Kitaoka, S; Morita, S; Oya, M; Shinoda, K; Takahashi, R; Tamaki, S; Yoshida, T | 1 |
| Antonescu, CR; Balachandran, VP; Brennan, MF; Cavnar, MJ; Coit, DG; Crago, AM; Curtin, C; DeMatteo, RP; Gönen, M; Seier, K; Singer, S; Strong, VE; Tap, WD; Yoon, SS | 1 |
| Friel, CM; Kane, WJ | 1 |
| Chang, JY; Chen, CT; Chen, LT; Hsu, T; Hsueh, CC; Jiaang, WT; Kung, FC; Lee, LC; Lin, HY; Lin, WH; Lu, CT; Peng, YH; Shiao, HY; Song, JS; Su, YC; Tsai, HJ; Tu, CH; Wang, PC; Wu, SY; Wu, TS; Yeh, TK | 1 |
| Bellera, CA; Blay, JY; Boidot, R; Bompas, E; Bouche, O; Duffaud, F; Esnaud, T; Geneste, D; Ghiringhelli, F; Isambert, N; Italiano, A; Le Loarer, F; Lucchesi, C; Mir, O; Penel, N; Toulmonde, M | 1 |
| Boichuk, S; Dunaev, P; Galembikova, A; Khromova, N; Kopnin, P; Micheeva, E; Novikova, M | 1 |
| Balachandran, V; Bowler, T; Cavnar, MJ; DeMatteo, RP; Liu, M; Loo, JK; Maltbaek, JH; Medina, BD; Param, NJ; Rossi, F; Seifert, AM; Vitiello, GA; Zeng, S; Zhang, JQ | 1 |
| Beck, MY; Kang, YK; Kim, JJ; Ma, JE; Ryu, MH; Yoo, C | 1 |
| Hirota, S; Kagimura, T; Kitagawa, Y; Kurokawa, Y; Masuzawa, T; Naito, Y; Nishida, T; Ozaka, M; Sakai, Y; Takagi, M | 1 |
| Li, WH; Li, WW; Wei, SC; Xu, L | 1 |
| Cai, W; Chen, H; Hou, Y; Liu, J; Ma, G; Zhou, Y | 1 |
| Contreras, CM; Theiss, L | 1 |
| Barisella, M; Casali, PG; Colombo, C; Fiore, M; Frezza, AM; Fumagalli, E; Gronchi, A; Morosi, C; Radaelli, S; Tirotta, F | 1 |
| Khoshnood, A | 1 |
| Jiang, Y; Wang, Y; Xia, X; Xiao, W; Xie, F | 1 |
| Desar, IME; Kievit, W; van Erp, NP; Zuidema, S | 1 |
| Brzozowska, M; Czech, M; Potemski, P; Połowinczak-Przybyłek, J; Śliwczyński, A; Szafraniec-Buryło, S; Wierzba, W | 1 |
| Ekert, K; Hinterleitner, C; Horger, M | 1 |
| Li, C; Liu, W; Shi, L; Tao, K; Wan, W; Wang, G; Yang, W; Yin, Y; Zeng, X; Zhang, P | 1 |
| Ha, SY; Kim, B; Kim, KM; Lee, S | 1 |
| Boye, K; Hølmebakk, T | 1 |
| Peparini, N | 1 |
| Ikeda, H; Inaguma, S; Kato, H; Kobayashi, M; Kuwabara, Y; Lasota, J; Miettinen, M; Mitsui, A; Raffeld, M; Suzuki, S; Takahashi, S; Wakasugi, T | 1 |
| Arora, A; Jamwal, KD; Kulkarni, AV; Sharma, MK | 1 |
| Banerjee, S; Burgoyne, AM; de la Torre, J; Fanta, PT; Parry, L; Ramamoorthy, S; Scherzer, N; Sicklick, JK; Stuart, E; Wang, Y | 1 |
| Flamourakis, M; Georgiou, G; Karmiris, K; Kazamias, G; Velegraki, M | 1 |
| Ali, CM; Chadli, D; Ibtissem, B; Leila, GE; Ramzi, N; Wejih, DM | 1 |
| Cho, H; Kang, YK; Kim, BS; Kim, CW; Kim, JH; Kim, KH; Lee, SM; Lee, Y; Park, Y; Park, YS; Ryu, MH; Yoo, MW | 1 |
| Abu Sammour, D; Erich, K; Findeisen, P; Geisel, A; Hohenberger, P; Hopf, C; Marsching, C; Marx, A; Rabe, JH; Ramallo Guevara, C; Schulz, S | 1 |
| Alessandrino, F; Jagannathan, JP; Ramaiya, NH; Tirumani, SH | 1 |
| Chang, HH; Chen, LT; Fletcher, JA; Hsueh, YS; Li, CF; Shan, YS; Sun, HS | 1 |
| Almaazmi, H; Atallah, C; Efron, JE; Fang, SH; Lo, BD; Safar, B; Stem, M; Taylor, JP | 1 |
| Agaimy, A; Croner, RS; Haller, F; Hohenberger, W; Köhler, J; Märkl, B; Matzel, K; Meidenbauer, N; Schneider-Stock, R; Spatz, J; Vassos, N | 1 |
| Gao, J; Li, J; Shen, L; Sun, N; Tian, Y; Yuan, J | 1 |
| Hashikura, Y; Hirota, S; Isozaki, K; Kajimoto, N; Liu, NN; Matsuda, I; Nishida, T; Ohkouchi, M; Takahashi, T; Toh, Y | 1 |
| Berman, E; Chanel, S; Cheng, C; Farooki, A; Fleisher, M; Girotra, M; Heller, G; Maki, R; Shelat, M; Strauss, HW | 1 |
| Huang, KE; Jia, J; Li, X; Tao, DY; Zheng, S | 1 |
| Berner, JM; Bruland, ØS; Holm, R; Joensuu, H; Kristian, A; Malinen, E; Revheim, ME; Seierstad, T | 1 |
| Patel, S | 2 |
| Ba-Ssalamah, A; Bareck, E; Brodowicz, T; Eisterer, W; Häfner, M; Högenauer, C; Kastner, U; Kühr, T; Längle, F; Liegl-Atzwanger, B; Ploner, F; Schoppmann, SF; Widmann, G; Wrba, F; Zacherl, J | 1 |
| Nishida, T; Tori, M; Yoshidome, K | 1 |
| Pan, ZZ; Wu, XJ | 1 |
| Dang, YZ; Gao, J; Li, J; Shen, L | 1 |
| Chen, ZF; Chi, P; Guan, GX; Jiang, WZ; Liu, X; Lu, HS | 1 |
| Bu, ZD; Ji, JF; Ji, X; Li, SX; Li, ZY; Shan, F; Wu, AW; Wu, XJ; Zhang, LH; Zong, XL | 1 |
| Cao, H; Xu, J | 1 |
| Ji, JF; Ji, X | 1 |
| Hayashi, S; Ichiba, M; Nakabori, T; Shibuya, M; Yamamoto, K | 1 |
| Conca, E; Dal Col, V; Fermeglia, M; Fumagalli, E; Greco, A; Laurini, E; Mazzoni, M; Miranda, C; Pelosi, G; Pierotti, MA; Pilotti, S; Pricl, S; Tamborini, E | 1 |
| Chen, MF; Chiang, KC; Fu, CJ; Jan, YY; Yeh, CN; Yen, TC | 1 |
| DeMatteo, RP; Demetri, G | 1 |
| Bauer, S; Breitenbuecher, F; Eilers, G; Ferrera, L; Fletcher, JA; Galietta, L; Grabellus, F; Mühlenberg, T; Schuler, M; Schwindenhammer, B; Simon, S; Taeger, G; Taguchi, T; Treckmann, J | 1 |
| Keill, R | 1 |
| Alyuruk, H; Baskin, Y; Calibasi, G; Cavas, L; Ellidokuz, H; Oztop, I; Yilmaz, U | 1 |
| Aupérin, A; Boudabous, S; Debaere, T; Deschamps, F; Domont, J; Farouil, G; Hakimé, A; Le Cesne, A | 1 |
| Beck, MY; Kang, YK; Ryoo, BY; Ryu, MH; Yoo, C | 1 |
| Blay, JY; Bonvalot, S; Caignard, A; Chaba, K; Chaigneau, L; Chaput, N; Coindre, JM; Commo, F; Concha, A; Cremer, I; Desbois, M; Dubreuil, P; Eggermont, A; Emile, JF; Flament, C; Garrido, F; Halama, N; Isambert, N; Jäger, D; Kroemer, G; Le Brun-Ly, V; Le Cesne, A; Locher, C; Mendez, R; Opolon, P; Poirier-Colame, V; Rusakiewicz, S; Sarabi, M; Semeraro, M; Terrier, P; Vimond, N; Zitvogel, L | 1 |
| Chen, HN; Chen, JP; Chen, ZX; Shen, CY; Yang, HX; Zhang, B | 2 |
| Atkinson, HD; Colović, N; Colović, R; Grubor, N; Matić, S; Micev, M | 1 |
| Bryon, J; Needham, SJ; Nicolle, A; Panter, S; Speight, RA; Verrill, MW | 1 |
| Jia, J; Lu, HS; Pan, YL; Tao, DY; Zheng, S | 1 |
| Chen, XL; Huang, YP; Shen, X; Sun, XC; Yan, JY; Ye, XH | 1 |
| Fukuda, K; Kawakubo, H; Kitagawa, Y; Ohmori, T; Saikawa, Y; Sako, H; Takahashi, T; Takeuchi, H; Wada, N; Yoshimura, Y | 1 |
| Hornick, JL; Jagannathan, JP; Ramaiya, NH; Tirumani, SH | 1 |
| Corless, CL; Hohenberger, P; Joensuu, H | 1 |
| Maretto, I; Pucciarelli, S | 1 |
| Antonescu, CR; Ballman, K; DeMatteo, R; Engel, LS; McCall, L; O'Brien, KM; Orlow, I | 1 |
| Belgaumkar, AP; Cananzi, FC; Lorenzi, B; Mudan, S | 1 |
| Bachet, JB; Blay, JY; Duffaud, F; Emile, JF; Italiano, A; Landi, B; Laurent-Puig, P; Le Cesne, A; Lévy, P; Safar, V | 1 |
| Abushahin, F; Bossaer, JB; Enck, RE | 1 |
| Despas, F; Laurent, G; Roche, H | 1 |
| Al-Barrak, J; Cheung, WY | 1 |
| Gronchi, A; Rutkowski, P | 1 |
| Bjerkehagen, B; Bruland, OS; Hole, KH; Julsrud, L; Reitan, E; Revheim, ME; Seierstad, T | 1 |
| Ako, M; Doki, Y; Fujimoto, M; Ikezoe, T; Kurokawa, Y; Miyata, H; Miyazaki, Y; Mori, M; Naka, T; Nakajima, K; Nakatsuka, R; Nishida, T; Serada, S; Shimada, K; Taguchi, T; Takahashi, T; Takiguchi, S; Yamasaki, M; Yokoyama, A | 1 |
| Angelini, S; Fletcher, JA; Hrelia, P; Maffei, F; Ravegnini, G | 1 |
| Gupta, SK; Louis, AR; Sharma, A; Singh, S | 1 |
| Diaz-Perez, JA; Mastrodimos, M; Reddy, A | 1 |
| Bauer, S; Bonvalot, S; Bylina, E; Casali, PG; Cats, A; de Wilt, JH; Fiore, M; Fumagalli, E; Gronchi, A; Hohenberger, P; Hoiczyk, M; Kerst, JM; Le Cesne, A; Nguyen, BP; Nyckowski, P; Rutkowski, P; Schöffski, P; Sleijfer, S; Stoeckle, E; Tielen, R; Treckmann, J; van Coevorden, F; van der Graaf, W; Verhoef, C | 1 |
| Fan, WC; Hsieh, JS; Huang, CJ; Yin, TC | 1 |
| Lopez, NE; Sicklick, JK | 1 |
| Aiba, S; Kagimoto, Y; Kikuchi, K; Mizuashi, M | 1 |
| Baron, JL; Boichuk, S; Debiec-Rychter, M; DeCaprio, JA; Duensing, A; Korzeniewski, N; Litovchick, L; Makielski, KR; Mehalek, KR; Parry, JA; Schöffski, P; Seneviratne, DS; Wozniak, A; Zewe, JP | 1 |
| Ananiadis, A; Atmatzidis, K; Atmatzidis, S; Chatzimavroudis, G; Kapoulas, S | 1 |
| Gelderblom, H; Gray, E; Majer, IM; van den Hout, WB; Verheggen, BG | 1 |
| Kamiryo, Y; Kinjo, M; Okumura, K; Otsubo, S; Shimokama, T | 1 |
| Bonkobara, M; Ito, K; Kobayashi, M; Kuroki, S; Ono, K; Sawada, H; Washizu, T; Yasuda, A | 1 |
| Fujisawa, T; Matsumoto, Y; Nishizawa, A; Takata, M | 1 |
| Chen, LT; Chen, TS; Chiang, NJ; Hsueh, YS; Ko, CH; Li, CF; Lin, CL; Shan, YS; Shih, NY; Wang, LM; Yen, CC | 1 |
| Dimitrova, V; Taneva, I | 1 |
| Antonescu, CR; Ballman, KV; Brennan, MF; Corless, C; DeMatteo, RP; Demetri, GD; Kolesnikova, V; Maki, RG; McCarter, MD; Norton, J; Owzar, K; Pisters, PW; von Mehren, M | 1 |
| De Giorgi, U | 2 |
| Hanada, N; Hori, K; Kawata, K; Okamura, S; Tomiyama, N | 1 |
| Endo, Y; Iwadate, M; Kobayashi, Y; Nakamura, I; Ohki, S; Sassa, M; Sugeno, H; Suzuki, S; Takenoshita, S | 1 |
| He, D; Hou, Y; Hu, Q; Jiang, D; Liu, J; Liu, Y; Lu, S; Lu, W; Shi, Y; Tan, Y; Xu, C; Zhu, X | 1 |
| Claxton, Z; Malik, V; Mongan, AM; Muldoon, C; O'Toole, D; Ravi, N; Reynolds, JV; Rowley, S | 1 |
| Reid, T | 1 |
| Akça, Z; Büyükçelik, A; Kaya, N; Mutlu, H | 1 |
| Blay, JY; Rutkowski, P | 1 |
| Blay, JY; Joensuu, H; Reichardt, P | 1 |
| Audureau, E; Garcia-Gonzalez, P; Ladner, J; Saba, J; Tavolacci, MP; Tekinturhan, E | 1 |
| Beck, MY; Kang, YK; Ryoo, BY; Ryu, MH; Yoo, C; Yoon, S | 1 |
| Lyseng-Williamson, KA | 1 |
| Bae, S; Desai, J | 1 |
| Aich, RK; Das, D; Deb, AR; Ganguly, S | 1 |
| Akasbi, Y; Arifi, S; Brahmi, SA; El Mesbahi, O; El Mrabet, FZ; Mellas, N; Mernisi, FZ | 1 |
| Akiyoshi, T; Fujimoto, Y; Fukunaga, Y; Konishi, T; Nagayama, S; Ueno, M | 1 |
| An, HJ; Kang, YK; Kim, BS; Kim, KH; Oh, ST; Ryoo, BY; Ryu, MH; Sohn, BS; Yook, JH; Yu, CS | 1 |
| Jacene, H; Jagannathan, JP; Krajewski, KM; Ramaiya, NH; Shinagare, AB; Tirumani, SH | 1 |
| Binot, E; Büttner, R; Hartmann, W; Hohenberger, P; Huss, S; Kleine, MA; Künstlinger, H; Loeser, H; Merkelbach-Bruse, S; Mittler, J; Reichardt, P; Schildhaus, HU; Wardelmann, E | 1 |
| Benson, C; Cananzi, FC; Judson, I; Lorenzi, B; Mudan, S | 1 |
| Cats, A; Kol, S; Stiekema, J; van Coevorden, F; van Sandick, JW; Yazdi, AT | 1 |
| Fujiya, M; Inoue, M; Kohgo, Y; Muto, M; Okada, T; Yabuki, H | 1 |
| Choi, YJ; Jo, J; Kang, YK; Lee, JJ; Park, I; Park, JH; Ryoo, BY; Ryu, JS; Ryu, MH; Tan, E; Yoo, C | 1 |
| Blay, JY; Joensuu, H; Le Cesne, A; Reichardt, P | 1 |
| Demetri, GD; Jagannathan, J; Kang, YK; Kim, HJ; Lee, JJ; Nam, BH; Ramaiya, N; Ryoo, BY; Ryu, MH; Yoo, C | 1 |
| Doi, T; Nishida, T | 1 |
| Abdalla, KC; Bragagnoli, AC; dos Anjos Jácome, A; dos Santos, LV; Lima, JP; Porto, FE; Santos, FA | 1 |
| Kamei, M; Kawahara, K; Maki, K; Moroga, T; Ono, K; Shiroshita, T; Takahashi, Y; Takeno, S; Yamana, I; Yamashita, Y | 1 |
| Bamboat, ZM; DeMatteo, RP | 2 |
| Jin, L; Kong, X; Lou, L; Quan, H; Xu, Y; Zhao, J | 1 |
| Fang, Y; Gao, X; Hou, Y; Ling, J; Qin, J; Qin, X; Shen, K; Shi, Y; Sun, Y; Wang, C; Wang, H | 1 |
| Andrzejuk, J; Bylina, E; Dębiec-Rychter, M; Grzesiakowska, U; Jerzak vel Dobosz, A; Jurkowska, M; Limon, J; Osuch, C; Rutkowski, P; Siedlecki, JA; Switaj, T; Woźniak, A | 1 |
| Wang, W; Xu, Z; Zhi, X; Zhou, X | 1 |
| Jagannathan, JP; Krajewski, KM; Ramaiya, NH; Raut, CP; Shinagare, AB; Tirumani, SH | 1 |
| Dourthe, LM; Heymann, S; Imperiale, A; Sauer, B; Schlund-Schoettel, E | 1 |
| Antonescu, CR; Balachandran, VP; Besmer, P; Cavnar, MJ; Cohen, NA; Crawley, MH; DeMatteo, RP; Green, BL; Greer, JB; Kim, TS; Ocuin, LM; Popow, R; Rossi, F; Seifert, AM; Sorenson, EC; Zeng, S | 1 |
| Dobbs, B; Fischer, J; Frizelle, F; Ing, A; Lim, M; Siu, J; Wakeman, C | 1 |
| Akahoshi, S; Inoue, K; Kiyota, Y; Kiyozumi, Y; Motooka, Y; Yamaguchi, R; Yoshida, Y | 1 |
| Cambrosio, A; Keating, P | 1 |
| Fancher, KM; Green, MR; Newton, MD | 1 |
| Hwang, SR; Kim, HU; Lee, NR; Park, J; Song, KH; Yun, SK | 1 |
| Butrynski, JE; D'Adamo, D; Demetri, GD; Fisher, GA; Ganjoo, KN; George, S; Kamaya, A; McMillan, A; Morgan, JA; Villalobos, VM; Wagner, AJ | 1 |
| Ahlen, J; Akcakaya, P; Aluthgedara, W; Berglund, E; Bergquist, J; Bränström, R; Fröbom, R; Karlsson, F; Larsson, C; Lui, WO; Nilsson, IL; Ubhayasekera, SJ; Zedenius, J | 1 |
| Choi, JW; Kim, Y; Kim, YS; Lee, JH | 1 |
| Choy, E; Demetri, GD; George, S; Jagannathan, JP; Kurra, V; Manola, J; Ramaiya, NH; Shinagare, AB; Urban, T | 1 |
| Allgayer, H; Hohenberger, P; Leupold, J; Nowak, K; Rotert, JV | 1 |
| Ebisui, C; Fukuchi, N; Kato, R; Kinuta, M; Makino, S; Murata, K; Nishigaki, T; Okada, K; Okamura, S; Owada, Y; Tamai, M; Wada, Y; Yanagisawa, T; Yokouchi, H | 1 |
| Fukushima, Y; Hashimoto, K; Ide, Y; Kodama, K; Matsuyama, J; Morimoto, T; Nomura, T; Sasaki, Y; Takeda, M; Tokuoka, M; Toshiyama, R; Yokoyama, S | 1 |
| Belgaumkar, A; Benson, C; Cananzi, FC; Judson, I; Lorenzi, B; Mudan, S | 1 |
| Girotti, P; Königsrainer, A; Kopp, HG; Ladurner, R; Rolinger, J | 1 |
| Ikehara, T; Inoue, T; Kanazawa, A; Nishiguchi, Y; Shimizu, S; Toyokawa, T; Tsukamoto, T; Yamamoto, A; Yamashita, Y | 1 |
| Ebisui, C; Kinuta, M; Murakami, M; Murata, K; Nakagomi, N; Okada, K; Okamura, S; Tamai, M | 1 |
| Abe, M; Gomi, K; Ikeda, Y; Kajikawa, S; Maruyama, K; Mihara, M; Shimada, K; Shirota, H | 1 |
| Ahrens, M; Bauer, S; Bock, E; Grabellus, F; Grunewald, S; Hilger, RA; Hoiczyk, M; Mühlenberg, T; Nagarajah, J; Pink, D; Pustowka, A; Reichardt, A; Reichardt, P; Scheulen, ME; Schuler, M | 1 |
| Binot, E; Buettner, R; Huss, S; Künstlinger, H; Merkelbach-Bruse, S; Schildhaus, HU; Wardelmann, E | 1 |
| Christopoulos, C; Kyriazoglou, A | 1 |
| Eriksson, M; Joensuu, H; Reichardt, P; Sundby Hall, K; Vehtari, A | 1 |
| Barry, PA; Bekers, DJ; Kloth, J; Krestin, GP; Mathijssen, RH; Ruggiero, A; Schiavon, G; Schöffski, P; Sleijfer, S; Verweij, J | 1 |
| Bauer, S; Casali, PG; Cats, A; Fiore, M; Fumagalli, E; Gronchi, A; Hohenberger, P; Hoiczyk, M; Kerst, M; Miceli, R; Nguyen, BP; Nyckowski, P; Rutkowski, P; Siedlecki, JA; Treckmann, J; van Coevorden, F | 1 |
| Liao, G; Liu, H; Yan, Z; Yin, H | 1 |
| Cerullo, C; Fonte, C; Iori, A; Lunghi, A; Molinara, E; Neri, B; Pellegrini, E; Rediti, M | 1 |
| Bertola, G; Buonadonna, A; Canzonieri, V; Gasparotto, D; Libra, M; Maestro, R; Marzotto, A; Miolo, G; Torrisi, E | 1 |
| Ariyan, CE; Bello, DM; Dematteo, RP | 1 |
| Arihiro, K; Ohdan, H; Suzuki, T; Tanabe, K; Tokumoto, N; Yanagawa, S | 1 |
| Antonescu, CR; Besmer, P; Cavnar, MJ; Cohen, NA; Crawley, MH; Dematteo, RP; Green, BL; Greer, JB; Kim, TS; Ku, AT; Pillarsetty, N; Popow, R; Rossi, F; Seifert, AM; Sorenson, EC; Veach, DR; Zeng, S | 1 |
| Schwartz, GK; Tap, WD | 1 |
| Antonescu, CR; Ballman, KV; Blackstein, ME; Blanke, CD; Corless, CL; DeMatteo, RP; Demetri, GD; Heinrich, MC; Kolesnikova, V; Maki, RG; McCarter, MD; Owzar, K; Patel, S; Pisters, PW; von Mehren, M | 1 |
| Betz, BL; Fanta, PT; Peterson, MR; Sicklick, JK | 1 |
| Beadling, C; Bertagnolli, MM; Corless, CL; Demetri, GD; Fletcher, JA; Heinrich, MC; Lee, JC; Mariño-Enríquez, A; Morgan, JA; Ravegnini, G; Serrano, C; Wang, Y | 1 |
| Ando, K; Ikeda, T; Ito, S; Kawanaka, H; Kawano, H; Kusumoto, T; Maehara, Y; Morita, M; Oki, E; Otsu, H; Saeki, H; Sakaguchi, Y; Soejima, Y; Sugimachi, K; Uchiyama, H | 1 |
| Demoulin, JB; Essaghir, A | 1 |
| Fan, R; Li, S; Wang, Z; Xu, Y; Yuan, F; Zheng, S; Zhong, J; Zhou, J | 1 |
| Cao, H; Gu, J; Ma, H; Ma, MZ; Qin, W; Yang, S; Yang, XM; You, H; Zhang, WM; Zhang, ZG; Zhang, ZZ; Zhuang, C | 1 |
| Al-Batran, SE; Ballman, KV; Bauer, S; DeMatteo, RP; Duyster, J; Eriksson, M; Hall, KS; Hartmann, JT; Hohenberger, P; Joensuu, H; Leinonen, M; Nilsson, B; Pink, D; Ramadori, G; Reichardt, P; Sarlomo-Rikala, M; Schlemmer, M; Schütte, J; Sihto, H; Wardelmann, E | 1 |
| Debiec-Rychter, M; Dewaele, B; Floris, G; Quattrone, A; Rutkowski, P; Schöffski, P; Sciot, R; Van Looy, T; Vanspauwen, V; Wozniak, A | 1 |
| Kanehara, I; Kitayama, K; Nishino, H; Nomura, S; Teraoka, H; Toyokawa, T | 1 |
| Iwasaki, K; Kagaya, A; Kurata, Y; Matsubara, H; Nimura, Y; Sakuma, Y; Takaishi, S; Tohma, T; Yamamoto, Y | 1 |
| Kimura, H; Mizuuchi, Y; Oda, Y; Ohtsuka, T; Takahata, S; Tanaka, M; Toma, H; Ueda, J; Ueki, T; Yamamoto, H | 1 |
| Friedenberg, FK; Iorio, N; Sawaya, RA | 1 |
| Devarajan, K; Godwin, AK; Hensley, H; Johnson, JR; Piwnica-Worms, D; Rink, L; von Mehren, M | 1 |
| Liang, H | 1 |
| Liang, X; Shi, Y | 2 |
| Dai, Y; Gong, H; Jiang, L; Lin, H; Ning, L; Yan, W; Zhang, D; Zhang, M; Zhou, Y | 1 |
| Cai, M; Cui, Q; Deng, J; Liang, H; Liu, N; Pan, Y; Wang, B; Wang, X; Zhang, L; Zhang, R | 1 |
| Chen, G; Ding, P; Fang, Y; Jiang, W; Kong, L; Li, L; Lin, J; Lu, Z; Pan, Z; Wan, D; Wang, F; Wu, X; Zhang, R | 1 |
| Chen, L; Liu, L; Liu, Y; Wu, X; Xu, W | 1 |
| Cao, H; Du, CY; He, YL; Jie, ZG; Liang, XB; Shi, YQ; Song, C; Wang, YP; Yan, ZS; Zhou, Y | 1 |
| Fujikawa, T; Fukuyama, K; Kuramitsu, S; Tanaka, A | 1 |
| Kaley, K; Niazi, AK; Saif, MW | 1 |
| Jones, RL | 1 |
| Adisa, AO; Alatishe, OI; Anomneze, EE; Ayansanwo, AO; Badmos, K; Bolarinwa, RA; Durosinmi, MA; Lawal, OO; Ojo, OS; Oyekunle, AA; Salawu, L | 1 |
| Conley, AP; Gauthier, G; Guerin, A; Keir, CH; Sasane, M; Schwiep, F; Wu, EQ | 2 |
| Bartsch, DK; Fendrich, V | 1 |
| Altinay, S; Kusaslan, R | 1 |
| Ashman, P; Cid Ruzafa, J; Desai, K; Khalid, JM; Maguire, A; Muston, D; Starczewska Amelio, JM; Tzivelekis, S | 1 |
| Kirii, Y; Misawa, S; Ota, H; Sakamoto, H; Takagi, H; Takeda, M | 1 |
| Akanuma, N; Akutsu, Y; Hoshino, I; Isozaki, Y; Kono, T; Maruyama, T; Matsubara, H; Nakano, A; Shuto, K; Uesato, M | 1 |
| Teng, X; Zhou, J | 1 |
| Cao, H; Tu, L; Wang, CJ; Wang, M; Xu, J; Zhang, ZG; Zhang, ZZ; Zhao, WY | 1 |
| Astsaturov, I; Boland, P; Cohen, SJ; Engstrom, P; Olszanski, AJ; Perkins, J; Zhou, Y | 1 |
| Benjamin, RS; Bergman, MA; Boles, S; Bui, MM; Casper, ES; Conrad, EU; DeLaney, TF; Ganjoo, KN; George, S; Gonzalez, RJ; Heslin, MJ; Kane, JM; Mayerson, J; McGarry, SV; Meyer, C; O'Donnell, RJ; Pappo, AS; Paz, IB; Pfeifer, JD; Randall, RL; Riedel, RF; Schuetze, S; Schupak, KD; Schwartz, HS; Sundar, H; Van Tine, BA; von Mehren, M; Wayne, JD | 1 |
| Hsu, KH; Hsu, YS; Lin, PW; Lu, PJ; Shan, YS; Tsai, HW | 1 |
| Chang, J; Connolly, MP; Currie, CJ; Poole, CD | 1 |
| Cao, H; Lin, TL; Liu, Q; Shen, YY; Tu, L; Wang, CJ; Wang, M; Xu, J; Zhang, ZZ; Zhao, WY | 1 |
| Kang, YK; Kim, BS; Kim, CW; Kim, HJ; Kim, KH; Park, SJ; Park, YS; Ryoo, BY; Ryu, MH; Sohn, BS; Yook, JH; Yu, CS | 1 |
| Ko, AH; Simko, JP; Walker, EJ | 1 |
| Chung, KM; Lai, EC; Lau, SH; Lau, WY | 1 |
| Ikemura, M; Ishihara, S; Kanazawa, T; Kitayama, J; Komuro, I; Nozawa, H; Sunami, E; Takahashi, M; Tanaka, T; Watanabe, T | 1 |
| Gao, Y; Liu, X; Ma, Y; Shen, Q; Shi, X; Yang, W; Yu, J; Zhang, Q; Zhao, Z; Zhu, K | 1 |
| Belev, B; Boban, L; Boban, M; Cicek, S; Madzar, Z; Tomas, D; Zovak, M | 1 |
| Balachandran, VP; DeMatteo, RP | 2 |
| Godwin, AK; Hirst, JJ; Ma, Y; Pessetto, ZY; von Mehren, M; Weir, SJ | 1 |
| Acin, Y; Adenis, A; Bertucci, F; Blay, JY; Blésius, A; Bompas, E; Bouché, O; Bui-Nguyen, B; Bulusu, VR; Chaigneau, L; Domont, J; Dubreuil, P; Hermine, O; Isambert, N; Le Cesne, A; Mansfield, CD; Moussy, A; Ray-Coquard, I; Van Tine, BA | 1 |
| Kobayashi, H; Sugihara, K | 1 |
| Hayakumo, T; Ikura, Y; Iwai, Y; Kadota, C; Shigaki, Y | 1 |
| Aihara, R; Ando, H; Fukuchi, M; Haga, N; Kimura, A; Kogure, N; Kuwano, H; Mochiki, E; Ogata, K; Ohno, T; Ojima, H; Suzuki, M; Toyomasu, Y; Uchida, N; Yokobori, T | 1 |
| Huang, KE; Jia, J; Li, X; Pan, SD; Pan, YL; Tao, DY; Zheng, S; Zheng, XL; Zhou, Y | 1 |
| Chen, JS; Chen, TW; Chen, YY; Cheng, CT; Chiang, KC; Hsu, CC; Jan, YY; Liu, YY; Tsai, CY; Tseng, JH; Wu, CE; Yeh, CN; Yeh, TS | 1 |
| Fukuda, K; Kawakubo, H; Kitagawa, Y; Nakamura, R; Ohmori, T; Saikawa, Y; Sako, H; Takahashi, T; Takeuchi, H; Wada, N | 1 |
| Brzuszkiewicz, K; Bylina, E; Limon, J; Osuch, C; Rutkowski, P; Siedlecki, JA | 1 |
| Anjum, R; Bauer, S; Clackson, T; Eilers, G; Fletcher, JA; Garner, AP; Gozgit, JM; Heinrich, MC; Ketzer, J; Kohlmann, A; Ning, Y; Rivera, VM; Schrock, A; Serrano, C; Song, Y; Vodala, S; Wang, F; Wardwell, S; Zhou, T; Zhu, M | 1 |
| Aoba, T; Hiramatsu, K; Kato, T; Minami, T; Natsume, S; Shibata, Y; Yoshihara, M | 1 |
| Chang, YR; Han, IW; Jang, JY; Kang, MJ; Kim, SW; Kwon, W; Lee, HJ; Lee, KB; Park, JW; Park, KJ | 1 |
| Benjelloun, E; Bouassria, A; Elbouhaddouti, H; Mazaz, K; Mouaqit, O; Ousadden, A; Taleb, KA | 1 |
| Debiec-Rychter, M; Fletcher, JA; Floris, G; Li, H; Manley, PW; Schöffski, P; Sciot, R; Van Looy, T; Vanleeuw, U; Wellens, J; Wozniak, A | 1 |
| Ayrton, J; Dezube, BJ; Kwak, E; Lyons, J; Mahadevan, D; Shapiro, GI; Yule, M | 1 |
| Subramanian, MP; Trent, JC | 1 |
| Åhlen, J; Akçakaya, P; Berglund, E; Bränström, R; Caramuta, S; Ghaderi, M; Larsson, C; Lui, WO; Östman, A | 1 |
| Alago, W; Brown, KT; Cornelis, F; Covey, A; Erinjeri, JP; Getrajdman, GI; Litchman, T; Maybody, M; Sofocleous, CT; Solomon, SB; Takaki, H | 1 |
| Francine, AT; Raherinantenaina, F; Rambel, AH; Rantomalala, HY; Rasoaherinomenjanahary, F; Ratsimba, HN; Samison, LH | 1 |
| Chen, TC; Chen, TW; Chen, YY; Cheng, CT; Chiang, KC; Jung, SM; Tsai, CY; Tseng, JH; Wang, SY; Yeh, CN; Yeh, TS | 1 |
| Chang, HH; Chen, LT; Chiang, NJ; Hsueh, YS; Li, CF; Yen, CC | 1 |
| Liu, K; Wen, Y; Wu, L; Xiong, L; Yao, H; Zhang, Z | 1 |
| Cao, H; Liu, Q; Qiu, WQ; Shen, YY; Tu, L; Wang, CJ; Wang, M; Xu, J; Zhang, Y | 1 |
| Beck, MY; Kang, YK; Kim, EY; Koo, DH; Lee, SS; Na, YS; Ryoo, BY; Ryu, MH; Shin, JG | 1 |
| Gauthier, G; Guerin, A; Keir, CH; Sasane, M; Wu, EQ; Zhdavana, M | 1 |
| Corless, CL; Druker, BJ; Dunlap, J; Gupta, A; Heinrich, MC; Javidi-Sharifi, N; Martinez, J; Rubin, BP; Taguchi, T; Traer, E; Tyner, JW | 1 |
| Belgaumkar, A; Cananzi, FC; Lorenzi, B; Mudan, S | 1 |
| Brulard, C; Chibon, F; Coindre, JM; Debiec-Rychter, M; Dei Tos, P; Italiano, A; Lagarde, P; Lartigue, L; Neuville, A; Rutkowski, P; Wardelmann, E | 1 |
| Chen, LT; Chen, TJ; Chen, YY; Chou, FF; Fang, FM; Huang, HY; Lan, J; Li, CF; Li, SH; Lin, CY; Tai, HC; Yu, SC | 1 |
| Bui, MM; Caracciolo, JT; Coppola, D; Hodul, PJ; Jones, DH; Strosberg, JR | 1 |
| Abou Al-Shaar, H; Abu-Zaid, A; Amin, T; Azzam, A; Solimanie, S | 1 |
| Chen, H; Chen, J; Chen, Z; Shen, C; Yin, Y; Zhang, B | 1 |
| Amadori, D; Bongiovanni, A; Calpona, S; Cavaliere, D; De Vita, A; Foca, F; Gunelli, E; Ibrahim, T; La Manna, F; Liverani, C; Mercatali, L; Oboldi, D; Pieri, F; Ricci, M; Riva, N | 1 |
| Amini, M; Campagna, D; Dei Tos, AP; Gasparotto, D; Maestro, R; Marzotto, A; Rossi, S; Scavina, P; Tiziano, FD; Toffolatti, L; Vitelli, CE | 1 |
| Maeyama, R; Manabe, T; Nagayoshi, K; Oda, Y; Tanaka, M; Ueki, T; Yamamoto, H; Yokomizo, A | 1 |
| Cooke, LS; Kurtzman, D; Mahadevan, D; Morales, C; Ong, E; Qi, W; Stejskal, AE; Swart, R; Theiss, N; Zhu, M | 1 |
| d'Hoore, A; Kramp, KH; Omer, MG; Schoffski, P | 1 |
| Andres, R; Calabuig, S; Casado, A; Cruz, J; De Juan, A; Del Muro, JG; Fra, J; Garcia-Albeniz, X; Lainez, N; Lopez-Pousa, A; Martin-Broto, J; Martinez-Trufero, J; Maurel, J; Poveda, A; Redondo, A; Rubió-Casadevall, J; Sevilla, I; Valverde, C | 1 |
| Blay, JY; Cassier, P; Dufresne, A; Heudel, P; Pissaloux, D; Ray-Coquard, I; Wang, Q | 1 |
| Boglione, A; Comandone, A | 1 |
| Demetri, GD; Doi, T; Kanda, T; Komatsu, Y; Kuss, I; Nishida, T; Sawaki, A; Yamada, Y | 1 |
| Fang, Y; Gao, X; Hou, Y; Li, H; Ling, J; Qin, J; Qin, X; Shen, K; Shu, P; Sun, Y; Xue, A | 1 |
| Chow, P; Huang, A; Huynh, H; Li, F; Li, X; Monahan, JE; Ong, R; Qiu, S; Rakiec, DP; Ruddy, DA; Schlegel, R; Tam, A; Wang, Y | 1 |
| Hayashi, K; Hirai, T; Inaba, K; Kanie, H; Nomura, S; Okawaki, M; Orito, E; Sawaki, A; Yamada, T; Yamaguchi, Y; Yamamura, M | 1 |
| Blay, JY; Casali, PG; Dei Tos, AP; Le Cesne, A; Reichardt, P | 1 |
| Egawa, C; Goto, T; Hashimoto, T; Ishida, T; Kagawa, Y; Kato, T; Katsura, Y; Kimura, K; Kuroda, Y; Kusama, H; Matsushita, K; Morimoto, Y; Nakahira, S; Nakatsuka, S; Nitta, K; Ohmura, Y; Ohzono, K; Okishiro, M; Sakisaka, H; Sato, Y; Takeda, Y; Takeno, A; Tamura, S; Taniguchi, H | 1 |
| Babaya, A; Fukunaga, M; Hoshino, H; Kawabata, R; Kawase, T; Kimura, Y; Nakata, K; Ohzato, H; Yamamoto, T | 1 |
| Cho, A; Denda, T; Ikeda, A; Kainuma, O; Muto, Y; Nabeya, Y; Nagata, M; Souda, H; Takano, E; Takiguchi, N; Tonooka, T; Yamamoto, H; Yanagibashi, H | 1 |
| Fukuoka, E; Iwatani, Y; Kuroda, D; Mii, Y; Murata, K; Oka, S; Otsubo, D; Sawa, H | 1 |
| Doki, Y; Hara, H; Kurokawa, Y; Miyata, H; Miyazaki, Y; Mori, M; Nakajima, K; Takahashi, T; Takiguchi, S; Yamasaki, M | 1 |
| Hata, T; Ishizu, H; Kuji, M; Masuko, H; Matsumoto, S; Tahara, M; Takahashi, H; Takahashi, M; Takahashi, S; Tanaka, K; Tanioka, T; Ueki, S; Yamagami, H | 1 |
| Funahashi, W; Harada, A; Hasegawa, H; Ikeda, Y; Kabashima, A; Kitagawa, D; Kondo, N; Nakamura, T; Shoji, F; Teramoto, S | 1 |
| Hosaka, S; Kawamoto, S; Kikutake, T; Nagao, S; Umemoto, S; Yonemitsu, K; Yoshida, T | 1 |
| Doki, Y; Kurokawa, Y; Miyata, H; Miyazaki, Y; Mori, M; Nakajima, K; Nakatsuka, R; Takahashi, T; Takiguchi, S; Yamasaki, M | 1 |
| Chong, H; Hagi, T; Ichikawa, Y; Ishikawa, S; Kanazawa, A; Lee, K; Maeda, T; Maruyama, K; Nishihara, M; Oka, H; Shimada, M; Takayama, S; Taniura, N; Ueno, G | 1 |
| Bauer, TW; Behman, R; Bischof, DA; Blazer, DG; Cocieru, A; Dodson, R; Fisher, SB; Gamblin, TC; Groeschl, RT; Jimenez, MC; Karanicolas, PJ; Kooby, DA; Law, C; Maithel, SK; Pawlik, TM; Quereshy, FA; Squires, MH | 1 |
| Lin, XK; Liu, XS; Shou, CH; Sun, JY; Yang, WL; Yu, JR; Zhang, Q | 1 |
| Dang, Y; Gao, J; Li, J; Li, Y; Shen, L; Zou, J | 1 |
| Chacón, M; Eleta, M; Espindola, AR; Méndez, G; Pupareli, C; Roca, E; Rojo, S | 1 |
| Bencsikova, B; Bortlicek, Z; Brabec, P; Jureckova, A; Kocak, I; Kocakova, I; Krejci, E; Spelda, S; Strenkova, J; Vyzula, R | 1 |
| Albegova, ZhK; Kanaev, PM; Kazani, Z; Kharitonov, SV; Myrksin, SA; Plotnikova, NA; Sabirov, AKh; Singkh, RB | 1 |
| Kang, YK; Kim, BS; Koh, YW; Park, HJ; Park, YS; Ryoo, BY; Ryu, MH; Yoo, C; Yook, JH | 1 |
| Casali, PG; Cioffi, A; Gibbs, E; Goldstein, D; Joensuu, H; Kanjanapan, Y; Lee, CK; Lord, SJ; Maki, RG; Mcarthur, G; Rutkowski, P; Verweij, J; Yip, D; Zalcberg, J | 1 |
| Bosma, JW; Farag, S; Gelderblom, H; Kerst, JM; Sleijfer, S; Steeghs, N; Verschoor, AJ | 1 |
| Elges, S; Hartmann, W; Huss, S; Sperveslage, J; Trautmann, M; Wardelmann, E | 1 |
| Andoh, A; Bamba, S; Ban, H; Hirota, S; Imaeda, H; Inatomi, O; Murata, S; Nishida, A; Nishimura, T; Sasaki, M; Shioya, M | 1 |
| Antonescu, CR; Beckman, MJ; Besmer, P; Cohen, NA; Crawley, MH; DeMatteo, RP; Green, BL; Greer, JB; Kim, TS; Rossi, F; Santamaria-Barria, JA; Seifert, AM; Sorenson, EC; Zeng, S | 1 |
| Bustamante-Lopez, LA; Cecconello, I; Marques, CF; Nahas, CS; Nahas, SC; Ribeiro, U; Schmerling, R | 1 |
| Bardsley, MR; Bingener-Casey, J; Choi, KM; Farrugia, G; Fletcher, JA; Gajdos, GB; Gibbons, SJ; Gupta, A; Hayashi, Y; Kendrick, ML; Milosavljevic, S; Ordog, T; Ramachandran, A; Reid-Lombardo, KM; Rubin, BP; Sicklick, JK; Taguchi, T; Tang, CM; Toyomasu, Y | 1 |
| Demlová, R; Juřica, J; Turjap, M | 1 |
| Blay, JY; Demetri, GD; Green, S; Kang, YK; Le Cesne, A; Mo, S; Nosov, D; Novick, S; Pápai, Z; Qin, S; Reichardt, P; Rutkowski, P; Shen, L; Srimuninnimit, V; Taningco, L; Trent, J; Wan, D | 1 |
| Pilotte, AP | 1 |
| Jeon, J; Koh, YI; Ryang, DW; Won, EJ | 1 |
| Berry, AC; Munoz, JC; Nakshabendi, R | 1 |
| Movva, S; Norberg, SM | 1 |
| He, Y; Zhang, X | 1 |
| Boccardi, V; Marano, L; Marrelli, D; Roviello, F | 1 |
| Amore, P; Arrigoni, G; Bearzi, I; Boscato, E; Capella, C; Casali, PG; Dei Tos, AP; Gallina, G; Gasparotto, D; Gronchi, A; Maestro, R; Mariani, L; Marzotto, A; Mazzoleni, G; Messerini, L; Miceli, R; Rossi, S; Scaramel, E; Sidoni, A; Sonzogni, A; Toffolatti, L | 1 |
| Benson, C; Fisher, C; Fitzgerald, JE; Hayes, AJ; Judson, I; Messiou, C; Strauss, DC; Tekkis, PP; Thomas, JM; Wilkinson, MJ | 1 |
| Akcakaya, P; Berggren, PO; Berglund, E; Branca, RM; Bränström, R; Daré, E; Fröbom, R; Kim, J; Larsson, C; Lehtiö, J; Lui, WO; Orre, L; Zedenius, J | 1 |
| Aloia, TA; Brudvik, KW; Conrad, C; Cormier, JN; Feig, BW; Hunt, KK; Patel, SH; Roland, CL; Torres, KE; Vauthey, JN | 1 |
| Cao, H; Ling, TL; Wang, M; Xu, J; Zhao, WY | 1 |
| Joensuu, H; Maki, RG; Martin-Broto, J; Nishida, T; Reichardt, P; Schöffski, P | 1 |
| Alwayn, I; Cimen, S; Guler, S; Panek, R | 1 |
| Pavlidis, N; Petrakis, D; Zarkavelis, G | 1 |
| Blay, JY; Demetri, GD; Fletcher, JA; Joensuu, H; Maki, RG; Martín-Broto, J; Nishida, T; Reichardt, P; Schöffski, P; Trent, JC | 1 |
| Irie, M; Kagawa, Y; Miyoshi, T; Nagata, N; Ohtake, Y; Suzuki, H; Takeuchi, Y; Yamagami, T | 1 |
| Abdel-Rahman, O; Fouad, M | 1 |
| Choi, H; Jang, BH; Ji, JS; Kim, BG; Kim, BW; Kim, JS; Lim, KJ; Park, SM | 1 |
| Chang, SC; Chen, YY; Cheng, CT; Chiang, KC; Liao, CH; Liu, CT; Ma, MC; Tsai, CY; Wang, SY; Yeh, CN; Yeh, TS | 1 |
| Jo, J; Kang, YK; Park, I; Ryoo, BY; Ryu, MH; Yoo, C | 1 |
| Afshar, M; Baxter, P; Hall, PS; Hamilton, P; Lord, S; Marples, M; Seligmann, J; Stark, D | 1 |
| Akan, S; Ürkmez, A; Verit, A; Yildirim, Ç; Yüksel, ÖH | 1 |
| Jang, JW; Kim, HS; Lee, NR; Yhim, HY | 1 |
| He, ZD; Huang, XE; Zhou, JN | 1 |
| Chen, H; Chen, J; Chen, Z; Han, L; Shen, C; Tang, S; Yin, Y; Zhang, B | 1 |
| Angelini, S; Astolfi, A; Biasco, G; Hrelia, P; Nannini, M; Pantaleo, MA; Ravegnini, G; Sammarini, G | 1 |
| Bauer, S; Joensuu, H | 1 |
| Barrios, CH; Blackstein, ME; Blay, JY; Casali, PG; Chacon, M; Gu, J; Kang, YK; Nishida, T; Purkayastha, D; Reichardt, P; Woodman, RC | 1 |
| Li, Y; Meng, X | 1 |
| Blay, JY; Hirota, S; Kang, YK; Kitagawa, Y; Nishida, T | 1 |
| Beck, MY; Choi, MJ; Kang, YK; Lee, IS; Lee, MW; Park, SR; Ryoo, BY; Ryu, MH | 1 |
| Cao, Y; Jiang, MJ; Li, XF; Wang, LH; Weng, SS; Xu, JH; Yuan, Y | 1 |
| Hirota, S; Ishikawa, T; Kanda, T; Kosugi, SI; Naito, T; Ueki, K; Wakai, T | 1 |
| Ahmad, A; Katz, SC; Libbey, NP; Somasundar, P | 1 |
| Badalamenti, G; Bronte, G; Casali, P; De Lisi, D; Dei Tos, AP; Frezza, AM; Fumagalli, E; Nannini, M; Pantaleo, MA; Russo, A; Santini, D; Spalato Ceruso, M; Tonini, G; Vincenzi, B | 1 |
| Cundy, T; Grey, A; Porter, D | 1 |
| Angelini, S; Astolfi, A; Biasco, G; Nannini, M; Pantaleo, MA; Ravegnini, G | 1 |
| Blay, JY; Levard, A | 1 |
| Ao, Q; Fei, Y; Wang, G; Wang, Y; Zhu, P | 1 |
| Hoang, U; Khan, U; Mehta, VR; Rachshtut, M | 1 |
| Alberti, L; Blay, JY; Brahmi, M; Cassier, P; Decouvelaere, AV; Dufresne, A; Meeus, P; Ranchère-Vince, D; Ray-Coquard, I | 1 |
| Bruland, ØS; Hompland, I | 1 |
| Lanzon-Miller, S; Sadeghi, P | 1 |
| Al-Batran, SE; Alvegård, T; Bauer, S; Bono, P; Eriksson, M; Hartmann, JT; Hohenberger, P; Joensuu, H; Junnila, J; Kallio, R; Nilsson, B; Pink, D; Ramadori, G; Reichardt, A; Reichardt, P; Schlemmer, M; Sihto, H; Sundby Hall, K; Wardelmann, E | 1 |
| Deutsch, JM; Milhem, M | 1 |
| Adenis, A; Blay, JY; Broto, JM; Casali, PG; Dei Tos, AP; Duffaud, F; Fumagalli, E; Gelderblom, H; Goldstein, D; Gronchi, A; Hartmann, JT; Hohenberger, P; Italiano, A; Judson, IR; Kotasek, D; Le Cesne, A; Litière, S; Marréaud, S; Poveda Velasco, A; Rutkowski, P; van der Graaf, WT; Zalcberg, JR | 1 |
| Blanke, CD; Corless, C; Eary, JF; George, S; Heinrich, M; Mulder, K; Okuno, SH; Rankin, C | 1 |
| Cissé, M; Dieng, M; Gueye, ML; Ka, I; Seck, M; Thiam, O; Touré, AO; Touré, CT | 1 |
| Cao, X; Hu, J; Lai, S; Luo, X; Wang, G; Wang, J; Xia, X | 1 |
| Fujita, J; Hirota, S; Imamura, H; Kishi, K; Nishida, T; Sato, S; Takagi, M; Takahashi, T; Tsujinaka, T; Yamamoto, K | 1 |
| Huang, JS; Pi, ZM; Yu, MY; Zhang, LY | 1 |
| Ding, Y; Wen, G; Xu, L; Zhao, L | 1 |
| Ivan, ME; Komotar, RJ; Shah, AH; Theodotou, CB | 1 |
| Benjamin, RS; Casali, PG | 1 |
| Akçakaya, P; Lui, WO | 1 |
| Adenis, A; Bertucci, F; Blay, JY; Bui-Nguyen, B; Chabaud, S; Chevreau, C; Coindre, JM; Cupissol, D; Domont, J; Duffaud, F; Emile, JF; Le Cesne, A; Patrikidou, A; Pérol, D; Ray-Coquard, I; Rios, M | 1 |
| Demetri, GD; Kang, YK; Nam, BH; Ryoo, BY; Ryu, MH; Yoo, C | 1 |
| Altimari, A; Biasco, G; Ceccarelli, C; Di Nunno, V; Di Scioscio, V; Fanti, S; Fiorentino, M; Gatto, L; Gruppioni, E; Nannini, M; Pantaleo, MA; Santini, D; Saponara, M; Tabacchi, E; Zompatori, M | 1 |
| Doki, Y; Hamakawa, T; Hirota, S; Kurokawa, Y; Makino, T; Miyazaki, Y; Mori, M; Naka, T; Nakajima, K; Takahashi, T; Takiguchi, S; Wada, N; Yamasaki, M | 1 |
| Hamaguchi, H; Iwanaga, T; Katsumori, T; Ohshima, H; Tsukamoto, Y; Yamamoto, S | 1 |
| Hasegawa, J; Hirota, M; Ikenaga, M; Kameda, C; Kawabata, R; Koga, C; Miwa, H; Murakami, M; Noura, S; Ozato, Y; Shimizu, J; Yoshikawa, M | 1 |
| Komatsu, T; Nomura, S; Ogasawara, T; Shida, T; Takahara, Y; Takahashi, M; Uno, H | 1 |
| Fairweather, M; Keung, EZ; Raut, CP | 1 |
| Dong, B; Gao, J; Gong, J; Li, J; Li, Y; Li, Z; Liu, N; Qi, C; Shen, L; Wu, J | 1 |
| Abouelfath, A; Adenis, A; Blay, JY; Bompas, E; Bouché, O; Bouchet, S; Bui, B; Chevreau, C; Collard, O; Cupissol, D; Duffaud, F; Italiano, A; Lassalle, R; Le Cesne, A; Molimard, M; Moore, N; Poulette, S; Ray-Coquard, I; Rios, M; Titier, K | 1 |
| Ben Ami, E; Demetri, GD | 1 |
| Chen, Z; Li, J; Su, K; Zhang, H | 1 |
| Bauer, S; Bright, SA; Butini, S; Campiani, G; Greene, LM; Kinsella, P; Pollock, JK; Williams, DC; Zisterer, DM | 1 |
| Fang, Y; Gao, X; Hou, Y; Ling, J; Qin, J; Qin, X; Shen, K; Shu, P; Sun, Y; Xue, A | 3 |
| Bando, E; Kawamura, T; Makuuchi, R; Miki, Y; Nakajima, T; Sugisawa, N; Tanizawa, Y; Terashima, M; Tokunaga, M | 1 |
| Nannini, M; Pantaleo, MA | 1 |
| Awny, S; Elalfy, AF; Megahed, N; Metwally, IH | 1 |
| Gonzalez, D; Jones, RL; Judson, I; Noujaim, J; Thway, K | 1 |
| Gao, X; Hou, Y; Hu, Q; Jiang, D; Li, X; Lin, J; Liu, Y; Lu, S; Shen, K; Shi, Y; Tan, Y; Xu, C; Xu, J; Xue, A | 1 |
| Azuma, M; Kanamaru, H; Koda, K; Kyo, K; Maema, A; Nakamura, T; Nishiyama, M; Okamoto, K; Shimamura, T; Shinmura, K; Shirakawa, M; Yokoyama, H | 1 |
| Desar, IM; Kaal, SE; van de Kerkhof, PC; van der Graaf, WT; van Erp, NP; van Herpen, CM | 1 |
| Asif, S; Gupta, G; Gupta, N; Mehta, A; Singh, S | 1 |
| Provost, N; Vadeboncoeur, S | 1 |
| Delgado, S; Fernandez-Esparrach, G; Hessheimer, A; Jimenez, M; Lacy, AM; Momblan, D; Navarrete, A | 1 |
| Ayyoub, M; Kroemer, G; Routy, B; Rusakiewicz, S; Zitvogel, L | 1 |
| Blanke, CD; DeMatteo, RP | 1 |
| Alvegård, T; Bauer, S; Cameron, S; Eriksson, M; Hohenberger, P; Joensuu, H; Leinonen, M; Reichardt, A; Reichardt, P; Rejmyr Davis, M; Schütte, J; Sundby Hall, K | 1 |
| de Jong, KP; de Wilt, JH; Nagtegaal, ID; Seesing, MF; Tielen, R; van Coevorden, F; van Hillegersberg, R; Verhoef, C | 1 |
| Amano, S; Aoyama, M; Hino, N; Inoue, S; Miyoshi, T; Mori, R; Sumitomo, H; Wada, D | 1 |
| Ando, T; Hosokawa, A; Kajiura, S; Nakada, N; Nanjyo, S; Sugiyama, T | 1 |
| Adenis, A; Bertucci, F; Blay, JY; Bompas, E; Bouché, O; Cassier, P; Cesne, AL; Chauzit, E; Cropet, C; Duffaud, F; Gautier, J; Isambert, N; Italiano, A; Mir, O; Molimard, M; Pérol, D; Ray-Coquard, I; Rios, M; Toulmonde, M | 1 |
| Hanazaki, K; Kitagawa, H; Kobayashi, M; Maeda, M; Munekage, E; Munekage, M; Namikawa, T; Obatake, M; Sakamoto, K; Yatabe, T | 1 |
| Boscato, E; Cacciatore, M; Carraro, V; Dei Tos, AP; Dell'Orto, MC; Gallina, G; Gasparotto, D; Maestro, R; Mancini, C; Mandolesi, A; Mazzoleni, G; Niero, M; Pilozzi, E; Romeo, S; Rossi, S; Sbaraglia, M; Sessa, F; Sonzogni, A; Toffolatti, L | 1 |
| Cheville, JC; Gleeson, FC; Henry, MR; Kerr, SE; Kipp, BR; Lazaridis, KN; Levy, MJ; Minot, DM; Tu, ZJ; Vasmatzis, G; Voss, JS | 1 |
| Angelini, S; Hrelia, P; Ravegnini, G; Sammarini, G | 1 |
| Chen, P; Li, Q; Ma, L; Røe, OD; Sun, L; Tao, R; Zhang, J; Zhi, X; Zhou, J | 1 |
| Agulnik, M; Corless, CL; Demetri, GD; Heinrich, MC; Keer, H; Lyons, JF; Mahadevan, D; Oganesian, A; Riedel, RF; Trent, J; von Mehren, M; Wagner, AJ; Yule, M | 1 |
| Bauer, S; Corless, C; Falkenhorst, J; Fletcher, JA; Grunewald, S; Heinrich, M; Marino-Enriquez, A; Mühlenberg, T; Podleska, LE; Reis, AC; Schuler, M; Treckmann, J | 1 |
| Basile, F; Brancato, G; Donati, M | 1 |
| Fujita, J; Hirota, S; Masuzawa, T; Nishida, T; Sato, S; Takagi, M; Takahashi, T; Tsujinaka, T; Yamamoto, K; Yamashita, Y | 1 |
| Gurav, M; Ostwal, V; Pai, T; Paul, D; Ramaswamy, A; Sahu, A; Shetty, N; Shetty, O; Shrikhande, S | 1 |
| Mathew, J; Natesh, B; Rajan, R; Raviram, S; Sindhu, RS; Valappil, FK | 1 |
| Ford, SJ; Gronchi, A | 1 |
| Patel, S; Schvartsman, G; Somaiah, N; Trinh, VA; Wagner, MJ; Zobniw, CM | 1 |
| Luo, JR; Xiang, XJ; Xiong, JP | 1 |
| Cisano, C; Crocetti, D; De Toma, G; Pedullà, G; Polistena, A; Sapienza, P; Tarallo, M; Venturini, L | 1 |
| Belinsky, MG; Devarajan, K; Gersz, L; Godwin, AK; Pathak, HB; Rink, L; von Mehren, M; Zhou, Y; Zook, P | 1 |
| Barysauskas, CM; Ben-Ami, E; Butrynski, JE; Choy, E; Corless, CL; Demetri, GD; Fletcher, JA; George, S; Heinrich, MC; Morgan, JA; Solomon, SM; Van den Abbeele, AD; von Mehren, M; Wagner, AJ; Yap, JT | 1 |
| Almenara, R; Lacy, A; Momblán, D; Navarrete, A | 1 |
| An, HJ; Cho, U; Choi, YG; Kim, SH; Kim, Y; Shim, BY; Yim, E | 1 |
| Ambrifi, M; Bottoni, U; Calvieri, S; Clerico, R; Corsetti, P; Didona, D; Paolino, G | 1 |
| Chang, XY; Li, Y; Ma, ZQ; Zhou, WX | 1 |
| Im, SA; Kang, YK; Kim, TY; Lee, SJ; Park, JO; Park, SR; Ryoo, BY; Ryu, MH; Son, MK | 1 |
| Chan, CK; Chau, KF; Cheng, IK; Cheung, CY; Li, FK; Lo, SH | 1 |
| Bins, S; de Bruijn, P; de Man, FM; Eechoute, K; Kloth, JS; Mathijssen, RH; Oosten, AW; Sleijfer, S | 1 |
| Antonescu, CR; Beckman, MJ; Besmer, P; Cohen, NA; Crawley, MH; DeMatteo, RP; Kim, TS; Loo, JK; Maltbaek, JH; Medina, BD; Rossi, F; Seifert, AM; Zeng, S; Zhang, JQ | 1 |
| Cao, H; Cao, XY; He, P; Jiang, SH; Li, Q; Li, RK; Tian, GA; Tu, L; Wang, Y; Yang, XM; Zhang, XX; Zhang, ZG; Zhu, CC; Zhu, L; Zhuang, C | 1 |
| Maki, RG; Martínez-Marín, V | 1 |
| Hompes, D; Rutkowski, P | 1 |
| Kim, CW; Kim, HY; Seo, KJ; Whang, IY; Won, HS | 1 |
| Le Cesne, A; Patrikidou, A | 1 |
| Ide, R; Ikeda, S; Itamoto, T; Matsugu, Y; Nakahara, H; Oshita, A; Shinozaki, K; Suzuki, T; Takakura, Y; Urushihara, T | 1 |
| Cao, CL; Cong, CL; Kang, SP; Kang, SR; Niu, HJ | 1 |
| Bai, J; Cai, KL; Chang, WL; Deng, R; Gao, JB; Liu, K; Shuai, XM; Tao, KX; Wang, GB; Zhang, P | 1 |
| Kondo, T | 1 |
| Angenendt, P; Diehl, F; Fredebohm, J; Holtrup, F; Löber, AK; Mehnert, DH; van Rahden, V | 1 |
| Ha, HK; Kim, AY; Kim, HJ; Kim, JS; Lee, JS; Park, SH | 1 |
| Albuquerque, C; Claro, I; Dias Pereira, A; Francisco, I; Lemos, MM; Limbert, M; Pereira da Silva, J; Santos, F; Vale Rodrigues, R | 1 |
| Aftab, DT; Cornillie, J; Debiec-Rychter, M; Gebreyohannes, YK; Schöffski, P; Sciot, R; Van Looy, T; Vanleeuw, U; Vreys, L; Wellens, J; Wozniak, A | 1 |
| Jain, D; Ostwal, V; Ramadwar, M; Ramaswamy, A; Sahu, A; Saklani, A; Shetty, N; Shrikande, SV; Zanwar, S | 1 |
| Buranapraditkun, S; Klaewsongkram, J; Mongkolpathumrat, P; Sodsai, P; Thantiworasit, P | 1 |
| Bardsley, MR; Burgoyne, AM; Chan, JC; Chmielecki, J; Gao, F; Harismendy, O; Kendrick, ML; Lee, TE; Leonard, SY; Mao, J; Morosini, D; Ordog, T; Ross, JS; Shi, E; Sicklick, JK; Siena, M; Syed, SA; Tang, CM; Wang, K | 1 |
| Abu-Amna, M; Awadie, H; Bar-Sela, G | 1 |
| Inayat, F; Saif, MW | 1 |
| Nayak, HK; Padhi, S | 1 |
| Cai, Z; Chen, Q; Chen, Y; Gu, M; Liu, C; Wang, Z; Xu, H | 1 |
| Angelini, S; Biasco, G; Gatto, L; Hrelia, P; Nannini, M; Pantaleo, MA; Ravegnini, G; Sammarini, G; Saponara, M; Simeon, V; Urbini, M; Venturoli, N; Zenesini, C | 1 |
| Cheng, J; Den, J; Hong, N; Pan, F; Wang, H; Wang, Y; Wu, W; Zhang, C | 1 |
| Cao, H; Wang, M | 1 |
| Shen, C; Zhang, B | 1 |
| Chen, T; Chen, Z; Feng, X; Li, G; Li, Y; Qiu, H; Sun, X; Tao, K; Yu, J; Zhang, P; Zhou, Z | 1 |
| Chen, T; Chen, Z; Du, C; Feng, X; Huang, C; Li, G; Li, J; Li, R; Li, Y; Liu, X; Pan, F; Qiu, H; Sun, X; Tao, K; Yin, X; Yu, J; Zhang, B; Zhang, P; Zhao, Y; Zheng, G; Zhou, Y; Zhou, Z | 1 |
| Chen, H; Guan, W; Li, F; Li, G; Li, L; Ma, L; Miao, Y; Sun, L; Wang, B; Wang, J; Wang, Y; Xu, H; Xu, J; Xu, W; Xu, Z; Yang, L; Yu, J; Zhang, D; Zhi, X | 1 |
| Cai, K; Cai, M; Gao, J; Liu, K; Liu, W; Liu, X; Shuai, X; Tao, K; Wang, G; Zeng, X; Zhang, P | 1 |
| Fang, Y; Gao, X; Hou, Y; Li, H; Ling, J; Qin, J; Qin, X; Shen, K; Shu, P; Sun, Y; Wang, L; Xue, A | 1 |
| Dong, Z; Gao, J; Gong, J; Li, J; Li, Y; Shen, L; Wang, X | 1 |
| Li, J | 1 |
| Lei, C; Liu, L; Wang, H; Wang, Q | 1 |
| Chen, J; Tang, S; Xiang, J; Yin, Y; Yu, Q; Zhang, B | 1 |
| Azouz, MM; Bouassida, M; Chelbi, E; El Bouchtili, S; Ezzine, H; Hamzaoui, L; Mahmoudi, M; Medhioub, M; Touinsi, H | 1 |
| Ali, AA; Boichuk, S; Brown, MF; Duensing, A; Kuan, SF; Lee, DM; Liu, L; Liu, Y; Makielski, KR; Patil, SS; Rausch, JL; Taguchi, T | 1 |
| Aime, S; Cabodi, S; Consolino, L; Dastrù, W; Giovenzana, GB; Longo, DL; Sciortino, M | 1 |
| Elzawahry, A; Furukawa, E; Hirota, S; Kato, M; Mimaki, S; Naka, T; Nakamura, H; Nakatsuka, R; Nishida, T; Nishigaki, T; Serada, S; Shibata, T; Takahashi, T; Tsuchihara, K | 1 |
| Campan, M; Chopra, S; Martin, SE; Naritoku, W; Pettersson, J; Ward, PM; Wei, CH | 1 |
| Glasgow, SC; Hawkins, AT; Hunt, SR; Krishnamurty, DM; Mutch, MG; Silviera, ML; Wells, KO; Wise, PE | 1 |
| Fu, Y; Guo, L; Hao, H; Yang, G; Zhang, X | 1 |
| Hata, Y; Hirai, T; Ikawa, O; Ishikawa, T; Kagimura, T; Kanda, T; Masuzawa, T; Mochizuki, I; Nishida, T; Ojima, H; Sodeyama, H; Takagane, A | 1 |
| Chandrashekar, L; Colombo, EA; Fontana, L; Gervasini, C; Gupta, D; Kate, V; Larizza, L; Rajappa, M; Rajendiran, KS; Sreenath, GS; Thappa, DM | 1 |
| Cao, LL; Chen, QF; Chen, QY; Huang, CM; Li, P; Lin, JX; Lin, M; Lu, J; Tu, RH; Wang, JB; Xie, JW; Zheng, CH | 1 |
| Kanazawa, Y; Nemoto, T; Ohira, H; Ozaki, A; Sawano, T; Tsukada, M | 1 |
| Hamaguchi, H; Iwanaga, T; Katsumori, T; Ohkawara, S; Oshima, H; Tsukamoto, Y; Yamamoto, S | 1 |
| Abe, T; Aoki, T; Imoto, H; Ishioka, C; Karasawa, H; Motoi, F; Musha, H; Nagao, M; Naitoh, T; Ohnuma, S; Sato, Y; Takahashi, M; Tanaka, N; Unno, M; Watanabe, K | 1 |
| Fujimura, T; Fukushima, W; Izumi, R; Kitagawa, H; Maruzen, S; Sasaki, S; Terada, I; Yagi, Y; Yoshikawa, A | 1 |
| Fujiwara, Y; Fukuda, S; Inoue, M; Kitani, K; Ohta, Y; Tsujie, M; Wakasa, T; Yukawa, M | 1 |
| Amit, K; Argawal, T; Gupta, A; Gupta, S | 1 |
| Baker, LH; Benjamin, RS; Blackstein, ME; Blanke, CD; Borden, EC; Corless, CL; Crowley, JJ; Demetri, GD; Fletcher, JA; Heinrich, MC; Maki, RG; Owzar, K; Priebat, DA; Rankin, C; Ryan, CW; Tap, WD; von Mehren, M | 1 |
| Abongwa, HK; Ansaloni, L; Catena, F; Coccolini, F; DE Simone, B; DI Saverio, S; Nannini, M; Napoli, JA; Pantaleo, MA; Saponara, M; Sartelli, M | 1 |
| Ishizaki, M; Katoh, T; Komine, C; Matsumoto, A; Morinaga, N; Nakamura, T; Nakazato, K; Saito, H; Shitara, Y; Tanaka, N | 1 |
| Benjamin, R; Boonstra, PA; Choi, H; Farag, S; Gelderblom, H; Grunhagen, D; Heeres, B; Nederlof, P; Reyners, AK; Somaiah, N; Steeghs, N; van Boven, H; van der Graaf, W; Wang, WL | 1 |
| Bhatt, L; Geh, JI; Gross, L; Lupton, SC; Peake, DR; Spooner, D; Tanière, P; Wong, DW | 1 |
| Hueman, MT; Schulick, RD | 1 |
| Alfieri, P; Arcari, A; Ferrari, A; Leonardi, G; Longo, G; Luppi, G; Maffei, R; Marasca, R; Martinelli, S; Piacentini, F; Santachiara, R; Torelli, G; Trabacchi, E; Vallisa, D | 1 |
| Demetri, GD; Fletcher, CD; Fletcher, JA; Ou, WB; Zhu, MJ | 1 |
| Chu, CC; Johnston, K; Knowling, M; Mabasa, VH; Moravan, V; Peacock, S; Taylor, SC | 1 |
| Akaike, M; Imada, T; Kameda, Y; Morinaga, S; Rino, Y; Shiozawa, M; Sugano, N; Sugimasa, Y; Takemiya, S; Tsuchida, K | 1 |
| Ando, T; Hosokawa, A; Kudo, T; Maeda, K; Miwa, S; Miyazaki, T; Nakajima, T; Nozawa, H; Sugiyama, T; Yamada, K | 1 |
| de Wilt, JH; den Bakker, MA; Eggermont, AM; Mearadji, A; Sleijfer, S; van Geel, AN; Verhoef, C; Verweij, J | 1 |
| Judson, I | 2 |
| Rutkowski, P; Siedlecki, JA; Symonides, M; Zdzienicki, M | 1 |
| Mac, K; Wójcik, M | 1 |
| Gusani, NJ; Jiang, Y; Kimchi, E; Liang, J; Nikfarjam, M; Sehmbey, M; Shereef, S; Staveley-O'Carroll, KF | 1 |
| Heger, U; Lordick, F; Weitz, J | 1 |
| Eisenberg, B; Flieder, D; Godwin, AK; Koumbi, D; Merkel, E; Pathak, H; Rink, L; Tarn, C; Testa, JR; von Mehren, M | 1 |
| Hirota, S; Koseki, M; Miyakawa, K; Nishida, T; Ohtsu, A; Okamura, T; Sawaki, A; Shirao, K; Sugiyama, T | 1 |
| Tuma, RS | 1 |
| Baghel, NS; Dutt, A; Nair, N; Shinto, A | 1 |
| Hosone, M; Liu, A; Maeda, S; Maruyama, H; Matsutani, T; Miyamoto, M; Sasajima, K; Suzuki, S; Tajiri, T; Watanabe, H; Yokoyama, T | 1 |
| Agaram, NP; Antonescu, CR; Besmer, P; Dematteo, RP; Guo, T; Maki, RG; Singer, S; Wong, GC | 1 |
| Corless, CL; Demetri, GD; Fletcher, CD; Fletcher, JA; Heinrich, MC; Kepten, I; Le, C; Liegl, B; Zhu, M | 1 |
| Gronchi, A; Hohenberger, P; Mussi, C; Schildhaus, HU; Wardelmann, E | 1 |
| Date, RS; Mughal, MM; Pursnani, KG; Stylianides, NA; Ward, JB | 1 |
| Blay, JY; Collin, F; Daugaard, S; Debiec-Rychter, M; Fisher, C; Hogendoorn, PC; Sciot, R; van Glabbeke, M; Verweij, J | 1 |
| Hamada, M; Horimi, T; Iwata, J; Nagata, Y; Nasu, Y; Ozaki, K; Tsuji, A | 1 |
| Artinyan, A; Bhatia, S; Chow, W; Ellenhorn, JD; Kim, J; Soriano, P | 1 |
| Alexandrescu, DT; Dasanu, CA; Farzanmehr, H; Kauffman, L | 1 |
| Hino, M; Koh, KR; Nakamae, H; Ohsawa, M; Osugi, H; Sakamoto, E; Sawada, T; Wakasa, K; Yamane, T | 1 |
| Canda, AE; Nalbant, OA; Ozsoy, Y; Sagol, O | 1 |
| Belinsky, MG; Cai, KQ; Eisenberg, B; Godwin, AK; Huang, M; Ochs, MF; Rink, L; von Mehren, M | 1 |
| Antonescu, CR; Corless, CL; Fletcher, CD; Hornick, JL; Liegl, B | 1 |
| Lin, CC; Lin, JT; Lin, MT; Liu, KL; Wang, HP | 1 |
| Sevinc, A; Turhal, NS | 1 |
| Hanada, N; Hori, K; Kusano, S; Sakashita, N; Tsurumoto, Y; Uchino, R | 1 |
| Hur, H; Jee, SB; Jeon, HM; Jung, SE; Kim, W; Park, AR | 1 |
| Battistella, M; Dubertret, L; Frémont, G; Gornet, JM; Vignon-Pennamen, MD; Viguier, M | 1 |
| de Jong, S; Fletcher, JA; Le, PT; Meersma, GJ; Meijer, C; Rikhof, B; Suurmeijer, AJ; van der Graaf, WT | 1 |
| Blanke, CD; Demetri, GD; Eisenberg, BL; Harris, J; Heinrich, MC; Hoffman, JP; Kane, JM; Okuno, S; von Mehren, M; Watson, JC | 1 |
| Hirota, S; Kubota, T; Minami, M; Nishida, T; Otani, Y; Shimada, Y; Sugino, Y; Takahashi, F; Yamamura, Y; Yanagisawa, A | 1 |
| Bórquez Ma, P; Neveu C, R | 1 |
| Saka, M; Tanaka, N | 1 |
| Benjamin, RS; Choi, H; Hunt, KK; Lazar, AJ; McAuliffe, JC; Pollock, RE; Qiao, W; Thall, P; Trent, JC | 1 |
| Judson, IR | 1 |
| Benjamin, RS; Bertagnolli, MM; Blanke, CD; Borden, EC; Bramwell, VH; Corless, CL; Demetri, GD; Fletcher, CD; Fletcher, JA; Heinrich, MC; Hollis, D; Owzar, K; Rankin, C; Ryan, CW; von Mehren, M | 1 |
| Antonescu, CR; Baum, CM; Cohen, DP; Corless, CL; Demetri, GD; Fletcher, CD; Fletcher, JA; Griffith, D; Harlow, A; Heinrich, MC; Huang, X; Maki, RG; McKinley, A; Ou, WB; Town, A | 1 |
| Bertulli, R; Bozzi, F; Brich, S; Conca, E; Fumagalli, E; Gronchi, A; Negri, T; Pierotti, MA; Pilotti, S; Tamborini, E | 1 |
| Chatterjee, P; Duensing, A; Kuan, SF; Liu, Y; Perdreau, SA; Wang, L | 1 |
| Camci, C; Sevinc, A | 1 |
| Azard, J; Barrois, M; Chatelut, E; Delbaldo, C; Geoerger, B; Kattygnarath, D; LeCesne, A; Petain, A; Séronie-Vivien, S; Vassal, G | 1 |
| Asano, S; Dairaku, N; Hiwatashi, N; Ikeya, S; Kojima, Y; Koshita, S; Kusano, M; Nakayama, H; Ojima, T; Shimada, N; Sugai, Y; Yamagiwa, T; Yokoyama, A | 1 |
| Asopa, R; Basu, S; Mohandas, KM; Peshwe, H; Vyawahare, M | 1 |
| Alberti, L; Arifi, S; Blay, JY; Bringuier, PP; Cassier, PA; Dufresne, A; El Sayadi, H; Ray-Coquard, I; Scoazec, JY | 1 |
| Akiyama, T; Higashida, M; Hirabayashi, Y; Hirai, T; Hironaka, K; Ikeda, M; Kawabe, Y; Kubota, H; Matsumoto, H; Murakami, H; Oka, Y; Okawaki, M; Okumura, H; Tsunoda, T; Urakami, A; Yamaguchi, Y; Yamamura, M; Yamashita, K | 1 |
| Cordier, JF; Cottin, V; Girard, N; Lapalus, MG; Tronc, F | 1 |
| Eslamy, HK; Quon, A | 1 |
| Albiter, M; Bonvalot, S; Dromain, C; Le Cesne, A; Le Péchoux, C; Mabille, M; Shapeero, LG; Terrier, P; Vanel, D | 1 |
| Chang, HM; Jang, G; Kang, YK; Kim, TW; Lee, H; Lee, JL; Lee, SS; Park, I; Ryu, MH; Sym, SJ | 1 |
| Loong, HH; Yeo, W | 1 |
| Bonvalot, S | 2 |
| Benhattar, J; Delaloye, AB; Elsig, V; Guillou, L; Leyvraz, S; Luthi, F; Michielin, O; Montemurro, M; Orcurto, MV; Prior, JO; Stupp, R | 1 |
| Brosa, M; Díaz, S; García del Muro, X; González, P; Grande, E; Paz-Ares, L | 1 |
| Barzilai, M; Domachevsky, L; Peled, N | 1 |
| Antonio López-Guerrero, J; Artigas, V; Casado, A; Cervera, J; García Del Muro, X; López-Pousa, A; Martín, J; Maurel, J; Ortega, L; Poveda, A; Ramos, R; Romero, I; Safont, MJ | 1 |
| Huang, KE; Pan, YL; Tao, DY; Wang, JL; Zheng, S | 1 |
| Ide, Y; Kinuta, M; Maruyama, K; Matsunaga, H; Murata, K; Nagase, H; Nakamichi, I; Okada, K; Ota, H; Yokouchi, H | 1 |
| Casali, PG; Fiore, M; Fumagalli, E; Gronchi, A; Palassini, E; Pennacchioli, E; Pilotti, S; Stacchiotti, S; Tamborini, E | 1 |
| Kayaselçuk, F; Koç, Z; Ulusan, S | 1 |
| Han, H; Wang, YH; Yu, YY | 1 |
| Haisa, M; Hatakeyama, S; Hirota, S; Matsuoka, J; Motoki, T; Naomoto, Y; Noma, K; Ohmori, O; Sakurama, K; Shirakawa, Y; Takaoka, M; Tanaka, N; Tomono, Y; Watanabe, N; Yamatsuji, T | 1 |
| Bajor, J | 1 |
| Ladha, A; Shaikh, MU | 1 |
| Christensen, J; Demetri, GD; Deshmukh, GD; Diehl, W; DiNitto, JP; Emmett, MR; English, JM; Gajiwala, KS; Greig, MJ; He, YA; Jacques, SL; Lunney, EA; Marshall, AG; McTigue, M; Molina, D; Quenzer, T; Wells, PA; Wu, JC; Yu, X; Zhang, HM; Zhang, Y; Zou, A | 1 |
| DeMatteo, RP | 3 |
| Fermeglia, M; Greco, A; Negri, T; Pavan, GM; Pierotti, MA; Pilotti, S; Pricl, S; Sandri, M; Tamborini, E; Virdis, E | 1 |
| Dietrich, C; Hartung, E; Ignee, A | 1 |
| Cheng, H; Geist, DE; Piperdi, B; Piperdi, M; Virk, R | 1 |
| Ahmed, T; Ali, MO; Rashid, MM; Saifullah, M | 1 |
| Bernstein, ML | 1 |
| DeMatteo, RP; Kingham, TP | 1 |
| Sevinc, A | 1 |
| Cohen, MH; Farrell, A; Justice, R; Pazdur, R | 1 |
| Hait, WN; Hambley, TW | 1 |
| Dirnhofer, S; Leyvraz, S | 1 |
| Guo, RP; Guo, ZX; Lao, XM; Li, JQ; Wang, GH; Ye, ZY; Zhang, YQ | 1 |
| George, S; Quek, R | 1 |
| Chaudhry, UI; DeMatteo, RP | 2 |
| Dogan, SS; Esmaeli, B | 1 |
| Sornmayura, P | 1 |
| Cheung, MC; Koniaris, LG; Yang, R; Zhuge, Y | 1 |
| Blay, JY; Casali, PG; Cohen, DP; Demetri, GD; Deprimo, SE; George, S; Harmon, CS; Law, CN; Le Cesne, A; Morgan, JA; Ray-Coquard, I; Stephenson, P; Tassell, V | 1 |
| Blanke, CD; Fernandes, Gdos S; Freitas, D; Guedes, R; Hoff, PM | 1 |
| von Mehren, M; Watson, JC | 2 |
| Bertagnolli, MM; Raut, CP | 1 |
| Blay, JY; Casali, PG; Cesne, AL; Gronchi, A; Hohenberger, P; Judson, I; Martin, J; Nishida, T; Poveda, A; Reichardt, P | 1 |
| Annaberdyev, S; Gibbons, J; Hardacre, JM | 1 |
| Dong, RZ; DU, CY; Fu, H; Shi, YQ; Wang, CM; Ye, YW; Zhao, GF; Zhou, Y | 1 |
| Hohenberger, P | 4 |
| Antonescu, CR; Ballman, KV; Blackstein, ME; Blanke, CD; Brennan, MF; Dematteo, RP; Demetri, GD; Maki, RG; McCarter, MD; Owzar, K; Patel, S; Pisters, PW; Polikoff, JA; Tan, BR; von Mehren, M | 1 |
| Bang, YJ; Chang, HM; Kang, HJ; Kang, JH; Kang, WK; Kang, YK; Kim, MK; Kim, TW; Kim, TY; Lee, H; Lee, KH; Lee, WK; Park, JO; Park, YS; Roh, JK; Ryoo, BY; Ryu, MH; Shin, DB | 1 |
| Astorino, M; Azzaroli, F; Biasco, G; Catena, F; Di Battista, M; Di Scioscio, V; Lolli, C; Maleddu, A; Pantaleo, MA; Santini, D; Saponara, M | 1 |
| Albritton, KH; Butrynski, JE; D'Amato, GZ; Demetri, GD; Heinrich, MC; Janeway, KA; Pedrazzoli, P; Picus, J; Schlemmer, M; Siena, S; Van Den Abbeele, AD | 1 |
| Ahlman, H; Nilsson, B; Nilsson, O | 1 |
| Jain, P; Jha, AK; Rai, RR | 1 |
| Duffaud, F; Le Cesne, A | 1 |
| Blay, JY; Borg, C; Chaput, N; Delahaye, NF; Emile, JF; Flament, C; Ghiringhelli, F; Le Cesne, A; Ménard, C; Michiels, S; Nonn, C; Robert, C; Taïeb, J; Zitvogel, L | 1 |
| Masaki, N; Nozaki, Y; Yanase, M | 1 |
| Armbrust, T; Cameron, S; Füzesi, L; Gunawan, B; Langer, C; Ramadori, G; Sobotta, M | 1 |
| Hou, J; Hou, YY; Lu, SH; Qi, WD; Tan, YS; Xu, C; Zhou, Y | 1 |
| Kim, DK; Kim, YH; Lee, HJ; Park, SI | 1 |
| Luketich, JD; Pennathur, A | 1 |
| Abe, S; Kubota, T | 1 |
| Chen, SS; Lazar, AJ; McAuliffe, JC; Pavan, GM; Pollock, RE; Pricl, S; Trent, JC; Wang, WL; Yang, D | 1 |
| Demetri, GD | 2 |
| Bang, YJ; Chang, HM; Kang, WK; Kang, YK; Kim, TW; Lee, H; Lee, JL; Lee, JS; Lee, KH; Park, YS; Ryu, MH; Shin, DB; Sym, SJ | 1 |
| Sato, Y; Taguchi, T; Taniguchi, S; Thao, le B; Vu, HA; Watanabe, T; Yagasaki, F; Yasuda, K | 1 |
| Blay, JY | 3 |
| Gervaz, P; Huber, O; Morel, P | 1 |
| Altavilla, G; Arrigo, C; Pitini, V; Sauta, MG | 1 |
| Blanke, CD; Demetri, GD; Joensuu, H; Nikolova, Z; Racine, A; von Mehren, M; Wang, Y; Wehrle, E | 1 |
| Gelderblom, H; Grünwald, V; Hartmann, JT; Joensuu, H; Leyvraz, S; Montemurro, M; Reichardt, P; Roth, A; Schöffski, P; Schütte, J; Seddon, B; von Moos, R; Weber, E; Wendtner, CM | 1 |
| Bachmann, K; Bogoevski, D; Izbicki, J; Kaifi, J; Kohrs, D; Reichelt, U; Schurr, P; Vashist, Y; Yekebas, E | 1 |
| Dan, D; Persad, R; Seetahal, S | 1 |
| Bovée, JV; Gelderblom, H; Hogendoorn, PC; Kroep, JR; van der Molen, AJ | 1 |
| Blay, JY; Reichardt, P | 1 |
| Bensimhon, D; Boudiaf, M; Dray, X; Duchat, F; Fargeaudou, Y; Hamzi, L; Idy-Peretti, I; Martin-Grivaud, S; Nemeth, J; Pocard, M; Rymer, R; Soyer, P | 1 |
| Blay, JY; Comite, P; Debiec-Rychter, M; Hogendoorn, PC; Oosting, J; Romeo, S; Schneider, U; Sciot, R; Terrier, P; Van Eijk, R; Van Glabbeke, M; Van Paassen, H; Verweij, J | 1 |
| Atadja, P; Debiec-Rychter, M; Faa, G; Fieuws, S; Floris, G; Machiels, K; Schöffski, P; Sciot, R; Stefan, C; Wozniak, A | 1 |
| Blanke, CD; Renouf, DJ; Wilson, L | 1 |
| Adenis, A; Blay, JY; Cassier, PA; Le Cesne, A; Ray-Coquard, I | 1 |
| Ben Slama, S; Bouraoui, S; Gharbi, L; Gharbi, W; Goutallier, C; Lahmar-Boufaroua, A; Manai, S; Mzabi-Regaya, S | 1 |
| Bachet, JB; Beauchet, A; Blay, JY; Brahimi, S; Bui, B; Coindre, JM; Duffaud, F; Emile, JF; Hostein, I; Le Cesne, A; Subra, F; Tabone-Eglinger, S; Terrier, P | 1 |
| Fernández, JA; Parrilla, P | 1 |
| Aoyama, T; Fujii, K; Fujisawa, J; Ishikawa, Y; Kawamoto, M; Masuda, M; Matsukawa, H; Rino, Y; Saeki, H; Samejima, J | 1 |
| Carney, JA; Chapman, AD; Dempsey, OJ; Gomersall, LN; Sawhney, SA | 1 |
| Fujiwara, H; Ichikawa, D; Ikoma, H; Kikuchi, S; Kokuba, Y; Kubota, T; Nakanishi, M; Ochiai, T; Okamoto, K; Otsuji, E; Sakakura, C; Sonoyama, T; Taniguchi, H | 1 |
| Choi, SH; Choi, WH; Hyung, WJ; Kim, S; Noh, SH; Park, CI; Yu, JS | 1 |
| Endo, S; Hosoya, Y; Kurashina, K; Lefor, A; Sakurai, S; Yasuda, Y | 1 |
| Chang, I; Choi, D; Kim, KM; Lee, JY; Lee, WJ; Sohn, TS; Yoo, EY | 1 |
| Blay, JY; Bui, B; Casali, PG; Findlay, M; Hogendoorn, PC; Issels, R; Judson, I; Le Cesne, A; Leyvraz, S; Reichardt, P; Schoffski, P; Sciot, R; Van Glabbeke, M; Verweij, J | 1 |
| Hirota, S; Matsumoto, T; Shiba, K | 1 |
| Blanpain, S; Brasseur, A; Brochart, C; Chatelain, D; Demuynck, F; Fuks, D; Morvan, J; Robert, B; Yzet, T | 1 |
| Casali, PG; Fiore, M; Gronchi, A; Hohenberger, P; Jakob, J; Mussi, C; Reichardt, P; Ronellenfitsch, U; Tamborini, E | 1 |
| Ahrar, K; Ensor, J; Gupta, S; Hicks, ME; Kobayashi, K; Madoff, DC; Murthy, R; Szklaruk, J; Trent, JC; Wallace, MJ | 1 |
| Fujimoto, J; Hatakeyama, K; Hirota, S; Ishikawa, T; Isozaki, K; Ito, T; Kanda, T; Liu, NN; Matsuda, I; Nakai, N; Shiba, K | 1 |
| Bolognese, L; Fiorentini, G; Grotti, S; Marinozzi, C; Montagnani, F; Turrisi, G | 1 |
| Akyurek, N; Benekli, M; Buyukberber, S; Coskun, U; Demirci, U; Karakan, T; Tonyali, O; Yildiz, R | 1 |
| Benjamin, RS; Debiec-Rychter, M; Demetri, GD; Joensuu, H; Le Cesne, A; Poveda, A; Schöffski, P; Sleijfer, S | 1 |
| Belinsky, MG; Blanke, CD; Eisenberg, B; Godwin, AK; Heinrich, MC; Kossenkov, AV; Ochs, MF; Pajak, T; Rink, L; Skorobogatko, Y; von Mehren, M | 1 |
| Castro Cotti, GC; Cutait, R; Freitas, D; Hoff, PM; Santos Fernandes, Gd | 1 |
| Baba, H; Doi, T; Kanda, T; Komatsu, Y; Koseki, M; Murakami, K; Nishida, T; Sawaki, A; Sun, YN; Yamada, Y | 1 |
| Bareck, E; Brodowicz, T; Eisterer, W; Häfner, M; Kühr, T; Längle, F; Ploner, F; Schima, W; Wrba, F; Zacherl, J | 1 |
| Bareck, E; Längle, F; Zacherl, J | 1 |
| Brodowicz, T; Kühr, T | 1 |
| Eisterer, W; Ploner, F | 1 |
| Kurtaran, A; Schima, W | 1 |
| Becker, CR; Berger, F; Nikolaou, K; Reiser, MF; Schinwald, N; Schlemmer, M; Sourbron, SP | 1 |
| Bailey, SM; Bertulli, R; Blay, JY; Borghaei, H; Casali, PG; Cassier, P; Cheung, W; Davey, M; Debiec-Rychter, M; Demetri, GD; Fumagalli, E; Morgan, JA; Pink, D; Ray-Coquard, I; Reichardt, A; Reichardt, P; Veronese, ML; von Mehren, M | 1 |
| Conca, E; Fermeglia, M; Fumagalli, E; Gronchi, A; Negri, T; Pavan, GM; Pierotti, MA; Pilotti, S; Pricl, S; Tamborini, E | 1 |
| Adenis, A; Blay, JY; Penel, N | 1 |
| Doi, T; Komatsu, Y; Li, Y; Muro, K; Nishida, T; Ohtsu, A; Shirao, K; Ueda, E | 1 |
| Dundamadappa, SK; Karam, AR; Shankar, S; Stay, RM; van Sonnenberg, E | 1 |
| Antonescu, CR; Baum, CM; Bello, CL; Chen, MH; Cohen, DP; Corless, CL; Demetri, GD; Fletcher, CD; Fletcher, JA; George, S; Heinrich, MC; Huang, X; Maki, RG; Morgan, JA; Van den Abbeele, AD | 1 |
| Baum, CM; Blackstein, ME; Demetri, GD; Deprimo, SE; Garrett, CR; Harmon, CS; Huang, X; Schöffski, P; Shah, MH; Verweij, J | 1 |
| Chi, HT; Hara, Y; Iwasaki, R; Sato, Y; Taguchi, T; Thao, le B; Vu, HA; Watanabe, T | 1 |
| Kang, DY; Kim, S; Lee, HJ; Lim, JS; Song, IC; Yun, HJ | 1 |
| Joensuu, H | 5 |
| Antonescu, CR; Brennan, MF; Broto, JM; DeMatteo, RP; Donohue, JH; García-del-Muro, X; Gold, JS; Gönen, M; Gutiérrez, A; Maki, RG; Singer, S; Smyrk, TC | 1 |
| D'Adamo, D | 1 |
| Rumpold, H; Wolf, D | 1 |
| Hyatt, BJ; Paull, PE; Wassef, W | 1 |
| Baba, N; Ishigami, S; Kitaguchi, K; Nakayama, Y; Ooe, H; Taira, K; Tamura, J; Ura, K; Yoshikawa, A | 1 |
| Adibelli, Z; Alacacioğlu, A; Aykaş, A; Ozan, E; Oztekin, O; Postaci, H | 1 |
| Gauthier, H | 1 |
| Izumiyama, N; Kikuchi, T; Kikuchi, Y; Miki, H; Nishimaki, K; Noguchi, K; Saitou, W; Sasamori, K; Shishikura, Y; Takahashi, H; Tezuka, F | 1 |
| Demetri, GD; Ganjoo, KN; Jacobs, C; Patel, S | 1 |
| Araujo, DM; Benjamin, RS; Fan, D; Khakoo, AY; Lenihan, DJ; Patel, SR; Patel, SS; Plana, JC; Trent, JC; Zhang, J | 1 |
| Emile, JF | 1 |
| Dewar, AL; Fitter, S; Hughes, TP; Vandyke, K; Zannettino, AC | 1 |
| Anagnostou, E; Christopoulos, C; Dedemadi, G; Emile, JF; Georgoulis, G; Kontopanos, D; Morphopoulos, G | 1 |
| Schöffski, P; Wolter, P | 1 |
| Dupart, JJ; Godwin, AK; Hess, KR; Lee, HY; Taguchi, T; Trent, JC; Zhang, W | 1 |
| Eisenberg, B; Godwin, AK; Mburu, S; Ochs, MF; Rink, L; Taguchi, T; Tarn, C | 1 |
| Biasco, G; Catena, F; Di Battista, M; Nannini, M; Pantaleo, MA | 1 |
| Campbell, T; Felsten, L; Moore, J | 1 |
| Cameron, S; Ramadori, G | 1 |
| Kensarah, AM; Saied, GM | 1 |
| Call, J; Josephy, PD; Scherzer, NJ; Walentas, C | 1 |
| Agaimy, A; Schneider-Stock, R | 1 |
| Aglietta, M; Aliberti, S; Allione, P; Fizzotti, M; Galatola, G; Grignani, G; Pisacane, A | 1 |
| Abu-Gazala, M; Almogy, G; Appelbaum, L; Bala, M; Elazary, R; Khalaileh, A; Khatib, A; Neuman, T; Rivkind, AI; Schlager, A | 1 |
| Cao, H; Shen, ZY; Wu, ZY; Zhang, Y; Zhao, WY | 1 |
| Berman, E; Fleisher, M; Gordon, JK; Magid, SK; Maki, RG | 1 |
| Enoki, Y; Fujimoto, S; Fukui, A; Hattori, T; Kamata, K; Kawakami, T; Kimura, H; Nakamura, H; Okuyama, Y; Sato, H; Sekoguchi, S; Shioaki, Y; Tomatsuri, N; Tomie, A; Yamada, N; Yoriki, H; Yoshida, N | 1 |
| Bacchi, CE; Lopes, LF | 1 |
| Kadokawa, Y; Kawabe, A; Nakajima, S; Sonoda, K; Yamamoto, T | 1 |
| Briaire-de Bruijn, IH; Gelderblom, H; Hogendoorn, PC; Jordanova, ES; Ottenhoff, TH; Savage, ND; van der Burg, SH; van Dongen, M; van Hall, T; Walburg, KV | 1 |
| Wang, ZY | 1 |
| Hou, J; Hou, YY; Liu, JL; Lu, SH; Qin, J; Shen, KT; Sun, YH; Tan, YS; Zhou, Y | 1 |
| Bach-Gansmo, T; Berner, JM; Bjerkehagen, B; Bruland, OS; Ohnstad, HO; Revheim, ME; Røe, K; Seierstad, T | 1 |
| Egawa, Y; Futami, K; Higashi, D; Hirano, K; Ishibashi, Y; Iwashita, A; Maekawa, T; Oshige, K; Ota, A; Shimomura, T; Tomiyasu, T; Watanabe, Y | 1 |
| Al-Refaie, WB; Ansel, H; Armstrong, LH; Askari, S; Dudeja, V; Gupta, P | 1 |
| Oka, M; Sakamoto, K; Tsutsui, M; Yoshino, S | 1 |
| Oka, M; Somura, H; Suzuki, N; Ueno, T; Yoshino, S | 1 |
| Du, CY; Fu, H; Huang, K; Shi, YQ; Wang, CM; Ye, YW; Zhou, XY; Zhou, Y | 1 |
| Miyazaki, Y; Nishida, T; Takahashi, T | 1 |
| Greenberg, RE; Kurtz, LE | 1 |
| Patel, SR; Pisters, PW | 1 |
| Waller, CF | 1 |
| Kong, M; Teng, XD; Wang, YL; Xu, LJ | 1 |
| Hou, J; Hou, YY; Lu, SH; Qi, WD; Qin, J; Sun, YH; Tan, YS; Xu, C | 1 |
| Abdul-Samad, M; Adesina, AO; Barghash, IA; Oteifa, M | 1 |
| Egorin, MJ; Mauro, MJ; Trent, JC | 1 |
| Papaetis, GS; Syrigos, KN | 1 |
| Büschenfelde, CM; Duyster, J; Fend, F; Licht, T; Peschel, C; Stollfuss, J; Verbeek, M | 1 |
| Cao, H; Liu, Q; Ni, XZ; Shen, DP; Shen, YY; Sheng, ZY; Song, YY; Wang, M; Wu, ZY; Zhang, Y | 1 |
| Baker, LH; Verweij, J | 1 |
| Rajasekaran, R; Sethumadhavan, R | 1 |
| Blay, JY; Gronchi, A; Trent, JC | 1 |
| Beck, MY; Chang, HM; Kang, BW; Kang, YK; Kim, TW; Lee, JL; Ryoo, BY; Ryu, MH; Yoo, C; Yoon, SK | 1 |
| Buclin, T; Csajka, C; Decosterd, LA; Haouala, A; Leyvraz, S; Montemurro, M; Widmer, N | 1 |
| Akiyoshi, T; Fujimoto, Y; Hatake, K; Katori, M; Kuroyanagi, H; Muto, T; Oya, M; Takahashi, S; Ueno, M; Yamaguchi, T; Yamamoto, N | 1 |
| Bamba, T; Hasegawa, T; Hironaka, M; Hirota, S; Hishima, T; Kanda, T; Keira, Y; Niki, T; Sakamoto, K; Sakuma, Y; Sakurai, S; Takano, Y | 1 |
| Cohen, MH; Cortazar, P; Justice, R; Pazdur, R | 1 |
| Ebihara, T; Ishida, Y; Kondo, S; Matsuda, R; Minami, T; Sato, S; Tanaka, T; Togo, G; Watanabe, Y; Yamada, A; Yamazaki, K; Yotsuya, S | 1 |
| Adenis, A; Blay, JY; Bonvalot, S; Bouché, O; Bui, BN; Cioffi, A; Domont, J; Hermine, O; Kinet, JP; Lassau, N; Le Cesne, A; Moussy, A; Ray-Coquard, I | 1 |
| Fisher, DE; Gordon, PM | 1 |
| Blay, JY; Cassier, PA | 2 |
| Liu, XS; Yang, WL; Yu, JR; Yu, JW; Zhang, Q | 1 |
| Cheng, JW; Hou, YY; Lu, SH; Tan, YS; Wang, H; Xu, ST; Zheng, RH | 1 |
| Duensing, A; Duensing, S | 1 |
| Eisenberg, B; Hohenberger, P | 1 |
| Blank, SD; Butrynski, JE; Corless, CL; Dressel, DM; Ebrahim, KS; Heinrich, MC; Hornick, JL; Long, KB | 1 |
| Daum, O; Grossmann, P; Michal, M; Mukensnabl, P; Zalud, R | 1 |
| Kabashima, K; Miyachi, Y; Murata, T | 1 |
| Antonescu, CR; DeMatteo, RP; Demetri, GD; Ganjoo, KN; Maki, RG; Pisters, PW; Raut, CP; Riedel, RF; Schuetze, S; Sundar, HM; Trent, JC; von Mehren, M; Wayne, JD | 1 |
| Hou, M; Jiang, M; Yang, Y; Zhou, L; Zhu, J | 1 |
| Casali, PG; Coco, P; Dileo, P; Fumagalli, E; Gronchi, A; Laurini, E; Negri, T; Pilotti, S; Posocco, P; Pricl, S; Stacchiotti, S; Tamborini, E | 1 |
| Ballman, KV; Bot, B; Buckner, JC; DeMatteo, RP; Hillman, SL; Mandrekar, SJ; Nelson, H; Perez, EA; Sargent, DJ | 1 |
| Bonvalot, S; Cioffi, A; Dômont, J; Le Cesne, A; Tardieu, M | 1 |
| George, S; Marrari, A; Trent, JC | 1 |
| Du, CY; Fu, H; Shi, YQ; Wang, CM; Ye, YW; Zhao, GF; Zhou, Y | 1 |
| Novak, C; Trevino, JG | 1 |
| Blay, JY; Demetri, GD; Dumez, H; Hollaender, N; Jappe, A; Morgan, JA; Ray-Coquard, I; Reichardt, P; Schöffski, P | 1 |
| Ahlman, H; Andersson, A; Nilsson, B; Nilsson, E; Nilsson, O; Sjölund, K | 1 |
| Bassaly, B; Hecker, A; Hecker, B; Hirschburger, M; Janssen, H; Padberg, W; Schwandner, T | 1 |
| Reynoso, D; Trent, JC | 1 |
| Bayraktar, S; Bayraktar, UD; Rocha-Lima, CM | 1 |
| Ghose, A; Mohamed, I; Rafiq, E; Tariq, Z | 1 |
| Nelson, B | 1 |
| Bonvalot, S; Bouzaiene, H; Rimareix, F | 1 |
| Benekli, M; Bilge Yilmaz, I; Buyukberber, S; Coskun, U; Demirci, U; Erdem, O; Ozturk, B | 1 |
| Blanke, C | 3 |
| Casado, A; Cubedo, R; de Alava, E; Garcia del Muro, X; Garcia-Albeniz, X; López-Guerrero, JA; Lopez-Pousa, A; Martínez-Trufero, J; Martins, AS; Maurel, J; Poveda, A; Ramón Ayuso, J | 1 |
| Bachmann, K; Brandl, S; Izbicki, JR; Kaifi, JT; Kunkel, M; Rawnaq, T; Sauter, G; Simon, R; Zander, H | 1 |
| Dietmaier, W; Füzesi, L; Gaumann, A; Haller, F; Kitz, J; Krohn, A; Mechtersheimer, G; Merkelbach-Bruse, S; Penzel, R; Schildhaus, HU; Schneider-Stock, R; Simon, R; Wardelmann, E | 1 |
| Asuzu, DT; Bardsley, MR; Farrugia, G; Hayashi, Y; Horváth, VJ; Lomberk, GA; Lorincz, A; Ordog, T; Popko, LN; Redelman, D; Rubin, BP; Urrutia, RA; Young, DL | 1 |
| Huang, MJ; Kang, L; Wang, JP; Wang, L; Wang, T; Wu, XJ | 1 |
| Cao, K; Cui, Y; Li, J; Qi, LP; Shen, L; Sun, YS; Tang, L; Zhang, XP | 1 |
| Cai, SR; Chen, CQ; Chen, JH; He, YL; Ma, JP; Wu, KM; Zhan, WH; Zhang, XH | 1 |
| Hou, YY; Liu, JL; Qin, J; Shen, KT; Su, P; Sun, YH; Yao, LQ | 1 |
| Debiec-Rychter, M; Debnath, J; Floris, G; Gupta, A; Lazar, AJ; McAuliffe, JC; McMahon, J; Reynoso, D; Roy, S; Rubin, BP; Schoffski, P; Taguchi, T; Trent, JA; Wang, WL | 1 |
| Blackstein, ME; Blay, JY; von Mehren, M | 1 |
| Chang, R; Chang, YW; Cho, KH; Dong, SH; Jang, JY; Kim, BH; Kim, HJ; Park, JE | 1 |
| Catania, V; Cavallaro, A; Consoli, A; Liardo, RL; Malaguarnera, M | 1 |
| Jayanthi, NV | 1 |
| Bae, WK; Cho, SH; Chung, IJ; Hwang, JE; Shim, HJ; Yoon, JY | 1 |
| Karamitopoulou, E; Karatzas, T; Machairas, A; Machairas, N; Misiakos, EP; Tsapralis, D | 1 |
| Conforti, AM; Herndon, MD; Stokes, A | 1 |
| Bollu, VK; Coombs, JH; Rubin, JL; Sanon, M; Taylor, DC | 1 |
| Antonescu, CR; Besmer, P; Clarkson, B; de Stanchina, E; Giancotti, FG; Manova, K; Rossi, F; Veach, D; Yozgat, Y | 1 |
| Chen, P; Shi, L; Zhao, W; Zong, L | 2 |
| Omotara, SM; Philip, I; Samuel, DO | 1 |
| Kelley, RK; Venook, AP | 1 |
| Baker, L; Benjamin, RS; Blay, JY; Bui, BN; Duyster, J; Hartmann, JT; McCoy, S; Reichardt, P; Rosen, LS; Schöffski, P; Schuetze, S; Skubitz, K; Stepan, DE; Sun, YN; Van Oosterom, A | 1 |
| Furutani, K; Harada, M; Morita, N; Nishitani, H; Otomi, Y; Otsuka, H; Terazawa, K | 1 |
| Hara, K; Hijioka, S; Kawai, H; Kondo, S; Matsumoto, K; Mizuno, N; Niwa, Y; Sawaki, A; Tajika, M; Yamao, K | 1 |
| Ji, L; Li, X; Wu, XT; Xia, L; Zhang, MM | 1 |
| Coyne, J; Janku, F; Kidney, D | 1 |
| Sanford, M; Scott, LJ | 2 |
| Bauer, S; Grabellus, F; Schmid, KW; Sheu, SY; Speich, N; Worm, K | 1 |
| Barros E Silva, MJ; de Azevedo, CR; de Mello, CA; de Souza Begnami, MD; Fanelli, MF; Guimarães, GC; Oliveira, TB; Paiva, TF; Rossi, BM | 1 |
| Berger, F; Bruns, C; Reichardt, P; Schinwald, N; Schlemmer, M | 1 |
| Allis, CD; Antonescu, CR; Chen, Y; Chi, P; Dewell, S; Fletcher, JA; Guo, X; Maki, RG; Sawyers, CL; Shamu, T; Wongvipat, J; Zhang, L; Zheng, D | 1 |
| Bae, SH; Baeg, MK; Jin, JY; Kim, J; Lee, KH; Park, IS | 1 |
| Debnath, J; Rubin, BP | 1 |
| Delank, S; Eich, H; Wendtner, CM | 1 |
| Corless, CL; Heinrich, MC | 3 |
| Alemany, R; López-Guerrero, JA; Martín-Broto, J; Rubio, L | 1 |
| Beck, MY; Chang, HM; Choi, DR; Kang, YK; Kim, KP; Kim, TW; Lee, JL; Ryoo, BY; Ryu, MH; Yoo, C | 1 |
| Chen, MF; Chen, TW; Chiang, KC; Hwang, TL; Jan, YY; Liu, YY; Tsai, CY; Tseng, JH; Wang, SY; Yeh, CN | 1 |
| Duek, D; Machlenkin, S; Pinsk, I; Rabau, M; Sayfan, J; Tulchinsky, H; Walfisch, S; Ziv, Y | 1 |
| Connock, M; Dretzke, J; Fry-Smith, A; Hulme, C; McCabe, C; Meads, C; Pennant, M; Round, J; Tubeuf, S | 1 |
| Bertz-Lepel, J; Pink, D; Reichardt, P | 1 |
| Liang, ZY | 1 |
| Choi, D; Kang, HJ; Kang, YK; Kim, KM; Kim, WH; Ryu, MH; Sohn, T; Yang, HK | 1 |
| Blanke, CD; Huse, DM | 1 |
| von Mehren, M; Widmer, N | 1 |
| Kishimoto, H; Nakamura, M; Otagiri, N; Sasahara, K; Tauchi, K; Tsukada, Y; Yoshifuku, S | 1 |
| Broelsch, CE; Frilling, A; Grabellus, F; Kronenberger, R; Li, J; Malago, M; Schleyer, E; Testa, G | 1 |
| Beck, M; Chang, HM; Cho, Y; Choi, DR; Kang, YK; Kim, TW; Lee, JL; Ryoo, BY; Ryu, MH; Yoon, DH | 1 |
| Bruland, OS; Hall, KS; Haugland, HK; Hole, KH; Revheim, ME; Seierstad, T | 1 |
| Conley, AP; Duensing, A; Dumont, AG; Dumont, SN; Nolden, LK; Reynoso, D; Trent, JC; Yang, D; Zhou, K | 1 |
| Gounder, MM; Maki, RG | 1 |
| Eisenberg, BL; Smith, KD | 1 |
| Patel, SR | 1 |
| Antonescu, CR | 1 |
| Alacacioglu, A; Camci, C; Dikilitas, M; Er, O; Kalender, ME; Sagol, O; Sari, I; Sevinc, A; Soyuer, I; Yilmaz, U | 1 |
| George, S; Trent, JC | 1 |
| Hauswirth, F; Jäger, D; Jungbluth, A; Metzger, U; Perez, D; Samartzis, EP; Went, P | 1 |
| Ayuso, JR; Casado, A; Cubedo, R; Del Muro, XG; Fuster, D; Lomeña, F; López-Pousa, A; Martínez-Trufero, J; Maurel, J; Pons, F; Poveda, A | 1 |
| Chu, DT | 1 |
| Burger, H; Eechoute, K; Franke, RM; Loos, WJ; Mathijssen, RH; Schiavon, G; Sparreboom, A; Verweij, J; Wiemer, EA | 1 |
| Hirota, S; Hori, K; Kim, Y; Matsumoto, T; Miwa, H; Oh, K; Oshima, T; Tanaka, J; Tomita, T; Watari, J | 1 |
| Al-Amri, AM; Al-Johi, KS; El-Hassan, AY; Shawarbi, MA | 1 |
| Conley, A; George, S; Lazar, AJ; Nolden, L; Reynoso, D; Trent, JC; Wang, WL | 1 |
| Agaimy, A; Croner, RS; Hohenberger, W; Schlabrakowski, A; Schneider-Stock, R; Vassos, N | 1 |
| Bellan, E; Biasco, G; Boschi, S; Castelli, M; Castellucci, P; Di Battista, M; Fanti, S; Gnocchi, C; Landuzzi, L; Lollini, PL; Nanni, C; Nannini, M; Nicoletti, G; Pantaleo, MA; Quarta, C; Rubello, D | 1 |
| Cui, Y; Li, J; Qi, LP; Shen, L; Sun, YS; Tang, L; Zhang, XP | 1 |
| Hamazoe, R; Hisamitsu, K; Kimura, O; Yamamoto, O; Yamane, N | 1 |
| Aoki, T; Katayanagi, S; Katsumata, K; Murakoshi, Y; Ogata, T; Serizawa, H; Shimazu, M; Tsuchida, A | 1 |
| Enomoto, M; Higuchi, T; Iida, S; Ishiguro, M; Ishikawa, T; Kato, S; Kikuchi, A; Kobayashi, H; Ono, H; Sugihara, K; Uetake, H; Yamauchi, S; Yasuno, M; Yoshimura, T | 1 |
| Beck, MY; Chang, HM; Kang, YK; Kim, TW; Lee, JL; Ryoo, BY; Ryu, MH; Yoo, C | 1 |
| Agaimy, A; Daniels, M; Evert, M; Lasota, J; Lüders, P; Miettinen, M; Müller, G; Pelz, AF; Röpke, A; Schneider-Stock, R; Schulz, HU; Wieacker, P | 1 |
| Fu, D; Jin, C; Ni, Q; Yang, F | 1 |
| Li, LQ; Ma, L; Ru, HM; Zhao, YN; Zhong, JH | 1 |
| Gong, JF; Li, J; Shen, L; Wu, AW | 1 |
| Bellosillo, B; Iglesias, M; Martínez-Avilés, L; Pera, M; Puig, S | 1 |
| Hirasawa, T; Iida, T; Kajiwara, H; Kikuchi, K; Mikami, M; Murakami, M; Muramatsu, T; Osamura, RY; Yamashita, E; Yasuda, M; Yasuda, S; Yasui, I | 1 |
| Ganjoo, KN; Patel, S | 1 |
| Adenis, A; Bertucci, F; Blay, JY; Blesius, A; Bui, B; Cassier, PA; Cupissol, D; Fayette, J; Le Cesne, A; Pérol, D; Ray-Coquard, I; Rios, M | 1 |
| Christerson, L; Halbritter, S; Mattsson, U; Mörner Serikoff, E; Warfvinge, G | 1 |
| Cano Megías, M; Carrasco De La Fuente, M; González Albarrán, O; Menacho Román, M; Pérez López, G | 1 |
| Diebold, J; Hirschmann, A; Rössle, M | 1 |
| Raut, CP; Winer, JH | 1 |
| Al-Haddabi, IH; Al-Qadhi, H; Chopra, PJ; Machado, NO | 1 |
| Agrawal, V; Pandey, R; Vij, M | 1 |
| Cooper, K; Essat, M | 1 |
| Hao, XS; Huang, H; Li, H; Liang, H; Ren, XB; Zhan, ZL | 1 |
| Kamiya, K; Kikuchi, H; Konno, H; Miyazaki, S; Ohta, M; Sakaguchi, T; Setoguchi, T; Yamamoto, M | 1 |
| Dvorák, J; Holecková, P; Hyšpler, R; Kalábová, H; Kašparová, M; Krcmová, L; Melichar, B; Plíšek, J; Solichová, D; Tichá, A | 1 |
| Bertulli, R; Brich, S; Casali, PG; Conca, E; Dileo, P; Gronchi, A; Orsenigo, M; Pierotti, MA; Pilotti, S; Riva, C; Tamborini, E | 1 |
| Cullus, P; Erneux, C; Gromova, P; Rubin, BP; Thys, A; Vanderwinden, JM | 1 |
| Foukas, PG; Leontara, V; Machairas, A; Panayiotides, IG; Samaras, VD; Triantafyllou, K; Tsapralis, D; Tsompanidi, EM | 1 |
| Hanazaki, K; Ikezoe, T; Nishioka, C; Taguchi, T; Takezaki, Y; Yang, J; Yokoyama, A | 1 |
| Onoe, S; Sakamoto, Y | 1 |
| Doi, T; Kakeji, Y; Kanda, T; Komatsu, Y; Nishida, T; Ohtsu, A; Onozawa, Y; Sawaki, A; Yamada, Y; Yamasaki, M | 1 |
| Kochatkov, AV; Kolygin, AV; Konstantinova, MM; Korolev, SV; Kriger, AG; Makeeva-Malinovskaia, NIu | 1 |
| Blanke, CD; Picus, J; Pisters, PWT; Sirulnik, A; Stealey, E; Trent, JC; von Mehren, M | 1 |
| Abbass, K; Agrawal, S; Akram, S; Markert, R; Poland, E | 1 |
| Abraham, I; De Geest, S; De Grève, J; Dirix, L; Duck, L; Focan, C; Forget, F; Joosens, E; Macdonald, K; Mazzeo, F; Muermans, K; VAN Lierde, MA | 1 |
| Batus, M; Coogan, C; Leslie, W; Saclarides, TJ; Turner, J | 1 |
| Bauer, S; Montemurro, M | 1 |
| Dupart, J; Trent, JC; Zhang, W | 1 |
| Cooper, K; Hanson, JA; Trent, JC; Yang, D | 1 |
| Allison, K; Jones, AP | 1 |
| Aglietta, M; Bono, P; Boselli, S; Casali, PG; Coco, P; De Braud, F; De Pas, T; Grignagni, G; Jalava, T; Joensuu, H; Kappeler, C; Laurent, D; Spitalieri, G; Spreafico, C; Toffalorio, F | 1 |
| Nishida, T; Omori, T; Ueshima, S | 1 |
| Onozawa, Y; Terashima, M | 1 |
| Akimoto, H; Chinen, Y; Kawano, H; Kojo, M; Minami, K; Morita, K; Okamura, T; Saeki, H; Sakaguchi, Y; Sakamoto, Y; Soejima, Y; Sugiyama, M; Toh, Y | 1 |
| Hanai, K; Hoshi, A; Kato, S; Kawakami, M; Kim, H; Nakajima, N; Nomoto, T; Sadahiro, S; Shinozaki, T; Soeda, S; Terachi, T; Usui, Y | 1 |
| Kiarie, GW; Othieno-Abinya, NA; Riyat, MS | 1 |
| Bertagna, F; Biasiotto, G; Bosio, G; Giubbini, R; Orlando, E | 1 |
| Pink, D; Reichardt, A; Reichardt, P | 1 |
| de Bruijn, P; Eechoute, K; Loos, WJ; Mathijssen, RH; Schiavon, G; Sleijfer, S; van der Bol, JM; Verweij, J | 1 |
| Dellaportas, D; Gennatas, K; Gkiokas, G; Kondi-Pafiti, A; Papaconstantinou, I; Polymeneas, G; Psychogiou, V; Theodosopoulos, T | 1 |
| Chao, TC; Chiou, TJ; Hsieh, YY; Lee, HJ; Liu, JH; Teng, HW; Tzen, CY; Tzeng, CH; Yeh, CN; Yen, CC | 1 |
| Dembélé, AK; Dembelé, M; Diallo, DA; Diallo, G; Koné, A; Ly, M; Sidibé, S; Touré, BA; Touré, M; Traore, BC | 1 |
| Blay, JY; Chaigneau, L; Curtit, E; Dobi, E; Kalbacher, E; Mansi, L; Nguyen, T; Pivot, X; Viel, E | 1 |
| Eisenberg, BL; Trent, JC | 1 |
| Hatakeyama, K; Ishikawa, T; Kanda, T; Kosugi, S; Yajima, K | 1 |
| Elders, A; Fraser, C; Hislop, J; Jenkinson, D; Mowatt, G; Petty, R; Quayyum, Z; Sharma, P; Vale, L | 1 |
| Guan, GX; Huang, HG; Jiang, WZ; Kang, DY; Lu, HS; Yang, YH | 1 |
| Judson, I; Thanopoulou, E | 1 |
| Bauer, S; Bokemeyer, C; Hartmann, JT; Hosius, C; Reichardt, P; Schlemmer, M; Schütte, R | 1 |
| Bugnon, O; Jeanneret, LA; Lüthi, F; Schneider, MP; Troxler, S | 1 |
| Abbott, DE; Bentrem, DJ; Bilimoria, KY; Cormier, JN; Feig, BW; Hunt, KK; Merkow, RP; Pisters, PW; Pollock, R; Wayne, JD | 1 |
| Bylina, E; Głuszek, S; Joensuu, H; Kroc, J; Matlok, M; Michej, W; Nasierowska-Guttmejer, A; Nowecki, ZI; Osuch, C; Rutkowski, P; Switaj, T; Wozniak, A; Wroński, M | 1 |
| Debiec-Rychter, M; Faa, G; Floris, G; Normant, E; Schöffski, P; Sciot, R; Van Looy, T; Wellens, J; Wozniak, A | 1 |
| Deneubourg, L; Erneux, C; Gromova, P; Parsons, R; Ralea, S; Vanderwinden, JM | 1 |
| Ishii, Y; Kikuchi, D; Saitou, M; Takenoshita, S; Yamada, M | 1 |
| Arezzo, A; Morino, M; Verra, M | 1 |
| Debiec-Rychter, M; Faa, G; Floris, G; Machiels, K; Normant, E; Schöffski, P; Sciot, R; Stefan, C; Vanleeuw, U; Wozniak, A | 1 |
| Hatakeyama, K; Ishikawa, T; Kanda, T; Kosugi, S; Ozaki, T; Yajima, K | 1 |
| Reichardt, A; Reichardt, P | 1 |
| Allison, JP; Antonescu, CR; Ariyan, C; Balachandran, VP; Bamboat, ZM; Besmer, P; Cavnar, MJ; DeMatteo, RP; Guo, T; Obaid, H; Ocuin, LM; Popow, R; Rossi, F; Sorenson, EC; Taguchi, T; Wolchok, JD; Yuan, J; Zeng, S | 1 |
| Kroemer, G; Zitvogel, L | 1 |
| Gotoh, M; Hasegawa, T; Kanda, T; Kaneko, K; Katai, H; Kawai, A; Kondo, T; Kubota, D; Orita, H; Shimada, Y; Tsuda, H; Yoshida, A | 1 |
| Armbrust, T; Binder, L; Brandhorst, G; Braulke, F; Cameron, S; Haase, D; Hafke, A; Oellerich, M; Ramadori, G; Streit, F; Walson, P | 1 |
| Fu, H; Shi, YQ; Wang, CM; Wang, J; Zhao, GF | 1 |
| Bongarzone, I; Bozzi, F; Da Riva, L; Fumagalli, E; Gronchi, A; Huber, V; Miccichè, F; Mondellini, P; Pierotti, MA; Pilotti, S; Tamborini, E; Tarantino, E; Vaghi, E | 1 |
| Barnes, T; Reinke, D | 1 |
| Patil, DT; Rubin, BP | 1 |
| Elders, A; Fraser, C; Hislop, J; Jenkinson, D; Mowatt, G; Petty, R; Sharma, P; Vale, L | 1 |
| Kitamura, N; Maruhashi, K; Nakamura, T; Okauchi, H; Shimomatsuya, T; Shiraishi, S; Taniguchi, M | 1 |
| Arrigoni, G; Bearzi, I; Capella, C; Casali, PG; Dei Tos, AP; Gnocchi, C; Gronchi, A; Laurino, L; Mariani, L; Mazzoleni, G; Messerini, L; Miceli, R; Rossi, S; Sidoni, A; Sonzogni, A; Toffolatti, L; Vinaccia, V | 1 |
| Barutca, S; Guney, E; Meydan, N; Sargin, G; Tanriverdi, O; Taskin, F; Unubol, M | 1 |
| Antonescu, C | 1 |
| Akcakaya, MO; Aras, Y; Bilgic, B; Unal, OF; Unal, SN | 1 |
| DeMatteo, RP; Joensuu, H | 1 |
| Akkus, M; Baykara, M; Benekli, M; Buyukberber, S; Coskun, U; Dane, F; Dursun, A; Gonul, II; Sevinc, A; Yildiz, R | 1 |
| Liao, G; Liu, H; Yan, Z | 1 |
| Adenis, A; Antonescu, CR; Blay, JY; Bompas, E; Bui, B; Casali, P; Cioffi, A; Coco, P; Coindre, JM; Debiec-Rychter, M; Duffaud, F; Isambert, N; Italiano, A; Keohan, ML; Le Cesne, A; Maki, RG; Rutkowski, P; Schöffski, P; Toulmonde, M | 1 |
| Caram, MV; Schuetze, SM | 1 |
| Colombo, C; Pisters, PW | 1 |
| Kim, EJ; Zalupski, MM | 1 |
| Akiyama, T; Hao, H; Hashikura, Y; Hirai, T; Hirota, S; Isozaki, K; Kajimoto, N; Nakai, M; Ohkouchi, M; Shiba, K; Tsukamoto, Y; Yamamura, M | 1 |
| Barnett, CM; Corless, CL; Heinrich, MC | 1 |
| Liang, J; Liu, ZM; Yu, Z | 1 |
| Bennett, JJ; Rubino, MS | 1 |
| Boku, N; Doi, T; Hirota, S; Kakeji, Y; Kanda, T; Katai, H; Kikuchi, S; Kobayashi, O; Komatsu, Y; Koseki, M; Miyachi, K; Nishida, T; Ogoshi, K; Ohtsu, A; Sawaki, A; Sugiyama, T; Toh, Y; Wada, N; Yamamoto, M | 1 |
| Egorin, MJ; Mulder, KE; Sawyer, MB | 1 |
| Bove, B; Cauchi, C; Davey, M; Engstrom, PF; Lee, J; Litwin, S; Lopez, M; Somaiah, N; von Mehren, M | 1 |
| O'Dwyer, PJ; Tse, GH; Wong, EH | 1 |
| Bae, HI; Baek, JH; Bang, YJ; Choi, J; Chung, IJ; Im, SA; Kang, HJ; Kang, YK; Kim, JG; Kim, KM; Kim, WH; Kwon, HC; Lee, JH; Lee, KE; Lee, KH; Park, SH; Park, YS; Ryoo, BY; Ryu, MH; Shin, DB; Song, HS | 1 |
| Ashley, SW; Grover, S; Raut, CP | 1 |
| Andtbacka, RH; Benjamin, RS; Cano, P; Chan, BK; Chen, LC; Chen, LL; Chen, X; Choi, H; Frazier, ML; Gouw, L; Hill, HR; Jensen, P; Jimenez, A; Jones, KA; Lazar, AJ; Lin, P; Martins, T; Morton, K; Oyedeji, CO; Patel, S; Randall, RL; Rodesch, CK; Sang, H; Scaife, CL; Schumacher, J; Trent, JC; Ward, JH; Willmore, C; Zhang, H | 1 |
| Amano, R; Hirakawa, K; Inoue, T; Ishikawa, T; Kubo, N; Maeda, K; Muguruma, K; Nagahara, H; Nakamoto, K; Noda, E; Ohira, G; Ohira, M; Tanaka, H; Yamada, N | 1 |
| Hosaka, S; Kawamoto, S; Yamashita, K; Yoshida, T | 1 |
| Chika, N; Kakimoto, M; Kikuchi, A; Koshiishi, H; Nishida, K; Okamura, T; Tokita, H; Yoshimura, T | 1 |
| Maeda, Y; Nagashima, Y; Nakamura, M; Nishimura, T; Okada, T; Sakata, K; Setoguchi, M | 1 |
| Miyake, Y; Mori, H; Nishihara, A; Ogura, S; Sakamoto, T; Takaishi, K; Tamura, S; Tani, N; Watanabe, Y; Yamakita, T; Yamazaki, M; Yura, M | 1 |
| Hazama, S; Inoue, Y; Oka, M; Suzuki, N; Yoshino, S | 1 |
| Goto, K; Ishikawa, O; Kishi, K; Kittaka, H; Miyashiro, I; Motoori, M; Noura, S; Ogawa, H; Ohigashi, H; Ohue, M; Shingai, T; Takahashi, H; Yamada, T; Yano, M | 1 |
| Blanke, CD; Demetri, GD; Eisenberg, BL; Heinrich, MC; Hoffman, JP; Kane, JM; Okuno, S; von Mehren, M; Wang, D; Watson, JC; Zhang, Q | 1 |
| Gronchi, A; Raut, CP | 1 |
| Ensom, MH; Mabasa, VH; Teng, JF | 1 |
| Hornick, JL; Marrari, A; Wagner, AJ | 1 |
| Janeway, KA; Weldon, CB | 1 |
| Lopez, M | 1 |
| Deneve, J; Gonzalez, RJ; Han, D | 1 |
| Anania, MC; Bordoni, A; Conca, E; Frattini, M; Greco, A; Mazzucchelli, L; Miranda, C; Molinari, F; Nucifora, M; Pierotti, MA; Pilotti, S; Saletti, P; Tamborini, E | 1 |
| Aggarwal, B; Ashraf, M; Biswas, J; Chakraborty, J; Choudhry, A; Jha, J; Majumder, S; Nayak, S | 1 |
| Ikeda, A; Kamata, H; Mitomi, H; Naito, M; Nakamura, T; Ogura, N; Onozato, W; Ooki, A; Sato, T; Watanabe, M | 1 |
| Chan, SW; Chiang, MH; Lai, HC; Lee, WL; Liu, TJ; Su, CS; Ting, CT | 1 |
| Ichihara, K; Iida, M; Maeda, T; Makino, T; Nakamura, T; Nishida, Y; Nomura, Y; Otsuka, A; Tada, H; Takeuchi, N | 1 |
| Buclin, T; Csajka, C; Decosterd, LA; Gotta, V; Haouala, A; Leyvraz, S; Montemurro, M; Widmer, N | 1 |
| Andrew, DR; Leeder, P; MacGoey, P; McCulloch, T; Parsons, SL; Reece-Smith, AM; Shah, MA | 1 |
| Schmidt, C | 1 |
| Arya, S; Bal, M; Goel, M; Marda, SS; Mohandas, KM; Shetty, GS; Shrikhande, SV; Shukla, PJ; Suradkar, K | 1 |
| Blay, JY; Le Cesne, A; Pérol, D | 1 |
| Blay, JY; Bui-Nguyen, B; Demetri, GD; Galetic, I; Gelderblom, H; Hsu, Y; McArthur, GA; Reichardt, P; Rutkowski, P; Schlemmer, M; Yazji, S | 1 |
| Gao, J; Gong, JF; Li, J; Shen, L; Sun, NP | 1 |
| George, S; Hornick, JL; Jagannathan, JP; Ramaiya, NH; Shinagare, AB | 1 |
| González, B; Pérez-Peña, M; Sánchez, A; Vázquez, J | 1 |
| Blevins, M; de Vries, DJ; Eisenberg, B; Gatsonis, C; Godwin, AK; Huang, M; Melenevsky, Y; Rink, L; Sicks, J; Siegel, BA; Szot-Barnes, A; Van den Abbeele, AD; Yap, JT | 1 |
| Agulnik, M; Huyck, TK; Svetlichnaya, J; Wayne, JD | 1 |
| Mourad, F; Saad Aldin, E; Tfayli, A | 1 |
| Call, J; Eickhoff, JC; Scherzer, N; Walentas, CD | 1 |
| Cho, J; Kang, GH; Kim, KM; Park, J; Shim, YM | 1 |
| Brzeskwiniewicz, M; Bylina, E; Falkowski, S; Grzesiakowska, U; Klimczak, A; Kroc, J; Limon, J; Lugowska, I; Melerowicz, W; Mierzejewska, E; Nowecki, ZI; Osuch, C; Rutkowski, P; Siedlecki, JA; Switaj, T; Wasielewski, K; Woźniak, A | 1 |
| Gürlich, R; Koldová, L; Kostka, R | 1 |
| Colucci, G; Giuliani, F | 1 |
| Adenis, A; Bay, JO; Bertucci, F; Blay, JY; Bouché, O; Cassier, P; Chevreau, C; Clisant, S; Collard, O; Fournier, C; Italiano, A; Kalbacher, E; Kramar, A; Penel, N | 1 |
| Al-Batran, SE; Alvegård, T; Bauer, S; Bono, P; Duyster, J; Eriksson, M; Hartmann, JT; Hohenberger, P; Joensuu, H; Kallio, R; Leinonen, M; Monge, OR; Nilsson, B; Pink, D; Ramadori, G; Reichardt, P; Sarlomo-Rikala, M; Schlemmer, M; Schütte, J; Sihto, H; Sundby Hall, K; Vehtari, A; Wardelmann, E | 1 |
| Blanke, CD | 1 |
| Shi, YQ | 1 |
| Cai, SR; Chen, CQ; Han, FH; He, YL; Ma, JP; Wu, H; Xu, JB; Zhan, WH; Zhang, XH | 1 |
| Liu, LC; Xu, WT | 1 |
| Liang, G; Liang, JF; Wu, LN; Xiao, H; Zhao, YZ; Zheng, HX | 1 |
| Lu, W; Lu, WQ | 1 |
| Arcieri, S; Filippini, A; La Gioia, G; Palazzini, G; Panarese, A; Pironi, D; Pontone, S; Romani, AM; Vendettuoli, M | 1 |
| Gulati, AP; Saif, MW | 1 |
| Hatoum, HT; Lin, SJ; Sasane, M; Trent, JC | 1 |
| Braggio, D; Cruz, F; Cubero, D; Ferreira, CG; Gonçalves, R; Guimarães, DP; Linhares, E; Martinho, O; Oliveira, AT; Pimenta-Inada, HK; Reis, RM; Romano, S; Santos, AF; Small, I; Valadão, M; Vilhena, B | 1 |
| Ajioka, Y; Hatakeyama, K; Hirota, S; Ishikawa, T; Kanda, T; Kosugi, S; Mashima, Y; Ohashi, M; Suzuki, S; Yajima, K | 1 |
| Adekola, K; Agulnik, M | 1 |
| Butrynski, J; Hornick, JL; Jagannathan, JP; Krajewski, KM; Ramaiya, NH; Shinagare, AB; Zukotynski, KA | 1 |
| Koshenkov, VP; Rodgers, SE | 1 |
| Gronchi, A; Morosi, C; Reichardt, P; Wardelmann, E | 1 |
| Inoue, M; Itoh, G; Matsuzaki, T; Ogawa, M; Osaka, H; Yamamoto, T | 1 |
| Biasco, G; Nannini, M; Pantaleo, MA; Saponara, M | 2 |
| Pericay Pijaume, C; Saigi Grau, E | 1 |
| Butrynski, JE; Choy, E; Corless, CL; Demetri, GD; Fletcher, JA; George, S; Heinrich, MC; Manola, JB; Morgan, JA; Solomon, SM; Tap, WD; Van den Abbeele, AD; von Mehren, M; Wagner, AJ; Wang, Q; Yap, JT; Zhu, M | 1 |
| Essodegui, F; Hermas, S; Hissane, EM; Mahdaoui, S; Noun, M; Oubaid, B; Samouh, N | 1 |
| Lai, EC; Lau, SH; Lau, WY | 1 |
| Andersen, MK; Gerdes, AM; Hansen, TV; Wadt, K | 1 |
| Blay, JY; Cassier, PA; Le Cesne, A; Ray-Coquard, IL | 1 |
| Cohen, MH; Johnson, JR; Justice, R; Pazdur, R | 1 |
| Gao, J; Hong, J; Li, J; Shen, L | 1 |
| Antonescu, CR; Besmer, P; Bosbach, B; de Stanchina, E; Deshpande, S; Manova-Todorova, K; Moore, MA; Rossi, F; Scandura, JM; Shieh, JH; Sommer, G; Veach, DR | 1 |
| Cao, XY; He, L; Jiang, J; Jin, MS; Suo, J; Wang, YP | 1 |
| de Jong, S; Groenen, PJ; Meersma, GJ; Meijer, C; Rikhof, B; Schuuring, EM; Suurmeijer, AJ; van der Graaf, WT; van Doorn, J | 1 |
| Blay, JY; Casali, PG; Cohen, DP; Demetri, GD; Garrett, CR; Goldstein, D; Harmon, CS; Huang, X; Hurwitz, HI; Le Cesne, A; Leyvraz, S; McArthur, GA; Paz-Ares, L; Pousa, AL; Schöffski, P; Shah, MH; Tassell, V; Verweij, J; Xu, QC | 1 |
| Bauer, S; Debiec-Rychter, M; Fletcher, JA; Grabellus, F; Henze, J; Mühlenberg, T; Rubin, B; Schuler, M; Simon, S; Taeger, G; Taguchi, T; Treckmann, J | 1 |
| Donsky, RS; Fletcher, JA; Griffith, DJ; Heinrich, MC; Liang, CW; Marino-Enriquez, A; McKinley, A; Patterson, J; Presnell, A; Taguchi, T | 1 |
| Bonenkamp, JJ; de Wilt, JH; Gelderblom, H; Hartgrink, HH; Sleijfer, S; Tielen, R; van Coevorden, F; van der Graaf, WT; Verhoef, C | 2 |
| Hamasu, S; Jinzai, Y; Kanto, S; Kobayashi, A; Konishi, S; Manaka, D; Nishitai, R; Sakamoto, K; Uehara, M; Yasuhara, Y; Yokoyama, D; Yoshino, K | 1 |
| Cubillo, A; Salas, NR | 1 |
| Curry, JE; Donsky, R; Fletcher, JA; Lyons, J; Mayeda, M; Morgan, JG; Rodriguez-Lopez, AM; Schöffski, P; Smyth, T; Thompson, NT; Van Looy, T; Wallis, NG; Wozniak, A; Zhu, M | 1 |
| Adenis, A; Bertucci, F; Blay, JY; Bompas, E; Bouché, O; Casali, P; Cassier, PA; Debiec-Rychter, M; Duffaud, F; Emile, JF; Fumagalli, E; Hohenberger, P; Judson, I; Landi, B; Leyvraz, S; Martin-Broto, J; Rutkowski, P; Schöffski, P; Van Glabbeke, M; Verweij, J | 1 |
| Antonescu, CR; Ballman, KV; Blanke, CD; Brennan, MF; DeMatteo, RP; Demetri, GD; Maki, RG; McCall, L; McCarter, MD; Ota, DM; Pisters, PW; von Mehren, M | 1 |
| Kinugasa, E; Misawa, S; Ogata, H; Shimada, A; Wada, Y | 1 |
| Cubedo, R; Quintero, CB | 1 |
| de Juan Ferré, A; Fernández, F; Garicano, F; Gutiérrez, L; Malaxetxebarria, S | 1 |
| Ballesteros, J; Pulido, EG; Riquelme, A; Vaz, MÁ | 1 |
| del Muro, XG; López, RL | 1 |
| Bonastre, MT; Izquierdo, ME | 1 |
| Casali, PG; Fumagalli, E; Gronchi, A | 1 |
| Debiec-Rychter, M; Griffith, D; Heinrich, MC; McKinley, A; Patterson, J; Presnell, A; Ramachandran, A | 1 |
| Coombs, J; Paolantonio, M; Parthan, A; Sanon, M; Sasane, M; Taylor, DC | 1 |
| Agulnik, M; Giel, JL | 1 |
| Agayeva, A; Andican, A; Gökçal, F; Gülşen, F; Özben, V; Özden, F | 1 |
| Huang, KE; Jia, J; Lu, HS; Pan, YL; Tao, DY; Wang, XJ; Zheng, S | 1 |
| Dasanu, CA | 1 |
| Bonenkamp, JJ; de Wilt, JH; Reyners, AK; Tielen, R; van Coevorden, F; van der Graaf, WT; van Etten, B; Verhoef, C | 1 |
| Chu, YC; Gong, NJ; Gu, J; Wong, CS | 1 |
| Dang, Y; Gao, J; Li, J; Shen, L; Sun, N | 1 |
| Donohue, JH; Nagorney, DM; Okuno, SH; Que, FG; Zaydfudim, V | 1 |
| Blay, JY; Boukovinas, I; Brodowicz, T; Broto, JM; Casali, PG; Decatris, M; Eriksson, M; Gelderblom, H; Joensuu, H; Kosmidis, P; Le Cesne, A; Pousa, AL; Reichardt, P; Schlemmer, M; Verweij, J | 1 |
| Bylina, E; Colombo, C; Gronchi, A; Hohenberger, P; Miceli, R; Raut, CP; Ronellenfitsch, U; Rutkowski, P; Yuxin, Z | 1 |
| Li, C; Wan, P; Yan, C; Yan, M; Zhu, ZG | 1 |
| Kochar, R; Pandey, R | 1 |
| Carrió-Gasset, I; Fuertes-Cabero, S; García-Garzón, JR; Lomeña-Caballero, F; Moragas-Solanes, M; Ponce-López, A; Riera-Gil, E; Soler-Peter, M; Valls-Ferrusola, E | 1 |
| De Giorgi, U; de Jong, FA; Eechoute, K; Fransson, MN; Friberg, LE; Loos, WJ; Mathijssen, RH; Reyners, AK; Schiavon, G; Sparreboom, A; van der Graaf, WT; Verweij, J; Wiemer, EA | 1 |
| Gudlaugsson, E; Haugland, HK; Mangseth, K; Sandvik, OM; Søreide, JA; Søreide, K | 1 |
| Cohen, DP; Demetri, GD; George, S; Lechner, T; Li, S; Reichardt, P | 1 |
| Chen, B; Wu, XT; Yang, P; Zhou, Y | 1 |
| Gallowitsch, HJ; Malle, P; Sorschag, M | 1 |
| Buclin, T; Csajka, C; Decosterd, LA; Eap, CB; Guidi, M; Haouala, A; Leyvraz, S; Montemurro, M; Widmer, N | 1 |
| Astolfi, A; Bertucci, F; Birnbaum, D; Finetti, P; Kim, H; Kim, WK; Ostrowski, J; Pantaleo, MA; Polkowski, M | 1 |
| Hong, JL; Li, J; Shen, L | 1 |
| Cavallaro, G; D'Ermo, G; De Toma, G; Pedullà, G; Polistena, A | 1 |
| Celestino, R; Faustino, A; Gouveia, A; Lima, J; Lopes, JM; Máximo, V; Soares, P; Vinagre, J | 1 |
| Bang, YJ; Heo, DS; Im, SA; Kim, DW; Kim, JH; Kim, SH; Kim, TY; Kim, WH; Koh, Y; Lee, HE; Lee, SH; Oh, DY | 1 |
| DeLuca, C; Haskes, C; Shenouda-Awad, N; Wrzesinski, S | 1 |
| Gronchi, A; Hohenberger, P; Jakob, J; Mussi, C; Negri, T; Ronellenfitsch, U; Wardelmann, E | 1 |
| Wardelmann, E | 1 |
| Nishida, T; Ueshima, S; Wakasugi, M | 1 |
| Fukuoka, M; Hirano, H; Hirota, S; Nishigami, T; Nishizawa, Y; Ohmura, N; Tachibana, S; Yoshida, T; Yoshimura, H; Zozumi, M | 1 |
| Bednarski, BK; Hunt, KK; Pisters, PW | 1 |
| Aberger, F; Antonescu, CR; Beissbarth, T; Binder, C; Bleckmann, A; Dittmann, K; Dressel, R; Gruber, W; Guijarro, MV; Hahn, H; Heijmans, J; Hernando, E; Hogendoorn, PC; Nitzki, F; Pelczar, P; Rubin, BP; Schulz-Schaeffer, W; Taguchi, T; Uhmann, A; van den Brink, GR; van Dop, WA; Wienands, J; Wojnowski, L; Zibat, A | 1 |
| Chang, HM; Im, SA; Jung, KH; Kang, BW; Kang, WK; Kang, YK; Kim, TW; Lee, JL; Oh, DY; Park, SR; Ryu, MH | 1 |
| Bartholomew, DM; Burke, LH; Miller, LA; Wegge, J | 1 |
| De la Hoz-Herazo, H; López, JI; López-Garrido, J; Macías-García, L; Pareja-Megía, MJ; Robles-Frías, A | 1 |
| Chen, G; Liu, SL; Wu, WM; Zhang, TP; Zhao, YP | 1 |
| Angelini, S; Biasco, G; Cantelli-Forti, G; Casali, PG; Cavrini, G; Di Battista, M; Fumagalli, E; Hrelia, P; Nannini, M; Palassini, E; Pantaleo, MA; Ravegnini, G; Saponara, M; Zenesini, C | 1 |
| Bekers, DJ; Eechoute, K; Krestin, GP; Mathijssen, RH; Ruggiero, A; Schiavon, G; Schöffski, P; Sleijfer, S; van der Holt, B; Vandecaveye, V; Verweij, J | 1 |
| Bauer, S; Bitz, U; Blay, JY; Duffaud, F; Gelderblom, H; Joensuu, H; Montemurro, M; Pink, D; Rutkowski, P; Schütte, J; Trent, J | 1 |
| Ikehara, T; Inoue, T; Kanehara, I; Nishiguchi, Y; Sakashita, K; Shimizu, S; Teraoka, H; Toyokawa, T; Yamamoto, A; Yamashita, Y | 1 |
| Adenis, A; Bertucci, F; Blay, JY; Bui, BN; Chabaud, S; Chevreau, C; Cupissol, D; Domont, J; Duffaud, F; Le Cesne, A; Patrikidou, A; Pérol, D; Ray-Coquard, I; Rios, M | 1 |
| Cunningham, D; Waddell, T | 1 |
| Badalamenti, G; Bauer, S; Blackstein, M; Blay, JY; Casali, PG; Chung, J; Demetri, GD; Gelderblom, H; Hohenberger, P; Joensuu, H; Kang, YK; Kappeler, C; Kuss, I; Laurent, D; Le Cesne, A; Leahy, M; Maki, RG; Nguyen, BB; Nishida, T; Reichardt, P; Rutkowski, P; Schöffski, P; von Mehren, M; Xu, J | 1 |
| Chen, LT; Chiang, NJ; Hsueh, YS; Li, CF; Shih, NY; Yen, CC | 1 |
| Chen, G; Ding, PR; Fang, YJ; Kong, LH; Li, LR; Lu, ZH; Pan, ZZ; Wan, DS; Wu, XJ; Zhang, RX | 1 |
| Gronchi, A | 1 |
| Koontz, MZ; Kunz, PL; Visser, BM | 1 |
| Agarwal, N; Bhaskaran, S; Goel, N; Malik, R; Mehta, S; Rajaram, S; Rathi, B | 1 |
| Bhalgami, R; Manish, K; Mehta, S; Mohandas, KM; Patil, P | 1 |
| Debiec-Rychter, M; Deroose, CM; Fletcher, JA; Floris, G; Friedman, L; Li, H; Schöffski, P; Sciot, R; Van Looy, T; Vermaelen, P; Wellens, J; Wozniak, A | 1 |
| Posner, MC; Roggin, KK | 1 |
| Adenis, A; Bouchet, S; Bui, B; Cioffi, A; Collard, O; Isambert, N; Italiano, A; Le Cesne, A; Maki, RG; Molimard, M; Poulette, S; Saada, E | 1 |
| Matsui, K; Moriyama, M; Nagata, T; Okumura, T; Omura, T; Sawada, S; Sekine, S; Shimada, Y; Tsukada, K; Yoshida, T; Yoshioka, I | 1 |
| Ariyoshi, Y; Fujita, Y; Fujiyama, J; Fukuda, K; Masuyama, M; Matsuo, H; Nakashima, S | 1 |
| Akasaka, H; Hakamada, K; Koyama, M; Morohashi, H; Murata, A; Sakamoto, Y; Yokoyama, H | 1 |
| Chikatani, K; Goto, H; Kakimoto, M; Kawashima, H; Kikuchi, A; Koshiishi, H; Liu, B; Miyamoto, H; Nishida, K; Okamura, T; Yoshimura, T | 1 |
| Funaki, H; Kaida, D; Kinami, S; Kosaka, T; Minato, H; Morioka, E; Nakano, Y; Nakata, S; Noguchi, M; Ohnishi, T; Ohno, Y; Omote, K; Takamura, H; Tomita, Y; Ueda, N | 1 |
| Lee, VK; Ong, CW; Pang, B; Tay, CM | 1 |
| Ballestrero, A; Battistuzzi, L; Bianchi Scarrà, G; Casella, C; Comandini, D; Cusano, R; Dei Tos, AP; Fiocca, R; Gargiulo, S; Garuti, A; Ghiorzo, P; Martinuzzi, C; Mastracci, L; Origone, P; Toffolatti, L | 1 |
| Gonda, H; Ikeda, K; Izumi, H; Kitamura, D; Seki, E; Unotoro, J | 1 |
| Akinci, MB; Aksoy, S; Ozdemir, NY; Sendur, MA; Uncu, D; Zengin, N | 1 |
| Eisenberg, BL | 2 |
| Ando, T; Hosokawa, A; Kajiura, S; Nakata, K; Saito, S; Sugiyama, T | 1 |
| Antonescu, CR; Dei Tos, PA; Fletcher, CD; Hornick, JL; Huang, HY; Mino-Kenudson, M; Mosquera, JM; Nafa, K; Nielsen, GP; Romeo, S; Zhang, L | 1 |
| Przybył, J; Rutkowski, P; Zdzienicki, M | 1 |
| Bedina-Zavec, A; Janša, R; Kralj-Iglič, V; Ogorevc, E; Simundić, M; Stukelj, R; Suštar, V | 1 |
| Centonze, D; Cinardi, N; Franco, S; Giannone, G; Pulvirenti D'Urso, A; Pulvirenti, E | 1 |
| Godwin, AK; Ochs, MF; Rink, L; von Mehren, M; Zhou, Y | 1 |
| Buti, S; Donini, M; Passalacqua, R; Rossi, G; Rossi, V; Sergio, P | 1 |
| Contreras-Trujillo, H; Czechowicz, A; Edris, B; Fletcher, JA; Montgomery, KD; Mühlenberg, T; van de Rijn, M; Volkmer, AK; Volkmer, JP; Weiskopf, K; Weissman, IL; West, RB; Willingham, SB | 1 |
| Bhutani, MS; Faruqi, S; Jones, DV; Logroño, R | 1 |
| Asaka, M; Ehira, N; Imamura, M; Kanamori, H; Kawamura, T; Masauzi, N; Miura, T; Obara, S; Tanaka, J; Tsutsumi, Y; Yamato, H | 1 |
| Blackstein, ME; Dubé, P; Fletcher, JA; Keller, OR; Knowling, M; Létourneau, R; Morris, D; Riddell, R; Rorke, S; Swallow, CJ | 1 |
| Egorin, MJ; Hayes, MJ; Lagattuta, TF; Ramalingam, S; Ramanathan, RK | 1 |
| Beshay, V; Chong, G; Goldstein, D; Hughes, B; Waring, P; Yip, D | 1 |
| Guillou, PJ; Leahy, M; Rahman, SH; Roy, A; Toogood, GJ | 1 |
| Durham, MM; Gow, KW; Katzenstein, HM; Lorenzo, RL; Ricketts, RR; Shehata, BM | 1 |
| Bainbridge, T; Corless, CL; Fletcher, JA; Harrell, P; Heinrich, MC; McGreevey, L; Schroeder, A; Town, A | 1 |
| Blay, JY; Bompas, E; Velay, B | 1 |
| Berger, A; Cellier, C; Landi, B; Lecomte, T | 1 |
| Klamová, H; Klener, P | 1 |
| Aparicio, J; Fernández, A | 1 |
| Bundi, M; Dimitrijevic, S; Dirnhofer, S; Kononen, J; Lugli, A; Mangialaio, S; Mirlacher, M; Sauter, G; Schraml, P; Simon, R; Went, PT | 1 |
| Ardau, R; Chillotti, C; De Lisa, R; Del Zompo, M; Severino, G | 1 |
| Benjamin, RS; Charnsangavej, C; Choi, H; de Castro Faria, S; Johnson, MM; Macapinlac, HA; Podoloff, DA; Tamm, EP | 1 |
| Hasuike, Y; Hirota, S; Ikenaga, M; Kashiwazaki, M; Mano, M; Mishima, H; Miyake, M; Takada, Y; Takeda, Y; Tsujinaka, T | 1 |
| Higuchi, T; Matsumoto, T; Tate, G; Yamaguchi, M | 1 |
| Hirotab, S; Kitamura, Y | 1 |
| di Paola, ED; Dimitrijevic, S; Dumez, H; Judson, I; Ma, P; Peng, B; Racine, A; Scurr, M; van Glabbeke, M; van Oosterom, A; Verweij, J | 1 |
| Aoki, R; Imoto, Y; Ito, S; Muguruma, N; Nakamoto, J; Okamoto, K; Okamura, S; Okitsu, H; Sano, T; Sato, Y | 1 |
| Bümming, P; Dortok, A; Gustavsson, B; Kindblom, LG; Meis-Kindblom, JM; Nilsson, B; Odén, A; Sablinska, K | 1 |
| Advani, SH; Bakshi, CA; Jain, RA; Sainani, AR; Sastry, PS | 1 |
| Ando, Y; Beck, Y; Tahara, H; Takayama, T; Tsunoda, T | 1 |
| Cools, J; Debiec-Rychter, M; Dumez, H; Hagemeijer, A; Marynen, P; Mentens, N; Prenen, H; Roesel, J; Sciot, R; Stul, M; Van Oosterom, A; Vranckx, H; Wasag, B | 1 |
| Bertulli, R; Casali, PG; Coco, P; Fumagalli, E; Grosso, F; Stacchiotti, S | 1 |
| Goldstein, D; Grimison, P; Murray, N; Schneeweiss, J | 1 |
| Gabanti, E; Lagonigro, MS; Negri, T; Pierotti, MA; Pilotti, S; Pricl, S; Tamborini, E | 1 |
| de Mestier, P; des Guetz, G | 1 |
| McAuliffe, JC; Steinert, DM; Trent, JC | 1 |
| Chehal, A; El Hajj, II; El Saghir, NS | 1 |
| Araki, K; Hamada, S; Jin, T; Kobayashi, M; Nakano, T; Nakatani, H; Sugimoto, T; Taguchi, T | 1 |
| Busalacchi, PJ; de la Calle, MA; Del Río, ST; Torroba, A | 1 |
| Chacón, M; Domenechini, E; Huertas, E; Loria, FS; Roca, E | 1 |
| Brümmendorf, T; Hartmann, JT; Herrlinger, U; Horger, M; Kanz, L; Lengerke, C | 1 |
| Goto, T; Igaki, N; Kanda, S; Matsuda, T; Ohyama, M; Takashima, M; Tamada, F | 1 |
| Caplin, ME; Dhillon, AP; Hochhauser, D; Khan, K; Kostoula, V; Quaglia, A; Savage, K; Stubbs, M | 1 |
| Akisik, FM; Henley, JD; Rajesh, A; Rushing, DA; Rydberg, J; Sandrasegaran, K | 1 |
| Chiarolini, F; Cossu, A; Ena, P; Siddi, GM | 1 |
| Armbrust, T; Füzesi, L; Gunawan, B; Langer, C; Ramadori, G; Schindler, CG | 1 |
| Aschoff, AJ; Henne-Bruns, D; Kramer, K; Siech, M; Sträter, J | 1 |
| Herbers, AH; Keuning, JJ | 1 |
| De Giorgi, U; Verweij, J | 1 |
| Clark, MA; Hayes, AJ; Judson, I; Neuhaus, SJ; Thomas, JM | 1 |
| Jin, ML; Shen, L | 1 |
| Blay, JY; Bonvalot, S; Casali, P; Choi, H; Debiec-Richter, M; Dei Tos, AP; Demetri, GD; Emile, JF; Gronchi, A; Hogendoorn, PC; Joensuu, H; Le Cesne, A; Mac Clure, J; Maurel, J; McClure, J; Nupponen, N; Ray-Coquard, I; Reichardt, P; Sciot, R; Stroobants, S; van Glabbeke, M; van Oosterom, A | 1 |
| Conroy, WP; Finkelstein, SD; Lo, SS; Papachristou, GI; Ramanathan, RK; Schraut, WH | 1 |
| Jones, RL; Judson, IR | 1 |
| Albiter, M; Bonvalot, S; Caillet, H; Dromain, C; Le Cesne, A; Le Pechoux, C; Petrow, P; Shapeero, L; Terrier, P; Vanel, D | 1 |
| Abdulkader, I; Cameselle-Teijeiro, J; Forteza, J | 1 |
| Bihl, H; Büttner, R; Heinicke, T; Hohenberger, P; Leutner, CC; Merkelbach-Bruse, S; Pauls, K; Speidel, N; Thomas, N; Wardelmann, E | 1 |
| Fry, RD; Ginsberg, GG; Livolsi, VA; Seethala, RR; Shah, JN; Sun, W | 1 |
| Eide, J; Haugland, HK; Horn, A; Jebsen, NL; Jensen, DK; Lilleng, PK; Mannelqvist, M; Monge, OR; Skar, R; Øvrebø, K | 1 |
| Demetri, GD; Desai, J; Dipiro, PJ; Shankar, S; Van Den Abbeele, A; vanSonnenberg, E | 1 |
| Antonescu, CR; Besmer, P; DeMatteo, RP; Eisenstat, J; Greco, AM; LaQuaglia, MP; Maki, RG; Prakash, S; Sarran, L; Socci, N; Wexler, LH | 1 |
| Amand, MS; Demetri, GD; Griffin, JM | 1 |
| Hattori, T; Miwa, K; Mukaisho, K; Shimomura, A; Sugihara, H; Totsuka, Y; Wakabayashi, K | 1 |
| Arnoletti, JP; Birbe, R; Canutescu, AA; Dunbrack, R; Eisenberg, B; Godwin, AK; Heslin, MJ; Merkel, E; Patchefsky, A; Shen, W; Skorobogatko, Y; Tarn, C; von Mehren, M | 1 |
| Antoch, G; Bauer, S; de Wit, M; Ebeling, P; Erhard, J; Flasshove, M; Grabellus, F; Hartmann, JT; Lang, H; Niebel, W; Schütte, J; Seeber, S; Taeger, G; Zeth, M | 1 |
| Cheng, S; Cong, W; Ding, G; Kai, L; Nan, L; Wu, M; Yang, J; Zhang, S | 1 |
| Hitre, E; Láng, I | 1 |
| Eckhardt, S | 1 |
| Bainbridge, T; Corless, CL; Griffith, D; Harrell, P; Heinrich, MC; McGreevey, L; Morich, J; Schroeder, A; Shiraga, S; Town, A | 1 |
| Antonescu, CR; Arkun, K; Besmer, P; Brennan, MF; DeMatteo, RP; Desantis, D; Guo, T; Hom, G; Jeffrey, PD; Koryotowski, B; Leversha, MA; Maki, RG; Singer, S | 1 |
| Ausania, F; Caricato, M; Coppola, R; Rabitti, C; Tonini, G; Valeri, S | 1 |
| Andtbacka, RH; Benjamin, RS; Chen, LL; Choi, H; Feig, BW; Frazier, ML; Macapinlac, HA; Patel, SR; Sabripour, M; Wu, EF | 1 |
| Chang, HM; Kang, HJ; Kang, YK; Kim, H; Kim, SE; Kim, TW; Lee, JS; Park, S; Ryu, MH; Sohn, HJ | 1 |
| Finne, J; Haapasalo, H; Isola, J; Korja, M; Salmi, TT; Tanner, M | 1 |
| Loughrey, MB; Mann, GB; Michael, M; Mitchell, C; Waring, PM | 1 |
| De Wever, I; Debiec-Rychter, M; Pauwels, P; Sciot, R; Stul, M; Van Oosterom, AT | 1 |
| Connock, M; Fry-Smith, A; Peake, D; Raftery, J; Song, F; Wilson, J; Yao, G | 1 |
| Capsambelis, P; Chatziantoniou, A; Erato, P; Kartsaklis, P; Kosmadakis, N; Panopoulos, I; Tsimara, M; Visvardis, EE | 1 |
| Gunduz, E; Gunduz, M; Hiroyuki, O; Matsuoka, J; Naomoto, Y; Nobuhisa, T; Noma, K; Okawa, T; Shirakawa, Y; Takaoka, M; Tanaka, N; Tomono, Y; Yamatsuji, T | 1 |
| Blay, JY; Brown, M; Casali, PG; Judson, IR; Le Cesne, A; Reichardt, P; Schlemmer, M; Van Glabbeke, M; Verweij, J; Zalcberg, JR | 1 |
| Clark, MA; Fisher, C; Judson, I; Thomas, JM | 1 |
| Bertulli, R; Brown, M; Casali, PG; Goldstein, D; Hogendoorn, PC; Hohenberger, P; Judson, IR; Le Cesne, A; Ray-Coquard, I; Schlemmer, M; Sciot, R; Van Glabbeke, M; van Oosterom, AT; Verweij, J | 1 |
| Beshay, V; Chong, G; Goldstein, D; Grimpen, F; Loughrey, M; McArthur, G; Waring, P; Yip, D | 1 |
| Chmelik, P; Felix, R; Gaffke, G; Hohenberger, P; Jost, D; Kretzschmar, A; Reichardt, P; Schneider, U; Stroszczynski, C | 1 |
| DeMatteo, RP; van der Zwan, SM | 1 |
| Aliberti, C; Benea, G; Conti, M; De Giorgi, U; Marangolo, M | 1 |
| Apice, G; Botti, G; De Chiara, A; De Rosa, V; Franco, R; Iaffaioli, VR; Lastoria, S | 1 |
| Hou, YY; Qin, XY; Shen, KT; Song, LJ; Sujie, A | 1 |
| Chen, SS; Chen, YZ; Hsu, S | 1 |
| Blanke, CD; Sanborn, RE | 1 |
| Bauer, S; Hartmann, JT; Lang, H; Schütte, J | 1 |
| Knipp, H; Kretzschmar, A; Lindner, T; Pink, D; Reichardt, P; Schoeler, D; Thuss-Patience, PC; Vanhoefer, U | 1 |
| Dalod, M; Vivier, E; Walzer, T; Zitvogel, L | 1 |
| de Groot, JW; Links, TP; Plukker, JT; van Der Graaf, WT; Zonnenberg, BA | 1 |
| Anthuber, M; Dietmaier, W; Hofstädter, F; Iesalnieks, I; Jantsch, T; Rümmele, P; Schlitt, HJ; Zülke, C | 1 |
| Bertagnolli, MM; Demetri, GD; Fletcher, CD; George, S; Hornick, JL | 1 |
| Kendler, D; Moncayo, R; Virgolini, I; Zaknun, JJ; zur Nedden, D | 1 |
| Hayashi, Y; Kajiyama, Y; Miyano, T; Okazaki, T; Tsurumaru, M; Yamashiro, Y; Yamataka, A; Yanai, T | 1 |
| Godwin, AK; Tarn, C | 2 |
| Erturk, SM | 1 |
| Efron, DT; Lillemoe, KD | 1 |
| Blay, JY; Bonichon, F; Bonvalot, S; Bouché, O; Bugat, R; Bui, NB; Chayvialle, JA; Coindre, JM; Duffaud, F; Emile, JF; Landi, B; Lassau, N; Le Cesne, A; Meeus, P; Monges, G; Nordlinger, B; Ranchère, D; Ray-Coquard, I; Rougier, P; Scoazec, JY; Stoeckle, E; Vanel, D | 1 |
| Ashman, LK; Binns, D; Conus, N; Cullinane, C; Dorow, DS; Hicks, RJ; Kansara, M; McArthur, GA; Thomas, DM | 1 |
| Abe, T; Kawabata, M; Kimura, H; Nasuno, M; Nishimura, S; Okuda, H; Shitani, M; Suzuki, C; Tanaka, H; Ueno, M; Yonezawa, K; Yoshida, Y | 1 |
| Hayashi, Y; Hirato, J; Hiwatari, M; Kuroiwa, M; Shimada, A; Shitara, T; Suzuki, N; Taki, T; Tsuchida, Y | 1 |
| Dixon, J; Goldstein, D; Haindl, W; Rossleigh, M; Tan, BS; Walker, B | 1 |
| Burger, H; de Bruin, AM; de Schipper, HP; den Bakker, MA; Kros, JM; Nooter, K; Oosterhuis, W; van den Ingh, HF; van der Harst, E; van Tol, H; Wiemer, EA | 1 |
| Christoffersen, T; Dajani, O; Guren, TK; Thoresen, GH; Tveit, KM; Wisløff, F | 1 |
| Fukuda, K; Hagiwara, A; Kin, S; Kuriu, Y; Miyagawa, K; Nakase, Y; Nakashima, S; Sagara, Y; Sakakura, C; Yamagishi, H; Yamaoka, N; Yoshikawa, T | 1 |
| Ide, H; Ito, T; Iwase, K; Kainuma, S; Michiura, T; Mikata, S; Mizushima, T; Nonaka, K; Yamanaka, H | 1 |
| Melichar, B; Michal, M; Nozicka, J; Ryska, A; Urminská, H; Vanecek, T; Voboril, Z | 1 |
| King, DM | 1 |
| Iwazawa, T; Katsushima, S; Matsui, S; Monden, T; Nakano, Y; Ohnishi, T; Okamoto, S; Takemoto, H; Tono, T; Yano, H | 1 |
| Boshoff, C; Frow, R; Gana-Weisz, M; Hartzoulakis, B; McLean, SR; Selwood, D; Whelan, J | 1 |
| Antoni, C; Erk, JU; Haroske, G; Jacobasch, L; Ludwig, K; Stelzner, S | 1 |
| Chung, JH; Ha, E; Jung, KH; Kim, BS; Park, HJ; Park, YH; Yim, SV; Yoon, SH | 1 |
| Hirota, S; Isozaki, K | 1 |
| Benjamin, RS; Blanke, CD; Blay, JY; Bonvalot, S; Eisenberg, B | 1 |
| Chang, HM; Kang, HJ; Kang, YK; Kim, TW; Lee, JL; Lee, JS; Ryu, MH; Sohn, HJ | 2 |
| Bremer, A; Glasbrenner, B; Ludolph, T; Schulz, U; Schweitzer, A | 1 |
| Gleeson, F; Warakaulle, DR | 1 |
| Baba, M; Hiramatsu, Y; Kamiya, K; Kawabata, T; Kikuchi, H; Kitagawa, K; Kitagawa, M; Kondo, K; Konno, H; Ohta, M; Sugimura, H; Suzuki, S; Tanaka, T; Yamamoto, M; Yamashita, K | 1 |
| Bar-Sela, G; Haim, N; Kuten, A; Lev, LM; Wollner, M | 1 |
| Dziewirski, W; Grzesiakowska, U; Krawczyk, M; Nasierowska-Guttmejer, A; Nowecki, Z; Nyckowski, P; Ruka, W; Rutkowski, P | 1 |
| Benjamin, RS; Choi, H; Medeiros, LJ; Oyarzo, M; Raymond, AK; Steinert, DM; Thall, PF; Trent, JC; Wang, X; Zhang, W | 1 |
| André, S; Barata, A; Cravo, M; Francisco, I; Nobre-Leitão, C; Salazar, M; Venâncio, J | 1 |
| de Boeck, G; de Bruijn, E; Debiec-Rychter, M; Guetens, G; Manley, P; Prenen, H; Schoffski, P; van Oosterom, AT | 1 |
| Buettner, R; Heinicke, T; Hohenberger, P; Merkelbach-Bruse, S; Pauls, K; Pietsch, T; Pink, D; Reichardt, P; Schildhaus, HU; Speidel, N; Thomas, N; Wardelmann, E | 1 |
| Bogusław, L; Piotr, R; Wanda, M; Włodzimierz, R; Zbigniew, N | 1 |
| Franceschi, D; Hodgson, N; Jorda, M; Koniaris, LG; Lee, DJ; Livingstone, AS; Perez, EA; Rocha-Lima, C | 1 |
| Beart, RW; Ker, TS; Nunoo-Mensah, JW; Wasserberg, N | 1 |
| Akimori, T; Araki, K; Hokimoto, N; Jin, T; Kitagawa, H; Kobayashi, M; Nakano, T; Nakatani, H; Namikawa, T; Okabayashi, T; Okamoto, K; Sugimoto, T; Taguchi, T | 1 |
| Kudoh, S; Ohnishi, K; Ohno, R; Sakai, F | 1 |
| Chen, TW; Chiang, KC; Jan, YY; Lee, HL; Liu, FY; Yeh, CN | 1 |
| von Mehren, M | 2 |
| Blay, JY; Casali, PG; Debiec-Rychter, M; Hagemeijer, A; Hohenberger, P; Judson, I; Le Cesne, A; Leyvraz, S; Schlemmer, M; Sciot, R; Stul, M; Van Glabbeke, M; van Oosterom, AT; Verweij, J; Zalcberg, J | 1 |
| Cools, J; Debiec-Rychter, M; Folens, C; Marynen, P; Mentens, N; Prenen, H; Schöffski, P; Sciot, R; Van Oosterom, A | 1 |
| Berman, E; Chanel, S; Fleisher, M; Heller, G; Maki, RG; Nicolaides, M; Sauter, NP; Scheu, K; Wilson, BA | 1 |
| Dirnhofer, S; Went, P; Zimpfer, A | 1 |
| Egerer, G; Geer, T; Herrmann, T; Ho, AD; Kallinowski, B; Kasper, B; Lehnert, T; Mechtersheimer, G | 1 |
| Ahlman, H; Andersson, J; Bümming, P; Kindblom, LG; Meis-Kindblom, JM; Nilsson, B | 1 |
| Eisenberg, B; Godwin, AK; Skorobogatko, YV; Taguchi, T; Tarn, C; von Mehren, M | 1 |
| Bertagnolli, MM; Demetri, GD; Desai, J; Fletcher, CD; George, S; Morgan, JA; Posner, M; Raut, CP; Zahrieh, D | 1 |
| Hagiwara, A; Kin, S; Miyagawa, K; Nakase, Y; Nakashima, S; Sagara, Y; Sakakura, C; Soga, K; Yamagishi, H; Yamaoka, N; Yoshikawa, T | 1 |
| Benjamin, RS; Trent, JC | 1 |
| Terracciano, LM; Tornillo, L | 1 |
| Goldstein, D; Harrison, ML | 1 |
| Bouché, O; Cadiot, G; Delattre, JF; Diébold, MD; Guillou, PJ; Lagarde, S; Lubrano, D; Nguyen, TD; Ramaholimihaso, F; Thiéfin, G | 1 |
| Ambrosini, G; Chen, JH; Decarolis, P; Geha, RC; Kennealey, PT; Motwani, M; O'connor, R; Sambol, EB; Schwartz, GK; Singer, S; Wu, YV | 1 |
| Carbone, A; Casali, PG; Fermeglia, M; Ferrone, M; Greco, A; Gronchi, A; Lagonigro, MS; Miselli, F; Negri, T; Pierotti, MA; Pilotti, S; Pricl, S; Tamborini, E | 1 |
| Bustamante Z, M; Capetillo Fuentes, M; Carvajal H, C; Contreras P, JE; Iturra U, S; Justiniano P, JC; Lombardi S, J | 1 |
| Bernardeschi, P; Biancalani, M; De Simone, M; Dentico, P; Fiorentini, G; Palomba, A; Rossi, S; Scuderi, S; Vaira, M | 1 |
| Hanada, N; Inoue, K; Kawamura, Y; Osako, T; Taneda, T; Yoshida, Y | 1 |
| Biour, M; Cales, V; Etcharry, F; Ferrari, S; Laborde, Y; Pariente, A | 1 |
| Chen, TW; Hsueh, S; Jan, YY; Wu, TJ; Yeh, CN | 1 |
| Boonstra, JG; de Jong, FA; Hamberg, P; Sleijfer, S; van Doorn, J; Verweij, J | 1 |
| Arduini, F; Bearzi, I; Costagliola, A; Mandolesi, A; Ranaldi, R | 1 |
| Naithani, R; Panigrahi, I | 1 |
| Jootar, S; Lassarat, S | 1 |
| Corless, CL; Downs-Kelly, E; Goldblum, JR; Heinrich, MC; Lam, MM; Rubin, BP | 1 |
| Azuma, M; Higuchi, K; Katada, C; Koizumi, W; Nakatani, K; Nishimura, K; Saigenji, K; Sasaki, T; Shimoda, T; Tanabe, S | 1 |
| Beshay, V; Dobrovic, A; Kovalenko, S; Lade, S; Loughrey, MB; McArthur, GA; Murray, W; Trivett, M; Turner, H; Waring, PM; Zalcberg, J | 1 |
| Beshay, V; Dobrovic, A; Loughrey, MB; Waring, PM; Zalcberg, J | 1 |
| Biollaz, J; Buclin, T; Csajka, C; Decosterd, LA; Duchosal, MA; Eap, CB; Henry, H; Leyvraz, S; Rochat, B; Rosselet, A; Widmer, N | 1 |
| Chow, PK; Chuah, KL; Goh, BK; Wong, WK; Yap, WM | 1 |
| Kubota, T | 1 |
| Cecere, V; Ferrarese, F | 1 |
| Basile, F; Benfatto, G; Di Stefano, G; Politi, V; Strazzanti, A; Zanghì, G | 1 |
| Dematteo, RP; Gold, JS | 2 |
| Linton, KM; Radford, JA; Taylor, MB | 1 |
| Araki, K; Ichikawa, K; Kitagawa, H; Kobayashi, M; Nakatani, H; Namikawa, T; Okabayashi, T; Okamoto, K | 1 |
| Chang, HM; Kang, HJ; Kang, YK; Kim, HC; Kim, JS; Kim, JY; Kim, TW; Lee, H; Lee, JL; Park, JH; Ryu, MH | 1 |
| Ito, T; Nakanishi, M; Noguchi, A; Okano, S; Suganuma, Y; Takeshita, H; Tani, N; Yamaguchi, M; Yamamoto, Y; Yamane, T | 1 |
| De Boeck, G; de Bruijn, EA; Guetens, G; Highley, M; Prenen, H; van Oosterom, AT | 1 |
| Blay, JY; Casali, PG; Issels, R; Judson, IR; Le Cesne, A; Reichardt, P; Simes, J; Van Glabbeke, M; van Oosterom, AT; Verweij, J | 1 |
| Al-Salam, S; El-Teraifi, HA; Taha, MS | 1 |
| Cowie, F | 1 |
| Joensuu, H; Reichardt, P | 1 |
| Agosti, V; Antonescu, CR; Besmer, P; Ehlers, I; Manova, K; Rossi, F; Socci, ND; Sommer, G; Viale, A; Yozgat, Y | 1 |
| Kashimura, H; Kobayashi, K; Koyama, T; Marushima, H; Mitsumori, N; Nimura, H; Odaira, H; Yanaga, K | 1 |
| Blanke, CD; Chen, CJ; Corless, CL; Demetri, GD; Eisenberg, BL; Fletcher, CD; Fletcher, JA; Heinrich, MC; Joensuu, H; McDougall, K; Ou, WB; Roberts, PJ; Sandau, K; von Mehren, M | 1 |
| Bonvalot, S; Cavalcanti, A; Cesne, AL; Eldweny, H; Lassau, N; Péchoux, CL; Robert, C; Terrier, P; Vanel, D | 1 |
| Bauer, S; Demetri, GD; Fletcher, JA; Yu, LK | 1 |
| Abbruzzese, JL; Benjamin, RS; Dupart, J; Hu, L; Hunt, K; Macapinlac, H; Pollock, R; Ramdas, L; Salvado, A; Taylor, E; Trent, JC; Zhang, W | 1 |
| Benjamin, RS; Chirieac, LR; Choi, H; Patel, SR; Raymond, AK; Steinert, DM; Trent, JC; Yang, Y; Zhang, J | 1 |
| Al-Kindy, S; Al-Moundhri, MS; Al-Thahli, K; Rao, L; Salam, J | 1 |
| Chen, MF; Chen, TW; Jan, YY; Liu, FY; Yeh, CN | 1 |
| Blanke, CD; Schnadig, ID | 1 |
| Shinomura, Y | 1 |
| Agullo, FJ; Landeros, MM; Santillan, AA | 1 |
| Bi, JW; Chen, DD; Ding, KF; Gu, J; Li, R; Lu, HS; Lu, YF; Shao, YF; Shi, YQ; Sun, YH; Wan, DS; Wang, PZ; Wu, XT; Yu, JR; Zhan, WH; Zhang, XH; Zou, XM | 1 |
| Cao, J; Chen, GQ; Dai, LH; DU, H; Huang, CM; Lai, YY; Lin, F; Wen, MJ; Xia, JT | 1 |
| Baum, CM; Bello, CL; Blackstein, ME; Casali, PG; Demetri, GD; Desai, J; Fletcher, CD; Garrett, CR; George, S; Heinrich, MC; Huang, X; Judson, IR; McArthur, G; Morgan, JA; Shah, MH; van Oosterom, AT; Verweij, J | 1 |
| Bonvalot, S; Chami, L; Lamuraglia, M; Lassau, N; Le Cesne, A; Leclère, J; Roche, A; Terrier, P | 1 |
| Chao, TC; Chen, MF; Hwang, TL; Jan, YY; Lee, LY; Wu, PY; Wu, TJ; Yeh, CN | 1 |
| Berthaud, P; Blay, JY; Chatelut, E; Delbaldo, C; Deroussent, A; Jambu, A; Le Cesne, A; Ré, M; Séronie-Vivien, S; Vassal, G | 1 |
| Demetri, G; Dobrovic, A; Kovalenko, S; Loughrey, MB; McArthur, G; Waring, PM | 1 |
| Epstein, JI; Herawi, M; Montgomery, EA | 1 |
| Driman, DK; Parfitt, JR; Riddell, RH; Streutker, CJ | 1 |
| Andtbacka, RH; Benjamin, RS; Burgess, MA; Chen, LL; Cormier, JN; Feig, BW; Hunt, KK; Ng, CS; Patel, SR; Pisters, PW; Pollock, RE; Raymond, K; Scaife, CL; Trent, J | 1 |
| Furui, J; Haraguchi, M; Kuroki, T; Tsuneoka, N | 1 |
| Antonescu, CR; Brennan, MF; De Matteo, RP; Gold, JS; Gönen, M; Maki, RG; Singer, S; van der Zwan, SM | 1 |
| Biolchini, F; Jovine, E; Lerro, FM; Martuzzi, F; Mastrangelo, L | 1 |
| Hirai, S; Ishikawa, A; Kakinoki, N; Kamoshida, T; Kishimoto, Y; Ochiai, T; Oka, Y; Ono, S; Shimokama, T; Teratani, T | 1 |
| Catley, L; Fabbro, D; Griffin, JD; Hall-Meyers, E; Jiang, J; Kung, AL; Manley, PW; Moreno, D; Podar, K; Ray, A; Weisberg, E; Wright, RD | 1 |
| Seynaeve, C; Sleijfer, S; Verweij, J; Wiemer, E | 2 |
| Baloglu, O; Gerin, F; Kesari, S; Morgan, JA | 1 |
| Chen, LT; Chuan, CH; Hsiao, HH; Lee, CP; Lin, SF; Liu, YC; Tsai, HJ; Tseng, YT; Wang, JY; Yang, SF | 1 |
| Detken, S; Füzesi, L; Gunawan, B; Haller, F; Happel, N; Kuhlgatz, J; Schulten, HJ | 1 |
| Krcmová, L; Melichar, B; Opletalová, V; Solich, P; Solichová, D; Urbánek, L | 1 |
| Chami, L; Lassau, N; Péronneau, P | 1 |
| Debiec-Rychter, M; Sciot, R | 1 |
| Lasota, J; Miettinen, M | 1 |
| Chao, TC; Chen, MF; Chen, TW; Hwang, TL; Jan, YY; Lee, HL; Liu, YY; Yeh, CN | 1 |
| Ekmektzoglou, KA; Samelis, GF; Zografos, GC | 1 |
| Agaram, NP; Antonescu, CR; Besmer, P; Brennan, MF; DeMatteo, RP; DeSantis, D; Guo, T; Maki, RG; Singer, S; Socci, ND; Wong, GC | 1 |
| Beckers, MM; Slee, PH | 1 |
| Fletcher, JA; Rubin, BP | 1 |
| Bojadzieva, S; Gogusev, J; Jankulovski, N; Popov, Z; Validire, P | 1 |
| Fujimi, S; Fukunaga, M; Furukawa, H; Imamura, H; Kamigaki, S; Kishimoto, T; Kondo, M; Miyazaki, Y; Nakata, Y; Nakayama, T; Ohsato, H; Ohshiro, R; Ohta, K; Takemoto, H; Tatsuta, M; Yamamoto, K | 1 |
| Fanucchi, M; Folpe, A; Guiteau, J; Kooby, DA; Staley, CA | 1 |
| Belev, B; Kralik, M; Petricević, B; Plestina, S; Sirotković-Skerlev, M; Vrbanec, D | 1 |
| Blanke, C; Demetri, G; Feng, W; Finkelstein, S; Huse, DM; Joensuu, H; Lenhart, G; von Mehren, M | 1 |
| Han, MK; Horowitz, JC; Moore, BB; Thannickal, VJ; Vittal, R; Zhang, H | 1 |
| Czyz, M; Jakubowska, J | 1 |
| Durosinmi, MA; Ogbe, PO; Oyekunle, AA; Salawu, L | 1 |
| Adamson, PC; Bernstein, ML; Blaney, SM; Bond, M; Krailo, M; Pappo, A; Schultz, KR | 1 |
| Geh, I; Gregg, RJ; Pallalau, A; Salmons, N; Tanière, P; Woolhouse, I | 1 |
| Loong, HH | 1 |
| Gelderblom, H; Guchelaar, HJ; Oostendorp, RL; Schellens, JH; van Erp, NP | 1 |
| Chen, G; Ding, PR; Li, LR; Lu, ZH; Pan, ZZ; Wan, DS; Wu, XJ; Zhou, ZW | 1 |
| Ikeda, E; Sakurai, N; Sasou, S; Shibuma, H; Yamauchi, J | 1 |
| Grossmann, P; Laco, J; Melichar, B; Slovácek, L; Vanecek, T | 1 |
| Bearss, D; Cooke, L; Della Croce, K; Garewal, H; Iorio, M; Mahadevan, D; Nagle, R; Riley, C; Shakalya, K; Simons, B; Swart, R; Wisner, L | 1 |
| Abraham, S; Booth, BP; Chidambaram, N; Dagher, R; Gobburu, JV; Goodman, VL; Jiang, JX; Justice, R; Liang, CY; Mahjoob, K; Morse, DE; Pazdur, R; Ramchandani, RP; Rock, EP; Tang, S; Verbois, SL | 1 |
| Blay, JY; Casali, PG; Issels, R; Judson, IR; Kotasek, D; Le Cesne, A; Reichard, P; Van Glabbeke, M; van Oosterom, AT; Verweij, J | 1 |
| Alberti, L; Blay, JY; Cassier, PA; Dufresne, A; Fayette, J; Ranchere, D; Ray-Coquard, I | 1 |
| Tanabe, KK; Yoon, SS | 1 |
| Ashman, LK; Baleato, RM; Byrnes, EM; Griffith, R; Lyons, AB; Odell, AF; Roberts, KG | 1 |
| Antonescu, C; Besmer, P; Duensing, A; Duensing, S; Fletcher, JA; Liu, Y; Perdreau, SA; Rossi, F; Tseng, M | 1 |
| Adenis, A; Berthaud, P; Blay, JY; Bompas, E; Bui, B; Chabaud, S; Cupissol, D; Delbaldo, C; Duffaud, F; Fayette, J; Guillemet, C; Kerbrat, P; Le Cesne, A; Perol, D; Ray-Coquard, I; Rios, M; Viens, P | 1 |
| Scott, LJ; Siddiqui, MA | 1 |
| Chang, BS; Cibas, ES; Fletcher, JA; Yang, T | 1 |
| Bickenbach, K; Kindler, HL; Noffsinger, A; Posner, MC; Roggin, KK; Veerapong, J; Wilcox, R | 1 |
| An, JY; Choi, MG; Kang, WK; Kim, S; Noh, JH; Park, CK; Sohn, TS | 1 |
| Casali, PG; Coco, P; Fiore, M; Gronchi, A; Lagonigro, MS; Messina, A; Miselli, F; Pilotti, S | 1 |
| Schulick, RD | 1 |
| Fletcher, CD; Hornick, JL | 1 |
| Bertulli, R; Carbone, A; Casali, PG; Casieri, P; Fiore, M; Gronchi, A; Lagonigro, MS; Miselli, FC; Negri, T; Orsenigo, M; Pierotti, MA; Pilotti, S; Tamborini, E | 1 |
| Schneider, J | 1 |
| Baltaci, S; Kankaya, D; Reşorlu, B; Reşorlu, M; Savaş, B | 1 |
| Debiec-Rychter, M; Grzesiakowska, U; Kakol, M; Limon, J; Michej, W; Nowecki, ZI; Osuch, C; Ruka, W; Rutkowski, P; Siedlecki, JA; vel Dobosz, AJ; Woźniak, A | 1 |
| Gatopoulou, A; Katodritou, E; Katsos, I; Patakiouta, F; Tarpagos, A; Tzilves, D; Zervas, K | 1 |
| Camci, C; Kalender, ME; Sevinc, A; Zincirkeser, S | 1 |
| Cavaliere, D; Dubini, A; Framarini, M; Giorgetti, G; Milandri, C; Mura, G; Padovani, F; Ricci, E; Ridolfi, L; Solfrini, G; Tauceri, F; Vagliasindi, A; Verdecchia, GM | 1 |
| Darwiche, SS; El-Kinge, N; Jamali, FR; Soweid, AM; Tawil, A | 1 |
| Benjamin, RS; Burgess, MA; Charnsangavej, C; Chen, LL; Choi, H; Faria, SC; Macapinlac, HA; Patel, SR; Podoloff, DA | 1 |
| Benjamin, RS; Burgess, MA; Charnsangavej, C; Chen, LL; Choi, H; Macapinlac, HA; Patel, SR; Podoloff, DA | 1 |
| Baum, C; Beaudry, P; Bello, C; Demetri, GD; DePrimo, SE; Desai, J; Folkman, J; Force, J; Heymach, JV; Maki, R; Manola, J; Norden-Zfoni, A; Shalinsky, DR | 1 |
| Bornmann, W; Crespo, A; Fernández, A; Lopez-Berestein, G; Ozturk, E; Peng, Z; Sanguino, A; Wang, S; Zhang, X | 1 |
| Blay, JY; Le Cesne, A | 1 |
| Balleine, RL; Clarke, CL; Collins, M; Delforce, SE; Gurney, H; Hoskins, JM; Lynch, K; Mann, GJ; McLachlan, AJ; Rivory, LP; Schran, H; Wilcken, N; Wong, M | 1 |
| Corless, CL; Heinrich, MC; Rubin, BP | 1 |
| Ahlman, H; Andersson, J; Bümming, P; Kindblom, LG; Meis-Kindblom, JM; Nilsson, B; Nilsson, O; Sjölund, K | 1 |
| Bauer, S; Demetri, GD; Duensing, A; Fletcher, JA | 1 |
| Hiki, N; Imamura, K; Kaminishi, M; Katayama, A; Kubota, K; Mafune, K; Nomura, S; Nozaki, K; Takeshita, Y; Ueda, T | 1 |
| Asakage, N; Gotou, T; Hirai, S; Kobayashi, S; Miyazaki, E; Sasaki, M; Sekine, M; Suzuki, T; Tsukada, K; Yamamoto, T; Yamasaki, S | 1 |
| Fujikawa, K; Hirahara, N; Motojima, R; Motojima, T; Saitoh, T; Sakurai, S; Sano, T; Segawa, A; Todoroki, T; Tsushima, Y; Yamada, S | 1 |
| Antoch, G; Ebeling, P; Frilling, A; Grabellus, F; Schmid, KW; Sheu, SY; Worm, K | 1 |
| Fukuda, M; Hasegawa, J; Hatakeyama, K; Hirota, S; Kanda, T; Kurosaki, I; Nishida, T; Nishitani, A; Takahashi, T; Tsutsui, S | 1 |
| Arce-Lara, C; Benson, DM; Clinton, SK; Jimenez, RE; Monk, JP; Patel, VR; Shah, MH | 1 |
| De Pennington, N; Fearnhead, N; Maynard, ND; Sujendran, V; Warren, BF | 1 |
| Blasco, SB; Calvet, JD; Carbajo-Ferré, EM; Déjardin, Ddel C; González, MH; Lanao, MA; Lara, CD; Marín, AS; Moreno, VV; Pereferrer, FS; Pérez, JS | 1 |
| Armbrust, T; Ramadori, G; Sobotta, M | 1 |
| Choi, EA; Feig, BW | 1 |
| Bonvalot, S; Cesne, AL; Cioffi, A; Domont, J; Pechoux, CL; Vanel, D | 1 |
| Butt, J; Byrne, PJ; Reynolds, JV; Rowley, S | 1 |
| Siehl, J; Thiel, E | 1 |
| Benjamin, RS; Blanke, CD; Blay, JY; Casali, P; Choi, H; Corless, CL; Debiec-Rychter, M; DeMatteo, RP; Demetri, GD; Ettinger, DS; Fisher, GA; Fletcher, CD; Gronchi, A; Hohenberger, P; Hughes, M; Joensuu, H; Judson, I; Le Cesne, A; Maki, RG; Morse, M; Pappo, AS; Pisters, PW; Raut, CP; Reichardt, P; Tyler, DS; Van den Abbeele, AD; von Mehren, M; Wayne, JD; Zalcberg, J | 1 |
| Bauer, S; Lang, H | 1 |
| Barni, S; Forloni, B; Guerra, U; Lagonigro, SM; Mandalà, M; Pezzica, E; Tamborini, E | 1 |
| Chosia, M; Kraszewska, E; Lasota, J; Michej, W; Miettinen, M; Ogun, G; Ptaszynski, K; Ruka, W; Rutkowski, P; Sarlomo-Rikala, M; Schneider-Stock, R; Siedlecki, JA; Stachura, J; Steigen, SE; vel Dobosz, AJ; Wasag, B; Wozniak, A | 1 |
| Hansen, MB; Ponsaing, LG | 1 |
| Boo, YJ; Chae, YS; Jung, CW; Kim, CS; Kim, JH; Kim, SD; Kim, SJ; Mok, YJ; Park, SS | 1 |
| Boyar, MS; Taub, RN | 1 |
| Akmansu, M; Atik, ET; Boruban, C; Ozbek, S; Sencan, O | 1 |
| Assie, G; Baudin, E; Bei, T; Boikos, SA; Briere, JJ; Carney, JA; Chompret, A; Ellison, JW; Eng, C; Ferrando, B; Gimenez-Roqueplo, AP; Matyakhina, L; McWhinney, SR; Muchow, M; Pacak, K; Pasini, B; Rustin, P; Stergiopoulos, S; Stratakis, CA | 1 |
| Apter, S; Catane, R; Kuten, A; Merimsky, O; Raccah, E | 1 |
| Cholongitas, E; Dasenaki, M; Katsogridakis, K; Pipili, C; Relos, K | 1 |
| Hara, Y; Iritani, E; Kanemura, T; Kondo, M; Nagai, A; Tagaya, E; Tamaoki, J | 1 |
| Nishida, T | 1 |
| Bono, P; Bosselli, S; Casali, PG; Coco, P; De Braud, F; De Pas, T; Jalava, T; Joensuu, H; Laurent, D; Putzu, C; Spreafico, C | 1 |
| Agaram, NP; Antonescu, CR; Besmer, P; Clarkson, BD; D'Adamo, D; DeMatteo, RP; Guo, T; Hom, G; Maki, RG; Schwartz, GK; Singer, S; Veach, D; Wong, GC | 1 |
| Czapiński-Tuzikiewicz, T; Dziki, AJ; Galbfach, PJ; Langner, EB; Spychalski, MI; Sroda, A | 1 |
| Bulusu, R; Carroll, N; Hatcher, H; Jessop, F; Judson, I; Murray, M; Williams, D | 1 |
| Demetri, G; Judson, I | 1 |
| Corless, CL; Davidson, R; Debiec-Rychter, M; Graham, J; Reid, R; White, JD | 1 |
| Shen, L | 1 |
| Chen, LR | 1 |
| Corless, CL; Demetri, GD; Desai, J; Fletcher, CD; Fletcher, JA; George, S; Heinrich, MC; Manola, J; Morgan, JA; Shankar, S; Silverman, SG; Tuncali, K; Van den Abbeele, AD; van Sonnenberg, E | 1 |
| Guillén Ponce, C; Molina Garrido, MJ | 1 |
| Bardales, RH; Gomes, AL; Milanezi, F; Reis, R; Schmitt, FC | 1 |
| Al-Batran, SE; Dechow, C; Düx, M; Fischer, T; Hartmann, JT; Heidel, F; Izbicki, JR; Jäger, E; Kraus, T; Stoehlmacher, J; Wardelmann, E | 1 |
| Papadopoulos, KP; Sankhala, KK | 1 |
| Gallwitz, B; Haap, M; Häring, HU; Hartmann, JT; Kanz, L; Müssig, K; Thamer, C | 1 |
| Gollard, R; Trent, J; Wierda, W | 1 |
| Hirota, S; Nakajima, K; Nishida, T; Nishitani, A; Sawa, Y; Souma, Y; Takahashi, T | 1 |
| Benjamin, RS; Chen, LL; Choi, H; Kleinbaum, EP; Lazar, AJ; Mcauliffe, JC; Strong, L; Sunnenberg, TD; Sylvestre, PB; Tamborini, E; Trent, JC; Zhang, W | 1 |
| de Jong, FA; Gietema, JA; Perik, PJ; Rikhof, B; van der Graaf, WT; Verweij, J | 1 |
| Debiec-Rychter, M; Grzesiakowska, U; Jerzak Vel Dobosz, A; Krawczyk, M; Limon, J; Michej, W; Nasierowska-Guttmejer, A; Nowecki, ZI; Nyckowski, P; Ruka, W; Rutkowski, P; Siedlecki, JA; Sygut, J; Wozniak, A | 1 |
| Bruguera, M; Fuster, F; Granell, M; Medina, L; Vallansot, R | 1 |
| Benjamin, RS; Lazar, AJ; McAuliffe, JC; Qiao, W; Raymond, AK; Steinert, DM; Thall, PF; Trent, JC; Yang, D | 1 |
| Asakawa, M; Esaki, M; Hamaguchi, T; Kajiwara, T; Kosuge, T; Nara, S; Sakamoto, Y; Shimada, K | 1 |
| Badawi, RD; Demetri, GD; Holdsworth, CH; Israel, DA; Kijewski, MF; Manola, JB; Van den Abbeele, AD | 1 |
| Bergenfeldt, M; Krarup-Hansen, A; Ludvigsen, L; Mahdi, B; Toxvaerd, A | 1 |
| Lazar, AJ; Trent, JC; Zhang, W | 1 |
| Bankson, JA; Bornmann, W; Chen, J; Crespo, A; Fernández, A; Gelovani, J; Han, HD; Lin, Y; Lopez-Berestein, G; Ma, J; Mangala, LS; Ozturk, E; Peng, Z; Qin, C; Samarel, A; Sanguino, A; Shavrin, A; Sood, AK; Trent, J; Wulf, S | 1 |
| Dova, L; Fountzilas, G; Georgiou, I; Golfinopoulos, V; Malamou-Mitsi, V; Ntemou, A; Pavlidis, N; Pentheroudakis, G; Vartholomatos, G | 1 |
| Chatwani, AJ; Dandolu, V; Lembert, L; Matteo, D; Thomas, RM | 1 |
| Fujiwara, M; Ishida, T; Kameyama, T; Kuma, S; Matsuyama, A; Okamoto, M; Utsunomiya, T; Yamamoto, M; Yano, S | 1 |
| Barker, B; Dowell, JE; Ghobadi, A; Kabbani, W | 1 |
| Baker, SD; Gelderblom, H; Guchelaar, HJ; Karlsson, MO; Li, J; Nortier, JW; Ouwerkerk, J; Sparreboom, A; van Erp, NP; Zhao, M | 1 |
| Croxatto, JO; Gentile, CM; Lombardi, AA | 1 |
| Alvarez Z, M; Galindo A, H; Garrido S, M; González, S; Huete G, A; Ibáñez A, L; Méndez O, G; Moneada M, M; Tapia N, G | 1 |
| Debiec-Rychter, M; Michej, W; Ruka, W; Rutkowski, P; Sciot, R; Woźniak, A | 1 |
| Artoni, A; Colombi, M; Deliliers, GL; Iurlo, A; Radaelli, F; Reda, G; Ripamonti, F; Vener, C | 1 |
| Araujo, DM; Esmaeli, B; Espandar, L; Hatef, E; Kim, SK; Shome, D; Song, CD; Trent, J | 1 |
| Astorino, M; Biasco, G; Brandi, G; Castellucci, P; Catena, F; Di Battista, M; Di Scioscio, V; Pantaleo, MA; Piazzi, G; Santini, D; Saponara, M | 1 |
| Hagiwara, A; Kumano, T; Mizuta, Y; Otsuji, E; Sagara, Y; Sakakura, C; Yamaoka, N | 1 |
| Chiarugi, M; Galatioto, C; Lippolis, PV; Seccia, M | 1 |
| Alberti, L; Arifi, S; Blay, JY; Cassier, P; Decouvelaere, AV; Dufresne, A; El Sayadi, H; Fayette, J; Méeus, P; Ranchère, D; Ray-Coquard, I; Tabone-Eglinger, S | 1 |
| Bui, B; Italiano, A | 1 |
| Patel, S; Zalcberg, JR | 1 |
| Gupta, P; Shukla, HS; Tewari, M | 1 |
| Blanke, CD; Corless, CL; Demetri, GD; Eisenberg, B; Fletcher, CD; Fletcher, JA; Heinrich, MC; Heinz, D; Joensuu, H; Nikolova, Z; Roberts, PJ; von Mehren, M; Wehre, E | 1 |
| Baker, LH; Benjamin, RS; Blanke, CD; Borden, EC; Bramwell, VH; Crowley, JJ; Demetri, GD; Fletcher, CD; Hecht, JR; Heinrich, MC; Maki, RG; Rankin, C; Raymond, AK; Ryan, CW; Tanaka, M; von Mehren, M | 1 |
| Sleijfer, S; Verweij, J; Wiemer, E | 1 |
| Ebihara, Y; Katoh, H; Kawarada, Y; Kitashiro, S; Kondo, S; Okushiba, S | 1 |
| Jatchavala, J; Phaisanphrukkun, C; Phongkitkarun, S; Sirachainan, E | 1 |
| Abhyankar, SA; Nair, N | 1 |
| Debiec-Rychter, M; Dziewirski, W; Grzesiakowska, U; Michej, W; Nowecki, Z; Ruka, W; Rutkowski, P; Siedlecki, JA; Szawłowski, A | 1 |
| Hirota, S; Ishikawa, T; Kanda, T; Nakajima, K; Nishida, T; Nishitani, A; Takahashi, T | 1 |
| Bottino, A; Cipolla, C; Graceffa, G; Grassi, N; Latteri, F; Mandala, S; Torcivia, A | 1 |
| Büttner, R; Merkelbach-Bruse, S; Schildhaus, HU; Wardelmann, E | 1 |
| Gurney, H; Klumpen, HJ; Liddle, C | 1 |
| Blackstein, ME; Chabot, I; LeLorier, J | 1 |
| Kim, MA; Kim, WH; Lee, BL; Lee, HE; Lee, HS | 1 |
| Apice, G; Bruni, GS; Caponigro, F; Iaffaioli, RV; Milano, A | 1 |
| Dimitrakopoulou-Strauss, A; Hohenberger, P; Kaehler, G; Ronellenfitsch, U; Schildhaus, HU; Schwarzbach, MH; Staiger, WI | 1 |
| Barrett, JS; Bernstein, M; Blaney, SM; Bond, M; Champagne, M; Fossler, MJ; Jayaraman, B; Menon-Andersen, D; Mondick, JT; Thompson, PA | 1 |
| Bensimhon, D; Boudiaf, M; Brouland, JP; Fargeaudou, Y; Rymer, R; Soyer, P | 1 |
| Agulnik, M; Aranha, O; Stein, E | 1 |
| Alberti, L; Arifi, S; Blay, JY; Cassier, PA; Decouvelaere, AV; Dufresne, A; El Sayadi, H; Labidi, I; Méeus, P; Ranchère, D; Ray-Coquard, I; Sunyach, MP; Tabone, S | 1 |
| Choi, H | 1 |
| Van den Abbeele, AD | 1 |
| Angelov, K; Gribnev, P; Iarŭmov, N; Lukanova, Ts; Sokolov, M; Todorov, G; Toshev, S; Velev, G | 1 |
| Chang, HM; Kang, YK; Kim, BS; Kim, HC; Kim, KH; Kim, TW; Lee, JL; Ryu, MH; Sym, SJ; Yook, JH | 1 |
| Ahlman, H; Andersson, A; Nilsson, B | 1 |
| Ghersi, MM; Mesko, TW; Paramo, JC; Radkani, P | 1 |
| De Giorgi, U; De Simone, M; Fayyaz, M; Fiorentini, G; Montenora, I; Morini, S; Pupi, A; Turrisi, G | 1 |
| Biollaz, J; Buclin, T; Csajka, C; Debiec-Rychter, M; Decosterd, LA; Duchosal, MA; Leyvraz, S; Rosselet, A; Widmer, N | 1 |
| Ahmed, MY; Almaroof, B; Castillo-Sang, M; Gociman, B; Mancho, S; Tsang, AW | 1 |
| Baker, SD; Burger, H; de Bruijn, EA; Filipski, KK; Franke, RM; Hu, C; Hu, S; Orwick, SJ; Sparreboom, A | 1 |
| Dryjski, J; Guérin, E; Lefebvre, JC; Mefire, Y; Ouazzani, A; Vaneukem, P | 1 |
| Doi, T | 1 |
| Chang, CS; Chen, LT; Hsieh, RK; Huang, MJ; Lim, KH; Liu, CL; Liu, MC; Tzen, CY; Wang, TE | 1 |
| Hou, M; Li, HY; Wang, Y; Zhang, J; Zhu, J | 1 |
| Contreras-Hernández, I; Dávila-Loaiza, G; Garduño-Espinosa, J; Granados-García, V; Mould-Quevedo, JF; Petersen, JA; Salinas-Escudero, G; Silva, A; Villasís-Keever, MA | 1 |
379 review(s) available for imatinib mesylate and Gastrointestinal Stromal Neoplasm
| Article | Year |
|---|---|
Unresectable GIST liver metastases and liver transplantation: A review and theoretical basis for a new indication.
Topics: Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Liver Transplantation; Prospective Studies | 2021 |
[Surgical and interdisciplinary treatment of gastrointestinal stromal tumors].
Topics: Antineoplastic Agents; Combined Modality Therapy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Prognosis; Proto-Oncogene Proteins c-kit | 2022 |
Current update on molecular cytogenetics, diagnosis and management of gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Cytogenetic Analysis; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Prognosis; Proto-Oncogene Proteins c-kit; Tomography, X-Ray Computed | 2021 |
KIT Exon 9-Mutated Gastrointestinal Stromal Tumours: Biology and Treatment.
Topics: Antineoplastic Agents; Biology; Exons; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit | 2022 |
New Tyrosine Kinase Inhibitors for the Treatment of Gastrointestinal Stromal Tumors.
Topics: Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit | 2022 |
New treatment strategies for advanced-stage gastrointestinal stromal tumours.
Topics: Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Protein Kinase Inhibitors; Sunitinib | 2022 |
The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours.
Topics: Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Protein Kinase Inhibitors; Sunitinib | 2022 |
Gastrointestinal Stromal Tumors: What Is the Best Sequence of TKIs?
Topics: Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Protein Kinase Inhibitors; Sunitinib | 2022 |
Avances en tumores del estroma gastrointestinal: ¿hacia dónde vamos?
Topics: Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Sunitinib | 2022 |
The GIST of Advances in Treatment of Advanced Gastrointestinal Stromal Tumor.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit | 2022 |
Next questions for the medical treatment of gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Tumor Microenvironment | 2022 |
Gastrointestinal stromal tumors caused by novel germline variants in SDHB and KIT: a report of two cases and literature review.
Topics: Adult; Female; Gastrointestinal Stromal Tumors; Germ Cells; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Proto-Oncogene Proteins c-kit; Stomach Neoplasms; Succinate Dehydrogenase | 2022 |
Ripretinib in advanced gastrointestinal stromal tumors: an overview of current evidence and drug approval.
Topics: Antineoplastic Agents; Drug Approval; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Naphthyridines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Urea | 2022 |
Complete response of advanced rectal gastrointestinal stromal tumors after imatinib treatment: A case report and literature review.
Topics: Anal Canal; Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Rectal Neoplasms; Rectum | 2022 |
Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Protein Kinase Inhibitors; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2022 |
A literature review and database of how the primary KIT/PDGFRA variant of a gastrointestinal stromal tumour predicts for sensitivity to imatinib.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2022 |
TKI Treatment Sequencing in Advanced Gastrointestinal Stromal Tumors.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Protein Kinase Inhibitors; Sunitinib | 2023 |
Progress in the Treatment of Small Intestine Cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Duodenal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestinal Neoplasms; Intestine, Small; Neuroendocrine Tumors | 2023 |
Clinicopathological and mutational characteristics of primary double mutant gastrointestinal stromal tumor: a single center study with review of the literature.
Topics: Aged; Aged, 80 and over; DNA Mutational Analysis; Exons; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestine, Small; Male; Middle Aged; Mutation; Proto-Oncogene Proteins c-kit; Receptor Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor alpha | 2023 |
Current status of and future prospects for the treatment of unresectable or metastatic gastrointestinal stromal tumours.
Topics: Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Stomach Neoplasms | 2023 |
Efficacy of post-first-line agents for advanced gastrointestinal stromal tumors following imatinib failure: A network meta-analysis.
Topics: Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Network Meta-Analysis; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2023 |
Precision Oncology in Gastrointestinal Stromal Tumors.
Topics: Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Precision Medicine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit | 2023 |
The multifaceted landscape behind imatinib resistance in gastrointestinal stromal tumors (GISTs): A lesson from ripretinib.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases; Sunitinib | 2023 |
Molecular Advances in the Treatment of Advanced Gastrointestinal Stromal Tumor.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2023 |
Ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with imatinib: a plain language summary of the phase 3 INTRIGUE trial.
Topics: Adult; Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Protein Kinase Inhibitors; Quality of Life; Sunitinib | 2023 |
Liver resection for metastatic GIST tumor improves survival in the era of tyrosine kinase inhibitors: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver; Peritoneal Neoplasms; Retrospective Studies; Tyrosine Kinase Inhibitors | 2023 |
Gastrointestinal Stromal Tumours (GIST): A Review of Cases from Nigeria.
Topics: DNA Mutational Analysis; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestines; Nigeria; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Stomach; Survival Analysis; Treatment Outcome; Tumor Burden | 2020 |
Open transanal resection of low rectal stromal tumor following neoadjuvant therapy of imatinib mesylate: Report of 11 cases and review of literature.
Topics: Anal Canal; Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Rectal Neoplasms; Retrospective Studies | 2020 |
Clinical significance of the molecular heterogeneity of gastrointestinal stromal tumors and related research: A systematic review.
Topics: Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Genetic Heterogeneity; Humans; Imatinib Mesylate; Phenylurea Compounds; Prognosis; Proto-Oncogene Proteins c-kit; Pyridines; Receptor, Platelet-Derived Growth Factor alpha; Succinate Dehydrogenase; Sunitinib | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Avapritinib in the treatment of PDGFRA exon 18 mutated gastrointestinal stromal tumors.
Topics: Exons; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Pyrazoles; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Standard of Care; Triazines | 2020 |
Ripretinib: First Approval.
Topics: Antineoplastic Agents; Drug Approval; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Protein Kinase Inhibitors; Proto-Oncogene Mas; Receptor, Platelet-Derived Growth Factor alpha | 2020 |
Gastrointestinal Stromal Tumor: Challenges and Opportunities for a New Decade.
Topics: Apoptosis; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Naphthyridines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrazoles; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Triazines; Urea | 2020 |
The Landmark Series: Systemic Therapy for Resectable Gastrointestinal Stromal Tumors.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Recurrence, Local | 2020 |
Non-Coding RNAs, a Novel Paradigm for the Management of Gastrointestinal Stromal Tumors.
Topics: Biomarkers, Tumor; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; MicroRNAs; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor beta; RNA, Neoplasm | 2020 |
Strategies for care of patients with gastrointestinal stromal tumor or soft tissue sarcoma during COVID-19 pandemic: A guide for surgical oncologists.
Topics: COVID-19; Gastrointestinal Stromal Tumors; Health Resources; Humans; Imatinib Mesylate; Oncologists; Practice Guidelines as Topic; SARS-CoV-2; Soft Tissue Neoplasms; Surgical Oncology | 2021 |
Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib.
Topics: Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Mutation; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Signal Transduction; Sunitinib; Treatment Outcome | 2021 |
Translating Knowledge About the Immune Microenvironment of Gastrointestinal Stromal Tumors into Effective Clinical Strategies.
Topics: Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunotherapy; Lymphocytes, Tumor-Infiltrating; Neoplasm Recurrence, Local; T-Lymphocytes; Tumor Microenvironment; Tumor-Associated Macrophages | 2021 |
The management of metastatic GIST: current standard and investigational therapeutics.
Topics: Animals; Antineoplastic Agents; Disease Management; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Metastasis; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sunitinib | 2021 |
Surgical management of rectal GIST. A case report and a review of literature.
Topics: Aged; Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Laparoscopy; Neoadjuvant Therapy; Rectal Neoplasms; Rectum | 2021 |
Gastrointestinal stromal tumor: a review of current and emerging therapies.
Topics: Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immune Checkpoint Inhibitors; Mutation; Neoadjuvant Therapy; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Randomized Controlled Trials as Topic; Receptor, Platelet-Derived Growth Factor alpha | 2021 |
Disease-free Interval Is Associated with Oncologic Outcomes in Patients with Recurrent Gastrointestinal Stromal Tumor.
Topics: Disease-Free Survival; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Metastasectomy; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies | 2021 |
Supraclavicular lymph node metastases from malignant gastrointestinal stromal tumor of the jejunum: A case report with review of the literature.
Topics: Antineoplastic Agents; Biopsy, Needle; Chemotherapy, Adjuvant; Erythrocyte Transfusion; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Jejunum; Lymph Nodes; Lymphatic Metastasis; Male; Melena; Middle Aged; Neck Dissection; Neoplasm Grading; Positron Emission Tomography Computed Tomography; Stomach Neoplasms; Ultrasonography | 2017 |
GEIS guidelines for gastrointestinal sarcomas (GIST).
Topics: Antineoplastic Agents; Combined Modality Therapy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Pyridines; Pyrroles; Sunitinib | 2017 |
Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.
Topics: Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit | 2017 |
Remarkable effects of imatinib in a family with young onset gastrointestinal stromal tumors and cutaneous hyperpigmentation associated with a germline KIT-Trp557Arg mutation: case report and literature overview.
Topics: Adult; Age of Onset; Antineoplastic Agents; Exons; Female; Gastrointestinal Stromal Tumors; Genetic Predisposition to Disease; Genetic Testing; Germ-Line Mutation; Humans; Hyperpigmentation; Imatinib Mesylate; Neoplastic Syndromes, Hereditary; Proto-Oncogene Proteins c-kit; Rectum; Skin; Stomach; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2018 |
A Rare Case of a Metastatic Gastrointestinal Stromal Tumor (GIST): a Case Report and Review of the Literature.
Topics: Biopsy; Cervical Vertebrae; Colonoscopy; Gastrointestinal Hemorrhage; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Radionuclide Imaging; Rectum; Spinal Neoplasms; Tomography, X-Ray Computed | 2019 |
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumor after failure with imatinib and sunitinib treatment: A meta-analysis.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Phenylurea Compounds; Pyridines; Pyrroles; Sunitinib | 2017 |
Long-Term Imatinib Treatment for Patients with Unresectable or Recurrent Gastrointestinal Stromal Tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Progression; Female; Follow-Up Studies; Gastrectomy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Japan; Long-Term Care; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome | 2018 |
CD117 is not always positive in infantile gastrointestinal stromal tumor.
Topics: Anastomosis, Surgical; Biomarkers, Tumor; Biopsy, Needle; Colectomy; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Infant; Laparotomy; Multimodal Imaging; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins c-kit; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography, Doppler, Color | 2018 |
The Story of Imatinib in GIST - a Journey through the Development of a Targeted Therapy.
Topics: Clinical Trials as Topic; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Protein Kinase Inhibitors | 2018 |
[A Case of Rectal Gastrointestinal Stromal Tumor(GIST)Treated with Imatinib Mesylate Neoadjuvant Therapy to Preserve the Anus].
Topics: Adult; Anal Canal; Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Rectal Neoplasms | 2018 |
Hepatitis B virus reactivation following imatinib therapy: A comparative review of 9 cases.
Topics: Aged, 80 and over; Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hepatitis B; Hepatitis B virus; Humans; Imatinib Mesylate; Male; Risk Factors; Virus Activation | 2019 |
The BRAF Status May Predict Response to Sorafenib in Gastrointestinal Stromal Tumors Resistant to Imatinib, Sunitinib, and Regorafenib: Case Series and Review of the Literature.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Drug Substitution; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Sunitinib; Treatment Outcome | 2019 |
Genomic Subtypes of GISTs for Stratifying Patient Response to Sunitinib following Imatinib Resistance: A Pooled Analysis and Systematic Review.
Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2018 |
Topics: Antineoplastic Agents; Combined Modality Therapy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha; Tomography, X-Ray Computed | 2018 |
Neoadjuvant imatinib therapy in rectal gastrointestinal stromal tumors.
Topics: Anal Canal; Antineoplastic Agents; Digestive System Surgical Procedures; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Organ Sparing Treatments; Receptor, Platelet-Derived Growth Factor alpha; Rectal Neoplasms; Risk; Time Factors; Treatment Outcome | 2019 |
Dedifferentiated gastrointestinal stromal tumor: Recent advances.
Topics: Biomarkers, Tumor; Cell Dedifferentiation; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry | 2019 |
PRE-OPERATIVE GASTRIC GIST DOWNSIZING: THE IMPORTANCE OF NEOADJUVANT THERAPY.
Topics: Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Neoplasm Staging; Stomach Neoplasms | 2019 |
[Imatinib and beyond-what is important for surgery?]
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Piperazines; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines | 2019 |
Gastrointestinal Stromal Tumors of the Stomach and Esophagus.
Topics: Aftercare; Antineoplastic Agents; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Esophageal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Profiling; Humans; Imatinib Mesylate; Laparoscopy; Neoplasm Metastasis; Prognosis; Proto-Oncogene Mas; Stomach Neoplasms; Tomography, X-Ray Computed | 2019 |
Gastrointestinal stromal tumor - A review of clinical studies.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sunitinib | 2019 |
Relationship between efficacy of sunitinib and KIT mutation of patients with advanced gastrointestinal stromal tumors after failure of imatinib: A systematic review.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Pharmacogenomic Variants; Proto-Oncogene Proteins c-kit; Sunitinib | 2019 |
Imaging surveillance of gastrointestinal stromal tumour: current recommendation by National Comprehensive Cancer Network and European Society of Medical Oncology-European Reference Network for rare adult solid cancers.
Topics: Chemotherapy, Adjuvant; Continuity of Patient Care; Contrast Media; Diagnostic Imaging; Drug Resistance, Neoplasm; Early Diagnosis; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Metastasis; Neoplasm Recurrence, Local; Practice Guidelines as Topic; Protein Kinase Inhibitors; Risk Assessment | 2019 |
Long-term efficacy of imatinib for treatment of metastatic GIST.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Progression; DNA Mutational Analysis; Dose-Response Relationship, Drug; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Metastasis; Patient Compliance; Piperazines; Pyrimidines; Survival Analysis; Treatment Outcome | 2013 |
[Molecular mechanism and therapeutic strategy for resistance to tyrosine kinase inhibitors in targeted treatment of gastrointestinal stromal tumors].
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2013 |
[Treatment progress of gastrointestinal stromal tumor].
Topics: Benzamides; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines | 2013 |
Resistance to treatment in gastrointestinal stromal tumours: what radiologists should know.
Topics: Antineoplastic Agents; Benzamides; Contrast Media; Disease Progression; Drug Resistance, Neoplasm; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Piperazines; Positron-Emission Tomography; Pyrimidines; Radiopharmaceuticals; Tomography, X-Ray Computed | 2013 |
Gastrointestinal stromal tumour.
Topics: Antineoplastic Agents; Benzamides; Chondroma; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leiomyosarcoma; Lung Neoplasms; Mutation; Neurofibromatosis 1; Paraganglioma, Extra-Adrenal; Piperazines; Preoperative Care; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Stomach Neoplasms | 2013 |
[Anticancer drug adherence].
Topics: Administration, Oral; Age Factors; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Breast Neoplasms; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Infusions, Intravenous; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma; Male; Medication Adherence; Neoplasms; Physician's Role; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Risk Factors; Socioeconomic Factors | 2013 |
Adherence to imatinib therapy in gastrointestinal stromal tumors and chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medication Adherence; Piperazines; Pyrimidines | 2013 |
Optimizing surgical and imatinib therapy for the treatment of gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Piperazines; Pyrimidines | 2013 |
[Case of primary retroperitoneal GIST (gastrointestinal stromal tumor) with rapid progression].
Topics: Antineoplastic Agents; Benzamides; Biopsy; Disease Progression; Fatal Outcome; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lymphatic Metastasis; Male; Middle Aged; Piperazines; Pyrimidines; Retroperitoneal Neoplasms; Tomography, X-Ray Computed | 2013 |
Gastrointestinal stromal tumors.
Topics: Animals; Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gastrointestinal Tract; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2011 |
[A case of a giant rectal gastrointestinal stromal tumor radically resectable after treatment with neoadjuvant imatinib mesylate].
Topics: Antinematodal Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Piperazines; Pyrimidines; Rectal Neoplasms; Tomography, X-Ray Computed | 2013 |
Reintroduction of imatinib in GIST.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Salvage Therapy | 2013 |
Adherence to imatinib therapy in patients with gastrointestinal stromal tumors.
Topics: Age Factors; Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Medication Adherence; Piperazines; Polypharmacy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Sex Factors; Treatment Outcome | 2014 |
New fronts in the adjuvant treatment of GIST.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Clinical Trials as Topic; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Prognosis; Pyrimidines; Risk Factors; Survival Rate; Time Factors | 2013 |
Regorafenib: a guide to its use in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib and sunitinib.
Topics: Animals; Benzamides; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Evaluation, Preclinical; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sunitinib | 2013 |
Personalized management: inoperable gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines | 2014 |
Intolerance to imatinib in gastrointestinal stromal tumors: a case report and a review of literature.
Topics: Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Piperazines; Pyrimidines | 2014 |
Imatinib and beyond in gastrointestinal stromal tumors: A radiologist's perspective.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Multimodal Imaging; Piperazines; Positron-Emission Tomography; Pyrimidines; Tomography, X-Ray Computed | 2013 |
Multidisciplinary care of gastrointestinal stromal tumour: a review and a proposal for a pre-treatment classification.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Clinical Trials as Topic; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Interdisciplinary Communication; Molecular Targeted Therapy; Neoadjuvant Therapy; Patient Care Team; Patient Selection; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Research Design; Terminology as Topic | 2013 |
Optimizing tyrosine kinase inhibitor therapy in gastrointestinal stromal tumors: exploring the benefits of continuous kinase suppression.
Topics: Benzamides; Disease Progression; Disease-Free Survival; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
Imatinib-induced bone edema: case report and review of literature.
Topics: Antineoplastic Agents; Benzamides; Bone and Bones; Edema; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Tomography, X-Ray Computed | 2013 |
Metastasectomy for gastrointestinal stromal tumors.
Topics: Benzamides; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Metastasectomy; Mutation; Patient Selection; Piperazines; Pyrimidines | 2014 |
Practical role of mutation analysis for imatinib treatment in patients with advanced gastrointestinal stromal tumors: a meta-analysis.
Topics: Benzamides; Disease-Free Survival; Exons; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Odds Ratio; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Treatment Outcome | 2013 |
Off-Target Effects of BCR-ABL and JAK2 Inhibitors.
Topics: Aniline Compounds; Antineoplastic Agents; Carbazoles; Dasatinib; Drug-Related Side Effects and Adverse Reactions; Eosinophilia; Furans; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Graft vs Host Disease; Harringtonines; Homoharringtonine; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Imidazoles; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mastocytosis; Myeloproliferative Disorders; Nitriles; Polycythemia Vera; Primary Myelofibrosis; Protein Kinase Inhibitors; Pulmonary Fibrosis; Pyrazoles; Pyridazines; Pyrimidines; Quinolines; Scleroderma, Systemic; Smallpox; Thrombocythemia, Essential; Tuberculosis, Multidrug-Resistant | 2016 |
Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis.
Topics: Antineoplastic Agents; Benzamides; DNA Mutational Analysis; Drug Resistance, Neoplasm; Exons; Gastrointestinal Stromal Tumors; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Mutation; Odds Ratio; Phenotype; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Risk Factors | 2013 |
The GIST of targeted therapy for malignant melanoma.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Melanoma; Molecular Targeted Therapy; Mutation; Piperazines; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Pyrimidines; Sulfonamides; Vemurafenib | 2014 |
PDGF receptor signaling networks in normal and cancer cells.
Topics: Benzamides; Fibrosis; Gastrointestinal Stromal Tumors; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Infections; Leukemia; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Stroke | 2014 |
[Long-term survival in a case of recurrent gastrointestinal stromal tumor treated with intermittent or low-dose imatinib].
Topics: Aged; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Recurrence; Stomach Neoplasms; Time Factors; Treatment Outcome | 2014 |
Review article: the biology, diagnosis and management of gastrointestinal stromal tumours.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2014 |
Gastrointestinal stromal tumor of colon: a case report and review of literature.
Topics: Antineoplastic Agents; Benzamides; Colonic Neoplasms; Combined Modality Therapy; Digestive System Surgical Procedures; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Piperazines; Pyrimidines | 2014 |
Practical aspects of risk assessment in gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Consensus Development Conferences, NIH as Topic; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mitotic Index; Molecular Targeted Therapy; Multicenter Studies as Topic; Mutation; Nomograms; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Risk Assessment; Treatment Outcome; Tumor Burden; United States | 2014 |
[Gastrointestinal stromal tumors: diagnostics and therapy].
Topics: Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Guideline Adherence; Humans; Imatinib Mesylate; Lymph Node Excision; Neoplasm Seeding; Neoplasm Staging; Piperazines; Pyrimidines; Risk Assessment | 2014 |
Prevalence of gastrointestinal stromal tumour (GIST) in the United Kingdom at different therapeutic lines: an epidemiologic model.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Incidence; Indoles; Models, Statistical; Piperazines; Prevalence; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rare Diseases; Registries; Sunitinib; Treatment Failure; United Kingdom | 2014 |
Spontaneous rupture of a giant gastrointestinal stromal tumor of the jejunum: a case report and literature review.
Topics: Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Jejunal Neoplasms; Male; Peritoneal Neoplasms; Piperazines; Prognosis; Pyrimidines; Rupture, Spontaneous; Tomography, X-Ray Computed | 2014 |
Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Metastasis; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2014 |
Gastrointestinal stromal tumors: who should get imatinib and for how long?
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Drug Resistance; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2014 |
Managing GIST in the imatinib era: optimization of adjuvant therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Child; Child, Preschool; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome; Young Adult | 2014 |
Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib; Treatment Outcome | 2014 |
[Molecular biology of sarcoma and therapeutic choices].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzamides; Bone Neoplasms; Crizotinib; Denosumab; Dermatofibrosarcoma; Gastrointestinal Stromal Tumors; Gene Amplification; Gene Deletion; Giant Cell Tumor of Bone; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Phenylurea Compounds; Piperazines; Point Mutation; Prognosis; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sarcoma; Sarcoma, Ewing; Sunitinib; Synovitis, Pigmented Villonodular; Translocation, Genetic | 2015 |
Management of Gastrointestinal Stromal Tumour: Current Practices and Visions for the Future.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Clinical Trials as Topic; Congresses as Topic; Consensus; Drug Administration Schedule; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Medical Oncology; Molecular Targeted Therapy; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome | 2015 |
Classification of KIT/PDGFRA wild-type gastrointestinal stromal tumors: implications for therapy.
Topics: Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha; Succinate Dehydrogenase | 2015 |
[Potential clinical benefit of therapeutic drug monitoring of imatinib in oncology].
Topics: Benzamides; Drug Monitoring; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2015 |
Current management of patients with gastrointestinal stromal tumor receiving the multitargeted tyrosine kinase inhibitor sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2015 |
Role of genetic and molecular profiling in sarcomas.
Topics: Antineoplastic Agents; Gastrointestinal Stromal Tumors; Gene Expression Profiling; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Precision Medicine; Prognosis; Sarcoma | 2015 |
Duodenal gastrointestinal stromal tumor: From clinicopathological features to surgical outcomes.
Topics: Age Distribution; Antineoplastic Agents; Benzamides; Biopsy, Fine-Needle; Endoscopy, Gastrointestinal; Endosonography; Europe; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Indoles; Mutation; Pancreaticoduodenectomy; Phenylurea Compounds; Piperazines; Prevalence; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Sex Distribution; Sunitinib; United States | 2015 |
Preoperative imatinib treatment in patients with advanced gastrointestinal stromal tumors: patient experiences and systematic review of 563 patients.
Topics: Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Preoperative Care; Retrospective Studies; Treatment Outcome | 2015 |
Follow-up strategies for patients with gastrointestinal stromal tumour treated with or without adjuvant imatinib after surgery.
Topics: Adjuvants, Immunologic; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Piperazines; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyrimidines; Tomography, X-Ray Computed | 2015 |
Gastrointestinal stromal tumors during pregnancy: a systematic review of an uncommon but treatable malignancy.
Topics: Antineoplastic Agents; Digestive System Surgical Procedures; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Treatment Outcome | 2015 |
Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion.
Topics: Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male | 2015 |
Systemic therapy options for advanced gastrointestinal stromal tumors beyond first-line imatinib: a systematic review.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Disease-Free Survival; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Treatment Outcome | 2015 |
Extraintestinal gastrointestinal stromal tumor of undetermined origin: Is the mass resection a wrong approach? A case report and review of the literature.
Topics: Aged; Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Pelvic Neoplasms; Piperazines; Postoperative Care; Prostatectomy; Prostatic Neoplasms; Pyrimidines; Treatment Outcome | 2015 |
Personalized Medicine in Gastrointestinal Stromal Tumor (GIST): Clinical Implications of the Somatic and Germline DNA Analysis.
Topics: DNA, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Precision Medicine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha | 2015 |
Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions.
Topics: Animals; Antineoplastic Agents; Drug Discovery; Drug Resistance, Neoplasm; Drugs, Investigational; Forecasting; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Signal Transduction; Treatment Outcome | 2015 |
The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Neoplasm Recurrence, Local; Phenylurea Compounds; Practice Guidelines as Topic; Proto-Oncogene Proteins c-kit; Pyridines | 2016 |
miRNA profiling in gastrointestinal stromal tumors: implication as diagnostic and prognostic markers.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Chromosome Deletion; Chromosomes, Human, Pair 14; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; MicroRNAs; Mutation; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Transcriptome | 2015 |
Recurrent retroperitoneal extra-GIST with rhabdomyosarcomatous and chondrosarcomatous differentiations: a rare case and literature review.
Topics: Antineoplastic Agents; Biomarkers, Tumor; DNA Mutational Analysis; Fatal Outcome; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Retroperitoneal Neoplasms | 2015 |
Can Imatinib Be Safely Withdrawn in Patients with Surgically Resected Metastatic GIST?
Topics: Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Prognosis; Withholding Treatment | 2015 |
Imatinib Dosing in Gastrointestinal Stromal Tumors (GISTs): When, How Much, and How Long?
Topics: Antineoplastic Agents; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Metastasis; Protein Kinase Inhibitors; Survival Analysis; Time Factors | 2015 |
[Mesenteric stromal tumor: report of a rare case and review of literature].
Topics: Abdomen, Acute; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Mesentery; Prognosis; Tomography, X-Ray Computed | 2015 |
A lethal mesenteric gastrointestinal stromal tumor: a case report and review of the literature.
Topics: Antineoplastic Agents; Fatal Outcome; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Mesentery; Middle Aged; Neoplasm Recurrence, Local; Peritoneal Neoplasms | 2015 |
MicroRNAs and Gastrointestinal Stromal Tumor.
Topics: Antineoplastic Agents; Cell Physiological Phenomena; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; MicroRNAs; Models, Genetic; Mutation; Proto-Oncogene Proteins c-kit | 2015 |
The Role of Surgery in Metastatic Gastrointestinal Stromal Tumors.
Topics: Antineoplastic Agents; Cytoreduction Surgical Procedures; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Protein Kinase Inhibitors | 2016 |
A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Safety | 2016 |
Immunological off-target effects of imatinib.
Topics: Antigens, Neoplasm; Antineoplastic Agents; B7 Antigens; Drug Approval; Forecasting; Gastrointestinal Stromal Tumors; Hematopoiesis; Humans; Imatinib Mesylate; Immune Tolerance; Immunity, Cellular; Immunologic Surveillance; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Chaperones; Molecular Targeted Therapy; Natural Cytotoxicity Triggering Receptor 3; Protein-Tyrosine Kinases; T-Lymphocytes; Tumor Escape; Vascular Endothelial Growth Factor A | 2016 |
Pharmacogenetics of tyrosine kinase inhibitors in gastrointestinal stromal tumor and chronic myeloid leukemia.
Topics: Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pharmacogenetics; Polymorphism, Genetic; Protein Kinase Inhibitors | 2016 |
Indications for surgery in advanced/metastatic GIST.
Topics: Antineoplastic Agents; Combined Modality Therapy; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Protein Kinase Inhibitors; Survival Analysis | 2016 |
An Unusual Case of Central Retinal Vein Occlusion and Review of the Toxicity Profile of Regorafenib in GIST Patients.
Topics: Aged; Fatal Outcome; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Retinal Vein Occlusion | 2016 |
Gastrointestinal stromal tumors in kidney transplant recipients: Report of two cases and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Everolimus; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kidney Transplantation; Male; Sirolimus; TOR Serine-Threonine Kinases | 2017 |
Knowns and Known Unknowns of Gastrointestinal Stromal Tumor Adjuvant Therapy.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Digestive System Surgical Procedures; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoadjuvant Therapy; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Pyridines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2016 |
Combined Therapy of Gastrointestinal Stromal Tumors.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Disease Management; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Treatment Outcome | 2016 |
Key messages from the BFR14 trial of the French Sarcoma Group.
Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Disease Progression; France; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Staging; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Sarcoma; Treatment Outcome | 2017 |
Imatinib-induced Gastrointestinal Vascular Ectasia in a Patient with Advanced GIST: Case Report and Literature Review.
Topics: Aged; Antineoplastic Agents; Female; Gastric Antral Vascular Ectasia; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Multimodal Imaging; Positron-Emission Tomography; Tomography, X-Ray Computed | 2016 |
[Umbilical Hernia Complicated by Gastrointestinal Stromal Tumor of the Small Intestine - A Case Report].
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Hernia, Umbilical; Humans; Imatinib Mesylate; Jejunal Neoplasms; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Tomography, X-Ray Computed | 2016 |
What is changing in the surgical treatment of gastrointestinal stromal tumors after multidisciplinary approach? A comprehensive literature's review.
Topics: Antineoplastic Agents; Combined Modality Therapy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Interdisciplinary Communication; Laparoscopy; Neoadjuvant Therapy; Neoplasm Staging; Preoperative Care; Prognosis; Robotic Surgical Procedures; Treatment Outcome | 2017 |
Management of gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Esophageal Neoplasms; Esophagectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Positron-Emission Tomography; Prognosis; Pyrimidines; Pyrroles; Risk Assessment; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
[Case of GIST of the rectum successfully treated with imatinib mesylate neoadjuvant therapy].
Topics: Antineoplastic Agents; Benzamides; Colectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Piperazines; Pyrimidines; Rectum | 2008 |
[Three cases of gastrointestinal stromal tumor (GIST) with bone metastasis].
Topics: Aged; Antineoplastic Agents; Benzamides; Bone Neoplasms; Digestive System Surgical Procedures; Fatal Outcome; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestine, Small; Male; Middle Aged; Piperazines; Pyrimidines; Rectum; Risk; Time Factors | 2008 |
Imatinib in advanced gastrointestinal stromal tumour: when is 800 mg the correct dose?
Topics: Benzamides; Dose-Response Relationship, Drug; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2008 |
Developments in targeted therapy of advanced gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Receptors, Vascular Endothelial Growth Factor; Sunitinib | 2008 |
[Clinical and molecular characterization of gastrointestinal stromal tumors (GIST)].
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Enzyme Activation; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines | 2007 |
[Indications for pre- and postoperative treatment with imatinib for gastrointestinal stromal tumors].
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Piperazines; Prognosis; Pyrimidines; Survival Rate | 2008 |
Recurrent rectal GIST resected successfully after preoperative chemotherapy with imatinib mesylate.
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Rectal Neoplasms | 2008 |
Novel approaches to imatinib- and sunitinib-resistant GIST.
Topics: Angiogenesis Inhibitors; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib | 2008 |
The insulin-like growth factor system as a potential therapeutic target in gastrointestinal stromal tumors.
Topics: Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Proto-Oncogene Proteins c-ret; Pyrimidines; Signal Transduction; Somatomedins | 2008 |
[Gastrointestinal stromal tumors. An update].
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib | 2008 |
[Two cases of primary unresectable and/or recurrent gastrointestinal stromal tumors of small intestine presenting hemoperitoneum caused by administration of imatinib mesylate].
Topics: Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Digestive System Surgical Procedures; Emergencies; Fatal Outcome; Gastrointestinal Stromal Tumors; Hemoperitoneum; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Treatment Outcome | 2008 |
FDG-PET and PET/CT in the clinical management of gastrointestinal stromal tumor.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Positron-Emission Tomography; Pyrimidines; Tomography, X-Ray Computed | 2008 |
Novel approaches to gastrointestinal stromal tumors resistant to imatinib and sunitinib.
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Pyrimidines; Pyrroles; Signal Transduction; Sunitinib | 2008 |
[Gastrointestinal stromal tumors in neurofibromatosis type 1].
Topics: Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Genes, Neurofibromatosis 1; Humans; Imatinib Mesylate; Male; Mitotic Index; Mutation; Neurofibromatosis 1; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Sex Factors | 2009 |
Multidisciplinary treatment of gastrointestinal stromal tumors.
Topics: Algorithms; Antineoplastic Agents; Benzamides; Catheter Ablation; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Mutation; Neoplasm Recurrence, Local; Piperazines; Positron-Emission Tomography; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Survival Analysis | 2009 |
Current standards and progress in understanding and treatment of GIST.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor Protein-Tyrosine Kinases | 2009 |
Gastrointestinal stromal tumor: a clinical overview.
Topics: Benzamides; Digestive System Surgical Procedures; Family Health; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines | 2009 |
Management of resectable gastrointestinal stromal tumor.
Topics: Benzamides; Combined Modality Therapy; Disease Management; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Receptor Protein-Tyrosine Kinases | 2009 |
Ocular side effects associated with imatinib mesylate and perifosine for gastrointestinal stromal tumor.
Topics: Benzamides; Eye Diseases; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Phosphorylcholine; Piperazines; Pyrimidines | 2009 |
Gastrointestinal stromal tumors (GISTs): a pathology view point.
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Diagnosis, Differential; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Piperazines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines | 2009 |
Perioperative treatment of gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Clinical Trials as Topic; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoadjuvant Therapy; Pharmacogenetics; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2009 |
Treatment of gastrointestinal stromal tumours: imatinib, sunitinib -- and then?
Topics: Animals; Antineoplastic Agents; Benzamides; Drug Design; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Pyrimidines; Pyrroles; Signal Transduction; Sunitinib | 2009 |
Imatinib in the treatment of solid tumours.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chordoma; Clinical Trials as Topic; Dermatofibrosarcoma; Fibromatosis, Aggressive; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Macrophage Colony-Stimulating Factor; Receptors, Platelet-Derived Growth Factor; Skin Neoplasms; Treatment Outcome | 2009 |
Surgical management of gastrointestinal stromal tumours.
Topics: Antineoplastic Agents; Benzamides; Digestive System Surgical Procedures; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Piperazines; Pyrimidines; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Extra-abdominal subcutaneous metastasis of a gastrointestinal stromal tumor: report of a case and a review of the literature.
Topics: Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Bone Neoplasms; Carcinoma; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Indoles; Liver Neoplasms; Piperazines; Pyrimidines; Pyrroles; Soft Tissue Neoplasms; Subcutaneous Fat; Sunitinib | 2009 |
Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; DNA Mutational Analysis; Europe; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Metastasis; Piperazines; Practice Guidelines as Topic; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib | 2009 |
Is there a role for discontinuing imatinib in patients with advanced gastrointestinal stromal tumour?
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Randomized Controlled Trials as Topic | 2009 |
[Surgical treatment of an advanced GIST the age of imatinib].
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Staging; Piperazines; Practice Guidelines as Topic; Pyrimidines | 2009 |
[Small-molecule inhibitors against KIT and PDGFRs especially in GISTs].
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor | 2009 |
[Gastrointestinal stromal tumors: recommendations for diagnosis, treatment and aftercare in Austria].
Topics: Antineoplastic Agents; Austria; Benzamides; Biomarkers, Tumor; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; DNA Mutational Analysis; Endosonography; Evidence-Based Medicine; Follow-Up Studies; Gastrointestinal Stromal Tumors; Gastrointestinal Tract; Guidelines as Topic; Humans; Imatinib Mesylate; Mitotic Index; Neoadjuvant Therapy; Neoplasm Staging; Patient Care Team; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2009 |
[Surgical treatment of gastrointestinal stromal tumors].
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Endoscopy, Gastrointestinal; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Laparoscopy; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Pancreaticoduodenectomy; Patient Care Team; Piperazines; Pyrimidines; Stomach Neoplasms | 2009 |
[GIST: adjuvant treatment in Austria].
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Disease-Free Survival; Dose-Response Relationship, Drug; Gastrointestinal Stromal Tumors; Gene Expression; Humans; Imatinib Mesylate; Long-Term Care; Neoplasm Recurrence, Local; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Randomized Controlled Trials as Topic | 2009 |
[Treatment of extensive disease].
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Therapy, Combination; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Long-Term Care; Neoplasm Invasiveness; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2009 |
Imatinib in gastrointestinal stromal tumor: does treatment duration matter?
Topics: Antineoplastic Agents; Benzamides; Disease-Free Survival; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Time Factors | 2009 |
Imaging of gastrointestinal stromal tumors before and after imatinib mesylate therapy.
Topics: Antineoplastic Agents; Benzamides; Contrast Media; Disease Progression; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Outcome Assessment, Health Care; Piperazines; Predictive Value of Tests; Pyrimidines; Tomography, X-Ray Computed | 2009 |
Advances in the treatment of gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Drug Delivery Systems; Drug Resistance, Neoplasm; Drugs, Investigational; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib | 2009 |
A benefit-risk assessment of imatinib in chronic myeloid leukaemia and gastrointestinal stromal tumours.
Topics: Animals; Antineoplastic Agents; Benzamides; Breast Feeding; Drug Delivery Systems; Drug Interactions; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Pyrimidines | 2009 |
Gastric oncology: an update.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Benzamides; Endoscopy, Gastrointestinal; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lymphoma, B-Cell, Marginal Zone; Neoplasm Metastasis; Neoplasm Staging; Piperazines; Pyrimidines; Stomach Neoplasms | 2009 |
[Positron emission tomography and evaluation of response to targeted therapies].
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Hypoxia; Cell Proliferation; Choline; ErbB Receptors; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lipid Metabolism; Lung Neoplasms; Neoplasms; Neovascularization, Pathologic; Piperazines; Positron-Emission Tomography; Protein Biosynthesis; Protein Kinases; Pyrimidines; Radiopharmaceuticals; Receptors, Androgen; Receptors, Estrogen; TOR Serine-Threonine Kinases | 2009 |
[Targeted therapies in soft-tissue and visceral sarcomas].
Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Drug Delivery Systems; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Neoplasm Proteins; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Viscera | 2009 |
Dysregulation of bone remodeling by imatinib mesylate.
Topics: Benzamides; Bone Remodeling; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Osteoclasts; Osteolysis; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2010 |
Extragastrointestinal stromal tumors of the omentum: review apropos of a case with a novel gain-of-function KIT mutation.
Topics: Aged; Antineoplastic Agents; Base Sequence; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Incidental Findings; Male; Molecular Sequence Data; Mutation; Neoplasm Recurrence, Local; Omentum; Peritoneal Neoplasms; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines | 2009 |
Targeted therapies in the treatment of GIST: Adverse events and maximising the benefits of sunitinib through proactive therapy management.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2010 |
Combined treatment strategies in gastrointestinal stromal tumors (GISTs) after imatinib and sunitinib therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib | 2010 |
[Aspects of surgical treatment for gastro-intestinal stromal tumors].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Diagnostic Imaging; Disease Progression; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Laparoscopy; Minimally Invasive Surgical Procedures; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2009 |
Gastrointestinal stromal tumors: diagnostics, therapy and beyond?
Topics: Benzamides; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Gastrointestinal Stromal Tumors; Gastroscopy; Histocytochemistry; Humans; Imatinib Mesylate; Immunophenotyping; Magnetic Resonance Imaging; Mutation; Piperazines; Positron-Emission Tomography; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Risk Factors; Tomography, X-Ray Computed | 2009 |
[Gastrointestinal stromal tumors: evolution of a tumor concept from unclassifiable neoplasms to targeted molecular therapy].
Topics: Antineoplastic Agents; Benzamides; DNA Mutational Analysis; Drug Delivery Systems; Gastrointestinal Stromal Tumors; Gastrointestinal Tract; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Indoles; Piperazines; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sequence Analysis, DNA; Sunitinib | 2010 |
Malignant appendiceal GIST: case report and review of the literature.
Topics: Abscess; Antineoplastic Agents; Appendiceal Neoplasms; Benzamides; Diabetes Mellitus, Type 2; Gastrointestinal Stromal Tumors; Humans; Hypertension; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Neoadjuvant Therapy; Piperazines; Pyrimidines; Tomography, X-Ray Computed | 2010 |
[Effect of c-kit mutation on the prognosis of gastrointestinal stromal tumors: a meta-analysis].
Topics: Antineoplastic Agents; Benzamides; Case-Control Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines | 2009 |
[A case of rectal GIST treated with imatinib mesylate neoadjuvant therapy to preserve the anus].
Topics: Anal Canal; Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Piperazines; Pyrimidines; Rectal Neoplasms | 2009 |
Imatinib treatment for gastrointestinal stromal tumour (GIST).
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2010 |
[Bemusement and strategy on the efficacy of clinical application of targeted anticancer drugs].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Deoxycytidine; Drug Delivery Systems; Gastrointestinal Stromal Tumors; Gemcitabine; Humans; Imatinib Mesylate; Indoles; Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2009 |
Gastrointestinal stromal tumor: a bridge between bench and bedside.
Topics: Animals; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2009 |
Gastrointestinal stromal tumors: current management.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2010 |
Imatinib mesylate.
Topics: Animals; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2010 |
[Gastrointestinal stromal tumor of small intestine associated with lymph node metastasis: a report of 2 cases with review of literatures].
Topics: Adult; Antineoplastic Agents; Benzamides; Codon; Exons; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lymphatic Metastasis; Male; Middle Aged; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines | 2009 |
Targeted therapy for gastrointestinal stromal tumors: current status and future perspectives.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Delivery Systems; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Medical Oncology; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines | 2010 |
Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients.
Topics: Antineoplastic Agents; Benzamides; Disease-Free Survival; Exons; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Mutation; Neoplasm Metastasis; Piperazines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines | 2010 |
Future treatment of soft tissue sarcomas will be driven by histological subtype and molecular aberrations.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Benzamides; Cytotoxins; Dermatofibrosarcoma; Disease Progression; Gastrointestinal Stromal Tumors; Hemangioendothelioma; Hemangiosarcoma; Humans; Imatinib Mesylate; Leiomyosarcoma; Liposarcoma, Myxoid; Piperazines; Pyrimidines; Research Design; Sarcoma; Sarcoma, Synovial; Skin Neoplasms | 2010 |
The role of high-dose imatinib in the management of patients with gastrointestinal stromal tumor.
Topics: Benzamides; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Neoplasm Metastasis; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2010 |
Molecular response prediction in gastrointestinal stromal tumors.
Topics: Animals; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib | 2010 |
Targeted therapies of gastrointestinal stromal tumors (GIST)--the next frontiers.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2010 |
Optimal use of targeted agents for advanced gastrointestinal stromal tumours.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; DNA Mutational Analysis; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Staging; Piperazines; Pyrimidines; Pyrroles; Sunitinib; Survival Rate; Treatment Outcome | 2010 |
Imatinib mesylate for the treatment of gastrointestinal stromal tumor.
Topics: Animals; Benzamides; Clinical Trials as Topic; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome | 2010 |
[Focus on GIST management].
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles | 2010 |
Personalized cancer therapy for gastrointestinal stromal tumor: synergizing tumor genotyping with imatinib plasma levels.
Topics: Benzamides; Disease-Free Survival; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor | 2010 |
Gastrointestinal stromal tumors: a paradigm for therapeutic options in solid organ tumors.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor | 2010 |
Neoadjuvant and adjuvant imatinib treatment in gastrointestinal stromal tumor: current status and recent developments.
Topics: Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Survival Analysis; Treatment Outcome | 2010 |
Molecular basis and management of gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib | 2010 |
[Surgical news of soft tissue sarcomas, fibromatosis and GIST].
Topics: Antineoplastic Agents; Benzamides; Fibromatosis, Aggressive; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Infusions, Intra-Arterial; Piperazines; Practice Guidelines as Topic; Pyrimidines; Retroperitoneal Neoplasms; Sarcoma; Surgical Flaps | 2010 |
Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors.
Topics: Benzamides; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Staging; Piperazines; Practice Guidelines as Topic; Pyrimidines; Recurrence | 2010 |
Gastrointestinal stromal tumors (GISTs): an updated experience.
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Diagnosis, Differential; Disease Progression; Endoscopy, Gastrointestinal; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Neoplasm Recurrence, Local; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2010 |
Efficacy evaluation of imatinib treatment in patients with gastrointestinal stromal tumors: a meta-analysis.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Exons; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Treatment Outcome | 2010 |
Imatinib: as adjuvant therapy for gastrointestinal stromal tumour.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines | 2010 |
[Multimodality therapy concepts for soft tissue sarcomas].
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Cross-Sectional Studies; Gastrointestinal Stromal Tumors; Humans; Hyperthermia, Induced; Imatinib Mesylate; Indoles; Neoadjuvant Therapy; Palliative Care; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Radiotherapy, Adjuvant; Sarcoma; Soft Tissue Neoplasms; Sunitinib | 2010 |
Clinical implications of KIT and PDGFRA genotyping in GIST.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2010 |
Imatinib as adjuvant treatment following resection of KIT-positive gastrointestinal stromal tumours.
Topics: Antineoplastic Agents; Benzamides; Cost-Benefit Analysis; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Randomized Controlled Trials as Topic; United Kingdom | 2010 |
[Systemic therapy of soft tissue sarcomas].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Drug Delivery Systems; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Survival Rate | 2011 |
Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Cost-Benefit Analysis; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Models, Economic; Neoplasm Metastasis; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib | 2010 |
Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing?
Topics: Antineoplastic Agents; Benzamides; Drug Monitoring; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Metastasis; Patient Compliance; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2011 |
Liver transplantation for metastasized extragastrointestinal stromal tumor: a case report and an overview of literature.
Topics: Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Living Donors; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Rectal Neoplasms; Time Factors; Treatment Outcome; Vaginal Neoplasms | 2010 |
Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Meta-Analysis as Topic; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Randomized Controlled Trials as Topic; Receptor, Platelet-Derived Growth Factor alpha | 2011 |
Adjuvant and neoadjuvant therapy for primary GIST.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2011 |
The GIST paradigm: lessons for other kinase-driven cancers.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines | 2011 |
The role of imatinib plasma level testing in gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Recurrence, Local; Pharmacogenetics; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines | 2011 |
[Clinical manifestation of targeted drugs in individualized therapy of malignant tumors].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Doxorubicin; Drug Delivery Systems; ErbB Receptors; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Lymphoma, Large B-Cell, Diffuse; Mutation; Neoplasms; Piperazines; Prednisone; Pyrimidines; Pyrroles; Remission Induction; Rituximab; Sunitinib; Vincristine | 2010 |
Drug transporters and imatinib treatment: implications for clinical practice.
Topics: Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Transport Proteins; Piperazines; Pyrimidines | 2011 |
Gastrointestinal stromal tumours (GISTs): case report and review of the literature.
Topics: Benzamides; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines | 2011 |
Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2011 |
A decade of tyrosine kinase inhibitor therapy: Historical and current perspectives on targeted therapy for GIST.
Topics: Adult; Angiogenesis Inhibitors; Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease-Free Survival; Drug Delivery Systems; Enzyme Inhibitors; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Neoplasm Staging; Pilot Projects; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib; Survival Analysis | 2011 |
Gastrointestinal stromal tumor presenting as a rectovaginal mass. Clinicopathologic and molecular-genetic characterization of a rare tumor with a literature review.
Topics: Adult; Antineoplastic Agents; Base Sequence; Benzamides; Comparative Genomic Hybridization; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Molecular Biology; Molecular Sequence Data; Mutation; Neoplasm Recurrence, Local; Piperazines; Polymerase Chain Reaction; Proto-Oncogene Proteins c-kit; Pyrimidines; Rectal Neoplasms; Vaginal Neoplasms | 2011 |
Extra-gastrointestinal stromal tumor of the pancreas: clinical characteristics, diagnosis, treatment, and outcome.
Topics: Abdominal Pain; Antineoplastic Agents; Benzamides; Fatigue; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Piperazines; Pyrimidines; Splenectomy; Weight Loss | 2011 |
Adjuvant imatinib for gastrointestinal stromal tumors: the current situation and problems.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines | 2011 |
Current and emerging pharmacological treatments for gastrointestinal stromal tumour.
Topics: Antineoplastic Agents; Benzamides; Drugs, Investigational; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2011 |
Management of recurrent gastrointestinal stromal tumors.
Topics: Benzamides; Combined Modality Therapy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2011 |
Large duodenal gastrointestinal stromal tumor presenting with acute bleeding managed by a whipple resection. A review of surgical options and the prognostic indicators of outcome.
Topics: Acute Disease; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Duodenal Neoplasms; Fatal Outcome; Gastrointestinal Hemorrhage; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Peritoneal Neoplasms; Piperazines; Pyrimidines | 2011 |
Malignant extra-gastrointestinal stromal tumor of the pancreas. A case report and review of literature.
Topics: Adult; Antineoplastic Agents; Benzamides; Diagnosis, Differential; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Pancreas; Pancreatic Neoplasms; Pancreaticoduodenectomy; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Treatment Outcome; Vimentin | 2011 |
Imatinib as adjuvant therapy for gastrointestinal stromal tumors: a systematic review.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Clinical Trials as Topic; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines | 2011 |
Synchronous well differentiated neuroendocrine tumour and gastrointestinal stromal tumour of the stomach: a case report.
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Gastroscopy; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasms, Multiple Primary; Neuroendocrine Tumors; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Stomach Neoplasms; Treatment Outcome | 2011 |
Gastrointestinal stromal tumor and its targeted therapeutics.
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Drug Delivery Systems; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2011 |
Adjuvant and neoadjuvant imatinib therapy: current role in the management of gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Disease Management; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Piperazines; Pyrimidines | 2011 |
Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day: a systematic review and economic eval
Topics: Antineoplastic Agents; Benzamides; Confidence Intervals; Cost-Benefit Analysis; Disease Progression; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Incidence; Models, Economic; Piperazines; Pyrimidines; Quality-Adjusted Life Years; Survival Analysis; Time Factors; Treatment Outcome; Uncertainty; United States | 2011 |
The safety profile of imatinib in CML and GIST: long-term considerations.
Topics: Animals; Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Time Factors | 2012 |
[Gastrointestinal stromal tumour (GIST): current standards in multimodal management].
Topics: Alleles; Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; DNA Mutational Analysis; Exons; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Maintenance Chemotherapy; Neoplasm Invasiveness; Neoplasm Staging; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2011 |
Pfetin as a prognostic biomarker for gastrointestinal stromal tumor: validation study in multiple clinical facilities.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Multivariate Analysis; Piperazines; Proteins; Pyrimidines; Reproducibility of Results; Survival Analysis | 2011 |
Practical management of imatinib in gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Nursing Methodology Research; Oncology Nursing; Piperazines; Practice Guidelines as Topic; Pyrimidines; Treatment Outcome | 2011 |
Gastrointestinal stromal tumor: advances in diagnosis and management.
Topics: Benzamides; Diagnosis, Differential; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Platelet-Derived Growth Factor; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib | 2011 |
Systematic review of escalated imatinib doses compared with sunitinib or best supportive care, for the treatment of people with unresectable/metastatic gastrointestinal stromal tumours whose disease has progressed on the standard imatinib dose.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Pyrimidines; Pyrroles; Sunitinib; Treatment Outcome | 2012 |
Imatinib-associated bilateral gynecomastia and unilateral testicular hydrocele in male patient with metastatic gastrointestinal stromal tumor: a literature review.
Topics: Aged; Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gynecomastia; Humans; Imatinib Mesylate; Male; Piperazines; Pyrimidines; Testicular Hydrocele | 2012 |
Gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Activation; Exons; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Molecular Targeted Therapy; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2012 |
The management of gastrointestinal stromal tumors: a model for targeted and multidisciplinary therapy of malignancy.
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Risk Factors | 2012 |
Managing progressive disease in patients with GIST: factors to consider besides acquired secondary tyrosine kinase inhibitor resistance.
Topics: Benzamides; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Patient Compliance; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib | 2012 |
Advanced or metastatic gastrointestinal stromal tumors: systemic treatment options.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib | 2011 |
Adjuvant imatinib therapy for gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Clinical Trials as Topic; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2011 |
Systemic therapy for advanced gastrointestinal stromal tumors: beyond imatinib.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Piperidines; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptors, Platelet-Derived Growth Factor; Sunitinib; Thiazoles | 2011 |
Gastrointestinal stromal tumours: origin and molecular oncology.
Topics: Benzamides; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Succinate Dehydrogenase | 2011 |
Small intestine gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Intestinal Neoplasms; Intestine, Small; Neoadjuvant Therapy; Neoplasm Metastasis; Piperazines; Prognosis; Pyrimidines; Pyrroles; Sunitinib | 2012 |
The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2012 |
Predictors of response to targeted therapies for gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2012 |
Efficacy evaluation of imatinib in the treatment of patients with gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Disease-Free Survival; Dose-Response Relationship, Drug; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Survival Rate; Treatment Outcome | 2011 |
Recurrence risk after resection of gastrointestinal stromal tumors: size is not all that matters... The consequences of tumor rupture.
Topics: Antineoplastic Agents; Benzamides; Biopsy; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Prognosis; Pyrimidines; Risk Factors; Rupture; Survival Rate | 2012 |
Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Administration Schedule; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
Gastric antral vascular ectasia in a patient with GIST after treatment with imatinib: case report and literature review.
Topics: Aged; Antineoplastic Agents; Benzamides; Endoscopy, Digestive System; Female; Gastric Antral Vascular Ectasia; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2012 |
Is there something other than imatinib mesilate in therapeutic options for GIST?
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2012 |
[Resistance and treatment strategy of gastrointestinal stromal tumor target therapy].
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib | 2012 |
Adjuvant treatment of GIST: patient selection and treatment strategies.
Topics: Adjuvants, Immunologic; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Patient Selection; Piperazines; Pyrimidines | 2012 |
Advances in adjuvant therapy of gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Clinical Trials as Topic; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2012 |
Adjuvant therapy of gastrointestinal stromal tumors.
Topics: Benzamides; Chemotherapy, Adjuvant; Clinical Trials as Topic; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib | 2012 |
Gastrointestinal stromal tumors: evolving role of the multidisciplinary team approach in management.
Topics: Benzamides; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Molecular Diagnostic Techniques; Neoplasm Staging; Patient Care Team; Piperazines; Preoperative Period; Pyrimidines; Risk Assessment; Treatment Outcome | 2012 |
Current management of gastrointestinal stromal tumors--a comprehensive review.
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2012 |
Gastrointestinal stromal tumors (GIST): a rare entity, a tumor model for personalized therapy, and yet ten different molecular subtypes.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Precision Medicine; Pyrimidines; Survival Analysis | 2012 |
Management of localized gastrointestinal stromal tumors and adjuvant therapy with imatinib.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mitotic Index; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Risk; Rupture, Spontaneous | 2012 |
Adjuvant therapy of gastrointestinal stromal tumors (GIST).
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome | 2012 |
Understanding rechallenge and resistance in the tyrosine kinase inhibitor era: imatinib in gastrointestinal stromal tumor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Patient Compliance; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2014 |
Adjuvant therapy in primary GIST: state-of-the-art.
Topics: Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome | 2012 |
Management of gastrointestinal stromal tumors: looking beyond the knife. An update on the role of adjuvant and neoadjuvant imatinib therapy.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Piperazines; Pyrimidines | 2012 |
Efficacy and safety evaluation of two doses of imatinib for the treatment of advanced gastrointestinal stromal tumors (GISTs).
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Staging; Piperazines; Pyrimidines | 2012 |
FDG PET and FDG PET/CT in patients with gastrointestinal stromal tumours.
Topics: Antineoplastic Agents; Benzamides; Blood Glucose; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Multimodal Imaging; Neoplasm Recurrence, Local; Piperazines; Positron-Emission Tomography; Prognosis; Pyrimidines; Pyrroles; Sensitivity and Specificity; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Duodenal gastrointestinal stromal tumors: review on clinical and surgical aspects.
Topics: Antineoplastic Agents; Benzamides; Digestive System Surgical Procedures; Duodenal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Piperazines; Pyrimidines | 2012 |
[Translational research and diagnosis in GIST].
Topics: Adult; Antineoplastic Agents; Benzamides; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Silencing; Germ-Line Mutation; Humans; Imatinib Mesylate; Lymphatic Metastasis; Male; Mitotic Index; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Succinate Dehydrogenase; Transcriptional Activation; Translational Research, Biomedical; Tumor Burden; Young Adult | 2012 |
The role of surgery in the multidisciplinary management of patients with localized gastrointestinal stromal tumors.
Topics: Benzamides; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Laparoscopy; Neoadjuvant Therapy; Patient Care Team; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines | 2012 |
Optimized dose of imatinib for treatment of gastrointestinal stromal tumors: a meta-analysis.
Topics: Antineoplastic Agents; Benzamides; Confidence Intervals; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Odds Ratio; Piperazines; Pyrimidines; Survival Rate | 2013 |
Risk stratification models and mutational analysis: keys to optimising adjuvant therapy in patients with gastrointestinal stromal tumour.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Models, Statistical; Mutation; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Risk Assessment | 2013 |
KIT gene mutation analysis in solid tumours: biology, clincial applications and trends in diagnostic reporting.
Topics: Antineoplastic Agents; Benzamides; Diagnosis, Differential; DNA Mutational Analysis; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Melanoma; Mutation; Piperazines; Precision Medicine; Proto-Oncogene Proteins c-kit; Pyrimidines; Research Report; Skin Neoplasms | 2013 |
Recent advances in cell biology, diagnosis, and therapy of gastrointestinal stromal tumor (GIST).
Topics: Antineoplastic Agents; Benzamides; Diagnosis, Differential; Enzyme Inhibitors; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Prognosis; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines | 2004 |
Gastrointestinal stromal tumours: etiology, pathology and clinical management.
Topics: Antineoplastic Agents; Benzamides; Cell Death; Cell Differentiation; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Metastasis; Piperazines; Pyrimidines; Signal Transduction | 2004 |
[Clinical management of gastrointestinal stromal tumors].
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Radiotherapy, Adjuvant | 2004 |
[Imatinib--a new perspective in the treatment of tumors].
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2004 |
Kit as a human oncogenic tyrosine kinase.
Topics: Animals; Benzamides; Dimerization; Gastrointestinal Stromal Tumors; Homozygote; Humans; Imatinib Mesylate; Leukemia, Mast-Cell; Mice; Models, Biological; Mutation; Neoplasms; Neoplasms, Germ Cell and Embryonal; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Rats; Signal Transduction; Structure-Activity Relationship | 2004 |
Some lessons learned from imatinib mesylate clinical development in gastrointestinal stromal tumors.
Topics: Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Neoplasm Staging; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Risk Assessment; Survival Analysis; Treatment Outcome | 2004 |
Treatment of gastrointestinal stromal tumors with imatinib mesylate: a major breakthrough in the understanding of tumor-specific molecular characteristics.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines | 2005 |
Imatinib mesylate in the treatment of gastrointestinal stromal tumour.
Topics: Benzamides; Clinical Trials as Topic; Drug Administration Schedule; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2005 |
Recurrent GI bleeding and surgery following the initial response to imatinib therapy in GIST of the stomach.
Topics: Antineoplastic Agents; Benzamides; Cell Division; Female; Gastrointestinal Hemorrhage; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Recurrence; Stomach Neoplasms; Time Factors; Tomography, X-Ray Computed | 2005 |
Imatinib and gastrointestinal stromal tumors: Where do we go from here?
Topics: Antineoplastic Agents; Benzamides; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Oncogene Proteins; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Time Factors | 2005 |
Surgery for gastrointestinal stromal tumour in the post-imatinib era.
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Digestive System Surgical Procedures; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines | 2005 |
Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO.
Topics: Benzamides; Disease Management; Europe; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines | 2005 |
[Surgical management of GIST in the era of Gleevec].
Topics: Benzamides; Combined Modality Therapy; Disease Progression; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Patient Selection; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Tomography, X-Ray Computed; Treatment Outcome | 2005 |
The development and application of imatinib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chronic Disease; Dermatofibrosarcoma; Gastrointestinal Stromal Tumors; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloproliferative Disorders; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines | 2005 |
Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature.
Topics: Adolescent; Adult; Amino Acid Sequence; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Child; DNA Mutational Analysis; Female; Gastrointestinal Stromal Tumors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Male; Molecular Sequence Data; Neoplasm Recurrence, Local; Oligonucleotide Array Sequence Analysis; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Sequence Homology, Amino Acid | 2005 |
Nursing implications of imatinib as molecularly targeted therapy for gastrointestinal stromal tumors.
Topics: Administration, Oral; Aged; Ambulatory Care; Antineoplastic Agents; Benzamides; Drug Delivery Systems; Drug Design; Drug Interactions; Drug Monitoring; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Nurse's Role; Oncology Nursing; Patient Education as Topic; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Receptor Protein-Tyrosine Kinases; Safety; Treatment Outcome | 2005 |
Gastric GI stromal tumors (GISTs): the role of surgery in the era of targeted therapy.
Topics: Benzamides; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Piperazines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor Protein-Tyrosine Kinases; Stomach Neoplasms | 2005 |
[Current aspects of treatment in gastrointestinal stromal tumors (GIST)].
Topics: Antineoplastic Agents; Benzamides; Cancer Care Facilities; Chemotherapy, Adjuvant; Disease Progression; Drug Administration Schedule; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Interdisciplinary Communication; Neoadjuvant Therapy; Patient Care Team; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2005 |
[Clinical studies with imatinib in 2004].
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dermatofibrosarcoma; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome | 2005 |
PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.
Topics: Animals; Antineoplastic Agents; Benzamides; CHO Cells; Cricetinae; Drug Resistance, Neoplasm; Exons; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Gene Frequency; Humans; Imatinib Mesylate; In Vitro Techniques; Mutation; Phosphorylation; Piperazines; Protein Isoforms; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Transfection | 2005 |
Gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines | 2005 |
Imatinib resistance in gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation, Missense; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Radiography | 2005 |
Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Controlled Clinical Trials as Topic; Cost-Benefit Analysis; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Pyrimidines; State Medicine; United Kingdom | 2005 |
The role of surgery in the management of gastrointestinal stromal tumors (GISTs) in the era of imatinib mesylate effectiveness.
Topics: Antineoplastic Agents; Benzamides; Digestive System Surgical Procedures; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines | 2005 |
Soft-tissue sarcomas in adults.
Topics: Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Radiotherapy; Sarcoma | 2005 |
Gastrointestinal stromal tumor: 5 years later.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Metastasis; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines | 2005 |
Gastrointestinal stromal tumors and the evolution of targeted therapy.
Topics: Benzamides; Clinical Trials as Topic; Combined Modality Therapy; Drug Delivery Systems; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta | 2005 |
Natural killer cell-dendritic cell crosstalk in the initiation of immune responses.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Benzamides; Cell Communication; Clinical Trials as Topic; Cytokines; Dendritic Cells; Drug Evaluation, Preclinical; Gastrointestinal Stromal Tumors; Herpesviridae Infections; Humans; Imatinib Mesylate; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Proteins; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Immunologic; Signal Transduction | 2005 |
Gastrointestinal stromal tumor in a child and review of the literature.
Topics: Adolescent; Benzamides; Bromhexine; Chemotherapy, Adjuvant; Endoscopy, Gastrointestinal; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Liver Neoplasms; Male; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2005 |
Molecular research directions in the management of gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor | 2005 |
The current management of gastrointestinal stromal tumors.
Topics: Benzamides; Chemotherapy, Adjuvant; Colonic Neoplasms; Decision Trees; Esophageal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Intestinal Neoplasms; Magnetic Resonance Imaging; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Rectal Neoplasms; Risk Assessment; Stomach Neoplasms; Tomography, X-Ray Computed | 2005 |
[Antineoplastic agents targeting tyrosine kinases].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gastrointestinal Stromal Tumors; Gefitinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Trastuzumab | 2005 |
The radiology of gastrointestinal stromal tumours (GIST).
Topics: Antineoplastic Agents; Benzamides; Diagnostic Imaging; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Positron-Emission Tomography; Pyrimidines; Tomography, X-Ray Computed | 2005 |
Pathology of gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Gastrointestinal Tract; Germ-Line Mutation; Humans; Imatinib Mesylate; Models, Biological; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Stromal Cells | 2006 |
Management of gastrointestinal stromal tumors in the imatinib era: selected case studies.
Topics: Adult; Aged; Antineoplastic Agents; Aortic Aneurysm, Abdominal; Benzamides; Chemotherapy, Adjuvant; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Tomography, X-Ray Computed | 2006 |
Imatinib-refractory gastrointestinal stromal tumors: the clinical problem and therapeutic strategies.
Topics: Antineoplastic Agents; Benzamides; Drug Delivery Systems; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Medical Oncology; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome | 2006 |
New developments in gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Benzamides; Dimerization; Disease Progression; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Medical Oncology; Piperazines; Prognosis; Pyrimidines | 2006 |
An update on molecular genetics of gastrointestinal stromal tumours.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Child; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Mutation; Neoplasm Proteins; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Signal Transduction | 2006 |
Management of metastatic gastrointestinal stromal tumour in the Glivec era: a practical case-based approach.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines | 2006 |
Imatinib mesylate-induced acute hepatitis in a patient treated for gastrointestinal stromal tumour.
Topics: Aged; Antineoplastic Agents; Benzamides; Chemical and Drug Induced Liver Injury; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2006 |
Imatinib mesylate: A designer drug.
Topics: Benzamides; Eosinophilia; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines | 2006 |
Gastrointestinal stromal tumor (GIST) and imatinib.
Topics: Algorithms; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Japan; Piperazines; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyrimidines | 2006 |
Combined surgical and molecular therapy: the gastrointestinal stromal tumor model.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines | 2006 |
Complete remission of recurrent gastrointestinal stromal tumors after treatment with imatinib: report of a case.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Tomography, X-Ray Computed | 2006 |
Treatment of rare cancers: gastrointestinal stromal tumours.
Topics: Antineoplastic Agents; Benzamides; Diagnosis, Differential; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Survival Analysis | 2006 |
[Targeted therapies of cancer: not lost in translation].
Topics: Antineoplastic Agents; Benzamides; Cell Transformation, Neoplastic; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Neoplasm Proteins; Neoplasms; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines | 2006 |
Gastrointestinal stromal tumors: imatinib and beyond.
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib | 2006 |
Gastrointestinal stromal tumors: a contemporary review.
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leiomyoma; Mutation; Piperazines; Pyrimidines; Risk Assessment; Stromal Cells | 2006 |
Practical aspects of managing gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines | 2006 |
Combining imatinib with surgery in gastrointestinal stromal tumors: rationale and ongoing trials.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Piperazines; Pyrimidines; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2006 |
The molecular pathogenesis of gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor | 2006 |
Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations.
Topics: Aged; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Neoadjuvant Therapy; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Stomach Neoplasms; Time Factors | 2007 |
[Current events about echography in 2006: position of the ultrasound functional imaging for the early evaluation of targeted therapeutics].
Topics: Antineoplastic Agents; Benzamides; Contrast Media; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kidney Neoplasms; Microcirculation; Neoplasms; Neovascularization, Pathologic; Phospholipids; Piperazines; Polysaccharides; Pyrimidines; Sulfur Hexafluoride; Treatment Outcome; Ultrasonography | 2006 |
GIST under imatinib therapy.
Topics: Aged; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Leiomyosarcoma; Male; Middle Aged; Phenotype; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines | 2006 |
KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs).
Topics: Adolescent; Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Benzamides; Child; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Molecular Conformation; Molecular Sequence Data; Mutation; Neurofibromatosis 1; Piperazines; Prognosis; Protein Structure, Tertiary; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2006 |
Gastrointestinal stromal tumours: clinical overview, surgery and recent advances in imatinib mesylate therapy.
Topics: Benzamides; Clinical Trials as Topic; Combined Modality Therapy; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2007 |
KIT mutations in GIST.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Indoles; Models, Biological; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Signal Transduction; Sunitinib | 2007 |
[Gastrointestinal stromal tumors (GIST)--a paradigm of successful targeted therapy of solid tumors].
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2006 |
[STI571: a summary of targeted therapy].
Topics: Animals; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Drug Therapy, Combination; Drug Tolerance; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Molecular Structure; Mutation; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction | 2006 |
[Gastrointestinal stromal tumors].
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Disease Progression; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neoplasm Metastasis; Piperazines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors | 2007 |
Gastro-intestinal stromal tumours: a review of current management options.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Piperazines; Prognosis; Pyrimidines | 2007 |
Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
Topics: Antineoplastic Agents; Benzamides; Carcinoma, Renal Cell; Drug Approval; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Kidney Neoplasms; Piperazines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib; United States; United States Food and Drug Administration | 2007 |
Emerging drugs for the treatment of soft tissue sarcomas.
Topics: Antineoplastic Agents; Benzamides; Dacarbazine; Doxorubicin; Gastrointestinal Stromal Tumors; Humans; Ifosfamide; Imatinib Mesylate; Indoles; Piperazines; Pyrimidines; Pyrroles; Sarcoma; Sunitinib | 2007 |
Imatinib: a review of its use in the management of gastrointestinal stromal tumours.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Treatment Outcome | 2007 |
A review of resistance patterns and phenotypic changes in gastrointestinal stromal tumors following imatinib mesylate therapy.
Topics: Aged; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoplasm Recurrence, Local; Phenotype; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Stomach Neoplasms | 2007 |
Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Everolimus; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunosuppressive Agents; Indoles; Niacinamide; Oligonucleotides; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sirolimus; Staurosporine; Sunitinib; Thiazoles | 2006 |
Recent advances in therapy for gastrointestinal stromal tumors.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoplasm Metastasis; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib | 2007 |
The role of KIT in the management of patients with gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2007 |
Gastrointestinal stromal tumour.
Topics: Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Molecular Biology; Piperazines; Positron-Emission Tomography; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Sunitinib | 2007 |
Second line therapies for the treatment of gastrointestinal stromal tumor.
Topics: Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib; Treatment Failure | 2007 |
Primary omental gastrointestinal stromal tumor (GIST).
Topics: Aged; Angiography; Benzamides; Biopsy, Needle; Chemotherapy, Adjuvant; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Laparotomy; Male; Omentum; Peritoneal Neoplasms; Piperazines; Pyrimidines; Risk Assessment; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography, Doppler | 2007 |
Surgical resection in metastatic gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Survival Rate | 2007 |
C-kit, GIST, and imatinib.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib | 2007 |
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.
Topics: Advisory Committees; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Indoles; Piperazines; Practice Guidelines as Topic; Prognosis; Pyrimidines; Pyrroles; Sunitinib; Tomography, X-Ray Computed; United States | 2007 |
The challenge of opportunities: how far can and should we go with targeted treatments and modern diagnostics in gastrointestinal stromal tumors?
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines | 2007 |
Therapeutic procedures for submucosal tumors in the gastrointestinal tract.
Topics: Benzamides; Endoscopy, Gastrointestinal; Female; Gastric Mucosa; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestinal Mucosa; Middle Aged; Piperazines; Pyrimidines | 2007 |
Advances in the treatment of gastrointestinal stromal tumours.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2007 |
[KIT mutation analysis in pathological diagnosis and target-therapy of gastrointestinal stromal tumors: an update].
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Exons; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Neurofibromatosis 1; Omentum; Peritoneal Neoplasms; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines | 2007 |
Future options for imatinib mesilate-resistant tumors.
Topics: Animals; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2007 |
[Imatinib-induced toxic hepatitis: description of two cases and review of the literature].
Topics: Antineoplastic Agents; Benzamides; Chemical and Drug Induced Liver Injury; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prednisone; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Stomach Neoplasms; Time Factors | 2007 |
Molecular pathobiology of gastrointestinal stromal sarcomas.
Topics: Benzamides; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sarcoma; Sunitinib | 2008 |
Molecular approaches to resolve diagnostic dilemmas: the case of gastrointestinal stromal tumor and leiomyosarcoma.
Topics: Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leiomyosarcoma; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines | 2007 |
Targeted therapies in solid tumours: results and promises.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lung Neoplasms; Male; Neoplasms; Piperazines; Pyrimidines; Trastuzumab | 2007 |
[Imatinib and solid tumours].
Topics: Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Female; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoplasms; Neoplasms, Second Primary; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Skin Neoplasms | 2008 |
[Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Proteins; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperazines; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib; Staurosporine; Sunitinib; Thiazoles | 2008 |
Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: lessons from the phase 3 trials.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Multicenter Studies as Topic; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Randomized Controlled Trials as Topic; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome | 2008 |
Gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Prognosis; Pyrimidines | 2008 |
Drug Insight: gastrointestinal stromal tumors (GIST)--the solid tumor model for cancer-specific treatment.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Signal Transduction | 2008 |
Medical treatment of gastrointestinal stromal tumors: state of the art and future perspectives.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Dioxoles; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoadjuvant Therapy; Niacinamide; Oligonucleotides; Phthalazines; Piperazines; Proto-Oncogene Mas; Pyridines; Pyrimidines; Pyrroles; Sunitinib; Tetrahydroisoquinolines; Trabectedin | 2006 |
[Gastrointestinal stromal tumors: role of computed tomography before and after treatment].
Topics: Antineoplastic Agents; Benzamides; Contrast Media; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Prognosis; Pyrimidines; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
New therapeutic options in gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib | 2008 |
Imatinib mesilate for the treatment of gastrointestinal stromal tumour.
Topics: Antineoplastic Agents; Benzamides; Controlled Clinical Trials as Topic; Drug Delivery Systems; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines | 2008 |
Response evaluation of gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Contrast Media; Disease Progression; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Positron-Emission Tomography; Pyrimidines; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
The lessons of GIST--PET and PET/CT: a new paradigm for imaging.
Topics: Benzamides; Contrast Media; Disease Progression; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Positron-Emission Tomography; Pyrimidines; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Critical update and emerging trends in imatinib treatment for gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Piperazines; Pyrimidines | 2007 |
[GIST].
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib | 2008 |
165 trial(s) available for imatinib mesylate and Gastrointestinal Stromal Neoplasm
| Article | Year |
|---|---|
Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Treatment Outcome | 2022 |
Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate | 2022 |
Exploratory analysis of tumor imaging in a Phase 2 trial with cabozantinib in gastrointestinal stromal tumor: lessons learned from study EORTC STBSG 1317 'CaboGIST'.
Topics: Anilides; Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Prospective Studies; Pyridines; Sunitinib; Treatment Outcome | 2022 |
A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor.
Topics: Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Protein Kinase Inhibitors; Thiazoles; Treatment Outcome | 2022 |
Efficacy and Safety of Ripretinib in Chinese Patients with Advanced Gastrointestinal Stromal Tumors as a Fourth- or Later-Line Therapy: A Multicenter, Single-Arm, Open-Label Phase II Study.
Topics: China; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Naphthyridines; Sunitinib; Urea | 2022 |
Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trial.
Topics: Antineoplastic Agents; Diarrhea; Double-Blind Method; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Pyrroles | 2022 |
Prediction of recurrence-free survival and adjuvant therapy benefit in patients with gastrointestinal stromal tumors based on radiomics features.
Topics: Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Nomograms; Retrospective Studies; Tomography, X-Ray Computed | 2022 |
FDA Approval Summary: Ripretinib for Advanced Gastrointestinal Stromal Tumor.
Topics: Adult; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Naphthyridines; Urea | 2023 |
Ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumors.
Topics: Adult; Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Protein Kinase Inhibitors | 2023 |
KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Receptor Protein-Tyrosine Kinases | 2023 |
Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data.
Topics: Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Prospective Studies; Retrospective Studies; Routinely Collected Health Data | 2023 |
Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Circulating Tumor DNA; Disease Progression; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Receptor Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor alpha | 2023 |
A randomised phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumours.
Topics: Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Protein Kinase Inhibitors; Sunitinib; Treatment Outcome; Tyrosine Kinase Inhibitors | 2023 |
Long-term outcomes of a phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumors of the stomach.
Topics: Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Stomach Neoplasms | 2023 |
Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study.
Topics: Constipation; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Patient Reported Outcome Measures; Quality of Life; Sunitinib | 2023 |
Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Patient Safety; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Salvage Therapy; Sunitinib; Treatment Outcome | 2019 |
Quality of surgery and surgical reporting for patients with primary gastrointestinal stromal tumours participating in the EORTC STBSG 62024 adjuvant imatinib study.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Digestive System Surgical Procedures; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Postoperative Complications; Prognosis; Quality of Health Care; Quality of Life; Survival Rate | 2019 |
Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial.
Topics: Administration, Oral; Aged; Benzamides; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Japan; Male; Middle Aged; Neoplasm Metastasis; Phenylurea Compounds; Pyrazoles; Pyridines; Sunitinib; Treatment Outcome | 2019 |
Safety of Imatinib Mesylate in a Multicenter Expanded Access Program in Adult Patients with Gastrointestinal Stromal Tumors in the Adjuvant Setting.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Protein Kinase Inhibitors; Survival Analysis; Treatment Outcome; Young Adult | 2019 |
Impact of L-carnitine on imatinib-related muscle cramps in patients with gastrointestinal stromal tumor.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carnitine; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Muscle Cramp; Protein Kinase Inhibitors; Quality of Life; Treatment Outcome; Young Adult | 2020 |
Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Naphthyridines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha; Research Design; Sunitinib; Survival Rate; Urea; Young Adult | 2020 |
Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Mental Disorders; Middle Aged; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Sunitinib | 2020 |
Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Digestive System Surgical Procedures; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; International Cooperation; Male; Middle Aged; Quality of Health Care; Treatment Outcome; Young Adult | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Determination of the absolute bioavailability of oral imatinib using a stable isotopically labeled intravenous imatinib-d8 microdose.
Topics: Administration, Intravenous; Administration, Oral; Aged; Antineoplastic Agents; Biological Availability; Chromatography, Liquid; Deuterium; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Isotope Labeling; Male; Middle Aged; Protein Kinase Inhibitors; Tandem Mass Spectrometry | 2020 |
Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up.
Topics: Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Fusion Proteins, bcr-abl; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Protein Kinase Inhibitors; Risk; Survival Analysis | 2020 |
Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II tri
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Pyridines; Salvage Therapy; Sunitinib; Survival Rate | 2020 |
Systemic Steroid Treatment for Imatinib-Associated Severe Skin Rash in Patients with Gastrointestinal Stromal Tumor: A Phase II Study.
Topics: Antineoplastic Agents; Exanthema; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Steroids; Treatment Outcome | 2020 |
A prospective multicenter phase II study on the efficacy and safety of dasatinib in the treatment of metastatic gastrointestinal stromal tumors failed by imatinib and sunitinib and analysis of NGS in peripheral blood.
Topics: Administration, Oral; Adult; Aged; Anemia; Antineoplastic Agents; Dasatinib; Diarrhea; DNA Copy Number Variations; Drug Administration Schedule; Fatigue; Female; Gastrointestinal Stromal Tumors; Genotype; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neutropenia; Progression-Free Survival; Prospective Studies; Protein Kinase Inhibitors; Proteinuria; Sunitinib | 2020 |
Outcomes of patients with metastatic gastrointestinal stromal tumors (GIST) treated with multi-kinase inhibitors other than imatinib as first-line treatment.
Topics: Adult; Aged; Aged, 80 and over; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Receptor, Platelet-Derived Growth Factor alpha; Retrospective Studies; Young Adult | 2020 |
Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sar
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Italy; Neoplasm Recurrence, Local; Sarcoma | 2021 |
Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors: A Phase 1b/2a Nonrandomized Clinical Trial.
Topics: Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Sunitinib | 2021 |
A Randomized Phase II Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab in Patients with Advanced Gastrointestinal Stromal Tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Ipilimumab; Nivolumab; Protein Kinase Inhibitors | 2022 |
Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.
Topics: Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; DNA Mutational Analysis; DNA, Neoplasm; Drug Administration Schedule; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha | 2017 |
Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Tr
Topics: Adult; Aged; Antineoplastic Agents; Cross-Over Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Prognosis | 2017 |
Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach.
Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Drug Eruptions; Female; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Japan; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Organ Sparing Treatments; Republic of Korea; Stomach Neoplasms; Tumor Burden | 2017 |
Does a glass of Coke boost the exposure to imatinib in gastrointestinal stromal tumour patients after gastrectomy?
Topics: Antineoplastic Agents; Carbonated Beverages; Cross-Over Studies; Food-Drug Interactions; Gastrectomy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate | 2017 |
Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib.
Topics: Adult; Aged; Benzimidazoles; Biomarkers, Tumor; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinolones; Salvage Therapy | 2017 |
Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis Regulatory Proteins; Cell Cycle Proteins; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Prognosis; Risk Factors; Tumor Suppressor Protein p53; Young Adult | 2018 |
Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib.
Topics: Adult; Aged; Antineoplastic Agents; Dasatinib; Drug Resistance, Neoplasm; Drug Substitution; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Proteins; Progression-Free Survival; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha; src-Family Kinases; Succinate Dehydrogenase; Young Adult | 2018 |
A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Receptors, Fibroblast Growth Factor; Tissue Distribution | 2019 |
Association of Imatinib Plasma Concentration and Single-nucleotide Polymorphisms with Adverse Drug Reactions in Patients with Gastrointestinal Stromal Tumors.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Polymorphism, Single Nucleotide | 2018 |
Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Staging; Risk Factors; Treatment Outcome | 2018 |
Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclin-Dependent Kinase Inhibitor p16; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Deletion; Humans; Imatinib Mesylate; Male; Middle Aged; Patient Safety; Piperazines; Pyridines; Sunitinib; Survival Rate; Treatment Outcome | 2019 |
Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Non-Randomized Controlled Trials as Topic; Phenylurea Compounds; Prognosis; Pyridines; Salvage Therapy; Sunitinib; Survival Rate | 2019 |
Gastrointestinal stromal tumors, somatic mutations and candidate genetic risk variants.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Benzamides; Cytochrome P-450 CYP1B1; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Piperazines; Polymorphism, Single Nucleotide; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Risk Factors | 2013 |
Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease-Free Survival; Drug Administration Schedule; Drug Costs; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Health Care Costs; Humans; Imatinib Mesylate; Male; Markov Chains; Middle Aged; Neoplasm Recurrence, Local; Netherlands; Piperazines; Pyrimidines; Quality-Adjusted Life Years; Risk Assessment; Survival Analysis | 2013 |
Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Risk; Survival Analysis; Treatment Outcome; Young Adult | 2013 |
Neoodjuvant imatinib mesylate for advanced primary and metastactic/recurrent gastro-intestinal stromal tumour (GIST).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Digestive System Surgical Procedures; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Preoperative Care; Pyrimidines; Treatment Outcome | 2013 |
Surgical Treatment of Gastrointestinal Stromal Tumors Located in the Stomach in the Imatinib Era.
Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Female; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Preoperative Care; Prospective Studies; Survival Analysis; Treatment Outcome | 2015 |
Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Benzamides; Benzimidazoles; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinolones; Sunitinib | 2013 |
Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Piperazines; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Republic of Korea; Sunitinib; Time Factors; Treatment Outcome | 2013 |
A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.
Topics: Adult; Aged; Angiogenesis Inhibitors; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indazoles; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Piperazines; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Treatment Failure; Tumor Burden; Young Adult | 2014 |
Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Outcome Assessment, Health Care; Phenylurea Compounds; Piperazines; Prospective Studies; Pyridines; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Tomography, X-Ray Computed; Treatment Failure; World Health Organization | 2014 |
Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Imatinib Mesylate; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Panobinostat; Piperazines; Pyrimidines | 2014 |
Gastrointestinal stromal tumor: a method for optimizing the timing of CT scans in the follow-up of cancer patients.
Topics: Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Contrast Media; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Piperazines; Placebos; Prospective Studies; Pyrimidines; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Chi-Square Distribution; Disease-Free Survival; DNA Mutational Analysis; Double-Blind Method; Exons; Female; Gastrointestinal Stromal Tumors; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Middle Aged; Mitotic Index; Multivariate Analysis; Mutation; Neoplasm Recurrence, Local; Patient Selection; Phenotype; Piperazines; Precision Medicine; Proportional Hazards Models; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Risk Factors; Time Factors; Treatment Outcome; Tumor Burden; Young Adult | 2014 |
Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Risk Factors | 2014 |
Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; China; Disease Progression; Disease-Free Survival; Early Termination of Clinical Trials; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Metastasectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm, Residual; Patient Selection; Piperazines; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Sample Size; Time Factors; Treatment Outcome | 2014 |
Imatinib (Glivec) and gastrointestinal stromal tumours in Nigerians.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Histocytochemistry; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Middle Aged; Nigeria; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines | 2013 |
Health utility of patients with advanced gastrointestinal stromal tumors (GIST) after failure of imatinib and sunitinib: findings from GRID, a randomized, double-blind, placebo-controlled phase III study of regorafenib versus placebo.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Double-Blind Method; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Phenylurea Compounds; Placebo Effect; Pyridines; Pyrroles; Quality of Life; Sunitinib; Treatment Failure | 2015 |
Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Piperidines; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Sunitinib; Thiazoles; Treatment Failure | 2014 |
First-in-human phase I dose escalation study of a second-generation non-ansamycin HSP90 inhibitor, AT13387, in patients with advanced solid tumors.
Topics: Adult; Aged; Benzamides; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointestinal Stromal Tumors; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Isoindoles; Leukocytes, Mononuclear; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Piperazines; Pyrimidines; Urinary Bladder Neoplasms | 2015 |
Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Double-Blind Method; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Middle Aged; Phenylurea Compounds; Pyridines; Pyrroles; Sunitinib; Survival Analysis; Young Adult | 2015 |
Adherence to Guidelines for Adjuvant Imatinib Therapy for GIST: A Multi-institutional Analysis.
Topics: Adult; Aged; Antineoplastic Agents; Digestive System Surgical Procedures; Female; Gastrointestinal Stromal Tumors; Guideline Adherence; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Risk Factors | 2015 |
Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Nomograms; Piperazines; Prognosis; Pyrimidines; Survival Analysis; Young Adult | 2015 |
Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Pyrimidines; Treatment Outcome | 2015 |
Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged | 2016 |
Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Tr
Topics: Adult; Aged; Aged, 80 and over; Australasia; Chemotherapy, Adjuvant; Disease-Free Survival; European Union; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; International Cooperation; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Odds Ratio; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Salvage Therapy; Treatment Failure | 2015 |
S0502: A SWOG Phase III Randomized Study of Imatinib, With or Without Bevacizumab, in Patients With Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Protein Kinase Inhibitors; Treatment Outcome | 2015 |
Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Survival; DNA Mutational Analysis; Exons; Female; France; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Mutation; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Risk Factors; Time Factors; Treatment Outcome | 2016 |
Impact of imatinib rechallenge on health-related quality of life in patients with TKI-refractory gastrointestinal stromal tumours: Sub-analysis of the placebo-controlled, randomised phase III trial (RIGHT).
Topics: Aged; Analysis of Variance; Antineoplastic Agents; Disease-Free Survival; Double-Blind Method; Drug Resistance, Neoplasm; Drug Substitution; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Protein Kinase Inhibitors; Quality of Life; Republic of Korea; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2016 |
Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour - Does it increase the risk for tumour cell seeding and recurrence?
Topics: Abdominal Wall; Antineoplastic Agents; Biopsy, Needle; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Neoplasm Seeding; Protein Kinase Inhibitors; Risk Factors; Tomography, X-Ray Computed | 2016 |
Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; France; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indazoles; Indoles; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Treatment Outcome | 2016 |
Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gastrointestinal Stromal Tumors; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Injections, Intravenous; Isoindoles; Male; Middle Aged; Protein Kinase Inhibitors | 2016 |
Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
Topics: Adult; Aged; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrroles; Sunitinib | 2016 |
Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retreatment; Sunitinib; Treatment Failure; Treatment Outcome | 2017 |
Surgery and imatinib therapy for liver oligometastasis of GIST: a study of Japanese Study Group on GIST.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Japan; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Salvage Therapy | 2017 |
Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202).
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Survival Rate | 2008 |
Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate.
Topics: Antigens, CD34; Antineoplastic Agents; Benzamides; Disease-Free Survival; Dose-Response Relationship, Drug; Exons; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Kaplan-Meier Estimate; Male; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2008 |
Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Prospective Studies; Pyrimidines; Survival Analysis; Treatment Outcome | 2009 |
A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Combined Modality Therapy; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Radiography; Remission Induction | 2009 |
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Gr
Topics: Benzamides; Disease-Free Survival; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Survival Rate | 2008 |
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.
Topics: Adult; Aged; Benzamides; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Exons; Female; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2008 |
Follow-up of hepatic and peritoneal metastases of gastrointestinal tumors (GIST) under Imatinib therapy requires different criteria of radiological evaluation (size is not everything!!!).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Peritoneal Neoplasms; Piperazines; Pyrimidines; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation; Piperazines; Positron-Emission Tomography; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Salvage Therapy; Sunitinib | 2009 |
Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib.
Topics: Algorithms; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease Progression; Double-Blind Method; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Health Resources; Humans; Imatinib Mesylate; Indoles; Markov Chains; Models, Econometric; Neoplasm Metastasis; Piperazines; Placebos; Pyrimidines; Pyrroles; Sunitinib; Survival Analysis; Treatment Failure | 2008 |
Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST).
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Piperazines; Preoperative Care; Prospective Studies; Pyrimidines; Survival Analysis; Treatment Outcome | 2009 |
Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Drug Approval; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome; Young Adult | 2009 |
Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Benzamides; Biomarkers, Tumor; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3 | 2009 |
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Double-Blind Method; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines | 2009 |
A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Staging; Piperazines; Polymorphism, Genetic; Prognosis; Prospective Studies; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction; Risk Factors; Survival Rate; Treatment Outcome | 2009 |
Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients.
Topics: Antineoplastic Agents; Benzamides; Dendritic Cells; Exons; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Interferon-gamma; Interleukin-2; Killer Cells, Natural; Male; Middle Aged; Natural Cytotoxicity Triggering Receptor 3; NK Cell Lectin-Like Receptor Subfamily K; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines | 2009 |
Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Benzamides; Female; Gastrointestinal Stromal Tumors; Half-Life; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Treatment Outcome | 2009 |
Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines | 2009 |
Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Gene Expression Profiling; Humans; Imatinib Mesylate; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Piperazines; Pyrimidines; Zinc Fingers | 2009 |
Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Benzamides; Drug Resistance, Neoplasm; Drug Tolerance; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Japan; Male; Middle Aged; Niacinamide; Oligonucleotides; Piperazines; Pyrimidines; Radiography; Treatment Outcome | 2010 |
A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Tolerance; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome; Young Adult | 2009 |
Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Benzamides; Biomarkers, Tumor; Demography; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Japan; Male; Middle Aged; Neoplasm Proteins; Piperazines; Pyrimidines; Pyrroles; Solubility; Sunitinib; Treatment Failure; Young Adult | 2010 |
Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure.
Topics: Adult; Aged; Benzamides; Cell Proliferation; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Positron-Emission Tomography; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib; Treatment Failure | 2009 |
Approval summary: imatinib mesylate in the adjuvant treatment of malignant gastrointestinal stromal tumors.
Topics: Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Drug Approval; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome | 2010 |
Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Dose-Response Relationship, Drug; Female; France; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Piperidines; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Thiazoles; Treatment Outcome | 2010 |
A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Resistance, Neoplasm; Everolimus; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Pyrimidines; Salvage Therapy; Sirolimus; Survival Rate; Treatment Outcome | 2010 |
Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish Group for Research on Sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Positron-Emission Tomography; Proto-Oncogene Proteins c-kit; Pyrimidines | 2010 |
Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Niacinamide; Oligonucleotides; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome | 2011 |
Clinical efficacy and safety of sunitinib after imatinib failure in Japanese patients with gastrointestinal stromal tumor.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Gastrointestinal Stromal Tumors; Humans; Hyperammonemia; Imatinib Mesylate; Indoles; Japan; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Piperazines; Portography; Pyrimidines; Pyrroles; Remission Induction; Retrospective Studies; Sunitinib; Tomography, X-Ray Computed; Treatment Failure; Treatment Outcome | 2011 |
Resection combined with imatinib therapy for liver metastases of gastrointestinal stromal tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Treatment Outcome | 2010 |
Value of FDG-PET for monitoring treatment response in patients with advanced GIST refractory to high-dose imatinib. A multicenter GEIS study.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Positron-Emission Tomography; Pyrimidines; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Spain; Treatment Outcome | 2011 |
Changes in imatinib plasma trough level during long-term treatment of patients with advanced gastrointestinal stromal tumors: correlation between changes in covariates and imatinib exposure.
Topics: Adult; Aged; Benzamides; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Staging; Piperazines; Pyrimidines; Time Factors | 2012 |
Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Asian People; Benzamides; Chemotherapy, Adjuvant; China; Disease-Free Survival; Drug Administration Schedule; Female; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Piperazines; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Risk Assessment; Risk Factors; Treatment Outcome | 2011 |
Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Disease Progression; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Piperazines; Pyrimidines | 2011 |
Surgical outcomes of gastrointestinal stromal tumors of the stomach: a single unit experience in the era of targeted drug therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Preoperative Care; Prognosis; Pyrimidines; Retrospective Studies; Survival Rate; Young Adult | 2012 |
Intestinal permeability, vitamin A absorption and serum alpha-tocopherol in gastrointestinal stromal tumor patients treated with imatinib.
Topics: Adult; Aged; Aged, 80 and over; alpha-Tocopherol; Antineoplastic Agents; Benzamides; Dietary Sucrose; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestinal Absorption; Intestinal Mucosa; Male; Middle Aged; Permeability; Piperazines; Pyrimidines; Vitamin A | 2010 |
Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Neoplasm Grading; Neoplasm Staging; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Salvage Therapy; Sunitinib; Time Factors; Treatment Outcome | 2011 |
A USA registry of gastrointestinal stromal tumor patients: changes in practice over time and differences between community and academic practices.
Topics: Academic Medical Centers; Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hospitals, Community; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Molecular Targeted Therapy; Piperazines; Practice Patterns, Physicians'; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Registries; Sunitinib; United States; Young Adult | 2011 |
Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Phthalazines; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sunitinib | 2011 |
Adjuvant imatinib treatment after R0 resection for patients with high-risk gastrointestinal stromal tumors: a median follow-up of 44 months.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Survival Analysis | 2011 |
Activity and side effects of imatinib in patients with gastrointestinal stromal tumors: data from a German multicenter trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Germany; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Young Adult | 2011 |
Adjuvant therapy with imatinib mesylate after resection of primary high-risk gastrointestinal stromal tumors in Japanese patients.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Piperazines; Postoperative Period; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Treatment Outcome | 2013 |
Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib.
Topics: Aged; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Exons; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib | 2012 |
Exploiting antitumor immunity to overcome relapse and improve remission duration.
Topics: Aged; Aged, 80 and over; Benzamides; Disease-Free Survival; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunotherapy; Interferon alpha-2; Interferon-alpha; Interferon-gamma; Lymphocytes; Middle Aged; Piperazines; Polyethylene Glycols; Pyrimidines; Recombinant Proteins; Recurrence; T-Lymphocytes, Cytotoxic | 2012 |
Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Survival Rate; Treatment Outcome; Young Adult | 2012 |
Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Palliative Care; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib; Treatment Outcome; Young Adult | 2012 |
Efficacy of imatinib dose escalation in Chinese gastrointestinal stromal tumor patients.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Benzamides; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Piperazines; Prospective Studies; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome | 2012 |
ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Biological Transport; Female; Fluorodeoxyglucose F18; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Genotype; Glucose Transporter Type 4; Humans; Image Processing, Computer-Assisted; Imatinib Mesylate; Male; Middle Aged; Mutation; Neoadjuvant Therapy; Piperazines; Positron-Emission Tomography; Proto-Oncogene Proteins c-kit; Pyrimidines; Time Factors; Treatment Outcome; Young Adult | 2012 |
One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Survival Analysis; Treatment Outcome; Young Adult | 2012 |
Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neoplasm Metastasis; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sunitinib; Treatment Outcome | 2012 |
Approval summary: imatinib mesylate for one or three years in the adjuvant treatment of gastrointestinal stromal tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Young Adult | 2012 |
Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure.
Topics: Adult; Aged; Benzamides; Biomarkers, Tumor; Cross-Over Studies; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neovascularization, Pathologic; Piperazines; Placebos; Pyrimidines; Pyrroles; Retreatment; Sunitinib; Survival Analysis; Young Adult | 2012 |
Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Blood Pressure; Carcinoma, Renal Cell; Child; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Hypertension; Imatinib Mesylate; Indoles; Kidney Neoplasms; Male; Middle Aged; Piperazines; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factors; Young Adult | 2012 |
Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Models, Biological; Orosomucoid; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Serum Albumin | 2013 |
Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Disease-Free Survival; Exons; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Piperazines; Prospective Studies; Proto-Oncogene Proteins c-kit; Pyrimidines; Republic of Korea; Treatment Outcome | 2013 |
Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial.
Topics: Adult; Aged; Benzamides; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Prospective Studies; Pyrimidines; Sarcoma; Treatment Outcome | 2013 |
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Benzamides; Double-Blind Method; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sunitinib; Survival Rate; Treatment Failure | 2013 |
CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Multivariate Analysis; Piperazines; Pyrimidines; Radionuclide Imaging; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2004 |
Gastrointestinal stromal tumor (GIST) -- single center experience of prolonged treatment with imatinib.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chromosome Aberrations; DNA, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nucleic Acid Hybridization; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Risk Factors; Safety; Time Factors; Tomography, X-Ray Computed | 2005 |
Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm, Residual; Piperazines; Pyrimidines; Survival Analysis; Time Factors | 2005 |
Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cross-Over Studies; Disease Progression; Dose-Response Relationship, Drug; Feasibility Studies; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome | 2005 |
Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Grou
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Logistic Models; Male; Middle Aged; Piperazines; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Pyrimidines; Treatment Outcome | 2005 |
Follow-up of gastro-intestinal stromal tumours (GIST) during treatment with imatinib mesylate by abdominal MRI.
Topics: Abdomen; Adult; Aged; Antineoplastic Agents; Benzamides; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome | 2005 |
Imatinib induces hypothyroidism in patients receiving levothyroxine.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Carcinoma, Medullary; Drug Synergism; Female; Gastrointestinal Stromal Tumors; Humans; Hypothyroidism; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Thyroid Neoplasms; Thyroidectomy; Thyrotropin; Thyroxine; Triiodothyronine | 2005 |
[Treatment of gastrointestinal stromal tumors with imatinib mesylate: a center-based study of 13 patients].
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Neoadjuvant Therapy; Palliative Care; Piperazines; Pyrimidines; Treatment Outcome | 2006 |
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; Exons; Female; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Retrospective Studies | 2006 |
Treatment of patients with advanced gastrointestinal stromal tumor of small bowel: implications of imatinib mesylate.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Exons; Female; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Intestinal Neoplasms; Male; Middle Aged; Mutation; Piperazines; Platelet-Derived Growth Factor; Prognosis; Prospective Studies; Proto-Oncogene Proteins c-kit; Pyrimidines; Survival Rate; Treatment Outcome | 2006 |
Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Gr
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Clinical Protocols; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Logistic Models; Male; Middle Aged; Piperazines; Pyrimidines; Risk Factors | 2006 |
Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Cohort Studies; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-kit; Pyrimidines; RNA Interference | 2006 |
Genetic changes in advanced gastrointestinal stromal tumor (GIST) patients during imatinib mesylate treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Piperazines; Prospective Studies; Proto-Oncogene Proteins c-kit; Pyrimidines; Treatment Outcome | 2006 |
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Double-Blind Method; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib; Survival Analysis; Treatment Outcome | 2006 |
Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography.
Topics: Antineoplastic Agents; Benzamides; Contrast Media; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Phospholipids; Piperazines; Polysaccharides; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Sulfur Hexafluoride; Ultrasonography, Doppler | 2006 |
Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.
Topics: Antineoplastic Agents; Benzamides; DNA Mutational Analysis; DNA, Neoplasm; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Mutagenesis, Site-Directed; Mutation; Piperazines; Prognosis; Prospective Studies; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Survival Rate; Taiwan | 2007 |
A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Bone Neoplasms; Carcinoma, Small Cell; Child; Child, Preschool; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoplasm Recurrence, Local; Neoplasms; Neuroblastoma; Osteosarcoma; Piperazines; Pyrimidines; Sarcoma, Ewing; Sarcoma, Synovial | 2008 |
Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Heart Failure; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome; Ventricular Dysfunction, Left | 2007 |
Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; France; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Piperazines; Practice Guidelines as Topic; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Surveys and Questionnaires; Treatment Outcome | 2007 |
Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.
Topics: Adult; Antineoplastic Agents; Benzamides; Biomarkers; Endothelial Cells; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Monocytes; Piperazines; Pyrimidines; Pyrroles; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2007 |
Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Cohort Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Monitoring; Female; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Metabolic Clearance Rate; Middle Aged; Organic Anion Transporters; Phenotype; Piperazines; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Pyrimidines | 2007 |
Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Ki-67 Antigen; Male; Middle Aged; Pilot Projects; Piperazines; Prognosis; Pyrimidines; Receptor Protein-Tyrosine Kinases; Recurrence; Risk Factors | 2007 |
Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Proteins; Phthalazines; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Salvage Therapy | 2008 |
CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Benzamides; Female; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Pilot Projects; Piperazines; Positron-Emission Tomography; Prognosis; Pyrimidines; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome; United States | 2007 |
Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib.
Topics: Aged; Antineoplastic Agents; Area Under Curve; Benzamides; Biological Availability; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Metabolic Clearance Rate; Middle Aged; Piperazines; Pyrimidines; Ritonavir | 2007 |
Ulcerative keratitis in gastrointestinal stromal tumor patients treated with perifosine.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Corneal Ulcer; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Glucocorticoids; Humans; Imatinib Mesylate; Intestinal Neoplasms; Male; Middle Aged; Phosphorylcholine; Piperazines; Prednisolone; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Pyrimidines; Retrospective Studies | 2008 |
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.
Topics: Aged; Albumins; Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukocyte Count; Male; Multivariate Analysis; Mutation; Neutrophils; Piperazines; Prospective Studies; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Survival Rate | 2008 |
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Retrospective Studies; Survival Rate | 2008 |
The challenge of conducting pharmacoeconomic evaluations in oncology using crossover trials: the example of sunitinib for gastrointestinal stromal tumour.
Topics: Antineoplastic Agents; Benzamides; Canada; Cost-Benefit Analysis; Cross-Over Studies; Disease-Free Survival; Drug Costs; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Markov Chains; Piperazines; Pyrimidines; Pyrroles; Quality-Adjusted Life Years; Sunitinib | 2008 |
Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
Topics: Administration, Oral; Adolescent; Aging; Antineoplastic Agents; Benzamides; Child; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Models, Biological; Multivariate Analysis; Piperazines; Pyrimidines; Young Adult | 2009 |
Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs).
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Digestive System Neoplasms; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm, Residual; Piperazines; Premedication; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Survival Rate | 2008 |
1349 other study(ies) available for imatinib mesylate and Gastrointestinal Stromal Neoplasm
| Article | Year |
|---|---|
Letter to the editor: new response evaluation criteria using early morphological change in imatinib treatment for patients with gastrointestinal stromal tumor.
Topics: Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Stomach Neoplasms | 2021 |
Comparison of outcomes between neoadjuvant imatinib and upfront surgery in patients with localized rectal GIST: An inverse probability of treatment weighting analysis.
Topics: Aged; Antineoplastic Agents; Case-Control Studies; Combined Modality Therapy; Digestive System Surgical Procedures; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoadjuvant Therapy; Prognosis; Retrospective Studies; Survival Rate | 2021 |
Gastrointestinal Stromal Tumours.
Topics: Adult; Aged; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Prognosis; Proto-Oncogene Proteins c-kit; Retrospective Studies | 2021 |
[Definition of tumor rupture in gastrointestinal stromal tumor].
Topics: Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Rupture, Spontaneous | 2021 |
[Adherence to adjuvant with therapy imatinib in patients with gastrointestinal stromal tumor: a national multi-center cross-sectional study].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Cross-Sectional Studies; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local | 2021 |
Pimitespib is effective on cecal GIST in a mouse model of familial GISTs with KIT-Asp820Tyr mutation through KIT signaling inhibition.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Proliferation; Disease Models, Animal; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mice; Mutation; Phosphorylation; Proto-Oncogene Proteins c-kit; Pyrazoles; Signal Transduction | 2021 |
Targeted therapy for drug-tolerant persister cells after imatinib treatment for gastrointestinal stromal tumours.
Topics: Animals; Disease Models, Animal; Ferroptosis; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mice; Protein Kinase Inhibitors | 2021 |
Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study.
Topics: Adjuvants, Immunologic; Antineoplastic Agents; Chemotherapy, Adjuvant; Exons; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Neoplasm Recurrence, Local; Proto-Oncogene Proteins c-kit; Retrospective Studies | 2022 |
E3 ubiquitin ligase Atrogin-1 mediates adaptive resistance to KIT-targeted inhibition in gastrointestinal stromal tumor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Therapy, Combination; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Mice; Muscle Proteins; Proto-Oncogene Proteins c-kit; Pyrazoles; Pyrimidines; SKP Cullin F-Box Protein Ligases; Sulfides; Sulfonamides; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
Imatinib Regulates
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Down-Regulation; Electron Transport Complex II; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; MicroRNAs; Mitochondria; Oxidative Phosphorylation; RNA, Messenger; Signal Transduction; Transfection | 2021 |
Rectal gastrointestinal stromal tumor: an unusual presentation of an uncommon pathology (a case report).
Topics: Adult; Antigens, CD34; Antineoplastic Agents; Combined Modality Therapy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestinal Obstruction; Male; Proto-Oncogene Proteins c-kit; Rectal Neoplasms; Urinary Retention | 2021 |
BRD9 inhibition promotes PUMA-dependent apoptosis and augments the effect of imatinib in gastrointestinal stromal tumors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Proliferation; DNA Damage; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Male; Mice, Nude; Middle Aged; Proto-Oncogene Proteins; RNA, Small Interfering; Transcription Factors; Xenograft Model Antitumor Assays | 2021 |
Successful Endoscopic Resection of a Rectal Gastrointestinal Stromal Tumor Larger Than 5 cm.
Topics: Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Rectal Neoplasms; Rectum | 2021 |
Glucose transporter‑1 inhibition overcomes imatinib resistance in gastrointestinal stromal tumor cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Glucose Transporter Type 1; Humans; Hydroxybenzoates; Imatinib Mesylate | 2022 |
Clinicopathological features, clinical efficacy on 101 cases of rectal gastrointestinal stromal tumors, and the significance of neoadjuvant therapy.
Topics: Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoadjuvant Therapy; Rectal Neoplasms; Retrospective Studies; Treatment Outcome | 2021 |
Endoscopic treatment can be a viable therapeutic option for esophageal gastrointestinal stromal tumors.
Topics: Disease-Free Survival; Esophageal Neoplasms; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Prognosis; Retrospective Studies | 2022 |
Adjuvant Imatinib Treatment for 5 Years versus 3 Years in Patients with Ruptured Localized Gastrointestinal Stromal Tumor: A Retrospective Analysis.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Retrospective Studies | 2022 |
Clinicopathological characteristics and prognosis of gastrointestinal stromal tumors containing air-fluid levels.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Digestive System Fistula; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gastrointestinal Tract; Humans; Imatinib Mesylate; Intestinal Mucosa; Magnetic Resonance Imaging; Male; Middle Aged; Prognosis; Retrospective Studies; Tomography, X-Ray Computed | 2021 |
Impact of preoperative tumor rupture timing on gastrointestinal stromal tumor prognosis: a retrospective multicentric cohort study.
Topics: Antineoplastic Agents; Cohort Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies | 2022 |
Indication-Specific Generic Uptake of Imatinib Demonstrates the Impact of Skinny Labeling.
Topics: Adult; Aged; Cross-Sectional Studies; Drugs, Generic; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medicare; United States | 2022 |
[A Case of Giant Intestinal GIST That Was Resected Just after TAE].
Topics: Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestine, Small; Intestines; Proto-Oncogene Proteins c-kit | 2021 |
[A Case of Hepatocellular Carcinoma with Extrahepatic Growth-A Difficult Preoperative Diagnosis].
Topics: Aged; Carcinoma, Hepatocellular; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Stomach Neoplasms | 2021 |
[A Case of HER2-Positive Recurrent Breast Cancer and Liver Metastases of GIST Treated with Combined Anti-HER2 Therapy and Imatinib].
Topics: Aged; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms | 2021 |
[Complete Response to Neoadjuvant Chemotherapy with Imatinib of a Large Gastric GIST-A Case Report].
Topics: Antineoplastic Agents; Female; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Neoadjuvant Therapy; Stomach Neoplasms | 2021 |
[Two Cases of Large Gastrointestinal Stromal Tumors Safely and Completely Resected by Laparoscopic Surgery Followed by Neoadjuvant Imatinib Therapy].
Topics: Aged; Antineoplastic Agents; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Laparoscopy; Male; Middle Aged; Neoadjuvant Therapy; Stomach Neoplasms | 2021 |
[Long-Term Suppression with Short-Term Dose Reduction of Imatinib for Metastatic Lateral Lymph Nodes after Resection of a Rectal Gastrointestinal Stromal Tumor-A Case Report].
Topics: Aged, 80 and over; Drug Tapering; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lymph Nodes; Rectal Neoplasms | 2021 |
[Long-Term Survival by Low-Dose Imatinib after Recurrence of GIST].
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoplasm Recurrence, Local; Piperazines; Pyrimidines | 2022 |
Hope as a Lifeline: Imatinib Discontinuation in Patients With Oligometastatic Gastrointestinal Stromal Tumours.
Topics: Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hope; Humans; Imatinib Mesylate; Interviews as Topic; Protein Kinase Inhibitors; Qualitative Research; Remission Induction; Withholding Treatment | 2022 |
Laparoscopic resection for imatinib-resistant recurrent tumors of gastric gastrointestinal stromal tumors: A case report.
Topics: Aged, 80 and over; Antineoplastic Agents; Female; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Laparoscopy; Stomach Neoplasms; Treatment Outcome | 2022 |
Impacts of SNPs on adverse events and trough concentration of imatinib in patients with gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Polymorphism, Single Nucleotide | 2022 |
Real-world data on the efficacy and safety of adjuvant chemotherapy in Japanese patients with a high-risk of gastrointestinal stromal tumor recurrence.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Japan; Neoplasm Recurrence, Local; Retrospective Studies | 2022 |
Surgical and histopathologic outcomes of gastrointestinal stromal tumors.
Topics: Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lymph Nodes; Male; Middle Aged; Omentum; Retrospective Studies | 2021 |
FGFR2::TACC2 fusion as a novel KIT-independent mechanism of targeted therapy failure in a multidrug-resistant gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Carrier Proteins; Gastrointestinal Stromal Tumors; Gene Fusion; Humans; Imatinib Mesylate; Liver Neoplasms; Mutation; Proto-Oncogene Proteins c-kit; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Platelet-Derived Growth Factor alpha; Tumor Suppressor Proteins | 2022 |
Nintedanib overcomes drug resistance from upregulation of FGFR signalling and imatinib-induced KIT mutations in gastrointestinal stromal tumours.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Proto-Oncogene Proteins c-kit; Pyrimidines; Up-Regulation | 2022 |
Symptoms reported by gastrointestinal stromal tumour (GIST) patients on imatinib treatment: combining questionnaire and forum data.
Topics: Cross-Sectional Studies; Fatigue; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Muscle Cramp; Protein Kinase Inhibitors; Quality of Life; Surveys and Questionnaires | 2022 |
[A Case of Long-Term Survival after Multimodal Therapy against Gastric GIST with Multiple Hepatic Metastasis].
Topics: Antineoplastic Agents; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Stomach Neoplasms | 2022 |
The nerve-tumour regulatory axis GDNF-GFRA1 promotes tumour dormancy, imatinib resistance and local recurrence of gastrointestinal stromal tumours by achieving autophagic flux.
Topics: Antineoplastic Agents; Autophagy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Glial Cell Line-Derived Neurotrophic Factor; Glial Cell Line-Derived Neurotrophic Factor Receptors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Prospective Studies | 2022 |
A Low rectal GIST.
Topics: Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Rectal Neoplasms; Rectum | 2022 |
Development and external validation of a nomogram for individualized adjuvant imatinib duration for high-risk gastrointestinal stromal tumors: A multicenter retrospective cohort study.
Topics: Adjuvants, Immunologic; Antineoplastic Agents; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Nomograms; Retrospective Studies; Risk Factors | 2022 |
[A Case of Rectal GIST Resected using the TAMIS Method].
Topics: Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Rectal Neoplasms; Rectum; Transanal Endoscopic Surgery | 2022 |
Do you get the GIST? Successful resection of a giant 3.5 kg gastrointestinal stromal tumour.
Topics: Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Pyrimidines | 2022 |
A Huge Malignant Gastric Gastrointestinal Stromal Tumor in a Young Patient.
Topics: Adult; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lymph Nodes; Male; Stomach Neoplasms | 2022 |
The role of neoadjuvant imatinib in gastrointestinal stromal tumor patients: 20 years of experience from a tertial referral center.
Topics: Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Referral and Consultation; Retrospective Studies | 2022 |
Targeting the translational machinery in gastrointestinal stromal tumors (GIST): a new therapeutic vulnerability.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Homoharringtonine; Humans; Imatinib Mesylate; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit | 2022 |
Clinical outcomes of surgical and imatinib treatment for rectal gastrointestinal stromal tumours: retrospective cohort study.
Topics: Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Rectal Neoplasms; Retrospective Studies | 2022 |
[Extraperitoneal gastrointestinal stromal tumor: a rare case].
Topics: Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate | 2022 |
Use of Neoadjuvant Imatinib to Facilitate Minimally Invasive Resection of Gastric Gastrointestinal Stromal Tumors.
Topics: Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Stomach Neoplasms | 2022 |
Long-term adjuvant therapy for high-risk gastrointestinal stromal tumors in the real world.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Stomach Neoplasms | 2022 |
Clinical outcomes and prognostic factors for patients with high-risk gastrointestinal stromal tumors treated with 3-year adjuvant imatinib.
Topics: Adjuvants, Immunologic; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Prognosis; Pyrimidines | 2022 |
Worse Outcome with Imatinib Mesylate as Neoadjuvant Therapy in Locally Advanced Rectal Gastrointestinal Stromal Tumors: Case Series of Four Patients.
Topics: Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoadjuvant Therapy; Rectal Neoplasms; Retrospective Studies | 2022 |
Establishment of the prediction model and biological mechanism exploration for secondary imatinib-resistant in gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines | 2022 |
GASTROINTESTINAL STROMAL TUMOR: OUTCOMES OF THE PAST DECADE IN A REFERENCE INSTITUTION IN SOUTHERN BRAZIL.
Topics: Antineoplastic Agents; Benzamides; Brazil; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Retrospective Studies | 2022 |
HSP90 inhibition improves GIST survival.
Topics: Apoptosis; Cell Line, Tumor; Gastrointestinal Stromal Tumors; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate | 2022 |
The analysis of prognostic factors of primary small intestinal gastrointestinal stromal tumors with R0 resection: A single-center retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestinal Neoplasms; Ki-67 Antigen; Male; Middle Aged; Prognosis; Retrospective Studies; Young Adult | 2022 |
Population pharmacokinetic modelling of imatinib in healthy subjects receiving a single dose of 400 mg.
Topics: Gastrointestinal Stromal Tumors; Healthy Volunteers; Humans; Imatinib Mesylate; Kinetics; Models, Biological; Therapeutic Equivalency | 2022 |
Dramatic disappearance of hyperglycemia and abnormal neurologic symptoms after resection of duodenal gastrointestinal stromal tumor.
Topics: Aged; Duodenum; Female; Gastrointestinal Stromal Tumors; Humans; Hyperglycemia; Imatinib Mesylate; Paraneoplastic Syndromes | 2022 |
Tyrosine Kinase Inhibition Alters Intratumoral CD8+ T-cell Subtype Composition and Activity.
Topics: Animals; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Chemokines; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immune Checkpoint Inhibitors; Interleukin-15; Mice; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Protein-Tyrosine Kinases | 2022 |
[Advanced GIST: Which treatments in 2022?]
Topics: Antineoplastic Agents; Electron Transport Complex II; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Metabolism, Inborn Errors; Mitochondrial Diseases; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha; Succinate Dehydrogenase; Sunitinib | 2022 |
Surgical treatment of the metastatic gastrointestinal stromal tumor after resistance to available tyrosine kinase inhibitors: A case report.
Topics: Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Tyrosine Kinase Inhibitors | 2023 |
SPK1/S1P axis confers gastrointestinal stromal tumors (GISTs) resistance of imatinib.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Proto-Oncogene Proteins c-kit; Signal Transduction; Stomach Neoplasms | 2023 |
Efficacy of SCF drug conjugate targeting c-KIT in gastrointestinal stromal tumor.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Escherichia coli; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mice; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Sepharose | 2022 |
Comparison of Safety and Outcomes between Endoscopic and Surgical Resections of Intermediate-Risk Primary Gastric Gastrointestinal Stromal Tumors.
Topics: Endoscopy, Gastrointestinal; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Retrospective Studies; Stomach Neoplasms; Treatment Outcome | 2023 |
Impact of neoadjuvant treatment on rectal gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Margins of Excision; Neoadjuvant Therapy; Rectal Neoplasms; Retrospective Studies | 2022 |
Integrated Antitumor Activities of Cellular Immunotherapy with CIK Lymphocytes and Interferons against KIT/PDGFRA Wild Type GIST.
Topics: Antineoplastic Agents; B7-H1 Antigen; Gastrointestinal Stromal Tumors; Granzymes; Humans; Imatinib Mesylate; Immunotherapy; Interferons; Lymphocytes; Mutation; Proto-Oncogene Proteins c-kit; Receptor Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2022 |
[Gastrointestinal stromal tumors (GIST)].
Topics: Aged; Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha | 2023 |
9.4 T static magnetic field ameliorates imatinib mesylate-induced toxicity and depression in mice.
Topics: Animals; Antineoplastic Agents; Body Weight; Depression; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mice; Pyrimidines | 2023 |
CYP2D6 and CYP2C8 pharmacogenetics and pharmacological interactions to predict imatinib plasmatic exposure in GIST patients.
Topics: Chromatography, Liquid; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochromes; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Pharmacogenetics; Prospective Studies; Tandem Mass Spectrometry | 2023 |
Circ-CCS enhances autophagy during imatinib resistance of gastrointestinal stromal tumor by regulating miR-197-3p/ATG10 signaling.
Topics: Apoptosis; Autophagy; Autophagy-Related Proteins; Cell Line, Tumor; Cell Proliferation; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; MicroRNAs; RNA, Circular; Vesicular Transport Proteins | 2022 |
[A Case of Curative Surgery for Locally Advanced Small Bowel GIST after Imatinib Therapy].
Topics: Antineoplastic Agents; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestinal Neoplasms; Male; Middle Aged; Neoadjuvant Therapy | 2022 |
Gastrointestinal Stromal Tumors: 10-Year Experience in Cancer Center-The Ottawa Hospital (TOH).
Topics: Antineoplastic Agents; Gastrointestinal Stromal Tumors; Hospitals; Humans; Imatinib Mesylate; Protein Kinase Inhibitors; Retrospective Studies; United States | 2022 |
Canine gastrointestinal stromal tumours treated with surgery and imatinib mesylate: three cases (2018-2020).
Topics: Animals; Antineoplastic Agents; Dog Diseases; Dogs; Gastrointestinal Stromal Tumors; Imatinib Mesylate; Mutation; Proto-Oncogene Proteins c-kit | 2023 |
4-(Imidazo[1,2-a]pyridin-3-yl): pyrimidine derivatives as anticancer agents.
Topics: Antineoplastic Agents; Cell Proliferation; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit | 2023 |
Dutch Gastrointestinal Stromal Tumor (GIST) Registry Data Comparing Sunitinib with Imatinib Dose Escalation in Second-Line Advanced Non-KIT Exon 9 Mutated GIST Patients.
Topics: Antineoplastic Agents; Exons; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Pyrimidines; Registries; Retrospective Studies; Sunitinib | 2022 |
Challenge of gastro-intestinal stromal tumor management in low-income countries: example of Benin.
Topics: Benin; Cross-Sectional Studies; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Retrospective Studies | 2022 |
N
Topics: Animals; Autophagy; Autophagy-Related Protein 5; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Methyltransferases; Mice; RNA-Binding Proteins; Ubiquitin-Specific Proteases | 2023 |
Large esophageal gastrointestinal stromal tumors resected thoracoscopically after oral imatinib therapy: a report of two cases.
Topics: Aged; Antineoplastic Agents; Esophageal Neoplasms; Esophagectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged | 2023 |
Imatinib use for gastrointestinal stromal tumors among older patients in Japan and Taiwan.
Topics: Adjuvants, Immunologic; Aged; Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Japan; Protein Kinase Inhibitors; Retrospective Studies; Taiwan | 2022 |
Gastric volvulus associated with shrinkage of a gastrointestinal stromal tumor by neoadjuvant imatinib: a case report.
Topics: Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Neoadjuvant Therapy; Stomach Neoplasms; Stomach Volvulus | 2023 |
Sunitinib therapy for imatinib-resistant and/or intolerant gastrointestinal stromal tumors: comparison of safety and efficacy between standard and reduced dosage regimens.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2023 |
Inflammation and nutritional status indicators as prognostic indicators for patients with locally advanced gastrointestinal stromal tumors treated with neoadjuvant imatinib.
Topics: Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Inflammation; Neoadjuvant Therapy; Nutrition Assessment; Nutritional Status; Prognosis; Retrospective Studies | 2023 |
Clinical characteristics and outcomes of gastrointestinal stromal tumor patients receiving surgery with or without TKI therapy: a retrospective real-world study.
Topics: Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Ki-67 Antigen; Prognosis; Retrospective Studies; Tyrosine Kinase Inhibitors | 2023 |
Disparities in tyrosine kinase inhibitor use in older patients with gastrointestinal stromal tumors.
Topics: Aged; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors | 2023 |
Genomic Complexity as a Biomarker to De-Escalate Adjuvant Imatinib Treatment in High-Risk Gastrointestinal Stromal Tumor.
Topics: Antineoplastic Agents; Biomarkers; Chemotherapy, Adjuvant; Chromosome Aberrations; Comparative Genomic Hybridization; Gastrointestinal Stromal Tumors; Genomics; Humans; Imatinib Mesylate | 2023 |
Deubiquitylation of Rab35 by USP32 promotes the transmission of imatinib resistance by enhancing exosome secretion in gastrointestinal stromal tumours.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Exosomes; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Proto-Oncogene Proteins c-kit; Pyrimidines; rab GTP-Binding Proteins | 2023 |
Identification of M4205─A Highly Selective Inhibitor of KIT Mutations for Treatment of Unresectable Metastatic or Recurrent Gastrointestinal Stromal Tumors.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Neoplasm Recurrence, Local; Proto-Oncogene Proteins c-kit | 2023 |
Extragastrointestinal stromal tumour of the transverse mesocolon mimicking giant ovarian cystic neoplasm.
Topics: Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mesocolon; Mutation; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha | 2023 |
[A Case of Multiple Gastric GIST with Lymph Nodes Metastases in a Young Woman].
Topics: Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lymph Node Excision; Lymph Nodes; Stomach Neoplasms; Young Adult | 2022 |
[A Case Report of a Giant GIST Markedly Responsive to Neoadjuvant Chemotherapy with Imatinib Mesylate].
Topics: Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoadjuvant Therapy; Rectum | 2022 |
[A Case of GIST of Stomach with Peritoneal Dissemination-Long-Term Survival with Imatinib and Surgical Resection].
Topics: Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Neoplasm Recurrence, Local; Stomach | 2022 |
[A Case of Rectal GIST under Long-Term Follow-Up with Oral Imatinib].
Topics: Aged; Antineoplastic Agents; Benzamides; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Piperazines; Pyrimidines; Rectal Neoplasms; Rectum | 2022 |
[Three Cases Who Underwent Laparoscopic Radical Resection after Preoperative Therapy for Massive Rectal GIST].
Topics: Adult; Aged; Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Laparoscopy; Male; Middle Aged; Neoadjuvant Therapy; Rectal Neoplasms | 2022 |
Combination of pimitespib (TAS-116) with sunitinib is an effective therapy for imatinib-resistant gastrointestinal stromal tumors.
Topics: Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mice; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Sunitinib; Vascular Endothelial Growth Factor A | 2023 |
Endoscopic submucosal dissection for ultra-low large rectal stromal tumor after preoperative imatinib therapy: A case report and review.
Topics: Endoscopic Mucosal Resection; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Rectal Neoplasms; Rectum | 2022 |
Transvaginal Resection of a Gastrointestinal Stromal Tumor (GIST) of the Rectum.
Topics: Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Rectal Neoplasms; Rectum | 2023 |
KIT A502_Y503 duplication mutation serves as a potential and universal target for neoantigen peptide in Chinese GIST patients.
Topics: Antineoplastic Agents; Cyclin-Dependent Kinase Inhibitor p15; East Asian People; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Proto-Oncogene Proteins c-kit; Sunitinib | 2023 |
Interruption of imatinib in advanced gastrointestinal stromal tumor after prolonged imatinib maintenance in the absence of gross tumor lesions.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Retrospective Studies; Stomach Neoplasms; Treatment Outcome | 2023 |
Co-targeting of ACK1 and KIT triggers additive anti-proliferative and -migration effects in imatinib-resistant gastrointestinal stromal tumors.
Topics: Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Signal Transduction | 2023 |
Mesenchymal stromal cells promote the drug resistance of gastrointestinal stromal tumors by activating the PI3K-AKT pathway via TGF-β2.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mesenchymal Stem Cells; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Transforming Growth Factor beta2; Tumor Microenvironment | 2023 |
Myosin Light-Chain Kinase Inhibition Potentiates the Antitumor Effects of Avapritinib in PDGFRA D842V-Mutant Gastrointestinal Stromal Tumor.
Topics: Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Myosins; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha | 2023 |
Plasma trough concentration of imatinib and its effect on therapeutic efficacy and adverse events in Japanese patients with GIST.
Topics: Antineoplastic Agents; Drug Monitoring; East Asian People; Edema; Fatigue; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Retrospective Studies; Treatment Outcome | 2023 |
Development of Highly Sensitive Digital Droplet PCR for Detection of cKIT Mutations in Circulating Free DNA That Mediate Resistance to TKI Treatment for Gastrointestinal Stromal Tumor (GIST).
Topics: Cell-Free Nucleic Acids; Circulating Tumor DNA; DNA; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Neoplasm Recurrence, Local; Polymerase Chain Reaction; Proto-Oncogene Proteins c-kit; Receptor Protein-Tyrosine Kinases | 2023 |
PATIENT MANAGEMENT TACTICS AT DIFFERENT STAGES OF GASTROINTESTINAL STROMAL TUMORS (GIST).
Topics: Antineoplastic Agents; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation | 2023 |
Local recurrence in primary localised resected gastrointestinal stromal tumours: A registry observational national cohort study including 912 patients.
Topics: Antineoplastic Agents; Cohort Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Registries; Retrospective Studies | 2023 |
LIX1 Controls MAPK Signaling Reactivation and Contributes to GIST-T1 Cell Resistance to Imatinib.
Topics: Antineoplastic Agents; Autophagy-Related Proteins; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; MAP Kinase Signaling System; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Sunitinib | 2023 |
GIST (ILEAL) Revealed by Peculiar Paraneoplastic-myositis and Hypo-Thyroidism.
Topics: Autoantibodies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Myositis; Paraneoplastic Syndromes; Thyrotropin | 2023 |
Gastrointestinal Stromal Tumor Patients with Molecular Testing Exhibit Superior Survival Compared to Patients without Testing: Results from the Life Raft Group (LRG) Registry.
Topics: Antineoplastic Agents; Disease-Free Survival; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Molecular Diagnostic Techniques; Registries; Retrospective Studies | 2023 |
Gene polymorphisms affect postoperative imatinib plasma levels and edema in adults with gastrointestinal stromal tumor.
Topics: Adult; Antineoplastic Agents; Edema; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Polymorphism, Genetic | 2023 |
SPRY4 inhibits and sensitizes the primary KIT mutants in gastrointestinal stromal tumors (GISTs) to imatinib.
Topics: Animals; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mice; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Stomach Neoplasms | 2023 |
The use of therapeutic drug monitoring to highlight an over-looked drug-drug interaction leading to imatinib treatment failure.
Topics: Antineoplastic Agents; Carbamazepine; Chromatography, Liquid; Drug Interactions; Drug Monitoring; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Tandem Mass Spectrometry; Treatment Failure | 2023 |
Topics: Aged; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Pelvis; Rectum | 2023 |
Cytoreductive surgery offers prognostic benefits in metastatic gastrointestinal stromal tumors with generalized progression following imatinib therapy: a single institute retrospective study.
Topics: Antineoplastic Agents; Cytoreduction Surgical Procedures; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Prognosis; Retrospective Studies | 2023 |
A multiplatform metabolomics approach for comprehensive analysis of GIST xenografts with various
Topics: Gastrointestinal Stromal Tumors; Heterografts; Humans; Imatinib Mesylate; Metabolome; Metabolomics; Mutation | 2023 |
Multiple intratumoral sources of kit ligand promote gastrointestinal stromal tumor.
Topics: Animals; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mice; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Stem Cell Factor | 2023 |
Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Adjuvant Therapy Era.
Topics: Gastrointestinal Stromal Tumors; Genomics; Humans; Imatinib Mesylate; Mutation; Proto-Oncogene Proteins c-kit; Risk Assessment | 2023 |
Targeting BCL6 in Gastrointestinal Stromal Tumor Promotes p53-Mediated Apoptosis to Enhance the Antitumor Activity of Imatinib.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Proto-Oncogene Proteins c-bcl-6; Proto-Oncogene Proteins c-kit; Pyrimidines; Tumor Suppressor Protein p53 | 2023 |
Chromosomal instability and a deregulated cell cycle are intrinsic features of high-risk gastrointestinal stromal tumours with a metastatic potential.
Topics: Antineoplastic Agents; Cell Cycle; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Recurrence | 2023 |
[Gastrointestinal stromal tumors: a retrospective study].
Topics: Disease Progression; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Retrospective Studies | 2023 |
DDR1/2 enhance KIT activation and imatinib resistance of primary and secondary KIT mutants in gastrointestinal stromal tumors.
Topics: Animals; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Imatinib Mesylate; Mice; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines | 2024 |
LncRNA HIF1A-AS2 mediates imatinib resistance by regulating autophagy in gastrointestinal stromal tumor cells.
Topics: Autophagy; Cell Line, Tumor; Cell Proliferation; Gastrointestinal Stromal Tumors; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Imatinib Mesylate; RNA, Long Noncoding | 2023 |
Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors (GISTs) is Effective and Safe: Results from a Prospective Single-Center Study with 108 Patients.
Topics: Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Piperazines; Pyrimidines | 2023 |
MicroRNA-409-5p Inhibits GIST Tumorigenesis and Improves Imatinib Resistance by Targeting KDM4D Expression.
Topics: Carcinogenesis; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Jumonji Domain-Containing Histone Demethylases; MicroRNAs; Vascular Endothelial Growth Factor A | 2023 |
Personalized radiomics signature to screen for KIT-11 mutation genotypes among patients with gastrointestinal stromal tumors: a retrospective multicenter study.
Topics: Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Mutation; Proto-Oncogene Proteins c-kit; Receptor Protein-Tyrosine Kinases; Retrospective Studies | 2023 |
Cost Evaluation Analysis of Genetic Testing and Tailored Adjuvant Imatinib in Patients With Resected High-Risk GI Stromal Tumors: The Brazilian Perspective.
Topics: Antineoplastic Agents; Brazil; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Genetic Testing; Humans; Imatinib Mesylate | 2023 |
Flashback Foreword: Kinase Mutations and Imatinib Response in Patients With Metastatic GI Stromal Tumor.
Topics: Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit | 2023 |
Urgent Surgical Treatment of GIST of Esophago-Gastric Junction in a Patient with Giant Hiatal Hernia.
Topics: Aged; Anastomosis, Surgical; Antineoplastic Agents; Esophageal Neoplasms; Esophagogastric Junction; Female; Gastrectomy; Gastrointestinal Stromal Tumors; Hernia, Hiatal; Humans; Imatinib Mesylate; Intraoperative Complications; Liver Neoplasms | 2019 |
[A Large Gastric Gastrointestinal Stromal Tumor Successfully Treated with Neoadjuvant Imatinib Followed by Surgery-A Case Report].
Topics: Aged; Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Stomach Neoplasms | 2019 |
[Research advances in the secondary resistance mechanism of imatinib in gastrointestinal stromal tumors].
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate | 2019 |
Gastrointestinal Stromal Tumors Presenting as Vaginal Bleeding.
Topics: Antineoplastic Agents; Biopsy; Combined Modality Therapy; Diagnosis, Differential; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Middle Aged; Rectal Neoplasms; Tomography, X-Ray Computed; Uterine Hemorrhage; Vaginal Neoplasms | 2019 |
Primary Gastrointestinal Stromal Tumor Mimicking as Gynecologic Mass: Characteristics, Management, and Prognosis.
Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Diagnosis, Differential; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Genital Neoplasms, Female; Humans; Ileum; Imatinib Mesylate; Jejunum; Laparoscopy; Length of Stay; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Risk Factors | 2020 |
Multidrug resistant gastrointestinal stromal tumor with multiple metastases to the skin and subcutaneous soft tissue: A case report and review of literature.
Topics: Adult; Aged; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Skin Neoplasms; Sunitinib | 2020 |
Development and validation of LC-MS/MS method for imatinib and norimatinib monitoring by finger-prick DBS in gastrointestinal stromal tumor patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chromatography, Liquid; Dried Blood Spot Testing; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Protein Kinase Inhibitors; Reproducibility of Results; Tandem Mass Spectrometry | 2019 |
Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS).
Topics: Adult; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha | 2020 |
Two step treatment for giant malignant gastrointestinal stromal tumor: A case report.
Topics: Combined Modality Therapy; Digestive System Surgical Procedures; Embolization, Therapeutic; Enzyme Inhibitors; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Laparoscopy; Male; Middle Aged; Molecular Targeted Therapy; Protein-Tyrosine Kinases; Tomography, X-Ray Computed | 2020 |
Coordinated targeting of CK2 and KIT in gastrointestinal stromal tumours.
Topics: Apoptosis; Casein Kinase II; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Cell Survival; Chaperonins; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Knockdown Techniques; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Naphthyridines; Phenazines; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Signal Transduction; TOR Serine-Threonine Kinases | 2020 |
Renal Clearable Theranostic Nanoplatforms for Gastrointestinal Stromal Tumors.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Delivery Systems; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kidney; Male; Mice; Nanoparticles; Surgery, Computer-Assisted; Theranostic Nanomedicine | 2020 |
TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours.
Topics: Animals; Benzamides; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Golgi Apparatus; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Proto-Oncogene Proteins c-kit; Pyrazoles; Signal Transduction; Xenograft Model Antitumor Assays | 2020 |
Long-Term Survival After Multidisciplinary Treatment Including Surgery for Metachronous Metastases of Small Intestinal Gastrointestinal Stromal Tumors after Curative Resection: A Case Report.
Topics: Bone Neoplasms; Combined Modality Therapy; Fatal Outcome; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leiomyosarcoma; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Sunitinib | 2019 |
Recurrence-free Survival and Safety of Imatinib in Patients With Gastrointestinal Stromal Tumour (GIST) in Greece.
Topics: Disease-Free Survival; DNA Mutational Analysis; Female; Gastrointestinal Stromal Tumors; Greece; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome | 2020 |
Just Another Flare of Ulcerative Colitis?
Topics: Aged; Antineoplastic Agents; Biopsy; Colitis; Colitis, Ulcerative; Colonoscopy; Diagnosis, Differential; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestinal Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Protein Kinase Inhibitors; Symptom Flare Up | 2020 |
Inhibition of FGFR2-Signaling Attenuates a Homology-Mediated DNA Repair in GIST and Sensitizes Them to DNA-Topoisomerase II Inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; DNA Breaks, Double-Stranded; Doxorubicin; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Knockdown Techniques; Gene Silencing; Histones; Humans; Imatinib Mesylate; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Pyrimidines; Rad51 Recombinase; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Recombinational DNA Repair; RNA, Small Interfering; Signal Transduction; Topoisomerase II Inhibitors | 2020 |
Adherence to Adjuvant Imatinib Therapy in Patients with Gastrointestinal Stromal Tumor in Clinical Practice: A Cross-Sectional Study.
Topics: Chemotherapy, Adjuvant; Cross-Sectional Studies; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Health Status; Humans; Imatinib Mesylate; Logistic Models; Male; Medication Adherence; Middle Aged; Protein Kinase Inhibitors; Quality of Life; Sex Factors; Social Support | 2019 |
Bromodomain and extraterminal domain inhibitor enhances the antitumor effect of imatinib in gastrointestinal stromal tumours.
Topics: Animals; Antineoplastic Agents; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Male; Mice; Mice, Nude; Middle Aged; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Signal Transduction; TOR Serine-Threonine Kinases; Transcription Factors | 2020 |
[Efficacy analysis of preoperative imatinib treatment in localized high-risk gastrointestinal stromal tumors].
Topics: Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines | 2020 |
Genetics and treatment of gastrointestinal stromal tumors with immune checkpoint inhibitors: what do we know?
Topics: Disease Progression; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immune Checkpoint Inhibitors; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Sunitinib | 2020 |
ALK expressed in a gastrointestinal stromal tumor harboring PDGFRA p. D842V mutation:a case report.
Topics: Adult; Amino Acid Substitution; Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Mutation; Piperazines; Receptor, Platelet-Derived Growth Factor alpha | 2020 |
A Giant Gastric Gastrointestinal Stromal Tumor Successfully Resected Following Neoadjuvant Treatment With Imatinib Mesylate.
Topics: Aged; Antineoplastic Agents; Biopsy; Combined Modality Therapy; Female; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Protein Kinase Inhibitors; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2020 |
Gastrointestinal stromal tumor of the rectum resected by transanal total mesorectal excision after neoadjuvant imatinib treatment: A case report.
Topics: Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Rectal Neoplasms; Rectum; Transanal Endoscopic Surgery | 2020 |
Hyperpigmentation due to imatinib: A rare case of cutaneous involvement.
Topics: Aged; Antineoplastic Agents; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Hyperpigmentation; Imatinib Mesylate; Protein Kinase Inhibitors | 2020 |
Decoding a mysterious morphology with molecular pathology: chondroid metaplasia in a metastatic gastrointestinal stromal tumour after imatinib therapy.
Topics: Antineoplastic Agents; Cartilage; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Metaplasia; Middle Aged | 2020 |
Preoperative imatinib treatment in patients with locally advanced and metastatic/recurrent gastrointestinal stromal tumors: A single-center analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; China; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Medical Records; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Retrospective Studies; Survival Analysis; Treatment Outcome | 2020 |
[A Case of Gastrointestinal Stromal Tumor in the Rectum with Preservation of Anal Function after Neoadjuvant Chemotherapy UsingImatinib].
Topics: Aged, 80 and over; Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Rectal Neoplasms; Rectum | 2019 |
[A Case of Surgical Resection of an Esophageal Gastrointestinal Stromal Tumor after Neoadjuvant Therapy with Imatinib].
Topics: Antineoplastic Agents; Esophageal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy | 2019 |
[A Case of Peritoneal Metastasis Resection from GIST of the Small Intestine with Focal Resistance Against Imatinib Mesylate].
Topics: Aged; Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestinal Neoplasms; Intestine, Small; Male; Peritoneal Neoplasms; Proto-Oncogene Proteins c-kit | 2019 |
[A Case of Omental Desmoid Tumor after a Small Bowel Resection for Gastrointestinal Stromal Tumor].
Topics: Aged; Fibromatosis, Aggressive; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestinal Neoplasms; Intestine, Small; Male; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Omentum | 2019 |
[Rectal Gastrointestinal Stromal Tumor(GIST)Excised by Two Teams Following Neoadjuvant Chemotherapy-A Case Report].
Topics: Aged; Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoadjuvant Therapy; Rectal Neoplasms; Rectum | 2019 |
[A Case of Gastrointestinal Stromal Tumor Re-Resected Ten Years after the Resection of Its Recurrence].
Topics: Aged; Angiomyolipoma; Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Neoplasm Recurrence, Local | 2019 |
Treatment options for giant gastrointestinal stromal tumours and related prognosis: a single-centre retrospective study.
Topics: Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Prognosis; Retrospective Studies | 2020 |
Clinical outcomes of different therapeutic modalities for rectal gastrointestinal stromal tumor: Summary of 14-year clinical experience in a single center.
Topics: Adult; Aged; Aged, 80 and over; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Rectal Neoplasms; Retrospective Studies | 2020 |
Differential antitumor activity of compounds targeting the ubiquitin-proteasome machinery in gastrointestinal stromal tumor (GIST) cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boron Compounds; Boronic Acids; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Glycine; Humans; Imatinib Mesylate; Male; Mice; Mice, Nude; Oligopeptides; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Signal Transduction; Threonine; Xenograft Model Antitumor Assays | 2020 |
Generalized lentigines associated with familial gastrointestinal stromal tumors dramatically improved by imatinib treatment.
Topics: Chemotherapy, Adjuvant; Dermoscopy; DNA Mutational Analysis; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Female; Gastrectomy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gastroscopy; Humans; Imatinib Mesylate; Lentigo; Middle Aged; Neoplastic Syndromes, Hereditary; Point Mutation; Proto-Oncogene Proteins c-kit; Skin; Stomach; Treatment Outcome | 2020 |
R1 Resection in Gastrointestinal Stromal Tumors Is Not Worse Than R0.
Topics: Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Pancreatic Neoplasms; Prognosis | 2020 |
Rectal GIST - A review. An invited commentary on "Clinical outcomes of different therapeutic modalities for rectal gastrointestinal stromal tumor: Summary of 14-year clinical experience in a single center--Retrospective cohort study".
Topics: Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Rectal Neoplasms; Rectum; Retrospective Studies | 2020 |
Living Donor Liver Transplantation for Imatinib-Resistant Gastrointestinal Stromal Tumor Liver Metastases: A New Therapeutic Option in Transplant Oncology.
Topics: Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Liver Transplantation; Living Donors | 2020 |
MicroRNA-30a targets BECLIN-1 to inactivate autophagy and sensitizes gastrointestinal stromal tumor cells to imatinib.
Topics: Animals; Antineoplastic Agents; Autophagy; Beclin-1; Cell Line, Tumor; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Mice; Mice, Nude; MicroRNAs; Transfection; Xenograft Model Antitumor Assays | 2020 |
Preoperative adjuvant therapy for locally advanced and recurrent/metastatic gastrointestinal stromal tumors: a retrospective study.
Topics: Adult; Chemotherapy, Adjuvant; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies | 2020 |
Rare tumors in China: A step in the right direction.
Topics: Antineoplastic Agents; China; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha | 2020 |
Cystic Ileal Gastrointestinal Stromal Tumor Masquerading as Metastatic Adnexal Carcinoma.
Topics: Abdominal Cavity; Aged; Carcinoma; Chemotherapy, Adjuvant; Cysts; Diagnosis, Differential; Female; Gastrointestinal Stromal Tumors; Humans; Ileal Neoplasms; Ileum; Imatinib Mesylate; Laparoscopy; Ovarian Neoplasms; Pelvis; Peritoneal Neoplasms; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography | 2020 |
Tumor-associated tertiary lymphoid structure predicts postoperative outcomes in patients with primary gastrointestinal stromal tumors.
Topics: Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Prognosis; Tertiary Lymphoid Structures | 2020 |
Primary Hepatic Gastrointestinal Stromal Tumour (GIST): Unusual Presentation and Diagnosis.
Topics: Aged; Anorexia; Chemotherapy, Adjuvant; Female; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Liver; Liver Neoplasms; Tomography, X-Ray Computed; Treatment Outcome; Weight Loss | 2020 |
Cardiovascular Toxicity in Cancer Patients Treated with Tyrosine Kinase Inhibitors: A Real-World Single-Center Experience.
Topics: Aged; Coronary Artery Disease; Dasatinib; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Pulse Wave Analysis; Pyridazines; Pyrimidines; Retrospective Studies; Treatment Outcome | 2020 |
[Gastric Gastrointestinal Stromal Tumor Appearing Nine Years after Resection of a Duodenal Gastrointestinal Stromal Tumor-A Case Report].
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Duodenal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Stomach Neoplasms | 2020 |
[Case of Intestinal GIST with Long-Term Survival after Multidisciplinary Treatment, Including Surgical Resection for Liver Metastasis].
Topics: Combined Modality Therapy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged | 2020 |
[Case of Peritoneal Dissemination from Gastrointestinal Stromal Tumor of Jejunum Treated with Repeated Non-Curative Surgery].
Topics: Aged; Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Jejunal Neoplasms; Jejunum; Liver Neoplasms; Male | 2020 |
[A Case of Multidisciplinary Treatment for a Recurrent Gastrointestinal Stromal Tumor of the Stomach].
Topics: Aged; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoplasm Recurrence, Local; Stomach | 2020 |
Anal Canal Gastrointestinal Stromal Tumor: a Case Report.
Topics: Adult; Anal Canal; Anus Neoplasms; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Treatment Outcome | 2021 |
Heterogeneity of Metabolic Vulnerability in Imatinib -Resistant Gastrointestinal Stromal Tumor.
Topics: Antimycin A; Cell Death; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Energy Metabolism; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Glycolysis; Gossypol; Humans; Imatinib Mesylate; Oligomycins; Organelle Biogenesis; Oxidative Phosphorylation; Phenotype; Pyruvates | 2020 |
Therapeutic drug monitoring-based dose optimization for imatinib-associated serious cutaneous reactions in a patient with gastrointestinal stromal tumours: A case report.
Topics: Aged; Drug Eruptions; Drug Monitoring; Eczema; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Skin Diseases | 2020 |
Prolapsed giant rectal gastrointestinal stromal tumor presented with incarceration A rare case of emergency rectal lesion.
Topics: Aged; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoplasm Recurrence, Local; Prolapse; Rectum | 2020 |
Comparison of prognostic prediction models for rectal gastrointestinal stromal tumor.
Topics: Adult; Aged; Chemotherapy, Adjuvant; Clinical Decision-Making; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestinal Mucosa; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Recurrence, Local; Nomograms; Predictive Value of Tests; Proctectomy; Rectal Neoplasms; Rectum; Retrospective Studies; Risk Assessment; Risk Factors | 2020 |
TAMIS excision of Rectal GIST following effective treatment with neoadjuvant Imatinib - a video vignette.
Topics: Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Rectal Neoplasms; Rectum; Transanal Endoscopic Surgery | 2020 |
Imatinib-induced superficial pemphigus in a patient with gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Pemphigus; Piperazines | 2020 |
Living Donor Liver Transplantation for Imatinib-Resistant Gastrointestinal Stromal Tumor Liver Metastases: A New Therapeutic Option in Transplant Oncology.
Topics: Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Liver Transplantation; Living Donors; Transplants | 2020 |
An Unexpected Response to Imatinib in a "Wild-Type" Gastrointestinal Stromal Tumor.
Topics: Antineoplastic Agents; DNA Mutational Analysis; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Middle Aged; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Treatment Outcome | 2020 |
Gastrointestinal stromal tumors and second primary malignancies: a retrospective monocentric analysis.
Topics: Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasms, Second Primary; Prognosis; Retrospective Studies | 2020 |
Gastric neoplasm: Gastrointestinal stromal tumor mimicking gastric carcinoma.
Topics: Aged; Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Stomach Neoplasms | 2021 |
Combined Partial Gastrectomy, Splenectomy, and Microwave Liver Ablation of Metastatic Gastrointestinal Stromal Tumor After 4 Years of Neoadjuvant Imatinib.
Topics: Antineoplastic Agents; Cholecystectomy; Female; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Lymph Node Excision; Microwaves; Middle Aged; Neoadjuvant Therapy; Splenectomy | 2020 |
Reply.
Topics: Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Liver Transplantation; Living Donors; Transplants | 2020 |
Therapeutic drug monitoring of imatinib in patients with gastrointestinal stromal tumours - Results from daily clinical practice.
Topics: Aged; Cohort Studies; Dose-Response Relationship, Drug; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Netherlands; Practice Patterns, Physicians'; Progression-Free Survival; Retrospective Studies | 2020 |
Adjuvant systemic therapy for small bowel gastrointestinal stromal tumor (GIST): Is there a survival benefit after R0 resection?
Topics: Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestinal Neoplasms; Intestine, Small; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Proportional Hazards Models; Retrospective Studies | 2020 |
HIF-1α regulates cellular metabolism, and Imatinib resistance by targeting phosphogluconate dehydrogenase in gastrointestinal stromal tumors.
Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Imatinib Mesylate; Male; Mice, Nude; Middle Aged; Models, Biological; Phosphogluconate Dehydrogenase; Reactive Oxygen Species; Up-Regulation | 2020 |
The role of novel fusion genes in human GIST cell lines derived from imatinib-resistant GIST patients: A therapeutic potential of fusion gene.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Oncogene Proteins, Fusion | 2020 |
Locally Advanced Gastrointestinal Stromal Tumor in a 33-Year-Old Woman Seeking to Conceive.
Topics: Adult; Combined Modality Therapy; Female; Fertility Preservation; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Staging; Protein Kinase Inhibitors; Treatment Outcome | 2020 |
Pemphigus foliaceus in a patient with gastrointestinal stromal tumor treated with adjuvant imatinib mesylate.
Topics: Aged, 80 and over; Antineoplastic Agents; Biopsy; Dose-Response Relationship, Drug; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunologic Factors; Male; Pemphigus; Rituximab; Skin | 2020 |
The analysis of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST) treated in routine practice.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Exons; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Proto-Oncogene Proteins c-kit | 2021 |
Primary pancreatic gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Combined Modality Therapy; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Neoadjuvant Therapy; Pancreas; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tomography, X-Ray Computed | 2021 |
[Significance of surgical treatment for recurrent and metastatic gastrointestinal stromal tumors].
Topics: Antineoplastic Agents; Cytoreduction Surgical Procedures; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Patient Care Team; Sunitinib; Treatment Outcome; Tumor Burden | 2020 |
[Tough choice of surgical treatment for duodenal gastrointestinal stromal tumor: pancreaticoduodenectomy or local resection?]
Topics: Antineoplastic Agents; Combined Modality Therapy; Duodenal Neoplasms; Duodenum; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Minimally Invasive Surgical Procedures; Pancreaticoduodenectomy; Prognosis; Robotic Surgical Procedures | 2020 |
[Current status and progress in novel drug research for gastrointestinal stromal tumors].
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Naphthyridines; Protein Kinase Inhibitors; Pyrazoles; Pyrroles; Triazines; Urea | 2020 |
[Research advance of liquid biopsy in gastrointestinal stromal tumors].
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Early Detection of Cancer; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liquid Biopsy; Neoplasm Recurrence, Local | 2020 |
Transanal endoscopic microsurgery with alternative neoadjuvant imatinib for localized rectal gastrointestinal stromal tumor: a single center experience with long-term surveillance.
Topics: Adult; Aged; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Microsurgery; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Rectal Neoplasms; Retrospective Studies; Transanal Endoscopic Microsurgery; Treatment Outcome | 2021 |
Minimally Invasive Resection of Large Gastric Gastrointestinal Stromal Tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Conversion to Open Surgery; Disease-Free Survival; Female; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intraoperative Complications; Laparoscopy; Length of Stay; Male; Margins of Excision; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Postoperative Complications; Retrospective Studies; Stomach Neoplasms; Tumor Burden | 2020 |
Cost-effectiveness Analysis of Genetic Testing and Tailored First-Line Therapy for Patients With Metastatic Gastrointestinal Stromal Tumors.
Topics: Antineoplastic Agents; Cost-Benefit Analysis; Drug Costs; Gastrointestinal Stromal Tumors; Genetic Testing; Humans; Imatinib Mesylate; Markov Chains; Neoplasm Metastasis; Neoplasm Staging; Pharmacogenetics; Proto-Oncogene Proteins c-kit; Quality-Adjusted Life Years | 2020 |
Diffuse primary extra-gastrointestinal stromal tumor of the peritoneum: A rare case report.
Topics: Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Peritoneal Neoplasms | 2020 |
Solitary peritoneal metastasis of gastrointestinal stromal tumor: A case report.
Topics: Aged; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Peritoneal Neoplasms; Peritoneum | 2020 |
[A case of gastrointestinal stromal tumor of the duodenum with ruptured liver metastasis during administration of imatinib].
Topics: Duodenum; Embolization, Therapeutic; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged | 2020 |
Gastric Gastrointestinal Stromal Tumor with Repeated Recurrence at the Anastomosis Site in a Very Elderly Patient.
Topics: Abdomen; Aged, 80 and over; Endoscopy, Gastrointestinal; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Metastasis; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Tomography, X-Ray Computed | 2020 |
Prognostic Factors After Neoadjuvant Imatinib for Newly Diagnosed Primary Gastrointestinal Stromal Tumor.
Topics: Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Prognosis; Prospective Studies; Retrospective Studies | 2021 |
Financial Implications of Avapritinib for Treatment of Unresectable Gastrointestinal Stromal Tumors in Patients With a PDGFRA Exon 18 Variant or After 3 Previous Therapies in a Hypothetical US Health Plan.
Topics: Antineoplastic Agents; Budgets; Cost-Benefit Analysis; Formularies as Topic; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indazoles; Managed Care Programs; Medicaid; Medicare; Molecular Diagnostic Techniques; Phenylurea Compounds; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sulfonamides; Sunitinib; Treatment Failure; Triazines; United States | 2020 |
Imatinib-induced pancreatic hypertrophy in patients with gastrointestinal stromal tumor: Association with overall survival.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Atrophy; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Hypertrophy; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Middle Aged; Pancreas; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis | 2021 |
Long induction of tolerance to imatinib.
Topics: Antineoplastic Agents; Drug Tolerance; Exanthema; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Pruritus | 2020 |
Demographic and clinicopathological profile of patients of gastrointestinal stromal tumor from a tertiary care center of North India: An observational study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Child; Female; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; India; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Risk Factors; Stomach; Stomach Neoplasms; Tertiary Care Centers; Treatment Outcome; Young Adult | 2020 |
An SPR investigation into the therapeutic drug monitoring of the anticancer drug imatinib with selective aptamers operating in human plasma.
Topics: Antineoplastic Agents; Drug Monitoring; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Surface Plasmon Resonance | 2021 |
[A Case of a Huge Gastrointestinal Stromal Tumor with Extraluminal Growth Arising in the Small Intestine Diagnosed as an Ovarian Tumor].
Topics: Aged; Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestine, Small; Ovarian Neoplasms | 2020 |
[Preoperative Imatinib Therapy Followed by Laparoscopic Local Gastrectomy for a Giant Gastric Gastrointestinal Stromal Tumor-A Case Report].
Topics: Antineoplastic Agents; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Laparoscopy; Male; Middle Aged; Neoplasm Recurrence, Local; Stomach Neoplasms | 2020 |
Prognostic and predictive values of the KIT11-mutated grading system in patients with gastrointestinal stromal tumors: a retrospective study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins c-kit; Retrospective Studies; Young Adult | 2021 |
Imatinib and nutritional support can make successful treatment for a case of huge liver metastasis of duodenal gastrointestinal stromal tumor that initially showed jaundice and cachexia.
Topics: Adult; Antineoplastic Agents; Cachexia; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Jaundice; Liver Neoplasms; Neoplasm Recurrence, Local; Nutritional Support | 2021 |
[Treatment of soft tissue sarcomas including GIST - Update 2021].
Topics: Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Phenylurea Compounds; Pyridines; Sarcoma; Sunitinib | 2021 |
Characteristics and prognosis of jejunoileal gastrointestinal stromal tumours (GISTs) in the era of imatinib: a comparative study with gastric GISTs.
Topics: Aged; Antineoplastic Agents; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Ileal Neoplasms; Imatinib Mesylate; Jejunal Neoplasms; Male; Middle Aged; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Rate | 2021 |
Adjuvant imatinib for GIST: duration likely matters.
Topics: Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Italy; Piperazines; Sarcoma | 2021 |
Clinical significance of surgical intervention for imatinib-resistant gastrointestinal stromal tumors in the era of multiple tyrosine kinase inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Retrospective Studies; Survival Rate; Treatment Outcome | 2021 |
[A Case of Gastrointestinal Stromal Tumor of the Lower Rectum That Enabled Minimally Invasive Surgery with Imatinib Mesylate as Neoadjuvant Chemotherapy].
Topics: Aged; Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Minimally Invasive Surgical Procedures; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Rectal Neoplasms; Rectum | 2021 |
Duodenal perforation caused by imatinib mesylate during adjuvant treatment of gastric stromal tumor: Case report.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Pyrimidines | 2021 |
Resection of a large gastrointestinal stromal tumor in the stomach after imatinib treatment in a 90-year-old patient.
Topics: Aged, 80 and over; Antineoplastic Agents; Female; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Stomach Neoplasms | 2021 |
Oncogenic KIT Modulates Type I IFN-Mediated Antitumor Immunity in GIST.
Topics: Animals; Antibodies, Monoclonal; Cell Line, Tumor; Cell Proliferation; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Interferon Type I; Mice; Mice, Inbred C57BL; Proto-Oncogene Proteins c-kit; Signal Transduction; Xenograft Model Antitumor Assays | 2021 |
Novel case of a scleroderma-mimicking syndrome associated with gastrointestinal stromal tumour.
Topics: Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Raynaud Disease; Scleroderma, Localized; Scleroderma, Systemic; Stomach Neoplasms | 2021 |
Integrated Screens Identify CDK1 as a Therapeutic Target in Advanced Gastrointestinal Stromal Tumors.
Topics: Adult; Aged; Animals; Antineoplastic Agents; CDC2 Protein Kinase; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cohort Studies; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; HEK293 Cells; Humans; Imatinib Mesylate; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Protein Kinase Inhibitors; Quinolines; Thiazoles; Transfection; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2021 |
Changes in expression of lysosomal membrane proteins in leucocytes of cancer patients treated with tyrosine kinase inhibitors.
Topics: Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Renal Cell; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukocytes; Lysosomal Membrane Proteins; Lysosomes; Male; Protein Kinase Inhibitors; Sunitinib | 2021 |
Sigmoid Sinus Thrombosis Followed by Splenic Infarction Due to Imatinib Therapy in a Patient with Gastrointestinal Stromal Tumor; Hematological Side Effects of Imatinib.
Topics: Aged; Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Sinus Thrombosis, Intracranial; Splenic Infarction | 2021 |
[A Case of the Large Rectal GIST Treated by Laparoscopic Anus Preserving Operation after Neoadjuvant Therapy with Imatinib Mesylate].
Topics: Anal Canal; Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Laparoscopy; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Rectal Neoplasms | 2021 |
LncRNA-HOTAIR activates autophagy and promotes the imatinib resistance of gastrointestinal stromal tumor cells through a mechanism involving the miR-130a/ATG2B pathway.
Topics: Autophagy; Autophagy-Related Proteins; Cell Line, Tumor; Cell Proliferation; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; MicroRNAs; Neoplasm Recurrence, Local; RNA, Long Noncoding; Vesicular Transport Proteins | 2021 |
Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): A large, retrospective multicenter European study.
Topics: Aged; Anastomotic Leak; Antineoplastic Agents; Biopsy, Fine-Needle; Chemotherapy, Adjuvant; Disease-Free Survival; Esophageal Neoplasms; Esophagectomy; Esophagoscopy; Europe; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Margins of Excision; Middle Aged; Mitotic Index; Neoadjuvant Therapy; Neoplasm Metastasis; Plastic Surgery Procedures; Postoperative Complications; Progression-Free Survival; Retrospective Studies; Treatment Outcome; Tumor Burden | 2021 |
Reversing Imatinib's Immunosuppressive Effects by Modulating Type I IFN Signaling.
Topics: Animals; Gastrointestinal Stromal Tumors; Imatinib Mesylate; Mice; Proto-Oncogene Proteins c-kit; Signal Transduction | 2021 |
Surgical Outcomes of Rectal Gastrointestinal Stromal Tumor in the Era of Imatinib.
Topics: Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Rectal Neoplasms; Rectum; Treatment Outcome | 2021 |
Rare case of a duodenal de novo dedifferentiated gastrointestinal stromal tumour.
Topics: Duodenum; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha | 2021 |
[A Case on the Long‒Term Effect of Imatinib on GIST of Unknown Primary Origin with Multiple Liver Metastases, Peritoneal Dissemination, and Bone Metastasis].
Topics: Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Middle Aged; Neoplasms, Unknown Primary | 2021 |
ASO Author Reflections: Imatinib Use Remains Inadequate for High-Risk GIST Patients.
Topics: Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines | 2021 |
Imatinib-induced podocytopathies in a patient with gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Gastrointestinal Stromal Tumors; Glomerulosclerosis, Focal Segmental; Humans; Imatinib Mesylate; Kidney Function Tests; Male; Middle Aged; Nephrosis, Lipoid | 2021 |
National Utilization of Imatinib in the Management of Resected Gastrointestinal Stromal Tumors.
Topics: Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestine, Small; Middle Aged; Neoplasm Recurrence, Local | 2021 |
Starting Imatinib at 400 mg Daily in Patients with Gastrointestinal Stromal Tumors Harboring KIT Exon 9 Mutations: A Retrospective, Multicenter Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Exons; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Retrospective Studies; Young Adult | 2021 |
Imatinib-resistant gastrointestinal stromal tumors in the era of second- and third-line tyrosine kinase inhibitors: Does surgical resection have a role?
Topics: Adult; Aged; Decision Making; Digestive System Surgical Procedures; Disease Progression; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Protein Kinase Inhibitors; Registries; Retrospective Studies; Time Factors | 2021 |
A liver metastasis 7 years after resection of a low-risk duodenal gastrointestinal stromal tumor.
Topics: Duodenal Neoplasms; Duodenum; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Middle Aged | 2021 |
Oncogene mutational analysis in imatinib naive population of gastrointestinal stromal tumor patients.
Topics: Adult; Aged; Anoctamin-1; Antigens, CD34; Antineoplastic Agents; DNA Mutational Analysis; Drug Resistance, Neoplasm; Exons; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neoplasm Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha | 2020 |
Clinicopathological Features and Outcomes of Gastrointestinal Stromal Tumours in Oman: A multi-centre study.
Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Oman; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Retrospective Studies; Survival Rate; United States | 2021 |
Delayed adjuvant imatinib in patients with high risk of recurrence of gastrointestinal stromal tumor after radical surgery: a retrospective cohort study.
Topics: Adjuvants, Immunologic; Adult; Antineoplastic Agents; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Retrospective Studies | 2022 |
The effect of neoadjuvant imatinib therapy on outcome and survival in rectal gastrointestinal stromal tumors: A multiinstitutional study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Prognosis; Rectal Neoplasms; Retrospective Studies | 2021 |
Inhibition of PI3K and MAPK pathways along with KIT inhibitors as a strategy to overcome drug resistance in gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; MAP Kinase Signaling System; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Xenograft Model Antitumor Assays | 2021 |
[Gastrointestinal stromal duodenal tumors: diagnostic mistakes and modern approaches to treatment].
Topics: Duodenal Neoplasms; Duodenum; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy | 2021 |
Gastrointestinal stromal tumors with BRAF gene fusions. A report of two cases showing low or absent KIT expression resulting in diagnostic pitfalls.
Topics: Adult; Anoctamin-1; Female; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; GTP-Binding Proteins; GTPase-Activating Proteins; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Male; Middle Aged; Mutation; Neoplasm Proteins; Nerve Tissue Proteins; Oncogene Proteins, Fusion; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Receptor, Fibroblast Growth Factor, Type 1; Receptor, trkC; Ribonucleoproteins; Young Adult | 2021 |
Humeral metastasis as the only recurrence of a 5-year resected gastrointestinal stromal tumor: a case report.
Topics: Aged; Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Humans; Humerus; Imatinib Mesylate; Liver Neoplasms; Neoplasm Recurrence, Local | 2021 |
A novel anti-c-Kit antibody-drug conjugate to treat wild-type and activating-mutant c-Kit-positive tumors.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunoconjugates; Lung Neoplasms; Mice; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Receptor Protein-Tyrosine Kinases; Small Cell Lung Carcinoma | 2022 |
New response evaluation criteria using early morphological change in imatinib treatment for patients with gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Retrospective Studies; Stomach Neoplasms; Treatment Outcome | 2022 |
Skeletal muscle metastasis from a gastrointestinal stromal tumor: A case report.
Topics: Drug Resistance, Neoplasm; Exome Sequencing; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Muscle Neoplasms; Muscle, Skeletal; Sunitinib; Thigh | 2021 |
Gastrointestinal stromal tumor of the stomach with axillary lymph node metastasis: A case report.
Topics: Aged; Axilla; Fatal Outcome; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Lymph Nodes; Lymphatic Metastasis; Male; Neoplasm Metastasis; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; Pyrroles; Stomach Neoplasms; Sunitinib; Tomography, X-Ray Computed | 2017 |
Defining the Impact of Adjuvant Therapy in Molecularly Defined Subsets of Gastrointestinal Stromal Tumor : From Lumping to Splitting.
Topics: Chemotherapy, Adjuvant; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation | 2017 |
SLUG transcription factor: a pro-survival and prognostic factor in gastrointestinal stromal tumour.
Topics: Adult; Aged; Aged, 80 and over; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Male; Middle Aged; Prognosis; Signal Transduction; Snail Family Transcription Factors | 2017 |
A Novel Curative Treatment Strategy for Patients with Lower Grade Rectal Gastrointestinal Stromal Tumor: Chemoreduction Combined with Transanal Endoscopic Microsurgery.
Topics: Adult; Aged; Antineoplastic Agents; China; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Postoperative Complications; Rectal Neoplasms; Retrospective Studies; Transanal Endoscopic Microsurgery; Treatment Outcome | 2017 |
Cost-Effectiveness Analysis of Regorafenib for Gastrointestinal Stromal Tumour (GIST) in Germany.
Topics: Aged; Antineoplastic Agents; Cost-Benefit Analysis; Drug Costs; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Phenylurea Compounds; Pyridines; Quality-Adjusted Life Years | 2017 |
An Epithelioid Gastrointestinal Stromal Tumor of the Stomach With Strong Expression of Keratin: Clinicopathologic Correlation and Follow-up Post-Imatinib Therapy.
Topics: Aged; Anoctamin-1; Antigens, CD34; Antineoplastic Agents; Biomarkers, Tumor; Diagnosis, Differential; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Keratins; Male; Mutation; Neoplasm Proteins; Proto-Oncogene Proteins c-kit; Stomach | 2019 |
Pharmacometric Modeling of Liver Metastases' Diameter, Volume, and Density and Their Relation to Clinical Outcome in Imatinib-Treated Patients With Gastrointestinal Stromal Tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Models, Biological; Protein Kinase Inhibitors; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2017 |
Influence of CYP2C8 polymorphisms on imatinib steady-state trough level in chronic myeloid leukemia and gastrointestinal stromal tumor patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Cytochrome P-450 CYP2C8; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Prospective Studies | 2017 |
Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST).
Topics: Adult; Aged; Antineoplastic Agents; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Preoperative Care; Prognosis; Retrospective Studies; Survival Rate | 2017 |
Characteristics and prognosis of rectal gastrointestinal stromal tumors: an analysis of registry data.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Data Interpretation, Statistical; Digestive System Surgical Procedures; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Perioperative Care; Prognosis; Rectal Neoplasms; Registries | 2017 |
Conventional transanal excision for a very low gastrointestinal stromal tumour.
Topics: Adult; Anal Canal; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Treatment Outcome | 2017 |
Patterns of care and clinical outcomes in primary oesophageal gastrointestinal stromal tumours (GIST): A retrospective study of the French Sarcoma Group (FSG).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Endosonography; Esophageal Neoplasms; Esophagectomy; Esophagoscopy; Female; Follow-Up Studies; France; Gastrointestinal Stromal Tumors; Humans; Image-Guided Biopsy; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Practice Patterns, Physicians'; Retrospective Studies; Tomography, X-Ray Computed | 2017 |
Long-term outcome of GIST patients treated with delayed imatinib therapy.
Topics: Aged; Bosnia and Herzegovina; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Retrospective Studies; Survival Analysis; Time-to-Treatment; Treatment Outcome; Waiting Lists | 2017 |
[Acute Promyelocytic Leukemia Developed during Imatinib Therapy for Gastrointestinal Stromal Tumors].
Topics: Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Promyelocytic, Acute; Middle Aged; Neoplasms, Second Primary; Oncogene Proteins, Fusion; Tretinoin | 2017 |
Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Treated With Tyrosine Kinase Inhibitors: A 2-institutional Analysis.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Metastasectomy; Neoplasm Metastasis; Prognosis; Retrospective Studies; Sunitinib; Survival Analysis | 2018 |
Phosphodiesterase 3A: a new player in development of interstitial cells of Cajal and a prospective target in gastrointestinal stromal tumors (GIST).
Topics: Aged; Animals; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Survival; Cilostazol; Cyclic Nucleotide Phosphodiesterases, Type 3; Drug Synergism; Female; Gastrointestinal Stromal Tumors; HEK293 Cells; Humans; Imatinib Mesylate; Interstitial Cells of Cajal; Male; Mice, 129 Strain; Mice, Knockout; Middle Aged; Phosphodiesterase 3 Inhibitors; Pyridazines; Tetrazoles | 2017 |
Discovery of Potent, Selective Stem Cell Factor Receptor/Platelet Derived Growth Factor Receptor Alpha (c-KIT/PDGFRα) Dual Inhibitor for the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs).
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chemistry Techniques, Synthetic; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Mice, Nude; Molecular Targeted Therapy; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Rats, Sprague-Dawley; Receptor, Platelet-Derived Growth Factor alpha; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2017 |
A Metastatic Rectal Gastrointestinal Stromal Tumor to the Small Bowel Mesentery Treated with Neoadjuvant Imatinib and Debulking Surgery Followed by Low Anterior Resection.
Topics: Antineoplastic Agents; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Gastrointestinal Stromal Tumors; Humans; Image-Guided Biopsy; Imatinib Mesylate; Intestinal Obstruction; Intestine, Small; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Rectal Neoplasms; Tomography, X-Ray Computed | 2017 |
Simultaneous quantification of imatinib and its main metabolite N-demethyl-imatinib in human plasma by liquid chromatography-tandem mass spectrometry and its application to therapeutic drug monitoring in patients with gastrointestinal stromal tumor.
Topics: Adult; Antineoplastic Agents; Chromatography, Liquid; Drug Monitoring; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Limit of Detection; Linear Models; Male; Middle Aged; Reproducibility of Results; Tandem Mass Spectrometry | 2017 |
Concurrent inflammatory bowel disease and gastrointestinal stromal tumor.
Topics: Aged, 80 and over; Combined Modality Therapy; Crohn Disease; Fatal Outcome; Gastrointestinal Stromal Tumors; Humans; Ileal Neoplasms; Imatinib Mesylate; Immunosuppressive Agents; Intestinal Obstruction; Intestinal Pseudo-Obstruction; Jejunal Neoplasms; Male; Middle Aged; Peritoneal Neoplasms; Sunitinib | 2018 |
Initial application of transanal endoscopic microsurgery for high-risk lower rectal gastrointestinal stromal tumor after imatinib mesylate neoadjuvant chemotherapy: A case report.
Topics: Antineoplastic Agents; Diagnosis, Differential; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Neoadjuvant Therapy; Rectum; Transanal Endoscopic Microsurgery | 2017 |
Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors.
Topics: Animals; Antigens, CD; Apoptosis; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Mice; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Receptor, Insulin; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2017 |
A decrease in ubiquitination and resulting prolonged life-span of KIT underlies the KIT overexpression-mediated imatinib resistance of KIT mutation-driven canine mast cell tumor cells.
Topics: Animals; Cell Line, Tumor; Dogs; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Mast Cells; Mutation; Proto-Oncogene Proteins c-kit; Ubiquitination | 2017 |
New Mechanisms of mTOR Pathway Activation in KIT-mutant Malignant GISTs.
Topics: 3T3 Cells; Adult; Aged; Aged, 80 and over; Animals; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Female; Fibroblasts; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Male; Mice; Middle Aged; Mutation; Patient Selection; Proto-Oncogene Proteins c-kit; PTEN Phosphohydrolase; Signal Transduction; TOR Serine-Threonine Kinases; Tuberous Sclerosis Complex 2 Protein | 2019 |
[Gastrointestinal stromal tumor and renal transplant].
Topics: Anoctamin-1; Antineoplastic Agents; Biomarkers, Tumor; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kidney Transplantation; Neoplasm Proteins; Neoplasm Recurrence, Local; Proto-Oncogene Proteins c-kit; Young Adult | 2017 |
Neoadjuvant Imatinib Therapy Followed by Intersphincteric Resection for Low Rectal Gastrointestinal Stromal Tumors.
Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Protein Kinase Inhibitors; Rectal Neoplasms; Treatment Outcome; Tumor Burden | 2017 |
An Unusual Liver Tumor.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Liver Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
[Updates on adjuvant therapy in gastrointestinal stromal tumor].
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate | 2017 |
[Targeted therapy combined with immunotherapy in gastrointestinal stromal tumor: a new era of hope and challenges].
Topics: Antineoplastic Agents; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunotherapy; Molecular Targeted Therapy | 2017 |
[Analysis of gastric gastrointestinal stromal tumors in Shandong Province: a midterm report of multicenter GISSG1201 study].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; China; Databases, Factual; Female; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Risk Assessment; Stomach Neoplasms; Young Adult | 2017 |
Early Evaluation of Response Using
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Retrospective Studies; Time Factors; Treatment Outcome; Young Adult | 2018 |
[Gastrointestinal stromal tumors. Analysis of 40 cases].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Prognosis; Retrospective Studies | 2017 |
Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib.
Topics: Angiogenic Proteins; Antineoplastic Agents; Biomarkers, Tumor; Disease Progression; Disease-Free Survival; Exons; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Genetic Association Studies; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Mutation; Pharmacogenetics; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Proportional Hazards Models; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Retrospective Studies; Risk Factors; Solute Carrier Organic Anion Transporter Family Member 1B3; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
Rectal Gastrointestinal Stromal Tumor (GIST) in the Era of Imatinib: Organ Preservation and Improved Oncologic Outcome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Medical Oncology; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Organ Preservation; Prognosis; Prospective Studies; Rectal Neoplasms; Retrospective Studies; Survival Rate | 2017 |
Recurrent gastrointestinal bleeding in a patient with IgM paraproteinaemia.
Topics: Antineoplastic Agents; Biopsy; Chemotherapy, Adjuvant; Diagnosis, Differential; Gastrointestinal Hemorrhage; Gastrointestinal Stromal Tumors; Humans; Ileal Diseases; Imatinib Mesylate; Immunoglobulin M; Lymph Nodes; Male; Middle Aged; Paraproteinemias; Proto-Oncogene Proteins c-kit; Recurrence; Treatment Outcome; Waldenstrom Macroglobulinemia | 2018 |
Treatment of gastrointestinal stromal tumours in paediatric and young adult patients with sunitinib: a multicentre case series.
Topics: Adolescent; Antineoplastic Agents; Child; Europe; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Proto-Oncogene Proteins c-kit; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Retrospective Studies; Sunitinib; Survival Analysis; Treatment Outcome; United States; Young Adult | 2017 |
Abdominal Ultrasound – The Leading Method in Duodenal Gist Diagnostics
Topics: Adult; Antineoplastic Agents; Digestive System Surgical Procedures; Duodenal Neoplasms; Endoscopy, Digestive System; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Liver Neoplasms; Magnetic Resonance Spectroscopy; Maintenance Chemotherapy; Metastasectomy; Tomography, X-Ray Computed; Ultrasonography | 2017 |
Gastrointestinal stromal tumor (GIST) with liver metastases: An 18-year experience from the GIST cooperation group in North China.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; China; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Protein-Tyrosine Kinases; Retrospective Studies; Young Adult | 2017 |
Gastrointestinal Stromal Tumor of the Prostate: Staging and Evaluation of Response to Therapy With 18F-FDG PET/CT.
Topics: Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Treatment Outcome | 2018 |
Synthesis, in vitro and in vivo evaluation of
Topics: Animals; Chemistry Techniques, Synthetic; Drug Stability; Fluorine Radioisotopes; Gastrointestinal Stromal Tumors; Hydrophobic and Hydrophilic Interactions; Imatinib Mesylate; Ligands; Mice; Permeability; Positron Emission Tomography Computed Tomography; Radiochemistry; Tissue Distribution | 2018 |
Gastric Gastrointestinal Stromal Tumors (GIST): a Case Series and Current State of the Art in the Workup and Treatment of This Rare Disease.
Topics: Adult; Aftercare; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Chemotherapy, Adjuvant; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Endosonography; Female; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Laparoscopy; Male; Middle Aged; Neoplasm Recurrence, Local; Rare Diseases; Retrospective Studies; Stomach Neoplasms; Treatment Outcome | 2019 |
Adjuvant imatinib for patients with high-risk gastrointestinal stromal tumors: a retrospective cohort study.
Topics: Aged; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies | 2017 |
A Novel Receptor Tyrosine Kinase Switch Promotes Gastrointestinal Stromal Tumor Drug Resistance.
Topics: Anilides; Antineoplastic Agents; Cell Line, Tumor; Crizotinib; Doxorubicin; Drug Resistance, Neoplasm; Epithelial Cells; Focal Adhesion Kinase 1; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Paclitaxel; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Platelet-Derived Growth Factor alpha; Signal Transduction; Vinblastine | 2017 |
Blistering and Skin Fragility Due to Imatinib Therapy: Loss of Laminin and Collagen IV as a Possible Cause of Cutaneous Basement Membrane Instability.
Topics: Aged; Antineoplastic Agents; Basement Membrane; Blister; Collagen Type IV; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Laminin; Skin | 2018 |
Clinicopathological and Prognostic Features of Surgical Management in Duodenal Gastrointestinal Stromal Tumors.
Topics: Adult; Aged; Anastomosis, Surgical; Antineoplastic Agents; Chemotherapy, Adjuvant; Disease-Free Survival; Duodenal Neoplasms; Duodenum; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Jejunum; Kaplan-Meier Estimate; Male; Middle Aged; Mitotic Index; Neoadjuvant Therapy; Neoplasm Grading; Pancreaticoduodenectomy; Postoperative Complications; Retrospective Studies; Survival Rate; Tumor Burden; Young Adult | 2018 |
Gastrointestinal stromal tumor of unusual phenotype after imatinib treatment: A case report and diagnostic utility of ETV1 mRNA in situ hybridization.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; DNA-Binding Proteins; Exons; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; In Situ Hybridization; Male; Mutation; Phenotype; Proto-Oncogene Proteins c-kit; RNA, Messenger; Stomach Neoplasms; Transcription Factors | 2017 |
Mitochondrial Inhibition Augments the Efficacy of Imatinib by Resetting the Metabolic Phenotype of Gastrointestinal Stromal Tumor.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Hydrazones; Imatinib Mesylate; Metabolic Networks and Pathways; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Mitochondria; Protein Kinase Inhibitors; Treatment Outcome; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
Regorafenib regresses an imatinib-resistant recurrent gastrointestinal stromal tumor (GIST) with a mutation in exons 11 and 17 of c-kit in a patient-derived orthotopic xenograft (PDOX) nude mouse model.
Topics: Animals; Antineoplastic Agents; Body Weight; Disease Models, Animal; Drug Resistance, Neoplasm; Exons; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Mice; Mice, Nude; Mutation; Neoplasm Recurrence, Local; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Pyridines; Transplantation, Heterologous; Tumor Cells, Cultured | 2018 |
[Treatment of Regorafenib in Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib].
Topics: Adult; Aged; Antineoplastic Agents; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Phenylurea Compounds; Pyridines; Pyrroles; Sunitinib | 2018 |
[A Case Survived Long Period after Repeated Operation against the Small Intestinal GIST with Perforation].
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestinal Neoplasms; Intestinal Perforation; Male; Middle Aged; Prognosis; Recurrence; Time Factors | 2018 |
[A Case of Small Intestinal GIST with Long-Term Survival after Tumor Resection for Repeated Peritoneal Recurrence].
Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestinal Neoplasms; Intestine, Small; Peritoneal Neoplasms; Recurrence; Time Factors | 2017 |
[Radical Resection of Huge Gastrointestinal Stromal Tumor of the Stomach Following Neoadjuvant Chemotherapy with lmatinib - ACase Report].
Topics: Aged; Antineoplastic Agents; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoadjuvant Therapy; Stomach Neoplasms | 2017 |
[A Case of Gastrointestinal Stromal Tumor of the Small Intestine Complicated by Hemorrhagic Shock Due to Gastrointestinal and Intraperitoneal Bleedings].
Topics: Adult; Antineoplastic Agents; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestinal Neoplasms; Intestine, Small; Intraoperative Complications; Male; Shock, Hemorrhagic | 2017 |
[A Long-Term Survivor Who Are Responding to Sunitinib Treatment for Recurrent Imatinib-Resistant Gastrointestinal Stromal Tumor(GIST)of the Stomach].
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Pyrroles; Recurrence; Stomach Neoplasms; Sunitinib; Time Factors | 2017 |
[A Case of Local Resection for Rectal GIST Following Neoadjuvant Imatinib Mesylate Treatment].
Topics: Aged; Anal Canal; Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Neoplasm Invasiveness; Rectal Neoplasms | 2017 |
[Gastrointestinal stromal tumors (GIST): The particularities aspects in African countries].
Topics: Adolescent; Adult; Africa; Aged; Antineoplastic Agents; Developing Countries; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Mali; Middle Aged; Retrospective Studies; Survival Analysis; Young Adult | 2018 |
[Gatrointestinal stromal tumor: a case report].
Topics: Abdominal Pain; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Laparotomy; Middle Aged; Tomography, X-Ray Computed | 2016 |
Recurrence-Free Survival After Resection of Gastric Gastrointestinal Stromal Tumors Classified According to a Strict Definition of Tumor Rupture: A Population-Based Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mitotic Index; Neoadjuvant Therapy; Retrospective Studies; Risk Assessment; Rupture, Spontaneous; Stomach Neoplasms; Young Adult | 2018 |
Macrophages and CD8
Topics: Animals; Biomarkers; CD40 Antigens; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Chemotaxis, Leukocyte; Disease Models, Animal; Drug Synergism; Gastrointestinal Stromal Tumors; Gene Expression; Humans; Imatinib Mesylate; Immunophenotyping; Immunotherapy; Macrophages; Mice; Monocytes; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
Advanced gastrointestinal stromal tumor patients benefit from palliative surgery after tyrosine kinase inhibitors therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Palliative Care; Peritoneal Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Retrospective Studies; Treatment Outcome | 2018 |
Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene.
Topics: Adult; Aged; Benzimidazoles; Drug Resistance, Neoplasm; Electron Transport Complex II; F-Box-WD Repeat-Containing Protein 7; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Isocitrate Dehydrogenase; Male; Middle Aged; Mutation, Missense; Piperidines; Protein Binding; Protein Kinase Inhibitors; Protein Stability; Receptor, Platelet-Derived Growth Factor alpha; Transcriptome; Tumor Suppressor Protein p53 | 2018 |
Adverse reactions of sorafenib, sunitinib, and imatinib in treating digestive system tumors.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointestinal Stromal Tumors; Humans; Hypertension; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Sorafenib; Sunitinib | 2018 |
Prediction of morbidity following cytoreductive surgery for metastatic gastrointestinal stromal tumour in patients on tyrosine kinase inhibitor therapy.
Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Cytoreduction Surgical Procedures; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Metastasectomy; Middle Aged; Protein-Tyrosine Kinases; Risk Factors | 2018 |
Treatment outcomes in older patients with advanced gastrointestinal stromal tumor (GIST).
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Progression-Free Survival; Prospective Studies; Protein Kinase Inhibitors; Sunitinib; Young Adult | 2018 |
SOCS1 gene therapy has antitumor effects in imatinib-resistant gastrointestinal stromal tumor cells through FAK/PI3 K signaling.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Focal Adhesion Kinase 1; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Genetic Therapy; Humans; Imatinib Mesylate; Mutation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Suppressor of Cytokine Signaling 1 Protein | 2018 |
[A Case of Gastric GIST with Pathological Complete Response Achieved by Long-Term Chemotherapy with Imatinib Mesylate].
Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Stomach Neoplasms; Time Factors | 2018 |
[A Case of Long-Term Survival of Metastatic and Recurrent Duodenal Gastrointestinal Stromal Tumor Treated with Multimodality Managements].
Topics: Antineoplastic Agents; Combined Modality Therapy; Drug Resistance, Neoplasm; Duodenal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Pyrroles; Sunitinib | 2018 |
Nationwide trends in the incidence and outcome of patients with gastrointestinal stromal tumour in the imatinib era.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Digestive System Surgical Procedures; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Incidence; Male; Middle Aged; Netherlands; Registries; Survival Rate | 2018 |
Inhibition of fibroblast growth factor receptor-signaling sensitizes imatinib-resistant gastrointestinal stromal tumors to low doses of topoisomerase II inhibitors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; DNA Damage; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Phenylurea Compounds; Pyrimidines; Rad51 Recombinase; Receptors, Fibroblast Growth Factor; Signal Transduction; Topoisomerase II Inhibitors | 2018 |
Blood neutrophil-to-lymphocyte ratio is associated with prognosis in advanced gastrointestinal stromal tumors treated with imatinib.
Topics: Aged; Antineoplastic Agents; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lymphocytes; Male; Neutrophils; Prognosis; Prospective Studies; Retrospective Studies | 2018 |
Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRA receptors expression and impairs gastrointestinal stromal tumors growth.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Imatinib Mesylate; Mice, Nude; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha | 2018 |
Imatinib-Related Conjunctival Pigmentation.
Topics: Aged; Antineoplastic Agents; Conjunctival Diseases; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Pigmentation Disorders | 2018 |
Inhibition of stromal-interacting molecule 1-mediated store-operated Ca
Topics: Adult; Aged; Animals; Antineoplastic Agents; Calcium; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; MAP Kinase Signaling System; Mice; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Neoplasm Proteins; Stromal Interaction Molecule 1 | 2018 |
Surgical resection as an adjuvant to tyrosine kinase inhibitors in metastatic GIST: Association or causation?/Are we any closer to an answer?
Topics: Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Protein Kinase Inhibitors; Protein-Tyrosine Kinases | 2018 |
Postoperative imatinib in patients with intermediate risk gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Postoperative Period; Prognosis; Survival Rate | 2018 |
Pemphigus foliaceus associated with imatinib therapy in a patient with gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Drug Eruptions; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Pemphigus | 2018 |
Using the recurrence risk score by Joensuu to assess patients with gastrointestinal stromal tumor treated with adjuvant imatinib: A retrospective cohort study.
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Agents; Area Under Curve; Chemotherapy, Adjuvant; Cohort Studies; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Risk Assessment; Risk Factors; Treatment Outcome; Young Adult | 2018 |
[Resection of an Advanced Rectal Gastrointestinal Stromal Tumor Following Neoadjuvant Chemotherapy].
Topics: Aged; Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoadjuvant Therapy; Rectal Neoplasms; Treatment Outcome | 2018 |
Primary Gastrointestinal Stromal Tumor of the Liver.
Topics: Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Female; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Immunohistochemistry; Liver Neoplasms; Tomography, X-Ray Computed | 2019 |
MRI in predicting the response of gastrointestinal stromal tumor to targeted therapy: a patient-based multi-parameter study.
Topics: Adult; Aged; Diffusion Magnetic Resonance Imaging; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Pyrroles; Sunitinib; Treatment Outcome | 2018 |
Genome-scale CRISPR-Cas9 knockout screening in gastrointestinal stromal tumor with Imatinib resistance.
Topics: Cell Line, Tumor; CRISPR-Cas Systems; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Imatinib Mesylate; Signal Transduction | 2018 |
Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib.
Topics: Adult; Antineoplastic Agents; Case-Control Studies; Disease Progression; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Prognosis; Progression-Free Survival; Sarcoma; Time Factors | 2019 |
miR-125a-5p regulation increases phosphorylation of FAK that contributes to imatinib resistance in gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Focal Adhesion Kinase 1; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; MicroRNAs; Oligoribonucleotides; Phosphorylation; Prognosis; Protein Kinase Inhibitors; Protein Tyrosine Phosphatases, Non-Receptor; RNA, Messenger; RNA, Small Interfering; Signal Transduction; STAT3 Transcription Factor; Survival Analysis | 2018 |
Possible modulation of concurrent Parkinson's disease in the management of metastatic GIST: a review of two cases.
Topics: Aged; Antineoplastic Agents; Antiparkinson Agents; Carbidopa; Drug Combinations; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Levodopa; Liver Neoplasms; Male; Parkinson Disease; Severity of Illness Index; Stomach Neoplasms | 2018 |
EPIGIST: An observational real-life study on patients with metastatic gastrointestinal stromal tumors receiving imatinib.
Topics: Adult; Aged; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Edema; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins c-kit; Treatment Outcome | 2018 |
An exploratory study by DMET array identifies a germline signature associated with imatinib response in gastrointestinal stromal tumor.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Disease Progression; Disease-Free Survival; Exons; Female; Gastrointestinal Stromal Tumors; Genotype; Germ Cells; Humans; Imatinib Mesylate; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Mutation; Polymorphism, Single Nucleotide | 2019 |
LMTK3 is essential for oncogenic KIT expression in KIT-mutant GIST and melanoma.
Topics: Animals; Cell Line, Tumor; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Melanoma; Membrane Proteins; Mice; Mutation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-kit; RNA, Small Interfering; Xenograft Model Antitumor Assays | 2019 |
Identification of critical microRNAs in gastrointestinal stromal tumor patients treated with Imatinib.
Topics: Gastrointestinal Stromal Tumors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Imatinib Mesylate; MicroRNAs | 2018 |
A 4-month-old boy with gastrointestinal stromal tumor of mesocolon.
Topics: Chemotherapy, Adjuvant; Fatal Outcome; Gastrointestinal Hemorrhage; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Infant; Male; Mesocolon; Peritoneal Neoplasms; Tomography, X-Ray Computed | 2019 |
Targeting of FGF-Signaling Re-Sensitizes Gastrointestinal Stromal Tumors (GIST) to Imatinib In Vitro and In Vivo.
Topics: Animals; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mice; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Random Allocation; Signal Transduction; Xenograft Model Antitumor Assays | 2018 |
Effect of imatinib on plasma glucose concentration in subjects with chronic myeloid leukemia and gastrointestinal stromal tumor.
Topics: Adult; Antineoplastic Agents; Blood Glucose; Cohort Studies; Diabetes Mellitus, Type 2; Fasting; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Young Adult | 2018 |
Radiofrequency ablation versus resection for resectable liver metastases of gastrointestinal stromal tumours: Results from three national centres in China.
Topics: Adult; Aged; China; Combined Modality Therapy; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Length of Stay; Liver Neoplasms; Male; Middle Aged; Postoperative Complications; Prognosis; Protein Kinase Inhibitors; Radiofrequency Ablation; Retrospective Studies; Sunitinib | 2019 |
Activated tyrosine kinases in gastrointestinal stromal tumor with loss of KIT oncoprotein expression.
Topics: Axl Receptor Tyrosine Kinase; Cell Line, Tumor; Cell Survival; ErbB Receptors; Focal Adhesion Protein-Tyrosine Kinases; Gastrointestinal Stromal Tumors; Gefitinib; Humans; Imatinib Mesylate; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-kit; Receptor Protein-Tyrosine Kinases; Receptor, EphA2; RNA Interference; RNA, Small Interfering | 2018 |
[Analysis of biological characteristics and prognosis on gastrointestinal stromal tumor with PDGFRA gene mutation].
Topics: Adult; Aged; Aged, 80 and over; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Prognosis; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha | 2018 |
[Transanal endoscopic microsurgery for local excision of rectal gastrointestinal stromal tumors].
Topics: Adult; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Rectal Neoplasms; Retrospective Studies; Transanal Endoscopic Microsurgery; Treatment Outcome | 2018 |
Relationship between R1 resection, tumour rupture and recurrence in resected gastrointestinal stromal tumour.
Topics: Adult; Aged; Databases, Factual; Digestive System Surgical Procedures; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hospitals, University; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Margins of Excision; Middle Aged; Neoplasm Recurrence, Local; Norway; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Rupture; Survival Analysis; Treatment Outcome | 2019 |
Serum miR-518e-5p is a potential biomarker for secondary imatinib-resistant gastrointestinal stromal tumor.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Case-Control Studies; Drug Resistance, Neoplasm; Early Diagnosis; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression; Humans; Imatinib Mesylate; Male; MicroRNAs; Middle Aged; Neoplasms, Second Primary; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha; ROC Curve | 2018 |
Pathologic Complete Response in a Large Gastric GIST: Using Molecular Markers to Achieve Maximal Response to Neoadjuvant Imatinib.
Topics: Aged; Biomarkers, Tumor; Biopsy; Female; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Neoadjuvant Therapy; Positron Emission Tomography Computed Tomography; Prognosis; Proto-Oncogene Proteins c-kit; Stomach; Stomach Neoplasms; Treatment Outcome | 2018 |
Tumour lysis syndrome: a rare side effect of imatinib therapy for GIST.
Topics: Allopurinol; Diagnosis, Differential; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Protein Kinase Inhibitors; Risk Factors; Treatment Outcome; Tumor Lysis Syndrome; Urate Oxidase | 2018 |
Imatinib and liver toxicity.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Duodenal Neoplasms; Female; Gastrointestinal Stromal Tumors; Glucocorticoids; Humans; Imatinib Mesylate; Liver Function Tests; Methylprednisolone; Middle Aged; Protein Kinase Inhibitors; Treatment Outcome | 2018 |
Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition.
Topics: Animals; Apoptosis; Azepines; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression; HEK293 Cells; Humans; Imatinib Mesylate; Mice; Mice, Nude; Protein Domains; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-kit; Triazoles; Xenograft Model Antitumor Assays | 2019 |
What is the appropriate duration of adjuvant imatinib mesylate treatment for primary gastrointestinal stromal tumors classified according to the strict definition of tumor rupture?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Prognosis; Retrospective Studies; Rupture, Spontaneous; Survival Rate; Treatment Outcome; Young Adult | 2019 |
Diagnosis and Treatment Monitoring of a Patient with Gastrointestinal Stromal Tumor by Next-Generation Sequencing and Droplet Digital Polymerase Chain Reaction Assay of a PDGFRA Mutation in Plasma-Derived Cell-Free Tumor DNA.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Circulating Tumor DNA; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Liquid Biopsy; Mutation; Polymerase Chain Reaction; Prognosis; Receptor, Platelet-Derived Growth Factor alpha | 2019 |
Repurposing cabozantinib to GISTs: Overcoming multiple imatinib-resistant cKIT mutations including gatekeeper and activation loop mutants in GISTs preclinical models.
Topics: Anilides; Antineoplastic Agents; Cell Line, Tumor; Drug Repositioning; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Proto-Oncogene Proteins c-kit; Pyridines | 2019 |
[A Case of Duodenal Gastrointestinal Stromal Tumor Resection with Preservation of the Pancreatic Head Following Chemotherapy with Imatinib].
Topics: Antineoplastic Agents; Digestive System Surgical Procedures; Duodenum; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Pancreatic Ducts | 2018 |
[A Case of Rectal Gastrointestinal Stromal Tumor(GIST)with Long-Term Survival Treated with Multidisciplinary Therapy].
Topics: Aged; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Piperazines; Pyrimidines | 2018 |
[A Case of Giant GIST Originating from the Greater Omentum].
Topics: Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mesentery; Middle Aged; Omentum; Proto-Oncogene Proteins c-kit | 2018 |
[A Case of GIST with Extensive Peritoneal Dissemination Controlled over Long-Term by Low-Dose, Intermittent Administration of Imatinib after Weight Loss Surgery].
Topics: Aged; Antineoplastic Agents; Bariatric Surgery; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Piperazines; Pyrimidines | 2018 |
Long-term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14-year, single-center experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cancer Survivors; Cohort Studies; Combined Modality Therapy; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Survival Rate; Treatment Outcome; Young Adult | 2019 |
Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cytochrome P-450 CYP1A2; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Proteins; Polymorphism, Single Nucleotide; Retrospective Studies; Young Adult | 2019 |
PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway.
Topics: Apoptosis; B7-H1 Antigen; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Interferon-gamma; Lymphocytes, Tumor-Infiltrating; Phosphatidylinositol 3-Kinases; Prognosis; Programmed Cell Death 1 Receptor; Proto-Oncogene Proteins c-akt; RNA, Messenger; RNA, Neoplasm; Signal Transduction; TOR Serine-Threonine Kinases | 2019 |
Long-term adjuvant imatinib treatment for a patient who underwent complete resection of a localized recurrent gastrointestinal stromal tumor after preoperative imatinib treatment: A case report.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local | 2019 |
Molecular modelling evaluation of exon 18 His845_Asn848delinsPro PDGFRα mutation in a metastatic GIST patient responding to imatinib.
Topics: Aged; Antineoplastic Agents; Binding Sites; Computer Simulation; Exons; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; INDEL Mutation; Models, Molecular; Molecular Docking Simulation; Mutant Proteins; Protein Conformation; Receptor, Platelet-Derived Growth Factor alpha | 2019 |
Secondary KIT mutations: the GIST of drug resistance and sensitivity.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines | 2019 |
Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours.
Topics: Animals; CHO Cells; Clinical Trials, Phase II as Topic; Cricetulus; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mice; Mice, Nude; Mutation; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Sunitinib; Xenograft Model Antitumor Assays | 2019 |
Imatinib treatments have long-term impact on placentation and embryo survival.
Topics: Animals; Antineoplastic Agents; Embryo Implantation; Embryo, Mammalian; Female; Gastrointestinal Stromal Tumors; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Models, Animal; Placentation; Pregnancy | 2019 |
Relative Factors Analysis of Imatinib Trough Concentration in Chinese Patients with Gastrointestinal Stromal Tumor.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Agents; Asian People; Body Surface Area; Body Weight; China; Dose-Response Relationship, Drug; Female; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Sex Factors | 2018 |
Intracellular concentration and transporters in imatinib resistance of gastrointestinal stromal tumor.
Topics: Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Line, Tumor; Chromatography, Liquid; Cross-Sectional Studies; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Protein Kinase Inhibitors; Tandem Mass Spectrometry | 2019 |
[Hepatic and Pancreatic Metastases of a Rectal Gastrointestinal Stromal Tumor in a Patient with Long-Term Survival following Combined Therapy-ACase Report].
Topics: Aged; Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Neoplasm Recurrence, Local; Pancreatic Neoplasms | 2019 |
Small intestinal perforation due to a huge gastrointestinal stromal tumor in a kidney transplant recipient: a case report and literature review.
Topics: Antineoplastic Agents; Digestive System Surgical Procedures; Dose-Response Relationship, Drug; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunocompromised Host; Intestinal Perforation; Intestine, Small; Kidney Transplantation; Male; Middle Aged; Mutation; Proto-Oncogene Proteins c-kit; Treatment Outcome; Tumor Burden | 2019 |
Outcome of 1000 Patients With Gastrointestinal Stromal Tumor (GIST) Treated by Surgery in the Pre- and Post-imatinib Eras.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Child; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2021 |
Diagnosis and Treatment of Rectal Gastrointestinal Stromal Tumors.
Topics: Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Neoadjuvant Therapy; Positron Emission Tomography Computed Tomography; Rectal Neoplasms; Sigmoidoscopy; Transanal Endoscopic Microsurgery | 2019 |
Discovery of Conformational Control Inhibitors Switching off the Activated c-KIT and Targeting a Broad Range of Clinically Relevant c-KIT Mutants.
Topics: Animals; Binding Sites; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Drug Evaluation, Preclinical; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mice; Mice, Inbred ICR; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-kit; Pyrimidines; Structure-Activity Relationship; Urea; Xenograft Model Antitumor Assays | 2019 |
Ethyl-2-amino-pyrrole-3-carboxylates are active against imatinib-resistant gastrointestinal stromal tumors in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carboxylic Acids; Cell Proliferation; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; In Vitro Techniques; Mice; Mice, Nude; Pyrroles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Oncogenic kinase inhibition limits Batf3-dependent dendritic cell development and antitumor immunity.
Topics: Animals; Antigens, CD; Basic-Leucine Zipper Transcription Factors; Carcinogenesis; CD8-Positive T-Lymphocytes; Cell Differentiation; Chemotactic Factors; Dendritic Cells; Gastrointestinal Stromal Tumors; Granulocyte-Macrophage Colony-Stimulating Factor; Imatinib Mesylate; Immunity; Immunologic Memory; Macrophages; Mice, Inbred C57BL; Monitoring, Immunologic; Oncogenes; Protein Kinase Inhibitors; Proto-Oncogene Mas; Receptors, Antigen, T-Cell, gamma-delta; Repressor Proteins | 2019 |
Adherence to the guidelines and the pathological diagnosis of high-risk gastrointestinal stromal tumors in the real world.
Topics: Aged; Anoctamin-1; Antineoplastic Agents; Chemotherapy, Adjuvant; Female; Gastrointestinal Stromal Tumors; Guideline Adherence; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Proteins; Prospective Studies; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha; Registries | 2020 |
Malignant jejunal gastrointestinal stromal tumor with history of prostate cancer: A case report.
Topics: Aged; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoplasm Metastasis; Peritoneal Neoplasms; Postoperative Complications; Prostatic Neoplasms; Protein Kinase Inhibitors; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Association of Hepatic Nuclear Factor 4 Alpha Gene Polymorphisms With Free Imatinib Plasma Levels and Adverse Reactions in Chinese Gastrointestinal Stromal Tumor Patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointestinal Stromal Tumors; Genotype; Hepatocyte Nuclear Factor 4; Humans; Imatinib Mesylate; Male; Middle Aged; Pharmacogenetics; Plasma; Polymorphism, Genetic; Young Adult | 2019 |
Management of complicated tumor response to tyrosine-kinase inhibitors in gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Incidence; Male; Middle Aged; Postoperative Complications; Protein Kinase Inhibitors; Retrospective Studies; Sunitinib | 2019 |
Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost-effectiveness study.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Computer Simulation; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Costs; Drug Monitoring; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Markov Chains; Models, Economic; Progression-Free Survival; Quality-Adjusted Life Years | 2019 |
Real-World Evidence of Patient Outcome Following Treatment of Advanced Gastrointestinal Stromal Tumor (GIST) with Imatinib, Sunitinib, and Sorafenib in Publicly Funded Health Care in Poland.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Poland; Protein Kinase Inhibitors; Public Health Practice; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2019 |
Prognosis assessment in metastatic gastrointestinal stromal tumors treated with tyrosine kinase inhibitors based on CT-texture analysis.
Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gastrointestinal Tract; Humans; Imatinib Mesylate; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Targeting the WEE1 kinase strengthens the antitumor activity of imatinib via promoting KIT autophagic degradation in gastrointestinal stromal tumors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Male; Middle Aged; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazoles; Pyrimidinones | 2020 |
Gastrointestinal stromal tumour with CDKN2A deletions: a report of three cases.
Topics: Anticarcinogenic Agents; Cyclin-Dependent Kinase Inhibitor p16; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Mutation; Proto-Oncogene Proteins c-kit; Sequence Deletion; Tomography, X-Ray Computed | 2019 |
Author response to comment on: Relationship between R1 resection, tumour rupture and recurrence in resected gastrointestinal stromal tumour.
Topics: Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines | 2019 |
Comment on: Relationship between R1 resection, tumour rupture and recurrence in resected gastrointestinal stromal tumour.
Topics: Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines | 2019 |
Epithelioid variant of gastrointestinal stromal tumor harboring PDGFRA mutation and MLH1 gene alteration: A case report.
Topics: Amino Acid Substitution; Anoctamin-1; Antineoplastic Agents; Epithelioid Cells; Exons; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gastrointestinal Tract; Humans; Imatinib Mesylate; Middle Aged; Mutation; MutL Protein Homolog 1; Neoplasm Proteins; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha | 2019 |
An unusual cause of gastrointestinal bleed in patients with liver cirrhosis.
Topics: Aged; Antineoplastic Agents; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gastrointestinal Tract; Humans; Imatinib Mesylate; Liver Cirrhosis; Male; Middle Aged; Tomography, X-Ray Computed | 2019 |
Frequent rectal gastrointestinal stromal tumor recurrences in the imatinib era: Retrospective analysis of an International Patient Registry.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; International Agencies; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Rectal Neoplasms; Registries; Retrospective Studies; Survival Rate | 2019 |
Replacement Resistant Iron Deficiency Anemia in a Patient With Ulcerative Colitis in Remission: Investigating Beyond the Obvious.
Topics: Anemia, Iron-Deficiency; Colitis, Ulcerative; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Iron; Iron Deficiencies; Middle Aged; Prognosis; Remission Induction | 2019 |
Rectal stromal tumor with an exceptional liver and bone metastatic locations.
Topics: Adult; Antineoplastic Agents; Bone Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Rectal Neoplasms; Tomography, X-Ray Computed | 2019 |
Role of Resection Following Focal Progression with Standard Doses of Imatinib in Patients with Advanced Gastrointestinal Stromal Tumors: Results of Propensity Score Analyses.
Topics: Adult; Aged; Disease Progression; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Propensity Score; Treatment Outcome | 2019 |
Quantitative Mass Spectrometry Imaging Reveals Mutation Status-independent Lack of Imatinib in Liver Metastases of Gastrointestinal Stromal Tumors.
Topics: Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver; Liver Neoplasms; Mutation; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2019 |
Nuclear KIT induces a NFKBIB-RELA-KIT autoregulatory loop in imatinib-resistant gastrointestinal stromal tumors.
Topics: Animals; Cell Nucleus; Chlorocebus aethiops; COS Cells; Drug Resistance, Neoplasm; Feedback, Physiological; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Homeostasis; Humans; I-kappa B Proteins; Imatinib Mesylate; Male; Mice; Mice, Inbred NOD; Mice, SCID; Proto-Oncogene Proteins c-kit; Signal Transduction; Transcription Factor RelA; Up-Regulation | 2019 |
The Impact of Imatinib on Survival and Treatment Trends for Small Bowel and Colorectal Gastrointestinal Stromal Tumors.
Topics: Aged; Antineoplastic Agents; Colorectal Neoplasms; Databases, Factual; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestine, Small; Kaplan-Meier Estimate; Male; Middle Aged; Retrospective Studies; United States | 2020 |
Anorectal gastrointestinal stromal tumors: a retrospective multicenter analysis of 15 cases emphasizing their high local recurrence rate and the need for standardized therapeutic approach.
Topics: Anus Neoplasms; Base Sequence; Benzamides; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Molecular Sequence Data; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Radiography; Rectal Neoplasms; Reference Standards; Retrospective Studies; Treatment Outcome | 2013 |
Secondary mutations of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumors.
Topics: Adult; Aged; Amino Acid Sequence; Antineoplastic Agents; Asian People; Benzamides; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Molecular Sequence Data; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Treatment Outcome; Young Adult | 2013 |
Extracellular domain c-kit mutation with duplication of Ser501Ala502 found in gastrointestinal stromal tumors is more imatinib- and nilotinib-sensitive than that with duplication of Ala502Tyr503.
Topics: Aged; Amino Acid Sequence; Animals; Antineoplastic Agents; Base Sequence; Benzamides; CHO Cells; Cricetinae; Cricetulus; Drug Resistance, Neoplasm; Exons; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Duplication; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Molecular Sequence Data; Mutation; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Transfection | 2013 |
Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors.
Topics: Absorptiometry, Photon; Adult; Aged; Antineoplastic Agents; Benzamides; Biomarkers; Bone Density; Bone Resorption; Collagen Type I; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Osteocalcin; Osteogenesis; Peptides; Piperazines; Prognosis; Prospective Studies; Pyrimidines; Survival Rate; Young Adult | 2013 |
Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after imatinib resistance: a potential diagnostic pitfall.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Histocytochemistry; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Mutation; Piperazines; Pyrimidines; Rhabdomyosarcoma | 2013 |
Intermittent and continuous imatinib in a human GIST xenograft model carrying KIT exon 17 resistance mutation D816H.
Topics: Amino Acid Substitution; Animals; Antineoplastic Agents; Aspartic Acid; Benzamides; Drug Administration Schedule; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Histidine; Humans; Imatinib Mesylate; Mice; Mice, Nude; Mutation, Missense; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Xenograft Model Antitumor Assays | 2013 |
Gastrointestinal stromal tumors: diagnosis, therapy and follow-up care in Austria.
Topics: Adult; Aftercare; Austria; Benzamides; Biopsy; Child; Combined Modality Therapy; Cooperative Behavior; Diagnosis, Differential; Diagnostic Imaging; Disease Progression; Endoscopy, Gastrointestinal; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gastrointestinal Tract; Humans; Imatinib Mesylate; Indoles; Interdisciplinary Communication; Mitotic Index; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Multiple Primary; Nomograms; Palliative Care; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Sunitinib | 2013 |
[Gastrointestinal stromal tumor (GIST)--tyrosine kinase inhibitors].
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib | 2012 |
[New prospective on adjuvant treatment for gastrointestinal stromal tumors].
Topics: Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines | 2013 |
[Efficacy observation on imatinib adjuvant therapy with longer duration in patients with gastrointestinal stromal at intermediate or high risk of recurrence].
Topics: Adult; Aged; Benzamides; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Retrospective Studies; Treatment Outcome | 2013 |
[Efficacy and safety of sunitinib on patients with imatinib-resistant gastrointestinal stromal tumor].
Topics: Adult; Aged; Benzamides; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2013 |
[Application of perioperative imatinib mesylate therapy in initial resectable primary local advanced gastrointestinal stromal tumor at intermediate or high risk].
Topics: Adult; Aged; Benzamides; Chemotherapy, Adjuvant; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Perioperative Care; Piperazines; Prognosis; Pyrimidines; Retrospective Studies | 2013 |
[A case of exfoliative esophagitis caused by endoscopic submucosal dissection during imatinib treatment for gastrointestinal stromal tumor].
Topics: Aged; Antineoplastic Agents; Benzamides; Endoscopy; Esophagitis; Female; Gastric Mucosa; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines | 2013 |
Are two better than one? A novel double-mutant KIT in GIST that responds to Imatinib.
Topics: Aged; Benzamides; Computational Biology; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines | 2013 |
Osteonecrosis of the tibia associated with imatinib in metastatic GI stromal tumor.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Drug Administration Schedule; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Incidental Findings; Liver Neoplasms; Middle Aged; Osteonecrosis; Pain; Peritoneal Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Range of Motion, Articular; Tibia | 2013 |
NCCN Task Force report: gastrointestinal stromal tumor (GIST).
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Disease Progression; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Piperazines; Pyrimidines | 2004 |
DOG1 regulates growth and IGFBP5 in gastrointestinal stromal tumors.
Topics: Animals; Anoctamin-1; Antineoplastic Agents; Benzamides; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Chloride Channels; Gastrointestinal Stromal Tumors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Insulin-Like Growth Factor Binding Protein 5; Mice; Mice, Inbred Strains; Mice, Nude; Mutation; Neoplasm Proteins; Niflumic Acid; Nitrobenzoates; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
Clinical trials.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Piperazines; Pyrimidines | 2003 |
Protein modelling of a novel KIT mutation (N567Y) in the gastrointestinal stromal tumour.
Topics: Benzamides; Binding Sites; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Models, Molecular; Mutation; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-kit; Pyrimidines | 2013 |
A role for adjuvant RFA in managing hepatic metastases from gastrointestinal stromal tumors (GIST) after treatment with targeted systemic therapy using kinase inhibitors.
Topics: Adult; Aged; Benzamides; Catheter Ablation; Combined Modality Therapy; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Radio Waves; Retrospective Studies; Survival Rate | 2014 |
Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Treatment Outcome | 2013 |
Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; CD3 Complex; CD56 Antigen; Cohort Studies; Female; Flow Cytometry; Forkhead Transcription Factors; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Kaplan-Meier Estimate; Killer Cells, Natural; Lymphocytes, Tumor-Infiltrating; Male; Middle Aged; Multivariate Analysis; Natural Cytotoxicity Triggering Receptor 1; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; T-Lymphocytes; Treatment Outcome | 2013 |
[Prognostic analysis of 349 cases with gastrointestinal stromal tumor].
Topics: Benzamides; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Postoperative Period; Prognosis; Pyrimidines; Retrospective Studies; Survival Analysis | 2013 |
Malignant stromal tumor of the stomach with giant cystic liver metastases prior to treatment with imatinib mesylate.
Topics: Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Middle Aged; Piperazines; Pyrimidines; Stomach Neoplasms | 2013 |
Rare, germline mutation of KIT with imatinib-resistant multiple GI stromal tumors and mastocytosis.
Topics: Adult; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Drug Resistance, Neoplasm; Exons; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Germ-Line Mutation; Humans; Imatinib Mesylate; Immunohistochemistry; Intestine, Small; Male; Mastocytosis; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Tomography, X-Ray Computed | 2013 |
[Molecular and histologic characteristics of secondary imatinib-resistant gastrointestinal stromal tumors].
Topics: Aged; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Exons; Gastrectomy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Piperazines; Point Mutation; Proto-Oncogene Proteins c-kit; Pyrimidines | 2013 |
Depletion of telomerase RNA inhibits growth of gastrointestinal tumors transplanted in mice.
Topics: Animals; Apoptosis; Benzamides; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mice; Mice, SCID; Middle Aged; Neoplasm Transplantation; Oligonucleotides, Antisense; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Real-Time Polymerase Chain Reaction; RNA; Telomerase; Transfection; Treatment Outcome | 2013 |
Establishment and characterization of novel cell lines and xenografts from patients with gastrointestinal stromal tumors.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Benzamides; Carcinogenesis; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Heterografts; Humans; Imatinib Mesylate; Male; Mice; Mice, Inbred NOD; Middle Aged; Molecular Targeted Therapy; Neoplasm Transplantation; Piperazines; Pyrimidines; Transplantation, Heterologous | 2013 |
Which is the best surgical approach for anorectal gastrointestinal stromal tumors in the post-imatinib era?
Topics: Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Piperazines; Pyrimidines; Rectal Neoplasms | 2013 |
Liver surgery in the multidisciplinary management of gastrointestinal stromal tumour.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Piperazines; Pyrimidines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2014 |
Diagnosis, prognosis and treatment of patients with gastrointestinal stromal tumour (GIST) and germline mutation of KIT exon 13.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Exons; Female; Gastrointestinal Stromal Tumors; Germ-Line Mutation; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Neoplasm Recurrence, Local; Pedigree; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Young Adult | 2013 |
Soft tissue calcification secondary to imatinib mesylate in a patient with gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Benzamides; Calcification, Physiologic; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome | 2014 |
Efficacy and economic value of adjuvant imatinib for gastrointestinal stromal tumors.
Topics: Benzamides; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cost-Benefit Analysis; Disease-Free Survival; Gastrointestinal Stromal Tumors; Health Care Costs; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
Multimodal functional imaging for early response assessment in GIST patients treated with imatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Feasibility Studies; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Neoplasm Staging; Piperazines; Positron-Emission Tomography; Pyrimidines; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
New findings of kinase switching in gastrointestinal stromal tumor under imatinib using phosphoproteomic analysis.
Topics: Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Focal Adhesion Protein-Tyrosine Kinases; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Phosphoproteins; Phosphorylation; Phosphotransferases; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Tyrosine | 2013 |
Clinical relevance of pharmacogenetics in gastrointestinal stromal tumor treatment in the era of personalized therapy.
Topics: Benzamides; Drug Monitoring; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Pharmacogenetics; Phosphorylation; Piperazines; Precision Medicine; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction | 2013 |
Primary GIST of the liver masquerading as primary intra-abdominal tumour: a rare extra-gastrointestinal stromal tumour (EGIST) of the liver.
Topics: Abdominal Neoplasms; Antineoplastic Agents; Benzamides; Diagnosis, Differential; Diagnostic Errors; Diagnostic Imaging; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Middle Aged; Multimodal Imaging; Piperazines; Positron-Emission Tomography; Pyrimidines; Tomography, X-Ray Computed | 2014 |
Gastrointestinal stromal tumor with synchronous gallbladder adenocarcinoma.
Topics: Adenocarcinoma; Aged; Anastomosis, Surgical; Antigens, Neoplasm; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Cholecystectomy; Combined Modality Therapy; Female; Gallbladder Neoplasms; Gastritis; Gastrointestinal Stromal Tumors; Helicobacter Infections; Helicobacter pylori; Humans; Ileal Neoplasms; Imatinib Mesylate; Laparotomy; Neoplasms, Multiple Primary; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines | 2014 |
Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Databases, Factual; Disease Progression; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Survival Rate | 2013 |
Spontaneous hemoperitoneum in recurrent jejunal gastrointestinal stromal tumor after imatinib therapy.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Gastrointestinal Stromal Tumors; Hemoperitoneum; Humans; Imatinib Mesylate; Jejunum; Neoplasm Recurrence, Local; Piperazines; Pyrimidines | 2013 |
Lichenoid drug eruption with hyperpigmentation caused by imatinib mesylate.
Topics: Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Hyperpigmentation; Imatinib Mesylate; Lichenoid Eruptions; Middle Aged; Piperazines; Pyrimidines | 2014 |
The DREAM complex mediates GIST cell quiescence and is a novel therapeutic target to enhance imatinib-induced apoptosis.
Topics: Apoptosis; Benzamides; Cell Death; Cell Line, Tumor; Dyrk Kinases; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kv Channel-Interacting Proteins; Molecular Targeted Therapy; Piperazines; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyrimidines; Repressor Proteins | 2013 |
Giant GIST of the small intestine in a young man.
Topics: Adult; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Jejunal Neoplasms; Male; Piperazines; Pyrimidines; Radiography | 2013 |
Imatinib-associated tumour response in a dog with a non-resectable gastrointestinal stromal tumour harbouring a c-kit exon 11 deletion mutation.
Topics: Animals; Antineoplastic Agents; Base Sequence; Benzamides; Dog Diseases; Dogs; Exons; Female; Gastrointestinal Stromal Tumors; Imatinib Mesylate; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Sequence Deletion | 2013 |
[A case of liver and bone metastases after complete resection of gastric GIST effectively treated with radiotherapy and imatinib mesylate].
Topics: Aged; Antineoplastic Agents; Benzamides; Bone Neoplasms; Combined Modality Therapy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Piperazines; Pyrimidines | 2013 |
Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations.
Topics: Amino Acid Motifs; Animals; Antineoplastic Agents; Benzamides; Chlorocebus aethiops; COS Cells; Dasatinib; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Hydrogen Bonding; Imatinib Mesylate; Indoles; Molecular Docking Simulation; Mutation, Missense; Piperazines; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib; Thiazoles | 2013 |
Value of pharmacokinetic studies for patients with gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2013 |
[Two cases of recurrent GIST successfully treated with imatinib mesylate at 100mg/day].
Topics: Abdominal Neoplasms; Abdominal Wall; Aged, 80 and over; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Female; Gastrointestinal Stromal Tumors; Humans; Ileal Neoplasms; Imatinib Mesylate; Liver Neoplasms; Middle Aged; Piperazines; Pyrimidines; Recurrence; Stomach Neoplasms; Tomography, X-Ray Computed | 2013 |
[Clinical analysis of efficacy and prognosis of intermediate risk gastric stromal tumor patients].
Topics: Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Prognosis; Pyrimidines; Retrospective Studies; Survival Rate; Treatment Outcome | 2013 |
Subsequent intra-abdominal fibromatosis mimicking recurrent gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Benzamides; Diagnostic Errors; Digestive System Surgical Procedures; Duodenal Neoplasms; Fibromatosis, Abdominal; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Jejunal Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Predictive Value of Tests; Pyrimidines; Reoperation; Risk Factors; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden; Unnecessary Procedures | 2013 |
Presentation and management of gastrointestinal stromal tumours.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Child; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Laparoscopes; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Retrospective Studies; Survival Rate; Young Adult | 2013 |
Sunitinib-induced reversible purpuric rash in a patient with gastrointestinal stromal tumor.
Topics: Aged; Antineoplastic Agents; Exanthema; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2014 |
Improving access to care in low and middle-income countries: institutional factors related to enrollment and patient outcome in a cancer drug access program.
Topics: Antineoplastic Agents; Benzamides; Developing Countries; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Health Services Accessibility; Humans; Imatinib Mesylate; Leukemia, Myeloid; Male; Middle Aged; Outcome Assessment, Health Care; Piperazines; Pyrimidines; Quality Improvement; Survival | 2013 |
Imatinib plasma monitoring-guided dose modification for managing imatinib-related toxicities in gastrointestinal stromal tumor patients.
Topics: Aged; Antineoplastic Agents; Benzamides; Drug Monitoring; Exons; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Mutation; Piperazines; Positron-Emission Tomography; Proto-Oncogene Proteins c-kit; Pyrimidines; Tomography, X-Ray Computed | 2013 |
Laparoscopic sphincter-preserving surgery (intersphincteric resection) after neoadjuvant imatinib treatment for gastrointestinal stromal tumor (GIST) of the rectum.
Topics: Adult; Aged; Anal Canal; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Laparoscopy; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Organ Sparing Treatments; Piperazines; Pyrimidines; Radiography; Rectum; Treatment Outcome | 2014 |
The effects of surgical cytoreduction prior to imatinib therapy on the prognosis of patients with advanced GIST.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Digestive System Surgical Procedures; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Peritoneal Neoplasms; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Retrospective Studies; Survival Rate | 2013 |
Gastrointestinal stromal tumors with KIT exon 9 mutations: Update on genotype-phenotype correlation and validation of a high-resolution melting assay for mutational testing.
Topics: Aged; Antineoplastic Agents; Benzamides; Chi-Square Distribution; DNA Mutational Analysis; Exons; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Nucleic Acid Denaturation; Phenotype; Piperazines; Predictive Value of Tests; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Registries; Reproducibility of Results; Treatment Outcome | 2013 |
An invasive extragastrointestinal stromal tumor curably resected following imatinib treatment.
Topics: Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Biopsy, Fine-Needle; Chemotherapy, Adjuvant; Digestive System Neoplasms; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Magnetic Resonance Imaging; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasms, Multiple Primary; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2013 |
Rechallenge of drugs in the era of targeted therapy.
Topics: Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib | 2013 |
Long-term survival after excision of a giant esophageal gastrointestinal stromal tumor with imatinib mesylate resistance: report of a case.
Topics: Aged; Antigens, CD34; Benzamides; Biomarkers, Tumor; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophagectomy; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Risk; Thoracotomy; Time Factors; Treatment Outcome | 2014 |
Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Imatinib Mesylate; Indoles; Interleukin-3; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Random Allocation; Sunitinib | 2014 |
MiR-320a downregulation is associated with imatinib resistance in gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Down-Regulation; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; MicroRNAs; Piperazines; Pyrimidines | 2014 |
What are the current outcomes of advanced gastrointestinal stromal tumors: who are the long-term survivors treated initially with imatinib?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Middle Aged; Piperazines; Poland; Prognosis; Pyrimidines; Registries; Survivors; Young Adult | 2013 |
Radiologic assessment of earliest, best, and plateau response of gastrointestinal stromal tumors to neoadjuvant imatinib prior to successful surgical resection.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Digestive System Surgical Procedures; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Piperazines; Pyrimidines; Retrospective Studies; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
[A rare case of bone metastasis from gastro-intestinal stromal tumour: place of radiotherapy].
Topics: Antineoplastic Agents; Benzamides; Bone Neoplasms; Femoral Neoplasms; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Humerus; Imatinib Mesylate; Ischium; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Osteolysis; Pain Management; Peritoneal Neoplasms; Piperazines; Pubic Bone; Pyrimidines; Stomach Neoplasms | 2014 |
KIT oncogene inhibition drives intratumoral macrophage M2 polarization.
Topics: Adult; Aged; Aged, 80 and over; Animals; Apoptosis; Benzamides; CCAAT-Enhancer-Binding Proteins; Cell Proliferation; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Inflammation; Macrophages; Male; Mice; Middle Aged; Mutation; Phenotype; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Sarcoma | 2013 |
Ten-year review of gastrointestinal stromal tumours at a tertiary referral hospital in New Zealand.
Topics: Aged; Clinical Decision-Making; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; New Zealand; Prognosis; Survival Analysis; Tertiary Care Centers; Treatment Outcome | 2016 |
[A case of imatinib-resistant gastrointestinal stromal tumor treated with low-dose sunitinib].
Topics: Aged, 80 and over; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Intestinal Neoplasms; Intestine, Small; Male; Peritoneal Neoplasms; Piperazines; Pyrimidines; Pyrroles; Recurrence; Salvage Therapy; Sunitinib | 2013 |
21st-century oncology: a tangled web.
Topics: Antineoplastic Agents; Benzamides; Biomedical Research; Drug Industry; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medical Oncology; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2013 |
Hair graying and loss induced by imatinib mesylate.
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hair; Hair Color; Hair Diseases; Humans; Imatinib Mesylate; Piperazines; Pyrimidines | 2014 |
Intracellular concentration of the tyrosine kinase inhibitor imatinib in gastrointestinal stromal tumor cells.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Reproducibility of Results | 2014 |
Src activity is increased in gastrointestinal stromal tumors--analysis of associations with clinical and other molecular tumor characteristics.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Exons; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Middle Aged; Multivariate Analysis; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; src-Family Kinases; Vascular Endothelial Growth Factor A | 2014 |
[A case of multiple liver metastases after resection of gastrointestinal stromal tumor of the small intestine that was successfully treated with imatinib mesylate].
Topics: Aged; Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestine, Small; Liver Neoplasms; Male; Piperazines; Pyrimidines; Treatment Outcome | 2013 |
[A case with a lower rectal gastrointestinal stromal tumor undergoing sphincter-preserving laparoscopic resection after neoadjuvant imatinib therapy].
Topics: Adult; Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Laparoscopy; Male; Neoadjuvant Therapy; Piperazines; Pyrimidines; Rectal Neoplasms | 2013 |
Prognostic factors for primary gastrointestinal stromal tumours: are they the same in the multidisciplinary treatment era?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Colectomy; Combined Modality Therapy; Disease-Free Survival; Female; Gastrectomy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; Treatment Outcome; Young Adult | 2014 |
[Gastrointestinal stromal tumours bigger than 20 cm: experience with imatinib chemotherapy in neoadjuvant intention].
Topics: Aged; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Pilot Projects; Piperazines; Pyrimidines; Treatment Outcome; Tumor Burden | 2014 |
[Clinical experience of imatinib mesylate for metastatic or recurrent gastrointestinal stromal tumor].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestinal Neoplasms; Male; Middle Aged; Piperazines; Pyrimidines; Recurrence; Stomach Neoplasms; Treatment Outcome | 2014 |
[A case of liver and bone metastasis from gastrointestinal stromal tumor treated using imatinib].
Topics: Aged; Antineoplastic Agents; Benzamides; Bone Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Piperazines; Positron-Emission Tomography; Pyrimidines; Recurrence; Stomach Neoplasms | 2014 |
[A case of rectal gastrointestinal stromal tumor in an elderly patient who was successfully treated with imatinib mesylate with no significant adverse events].
Topics: Aged, 80 and over; Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Piperazines; Pyrimidines; Rectal Neoplasms; Treatment Outcome | 2014 |
High-resolution melting analysis is a sensitive diagnostic tool to detect imatinib-resistant and imatinib-sensitive PDGFRA exon 18 mutations in gastrointestinal stromal tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Exons; Female; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Nucleic Acid Denaturation; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2014 |
Severe dental erosion associated with imatinib mesylate therapy.
Topics: Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Tooth Erosion | 2014 |
The effect of baseline morphology and its change during treatment on the accuracy of Response Evaluation Criteria in Solid Tumours in assessment of liver metastases.
Topics: Benzamides; Cohort Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver; Liver Neoplasms; Observer Variation; Outcome Assessment, Health Care; Piperazines; Pyrimidines; Time Factors; Tomography, X-Ray Computed; Tumor Burden | 2014 |
Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib -- analysis of prognostic factors (EORTC-STBSG collaborative study).
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Confounding Factors, Epidemiologic; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Liver Neoplasms; Male; Metastasectomy; Middle Aged; Patient Selection; Peritoneal Neoplasms; Piperazines; Predictive Value of Tests; Prognosis; Pyrimidines; Retrospective Studies; Risk Assessment; Risk Factors; Selection Bias; Treatment Outcome | 2014 |
Treatment strategy of rectal gastrointestinal stromal tumor (GIST).
Topics: Adult; Aged; Benzamides; Combined Modality Therapy; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Proportional Hazards Models; Pyrimidines; Rectal Neoplasms; Retrospective Studies | 2014 |
Complete pathological response in advanced extra-gastrointestinal stromal tumor after imatinib mesylate therapy: a case report.
Topics: Aged; Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Mesentery; Omentum; Peritoneal Neoplasms; Piperazines; Pyrimidines; Rectal Neoplasms; Urinary Bladder Neoplasms | 2014 |
Improved outcome with multimodal treatment and imatinib rechallenge in advanced GIST.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Disease Progression; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Treatment Outcome | 2014 |
A large esophageal gastrointestinal stromal tumor that was successfully resected after neoadjuvant imatinib treatment: case report.
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Digestive System Surgical Procedures; Esophageal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Piperazines; Prognosis; Pyrimidines | 2014 |
Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumor.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzamides; Biopsy; Cell Survival; Disease Models, Animal; Drug Evaluation, Preclinical; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Mice, Knockout; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor; Tumor Burden | 2014 |
That's the "GIST" of it: use of adjuvant imatinib after resection of a primary GI stromal tumor.
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Biopsy; Chemotherapy, Adjuvant; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Mitotic Index; Multimodal Imaging; Mutation; Neoplasm Staging; Patient Selection; Piperazines; Positron-Emission Tomography; Precision Medicine; Predictive Value of Tests; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Risk Factors; Stomach Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
In vivo imatinib sensitivity in a patient with GI stromal tumor bearing a PDGFRA deletion DIM842-844.
Topics: Aged; Antineoplastic Agents; Benzamides; Biopsy; DNA Mutational Analysis; Exons; Gastrointestinal Stromal Tumors; Gene Deletion; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Mutation; Necrosis; Neoplasm Metastasis; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Tomography, X-Ray Computed | 2015 |
KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation.
Topics: Antineoplastic Agents; Arginine; Benzamides; Carcinoma; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Glycine; Humans; Imatinib Mesylate; Isoleucine; Male; Middle Aged; Mutation; Phosphatidylinositol 3-Kinase; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins p21(ras); Pyrimidines; ras Proteins; Sequence Analysis, DNA; Signal Transduction; Stomach Neoplasms; Threonine; Time Factors; TOR Serine-Threonine Kinases | 2015 |
[Patient with bulky duodenum GIST became complete resection possible after primary systemic therapy: a case report].
Topics: Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Digestive System Surgical Procedures; Duodenal Neoplasms; Duodenum; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoplasm Invasiveness; Piperazines; Preoperative Care; Pyrimidines; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
microRNA-218 increase the sensitivity of gastrointestinal stromal tumor to imatinib through PI3K/AKT pathway.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Gastrointestinal Stromal Tumors; Gene Expression Profiling; Humans; Imatinib Mesylate; MicroRNAs; Models, Biological; Real-Time Polymerase Chain Reaction | 2015 |
CTHRC1 acts as a prognostic factor and promotes invasiveness of gastrointestinal stromal tumors by activating Wnt/PCP-Rho signaling.
Topics: Benzamides; Cell Movement; Extracellular Matrix Proteins; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Prognosis; Proto-Oncogene Proteins; Pyrimidines; rac1 GTP-Binding Protein; rhoA GTP-Binding Protein; Wnt Proteins; Wnt Signaling Pathway; Wnt-5a Protein | 2014 |
Frequent mono-allelic loss associated with deficient PTEN expression in imatinib-resistant gastrointestinal stromal tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Cell Line, Tumor; Child; DNA Mutational Analysis; Drug Resistance, Neoplasm; Enzyme Activation; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; In Situ Hybridization, Fluorescence; Loss of Heterozygosity; Male; Middle Aged; Mitogen-Activated Protein Kinases; Mutation; Phosphatidylinositol 3-Kinase; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrimidines; RNA Interference; Signal Transduction; TOR Serine-Threonine Kinases; Transfection; Treatment Failure; Young Adult | 2014 |
[A case report of two-term surgery for focal progression of a huge liver metastasis and peritoneal dissemination from gastrointestinal stromal tumor during imatinib mesylate treatment].
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Fatal Outcome; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Peritoneal Neoplasms; Piperazines; Pyrimidines; Stomach Neoplasms | 2014 |
[A case of gastrointestinal stromal tumor of the jejunum successfully treated by preoperative induction chemotherapy with imatinib mesylate administered through jejunostomy and subsequent surgical resection].
Topics: Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Jejunal Neoplasms; Jejunostomy; Piperazines; Pyrimidines | 2014 |
Evaluating new therapies in gastrointestinal stromal tumor using in vivo molecular optical imaging.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Biomarkers, Tumor; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Heterografts; Imatinib Mesylate; Magnetic Resonance Imaging; Mice, Nude; Molecular Imaging; Molecular Probes; Neoplasm Transplantation; Piperazines; Pyrimidines; Tomography, Optical | 2014 |
[Treatment strategy for recurrent and metastatic gastrointestinal stromal tumors].
Topics: Benzamides; Disease-Free Survival; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Indazoles; Indoles; Liver Neoplasms; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Recurrence; Sulfonamides; Sunitinib | 2014 |
[Drug resistance mechanism and new therapy strategy progression in targeted treatment of gastrointestinal stromal tumors].
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Quality of Life; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2014 |
[A multicentre retrospective cohort study of patients with gastrointestinal stromal tumors in Shandong Province].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Cohort Studies; Combined Modality Therapy; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Piperazines; Prognosis; Proportional Hazards Models; Pyrimidines; Retrospective Studies; Survival Rate; Young Adult | 2014 |
[Clinical analysis of 156 patients with gastrointestinal stromal tumors receiving imatinib therapy].
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Prognosis; Pyrimidines; Retrospective Studies; Survival Rate | 2014 |
[Clinicopathological analysis of 61 patients with rectal gastrointestinal stromal tumors].
Topics: Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoplasm Recurrence, Local; Piperazines; Prognosis; Pyrimidines; Rectal Neoplasms; Retrospective Studies; Survival Rate | 2014 |
[Efficacy and prognosis of different treatments on 63 patients with small intestinal gastrointestinal stromal tumors].
Topics: Antineoplastic Agents; Benzamides; Disease-Free Survival; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestinal Neoplasms; Intestine, Small; Neoplasm Recurrence, Local; Piperazines; Prognosis; Pyrimidines; Retrospective Studies | 2014 |
Successful treatment of bleeding large duodenal gastrointestinal stromal tumour in a patient under dual antiplatelet therapy after recent drug-eluting coronary stent implantation.
Topics: Aged; Aspirin; Benzamides; Chemotherapy, Adjuvant; Clopidogrel; Coronary Stenosis; Drug-Eluting Stents; Duodenal Neoplasms; Gastrointestinal Hemorrhage; Gastrointestinal Stromal Tumors; Hemostatic Techniques; Humans; Imatinib Mesylate; Male; Neoadjuvant Therapy; Piperazines; Platelet Aggregation Inhibitors; Pyrimidines; Ticlopidine | 2014 |
Treatment patterns, prescribing decision drivers, and predictors of complete response following disease recurrence in gastrointestinal stromal tumor patients-a chart extract-based approach.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Retrospective Studies; Treatment Outcome | 2014 |
Gastrointestinal autonomic nerve tumour of jejunum presenting as a perforated mass.
Topics: Abdomen, Acute; Aged; Antineoplastic Agents; Autonomic Nervous System Diseases; Benzamides; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Jejunal Neoplasms; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sarcoma | 2014 |
Giant esophageal gastrointestinal stromal tumor: report of a case.
Topics: Aged; Benzamides; Endoscopy, Gastrointestinal; Esophageal Neoplasms; Esophagectomy; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Piperazines; Plastic Surgery Procedures; Pyrimidines; Thoracotomy; Treatment Outcome | 2015 |
Primary extragastrointestinal stromal tumor of the prostate: a case report.
Topics: Adult; Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Piperazines; Prostate; Prostatectomy; Prostatic Neoplasms; Pyrimidines | 2014 |
Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome.
Topics: Antineoplastic Agents; Area Under Curve; Benzamides; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mitotic Index; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Piperazines; Prognosis; Proportional Hazards Models; Pyrimidines; Risk Factors; Treatment Outcome | 2014 |
Successful imatinib therapy for neuroendocrine carcinoma with activating Kit mutation: a case study.
Topics: Benzamides; Carcinoma, Neuroendocrine; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kinesins; Male; Middle Aged; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction | 2014 |
Gastrointestinal stromal tumors, version 2.2014.
Topics: Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2014 |
Anti-apoptotic effects of osteopontin through the up-regulation of Mcl-1 in gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; beta Catenin; Blotting, Western; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Male; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Staging; Osteopontin; Piperazines; Prognosis; Pyrimidines; Tumor Cells, Cultured; Up-Regulation | 2014 |
Prognostic value of Ki67 index in gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Biopsy; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Kaplan-Meier Estimate; Ki-67 Antigen; Male; Middle Aged; Mitotic Index; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Risk Factors; Time Factors; Tissue Array Analysis; Treatment Outcome | 2014 |
The role of surgical resection following imatinib treatment in patients with recurrent or metastatic gastrointestinal stromal tumors: results of propensity score analyses.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Disease Progression; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Prognosis; Propensity Score; Pyrimidines; Retrospective Studies; Survival Rate; Young Adult | 2014 |
Hepatitis B viral reactivation secondary to imatinib treatment in a patient with gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hepatitis B virus; Humans; Imatinib Mesylate; Liver Failure, Acute; Liver Transplantation; Male; Middle Aged; Piperazines; Pyrimidines; Virus Activation | 2014 |
A ruptured recurrent small bowel gastrointestinal stromal tumour causing hemoperitoneum.
Topics: Antineoplastic Agents; Benzamides; Cytoreduction Surgical Procedures; Disease Progression; Dissection; Dose-Response Relationship, Drug; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hemoperitoneum; Humans; Imatinib Mesylate; Intestine, Small; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Postoperative Complications; Pyrimidines; Risk Assessment; Rupture, Spontaneous | 2015 |
Laparoscopic resection of a gastrointestinal stromal tumor of the lower rectum in a patient with coronary artery disease following long-term neoadjuvant imatinib treatment and anticoagulation therapy.
Topics: Aged; Anal Canal; Anticoagulants; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Laparoscopy; Male; Neoadjuvant Therapy; Organ Sparing Treatments; Piperazines; Pyrimidines; Rectal Neoplasms; Treatment Outcome | 2014 |
Preoperative imatinib facilitates complete resection of locally advanced primary GIST by a less invasive procedure.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Preoperative Period; Pyrimidines; Retrospective Studies; Treatment Outcome | 2014 |
Significance of surgery for prognosis of GIST in cohort from transitional healthcare settings.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Croatia; Developing Countries; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Paraganglioma; Piperazines; Pyrimidines; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2014 |
Adjuvant imatinib for GIST: the pie is shrinking.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines | 2014 |
Drug repurposing identifies a synergistic combination therapy with imatinib mesylate for gastrointestinal stromal tumor.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Proliferation; Drug Repositioning; Drug Synergism; Female; Gastrointestinal Stromal Tumors; High-Throughput Screening Assays; Humans; Imatinib Mesylate; Mice; Mice, Nude; Piperazines; Pyrimidines; Vidarabine Phosphate; Xenograft Model Antitumor Assays | 2014 |
Intra-abdominal desmoid tumor after resection for gastrointestinal stromal tumor of the small intestine: case report.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Fibromatosis, Abdominal; Fibromatosis, Aggressive; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestine, Small; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Rare Diseases | 2014 |
Unexpected DOG-1 immunoreactivity in sarcomatous carcinoma of the liver: a diagnostic pitfall.
Topics: Aged; Anoctamin-1; Antineoplastic Agents; Autopsy; Bile Duct Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Chloride Channels; Diagnosis, Differential; Fatal Outcome; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver; Liver Neoplasms; Male; Neoplasm Proteins; Sarcoma; Tomography, X-Ray Computed; Ultrasonography | 2014 |
A multicenter long-term study of imatinib treatment for Japanese patients with unresectable or recurrent gastrointestinal stromal tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Retrospective Studies | 2014 |
KIT and BRAF heterogeneous mutations in gastrointestinal stromal tumors after secondary imatinib resistance.
Topics: Aged; Antineoplastic Agents; Blotting, Western; Cell Transdifferentiation; Chromatography, High Pressure Liquid; DNA Mutational Analysis; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Mutation; Neoplasm Recurrence, Local; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Reverse Transcriptase Polymerase Chain Reaction; Stomach Neoplasms | 2015 |
Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Drug Substitution; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation; Neoplasm Metastasis; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Retreatment; Sunitinib; Treatment Outcome; Young Adult | 2014 |
Antitumor effect of the tyrosine kinase inhibitor nilotinib on gastrointestinal stromal tumor (GIST) and imatinib-resistant GIST cells.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mice; Neoplasm Proteins; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Mas; Pyrimidines; Signal Transduction; Xenograft Model Antitumor Assays | 2014 |
The outcome of targeted therapy in advanced gastrointestinal stromal tumors (GIST) with non-exon 11 KIT mutations.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; Exons; Female; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Male; Middle Aged; Predictive Value of Tests; Prognosis; Sex Factors | 2014 |
Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Exons; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Imidazoles; Indoles; Inhibitory Concentration 50; Models, Molecular; Molecular Conformation; Mutation; Neoplasm Recurrence, Local; Piperazines; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridazines; Pyrimidines; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
[Surgical resection of a huge gastric gastrointestinal stromal tumor after preoperative adjuvant chemotherapy].
Topics: Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Piperazines; Pyrimidines; Stomach Neoplasms | 2014 |
Clinicopathologic analysis of gastrointestinal stromal tumors in duodenum and small intestine.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Duodenal Neoplasms; Female; Gastrointestinal Stromal Tumors; Humans; Ileal Neoplasms; Imatinib Mesylate; Jejunal Neoplasms; Male; Middle Aged; Mitotic Index; Neoplasm Staging; Piperazines; Pyrimidines; Retrospective Studies; Rupture, Spontaneous; Survival Analysis; Survival Rate; Young Adult | 2015 |
[Curative resection of an extra-gastrointestinal stromal tumor locally advanced and fistulizing in the small intestine after treatment with imatinib: report of a case].
Topics: Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestine, Small; Male; Piperazines; Pyrimidines; Treatment Outcome | 2014 |
Phosphoinositide 3-kinase inhibitors combined with imatinib in patient-derived xenograft models of gastrointestinal stromal tumors: rationale and efficacy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Disease Models, Animal; Drug Therapy, Combination; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mice; Mitosis; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; PTEN Phosphohydrolase; Pyrimidines; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; MicroRNAs; Mutation; Piperazines; Protein Tyrosine Phosphatases, Non-Receptor; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2014 |
Hepatic artery embolization for liver metastasis of gastrointestinal stromal tumor following imatinib and sunitinib therapy.
Topics: Adult; Aged; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Embolization, Therapeutic; Female; Gastrointestinal Stromal Tumors; Hepatic Artery; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Survival Analysis; Treatment Outcome | 2014 |
[Gastrointestinal stromal tumor of the ileum with metastatic relapse developed in the mesentery].
Topics: Adult; Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Ileal Neoplasms; Imatinib Mesylate; Male; Mesentery; Peritoneal Neoplasms; Piperazines; Pyrimidines | 2014 |
Clinical significance of pathological complete response in patients with metastatic gastrointestinal stromal tumors after imatinib mesylate treatment--lessons learned.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Piperazines; Prognosis; Prospective Studies; Pyrimidines; Remission Induction; Survival Rate | 2014 |
MTOR inhibition enhances NVP-AUY922-induced autophagy-mediated KIT degradation and cytotoxicity in imatinib-resistant gastrointestinal stromal tumors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Benzamides; Cell Death; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Immunohistochemistry; Inhibitory Concentration 50; Isoxazoles; Mice; Mice, Inbred NOD; Mice, SCID; Mutation; Necrosis; Neoplasm Transplantation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Resorcinols; RNA Interference; RNA, Small Interfering; Sirolimus; TOR Serine-Threonine Kinases | 2014 |
Gastrointestinal stromal tumor: 15-years' experience in a single center.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lymphatic Metastasis; Male; Middle Aged; Mitotic Index; Neoplasm Grading; Neoplasm Invasiveness; Piperazines; Proportional Hazards Models; Pyrimidines; Risk Factors; Tumor Burden; Young Adult | 2014 |
Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor.
Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Genetic Association Studies; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Proteins; Piperazines; Polymorphism, Single Nucleotide; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Republic of Korea; Retrospective Studies; Survival Analysis | 2015 |
The economic burden of gastrointestinal stromal tumor (GIST) recurrence in patients who have received adjuvant imatinib therapy.
Topics: Adult; Aged; Algorithms; Antineoplastic Agents; Chemotherapy, Adjuvant; Female; Gastrointestinal Stromal Tumors; Health Services; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local | 2015 |
Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance.
Topics: Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Gastrointestinal Stromal Tumors; Gene Knockdown Techniques; HEK293 Cells; Humans; Imatinib Mesylate; Immunoprecipitation; MAP Kinase Signaling System; Mutation; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor Cross-Talk; Receptor, Fibroblast Growth Factor, Type 3; RNA, Small Interfering | 2015 |
Liver surgery in the multidisciplinary management of gastrointestinal stromal tumour.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Piperazines; Pyrimidines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2014 |
Genomic index predicts clinical outcome of intermediate-risk gastrointestinal stromal tumours, providing a new inclusion criterion for imatinib adjuvant therapy.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoplasm Metastasis; Piperazines; Prognosis; Pyrimidines; Treatment Outcome | 2015 |
AMACR amplification and overexpression in primary imatinib-naïve gastrointestinal stromal tumors: a driver of cell proliferation indicating adverse prognosis.
Topics: Azoles; Benzamides; Cell Line, Tumor; Cell Proliferation; Comparative Genomic Hybridization; Cyclin D1; Cyclin E; Cyclin-Dependent Kinase 4; Disease-Free Survival; DNA Mutational Analysis; Flow Cytometry; G1 Phase; Gastrointestinal Stromal Tumors; Gene Dosage; Genotype; Humans; Imatinib Mesylate; Immunohistochemistry; In Situ Hybridization, Fluorescence; Isoindoles; Multivariate Analysis; Oncogene Proteins; Organoselenium Compounds; Piperazines; Predictive Value of Tests; Prognosis; Pyrimidines; Racemases and Epimerases; RNA Interference; Treatment Outcome; Up-Regulation | 2014 |
Familial gastrointestinal stromal tumor syndrome: report of 2 cases with KIT exon 11 mutation.
Topics: Adult; Anoctamin-1; Antigens, CD34; Antineoplastic Agents; Benzamides; Chloride Channels; Desmin; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Proteins; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Radiography; Receptor, Platelet-Derived Growth Factor alpha; Retrospective Studies; S100 Proteins | 2015 |
Gastrointestinal stromal tumor of the adrenal gland:a case report and review of the literature.
Topics: Adrenal Gland Neoplasms; Adult; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Biopsy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Piperazines; Positron-Emission Tomography; Pyrimidines | 2015 |
Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Preoperative Care; Preoperative Period; Pyrimidines; Reproducibility of Results; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2014 |
Pleural effusion in a patient with metastatic gastrointestinal stromal tumor treated with imatinib: case report.
Topics: Aged; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pleural Effusion, Malignant; Pyrimidines; Radiography; Treatment Outcome | 2014 |
Imatinib-Sensitizing KIT Mutation in a Carney-Stratakis-Associated GI Stromal Tumor.
Topics: Abdominal Wall; Adult; Antineoplastic Agents; Chemotherapy, Adjuvant; Disease Progression; Drug Administration Schedule; Female; Gastrointestinal Stromal Tumors; Germ-Line Mutation; Humans; Imatinib Mesylate; Mutation; Paraganglioma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha; Rectal Neoplasms; Succinate Dehydrogenase; Treatment Outcome | 2016 |
Laparoscopic en bloc excision of gastrointestinal stromal tumors of the rectum after neoadjuvant imatinib therapy: anteriorly extended intersphincteric resection combined with partial resection of the prostate.
Topics: Adult; Aged; Anal Canal; Antineoplastic Agents; Digestive System Surgical Procedures; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Laparoscopy; Male; Neoadjuvant Therapy; Prostate; Rectal Neoplasms | 2015 |
Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST).
Topics: Afatinib; Aged; Aged, 80 and over; Axl Receptor Tyrosine Kinase; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunoblotting; Immunohistochemistry; Male; Middle Aged; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins c-met; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; Thiourea | 2015 |
Sphincter sparing resection of a large obstructive distal rectal gastrointestinal stromal tumour after neoadjuvant therapy with imatinib (Glivec).
Topics: Adult; Anal Canal; Anastomosis, Surgical; Antineoplastic Agents; Benzamides; Colon; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoadjuvant Therapy; Piperazines; Pyrimidines; Rectal Neoplasms; Rectum | 2015 |
Role of surgery in patients with recurrent, metastatic, or unresectable locally advanced gastrointestinal stromal tumors sensitive to imatinib: a retrospective analysis of the Spanish Group for Research on Sarcoma (GEIS).
Topics: Antineoplastic Agents; Combined Modality Therapy; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Metastasectomy; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate | 2015 |
[The importance of mutational status in prognosis and therapy of GIST].
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; Exons; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Phenylurea Compounds; Piperazines; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sensitivity and Specificity; Sunitinib | 2015 |
[Clinicopathological analysis of 80 patients with duodenum gastrointestinal stromal tumors].
Topics: Abdominal Pain; Benzamides; Duodenal Neoplasms; Female; Gastrointestinal Hemorrhage; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Pancreaticoduodenectomy; Piperazines; Prognosis; Pyrimidines; Retrospective Studies; Survival Rate | 2015 |
FGFR-Mediated Reactivation of MAPK Signaling Attenuates Antitumor Effects of Imatinib in Gastrointestinal Stromal Tumors.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Fibroblast Growth Factors; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Ligands; MAP Kinase Signaling System; Phosphorylation; Protein Kinase Inhibitors; Proteome; Proteomics; Xenograft Model Antitumor Assays | 2015 |
Imatinib plasma levels during successful long-term treatment of metastatic-gastrointestinal stromal tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Body Surface Area; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Dosage Calculations; Drug Monitoring; Female; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Japan; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Stomach Neoplasms; Treatment Outcome | 2014 |
[A case of recurrent duodenal gastrointestinal stromal tumor resistant to imatinib and sunitinib, successfully treated with regorafenib].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Resistance, Neoplasm; Duodenal Neoplasms; Fatal Outcome; Female; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Middle Aged; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Recurrence; Sunitinib; Treatment Outcome | 2014 |
[A case of rectal GIST treated by perineal partial rectal resection using laparoscopic surgery].
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Laparoscopy; Male; Middle Aged; Neoadjuvant Therapy; Piperazines; Pyrimidines; Rectal Neoplasms | 2014 |
[A case of rectal gastrointestinal stromal tumor (GIST) locally resected after long-term chemotherapy with imatinib mesylate].
Topics: Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Rectal Neoplasms; Time Factors | 2014 |
[Pathological complete response in a large gastric GIST that became resectable after neoadjuvant chemotherapy with imatinib mesylate].
Topics: Antineoplastic Agents; Benzamides; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Piperazines; Pyrimidines; Remission Induction; Splenectomy; Stomach Neoplasms; Treatment Outcome | 2014 |
[A case of giant gastric GIST with multiple hepatic metastases with long-term survival after multimodal therapy].
Topics: Antineoplastic Agents; Benzamides; Catheter Ablation; Combined Modality Therapy; Gastrectomy; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Piperazines; Pyrimidines; Stomach Neoplasms | 2014 |
[A case of an elderly patient with recurrent GIST, which was effectively treated with low-dose imatinib mesylate].
Topics: Aged, 80 and over; Antineoplastic Agents; Benzamides; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Piperazines; Pyrimidines; Recurrence; Stomach Neoplasms | 2014 |
[No recurrent case of the combination of surgical management with chemotherapy].
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Jejunal Neoplasms; Male; Middle Aged; Piperazines; Pyrimidines; Sigmoid Neoplasms; Tomography, X-Ray Computed | 2014 |
[A case of small intestinal gastrointestinal stromal tumor (GIST) with peritoneal dissemination, treated effectively with molecular target drug after operation].
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Intestinal Neoplasms; Intestine, Small; Male; Middle Aged; Molecular Targeted Therapy; Peritoneal Neoplasms; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2014 |
[A case of recurrent gastrointestinal stromal tumor progressing after interruption of long-term imatinib therapy].
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Piperazines; Pyrimidines; Recurrence; Stomach Neoplasms; Time Factors | 2014 |
[A case of extragastrointestinal stromal tumor with peritoneal dissemination].
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestinal Neoplasms; Male; Middle Aged; Peritoneal Neoplasms; Piperazines; Pyrimidines; Tomography, X-Ray Computed | 2014 |
Primary gastrointestinal stromal tumor of the liver treated with sequential therapy.
Topics: Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Biopsy; Chemotherapy, Adjuvant; DNA Mutational Analysis; Drug Substitution; Female; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Immunohistochemistry; Indoles; Liver Neoplasms; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
PI3K/AKT/mTOR pathway is activated after imatinib secondary resistance in gastrointestinal stromal tumors (GISTs).
Topics: Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Phosphatidylinositol 3-Kinases; Phosphorylation; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; PTEN Phosphohydrolase; Signal Transduction; Survival Rate; TOR Serine-Threonine Kinases | 2015 |
Assessment of early response to imatinib 800 mg after 400 mg progression by ¹⁸F-fluorodeoxyglucose PET in patients with metastatic gastrointestinal stromal tumors.
Topics: Adult; Aged; Antineoplastic Agents; Female; Fluorodeoxyglucose F18; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Image Interpretation, Computer-Assisted; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Prospective Studies; Protein Kinase Inhibitors; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Long term experience of patients with unresectable or metastatic KIT positive gastrointestinal stromal tumours.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Czech Republic; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Time Factors | 2015 |
[Molecular-genetic methods for diagnostics of tumour growth].
Topics: Aged; Antineoplastic Protocols; Benzamides; Biomarkers, Tumor; Digestive System Surgical Procedures; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gastrointestinal Tract; Genetic Testing; Humans; Imatinib Mesylate; Male; Middle Aged; Molecular Diagnostic Techniques; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Treatment Outcome | 2014 |
Prognostic Relevance of p53 Overexpression in Gastrointestinal Stromal Tumors of the Small Intestine: Potential Implication for Adjuvant Treatment with Imatinib.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Cohort Studies; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Intestinal Neoplasms; Intestine, Small; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate; Tumor Suppressor Protein p53; Young Adult | 2015 |
Imatinib-induced agranulocytosis in patients with gastrointestinal stromal tumors.
Topics: Adrenal Cortex Hormones; Adult; Aged, 80 and over; Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; Leukocyte Count; Male; Middle Aged; Neutropenia; Proto-Oncogene Mas | 2015 |
Familial and multiple gastrointestinal stromal tumors with fair response to a half-dose of imatinib.
Topics: Aged; Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Exons; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Germ-Line Mutation; Humans; Imatinib Mesylate; Male; Middle Aged; Pedigree; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Siblings | 2015 |
Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors.
Topics: Anilides; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Inhibitory Concentration 50; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Piperazines; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins c-met; Pyridines; Pyrimidines; Pyrroles; Signal Transduction; Sunitinib; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Gastrointestinal stromal tumor of the rectum treated with neoadjuvant Imatinib followed by transanal endoscopic microsurgery.
Topics: Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Neoadjuvant Therapy; Rectal Neoplasms; Transanal Endoscopic Microsurgery | 2015 |
Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1.
Topics: Animals; Benzamides; Benzimidazoles; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Flow Cytometry; Gastrointestinal Stromal Tumors; Gene Knockdown Techniques; Humans; Imatinib Mesylate; Immunohistochemistry; Mice; Mice, Inbred BALB C; Mutation; Nucleic Acid Precursors; Phosphorylation; Piperazines; Piperidines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; Transcription Factors | 2015 |
Strongyloidiasis in a diabetic patient accompanied by gastrointestinal stromal tumor: cause of eosinophilia unresponsive to steroid therapy.
Topics: Aged; Albendazole; Animals; Diabetes Mellitus, Type 2; Eosinophilia; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Steroids; Strongyloides stercoralis; Strongyloidiasis | 2015 |
A plunging case of intermittent dysphagia.
Topics: Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Chemotherapy, Adjuvant; Deglutition Disorders; Endoscopy, Gastrointestinal; Endosonography; Esophageal Neoplasms; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2015 |
[Neoadjuvant therapy of imatinib in gastrointestinal stromal tumors and the timing of surgery].
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy | 2015 |
[Clinical management of advanced gastrointestinal stromal tumors after failure of at least both imatinib and sunitinib targeted therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Pyrroles; Sunitinib | 2015 |
KIT, PDGFRA, and BRAF mutational spectrum impacts on the natural history of imatinib-naive localized GIST: a population-based study.
Topics: Aged; Antineoplastic Agents; Benzamides; DNA Mutational Analysis; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Piperazines; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2015 |
Surgical treatment of gastrointestinal stromal tumour of the rectum in the era of imatinib.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mitotic Index; Neoadjuvant Therapy; Piperazines; Pyrimidines; Rectal Neoplasms | 2015 |
Secretome protein signature of human gastrointestinal stromal tumor cells.
Topics: Animals; Antineoplastic Agents; Benzamides; Blotting, Western; Cells, Cultured; Chromatography, Liquid; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Insulin-Secreting Cells; Mice; Neoplasm Proteins; Piperazines; Proteome; Proteomics; Pyrimidines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2015 |
Survival After Resection of Gastrointestinal Stromal Tumor and Sarcoma Liver Metastases in 146 Patients.
Topics: Abdominal Neoplasms; Adolescent; Adult; Aged; Antineoplastic Agents; Child; Child, Preschool; Databases, Factual; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leiomyosarcoma; Liver Neoplasms; Male; Metastasectomy; Middle Aged; Retroperitoneal Neoplasms; Retrospective Studies; Sarcoma; Survival Rate; Young Adult | 2015 |
Gastrointestinal stromal tumour in a recipient with kidney transplantation.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Female; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kidney Transplantation; Middle Aged; Neoplasm Recurrence, Local; Stomach Neoplasms; Treatment Outcome | 2015 |
Imatinib mesylate treatment in a dog with gastrointestinal stromal tumors with a c-kit mutation.
Topics: Animals; Antineoplastic Agents; DNA, Complementary; Dog Diseases; Dogs; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation; Imatinib Mesylate; Mutation; Proto-Oncogene Proteins c-kit | 2015 |
A Case of Disseminated Intra-abdominal Gastrointestinal Stromal Tumor Managed with Low Dose Imatinib.
Topics: Aged; Antineoplastic Agents; Exanthema; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Proto-Oncogene Proteins c-kit; Tomography, X-Ray Computed | 2015 |
Feasibility and Timing of Cytoreduction Surgery in Advanced (Metastatic or Recurrent) Gastrointestinal Stromal Tumors During the Era of Imatinib.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Prognosis; Prospective Studies; Pyrimidines; Retrospective Studies; Severity of Illness Index; Survival Analysis; Time Factors | 2015 |
Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors.
Topics: Adult; Aged; Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Receptor, Platelet-Derived Growth Factor alpha; Republic of Korea; Retrospective Studies; Seoul | 2016 |
Can D-Dimer Measurement Reduce the Frequency of Radiological Assessment in Patients Receiving Palliative Imatinib for Gastrointestinal Stromal Tumor (GIST)?
Topics: Aged; Antineoplastic Agents; Female; Fibrin Fibrinogen Degradation Products; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Middle Aged; Palliative Care; Predictive Value of Tests; Proportional Hazards Models; ROC Curve; Tomography, X-Ray Computed | 2015 |
Imatinib mesylate-induced interstitial lung disease in a patient with prior history of Mycobacterium tuberculosis infection.
Topics: Adult; Antineoplastic Agents; Antitubercular Agents; Biopsy; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lung Diseases, Interstitial; Mycobacterium tuberculosis; Protein Kinase Inhibitors; Rectal Neoplasms; Tomography, X-Ray Computed; Tuberculosis, Pulmonary | 2015 |
Clinical Observations on Treatment for Chinese Patients with Gastrointestinal Stromal Tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Digestive System Surgical Procedures; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Preoperative Care; Prognosis; Retrospective Studies; Survival Rate | 2015 |
Treatment and Prognoses in Patients With Primary Gastrointestinal Stromal Tumors ≥10 cm: A Single-Institution Experience in China.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; China; Digestive System Surgical Procedures; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Retrospective Studies | 2015 |
The GOLD ReGISTry: a Global, Prospective, Observational Registry Collecting Longitudinal Data on Patients with Advanced and Localised Gastrointestinal Stromal Tumours.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Asia; Biomarkers, Tumor; Canada; Digestive System Surgical Procedures; Disease Progression; DNA Mutational Analysis; Europe; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Practice Patterns, Physicians'; Predictive Value of Tests; Prospective Studies; Protein Kinase Inhibitors; Registries; Risk Factors; South America; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2015 |
The efficacy of adjuvant imatinib therapy in improving the prognosis of patients with colorectal gastrointestinal stromal tumours.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Staging; Piperazines; Pyrimidines; Retrospective Studies; Time Factors; Treatment Outcome | 2015 |
Severe Imatinib-Associated Skin Rash in Gastrointestinal Stromal Tumor Patients: Management and Clinical Implications.
Topics: Antineoplastic Agents; Exanthema; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate | 2016 |
Metachronous Primary Adenocarcinoma of Lung During Adjuvant Imatinib Mesylate Therapy for Gastrointestinal Stromal Tumor of Stomach: A Case Report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Biopsy; Carboplatin; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Incidental Findings; Lung; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Stomach; Stomach Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Prognostic factors after imatinib secondary resistance: survival analysis in patients with unresectable and metastatic gastrointestinal stromal tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Retrospective Studies; Survival Analysis; Survival Rate | 2016 |
Gastrointestinal stromal tumour metastatic to the epididymis.
Topics: Antineoplastic Agents; Epididymis; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Genital Neoplasms, Male; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Pyridines; Scrotum; Tomography, X-Ray Computed | 2015 |
Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Exons; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation; Proto-Oncogene Proteins c-kit; Pyrroles; Retrospective Studies; Sunitinib; Time Factors | 2016 |
Hypertrophic osteoarthropathy with imatinib therapy.
Topics: Alkaline Phosphatase; Antineoplastic Agents; Diabetes Mellitus, Type 2; Dyslipidemias; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Osteoarthropathy, Secondary Hypertrophic; Vitiligo | 2015 |
Adjuvant imatinib treatment in gastrointestinal stromal tumor: which risk stratification criteria and for how long? A case report.
Topics: Adult; Antineoplastic Agents; Chemotherapy, Adjuvant; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Risk; Time Factors | 2016 |
Killing two birds with one stone: a case of GIST and supervening CML.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytosis; Male; Middle Aged; Neoplasms, Multiple Primary | 2015 |
KIT exon 10 variant (c.1621 A > C) single nucleotide polymorphism as predictor of GIST patient outcome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Line, Tumor; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Multivariate Analysis; Phosphorylation; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Recurrence; Retrospective Studies; Young Adult | 2015 |
A jejunal GIST presenting with obscure gastrointestinal bleeding and small bowel obstruction secondary to intussusception.
Topics: Aged; Antineoplastic Agents; Capsule Endoscopy; Gastrointestinal Hemorrhage; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intussusception; Jejunal Neoplasms; Male; Treatment Outcome | 2015 |
KIT over-expression by p55PIK-PI3K leads to Imatinib-resistance in patients with gastrointestinal stromal tumors.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Mice, Nude; Mutation; NF-kappa B; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Signal Transduction; Time Factors; Transfection; Up-Regulation; Xenograft Model Antitumor Assays | 2016 |
Primary surgery as a frontline treatment for synchronous metastatic gastrointestinal stromal tumors: an analysis of the Kinki GIST registry.
Topics: Aged; Catheter Ablation; Combined Modality Therapy; Digestive System Surgical Procedures; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Japan; Liver Neoplasms; Male; Middle Aged; Peritoneal Neoplasms; Protein Kinase Inhibitors; Registries; Retrospective Studies; Survival Rate; Treatment Outcome | 2016 |
Inhibition effect of Peg-IFNα-2b and Imatinib alone or combination on imatinib-resistant gastrointestinal stromal tumors cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Phosphorylation; Polyethylene Glycols; Proto-Oncogene Proteins c-bcl-2; Recombinant Proteins; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2015 |
Subdural hematoma in a patient taking imatinib for GIST: a case report and discussion of risk with other chemotherapeutics.
Topics: Antineoplastic Agents; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hematoma, Subdural, Intracranial; Humans; Imatinib Mesylate; Middle Aged; Neoadjuvant Therapy; Risk | 2016 |
Adjuvant Imatinib for GI Stromal Tumors: When and For How Long?
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged | 2016 |
Successful treatment with personalized dosage of imatinib in elderly patients with gastrointestinal stromal tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Precision Medicine; Protein Kinase Inhibitors; Treatment Outcome | 2016 |
Detecting Secondary C-KIT Mutations in the Peripheral Blood of Patients with Imatinib-Resistant Gastrointestinal Stromal Tumor.
Topics: Antineoplastic Agents; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; Exons; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Proto-Oncogene Proteins c-kit | 2016 |
[A Case of Laparoscopic Gastrectomy for Gastric GIST after Neoadjuvant Chemotherapy with Imatinib Mesylate].
Topics: Aged; Antineoplastic Agents; Female; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Laparoscopy; Neoadjuvant Therapy; Stomach Neoplasms | 2015 |
[A Case of Intraductal Growth Pattern Gastrointestinal Stromal Tumor of the Stomach That Was Difficult to Diagnose by Biopsy].
Topics: Aged; Antineoplastic Agents; Biopsy; Drug Combinations; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Oxonic Acid; Stomach Neoplasms; Tegafur | 2015 |
[A Case of Multiple Liver Metastases and Peritoneal Dissemination after Resection of a Gastrointestinal Stromal Tumor of the Stomach Successfully Treated with Imatinib Mesylate].
Topics: Aged; Antineoplastic Agents; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Peritoneal Neoplasms; Prognosis; Stomach Neoplasms | 2015 |
Intratumoral KIT mutational heterogeneity and recurrent KIT/ PDGFRA mutations in KIT/PDGFRA wild-type gastrointestinal stromal tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha; Retrospective Studies; Treatment Outcome; Young Adult | 2016 |
Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Drug Monitoring; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestine, Small; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies; Stomach; Treatment Outcome | 2016 |
Clinico-pathological characteristics and prognostic factors of gastrointestinal stromal tumors among a Chinese population.
Topics: Aged; Antineoplastic Agents; Asian People; Biomarkers, Tumor; Chemotherapy, Adjuvant; China; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Mitotic Index; Multivariate Analysis; Neoplasm, Residual; Predictive Value of Tests; Proportional Hazards Models; Risk Factors; Time Factors; Treatment Outcome; Tumor Burden; Tumor Suppressor Protein p53 | 2015 |
The novel pyrrolo-1,5-benzoxazepine, PBOX-15, synergistically enhances the apoptotic efficacy of imatinib in gastrointestinal stromal tumours; suggested mechanism of action of PBOX-15.
Topics: Apoptosis; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Chaperonins; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Flow Cytometry; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Myeloid Cell Leukemia Sequence 1 Protein; Oxazepines; Proto-Oncogene Proteins c-kit; Pyrroles; Signal Transduction; Treatment Outcome | 2016 |
RACK1 overexpression is linked to acquired imatinib resistance in gastrointestinal stromal tumor.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Receptors for Activated C Kinase; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Risk Classification using the Ki-67 Labeling Index for Surgically-Treated Gastric Gastrointestinal Stromal Tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Cohort Studies; Female; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Ki-67 Antigen; Male; Middle Aged; Mitotic Index; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Risk Assessment; Stomach Neoplasms; Tumor Burden | 2015 |
Long-term outcome of molecular subgroups of gastrointestinal stromal tumour patients treated with standard-dose imatinib in the BFR14 trial: The wild-type gastrointestinal stromal tumours are not a single group yet.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit | 2016 |
Meckel's diverticulum complicated with gastro-intestinal stromal tumor: Case report.
Topics: Antineoplastic Agents; Biopsy; Chemotherapy, Adjuvant; Diagnosis, Differential; Digestive System Surgical Procedures; Egypt; Gastrointestinal Stromal Tumors; Humans; Ileal Neoplasms; Imatinib Mesylate; Male; Meckel Diverticulum; Middle Aged; Neurilemmoma; Pelvic Pain; Tomography, X-Ray Computed; Ultrasonography | 2016 |
p.(L576P) -KIT mutation in GIST: Favorable prognosis and sensitive to imatinib?
Topics: Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Mutation; Prognosis | 2016 |
Role of surgery in patients with focally progressive gastrointestinal stromal tumors resistant to imatinib.
Topics: Adult; Aged; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Survival Analysis; Treatment Outcome | 2016 |
PIK3C2A is a gene-specific target of microRNA-518a-5p in imatinib mesylate-resistant gastrointestinal stromal tumor.
Topics: 3' Untranslated Regions; Adult; Aged; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Imatinib Mesylate; Male; MicroRNAs; Middle Aged; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; RNA, Neoplasm | 2016 |
Neoadjuvant imatinib treatment and laparoscopic anus-preserving surgery for a large gastrointestinal stromal tumor of the rectum.
Topics: Anal Canal; Antineoplastic Agents; Combined Modality Therapy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Laparoscopy; Male; Middle Aged; Neoadjuvant Therapy; Organ Sparing Treatments; Prognosis; Rectal Neoplasms | 2016 |
A successful approach to overcome imatinib-induced skin toxicity in a GIST patient.
Topics: Aged; Antineoplastic Agents; Clemastine; Doxycycline; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Protein Kinase Inhibitors; Skin Diseases | 2016 |
Effective Downsizing of a Gastroesophageal GIST Using Neoadjuvant Imatinib Mesylate: a Case Report.
Topics: Antineoplastic Agents; Esophagogastric Junction; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Prognosis | 2017 |
Multiple Xanthogranulomas in an Adult: Known Entity, New Association.
Topics: Adult; Antineoplastic Agents; Chemotherapy, Adjuvant; Drug Eruptions; Female; Gastrointestinal Stromal Tumors; Granuloma; Histiocytosis, Non-Langerhans-Cell; Humans; Imatinib Mesylate; Stomach Neoplasms; Xanthomatosis | 2016 |
Endoscopic full-thickness resection of esophagogastric junction gastrointestinal stromal tumor assisted by laparoscopy after neoadjuvant therapy.
Topics: Aged, 80 and over; Antineoplastic Agents; Dissection; Endoscopy, Digestive System; Esophagogastric Junction; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Laparoscopy; Neoadjuvant Therapy; Surgery, Computer-Assisted; Treatment Outcome | 2016 |
Duration of Adjuvant Therapy for Patients With Gastrointestinal Stromal Tumors: Where Is Goldilocks When We Need Her?
Topics: Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Medication Therapy Management; Molecular Targeted Therapy | 2016 |
Resection of liver metastases in patients with gastrointestinal stromal tumors in the imatinib era: A nationwide retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Liver Neoplasms; Male; Metastasectomy; Middle Aged; Netherlands; Proportional Hazards Models; Retrospective Studies; Survival Rate | 2016 |
Efficacy of erlotinib and imatinib in a patient with a rectal gastrointestinal stromal tumor and synchronous pulmonary adenocarcinoma: A case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Erlotinib Hydrochloride; Female; Gastrointestinal Stromal Tumors; Genes, erbB-1; Humans; Imatinib Mesylate; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasms, Multiple Primary; Proto-Oncogene Proteins c-kit; Rectal Neoplasms | 2016 |
[A case of a gastrointestinal stromal tumor of the rectum effectively treated with continuously-administered regorafenib after failure of imatinib and sunitinib].
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Phenylurea Compounds; Pyridines; Pyrroles; Rectal Neoplasms; Sunitinib | 2016 |
Synchronous Large Gastrointestinal Stromal Tumor and Adenocarcinoma in the Stomach Treated with Imatinib Mesylate Followed by Total Gastrectomy.
Topics: Adenocarcinoma; Antineoplastic Agents; Combined Modality Therapy; Gastrectomy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Protein Kinase Inhibitors; Radiography | 2016 |
Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; DNA Mutational Analysis; Drug Resistance, Neoplasm; Exons; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Mutation; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha; Sequence Analysis, DNA; Tissue Array Analysis | 2016 |
Molecular cytology genotyping of primary and metastatic GI stromal tumors by using a custom two-gene targeted next-generation sequencing panel with therapeutic intent.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Cytogenetic Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Genotyping Techniques; High-Throughput Nucleotide Sequencing; Histone-Lysine N-Methyltransferase; Humans; Imatinib Mesylate; Neurofibromin 1; Precision Medicine; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Radiology, Interventional; ras Proteins; Receptor, Platelet-Derived Growth Factor alpha; Succinate Dehydrogenase; Tomography, X-Ray Computed | 2016 |
Circulating tumor cells as a prognostic and predictive marker in gastrointestinal stromal tumors: a prospective study.
Topics: Anoctamin-1; Antineoplastic Agents; Biomarkers, Tumor; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukocytes, Mononuclear; Male; Middle Aged; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Prognosis; Prospective Studies | 2016 |
Inhibitor of Apoptosis Proteins (IAPs) are commonly dysregulated in GIST and can be pharmacologically targeted to enhance the pro-apoptotic activity of imatinib.
Topics: Apoptosis; Cell Line, Tumor; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Inhibitor of Apoptosis Proteins; Molecular Targeted Therapy; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Signal Transduction | 2016 |
Giant mesenterial gastrointestinal stromal tumour mimicking a permagna hernia: a wolf in sheep's clothing.
Topics: Aged; Antineoplastic Agents; Gastrointestinal Stromal Tumors; Hernia; Humans; Image-Guided Biopsy; Imatinib Mesylate; Male; Mesentery; Peritoneal Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Role of metastasectomy for recurrent/metastatic gastrointestinal stromal tumors based on an analysis of the Kinki GIST registry.
Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Japan; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Protein Kinase Inhibitors; Registries; Retrospective Studies; Survival Rate; Time Factors | 2017 |
Neoadjuvant Imatinib in Locally Advanced Gastrointestinal stromal Tumours, Will Kit Mutation Analysis Be a Pathfinder?
Topics: Adult; Aged; Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neoadjuvant Therapy; Young Adult | 2016 |
Evaluation of Gold's nomogram for predicting recurrence-free survival in gastrointestinal stromal tumors in Indian patients.
Topics: Chemotherapy, Adjuvant; Digestive System Surgical Procedures; Disease-Free Survival; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; India; Neoplasm Recurrence, Local; Probability; Retrospective Studies; Risk; Time Factors; Validation Studies as Topic | 2016 |
Lichenoid drug eruption caused by imatinib mesylate in a Chinese patient with gastrointestinal stromal tumor.
Topics: Aged; Antineoplastic Agents; Asian People; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lichenoid Eruptions; Male | 2016 |
Pancreas preserving surgery for duodenal gastrointestinal stromal tumor removal.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Duodenal Neoplasms; Duodenum; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Hospitals, University; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Middle Aged; Organ Sparing Treatments; Pancreas; Preoperative Care; Retrospective Studies; Treatment Outcome | 2016 |
Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Exome Sequencing; Gastrointestinal Stromal Tumors; Gene Expression Profiling; Heterocyclic Compounds, 3-Ring; Humans; Imatinib Mesylate; Mice; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Signal Transduction; Survival Analysis; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Giant Gastric Gastrointestinal Stromal Tumor (GIST).
Topics: Antineoplastic Agents; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Neoadjuvant Therapy; Tomography, X-Ray Computed | 2017 |
Two different KIT mutations may lead to different responses to imatinib in metastatic gastrointestinal stromal tumor.
Topics: Aged; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines | 2018 |
Skin lesions in patients treated with imatinib mesylate: a 5-year prospective study.
Topics: Antineoplastic Agents; Carcinoma, Basal Cell; Dermatitis, Seborrheic; Dermatomycoses; Drug Eruptions; Eczema; Edema; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Histiocytoma, Benign Fibrous; Humans; Imatinib Mesylate; Keratosis, Actinic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nail Diseases; Orbital Diseases; Prospective Studies; Pruritus; Psoriasis; Skin Neoplasms | 2016 |
[Rectal gastrointestinal stromal tumor: a clinical and pathologic analysis].
Topics: Antineoplastic Agents; Biopsy; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Prognosis; Rectal Neoplasms; S100 Proteins | 2016 |
Prospective Analysis in GIST Patients on the Role of Alpha-1 Acid Glycoprotein in Imatinib Exposure.
Topics: Aged; Antineoplastic Agents; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Orosomucoid; Prospective Studies | 2017 |
PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.
Topics: Animals; Antibodies, Monoclonal; B7-H1 Antigen; Cell Line, Tumor; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunotherapy; Lymphocyte Activation; Mice; Molecular Targeted Therapy; Programmed Cell Death 1 Receptor; STAT1 Transcription Factor; T-Lymphocytes; Xenograft Model Antitumor Assays | 2017 |
CCBE1 promotes GIST development through enhancing angiogenesis and mediating resistance to imatinib.
Topics: Antineoplastic Agents; Calcium-Binding Proteins; Carcinogenesis; Cell Line, Tumor; Drug Resistance; Female; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Male; Middle Aged; Neovascularization, Pathologic; Prognosis; Survival Analysis; Tumor Suppressor Proteins; Up-Regulation | 2016 |
A huge necrotic liver mass in a 45-year-old woman: delayed hepatic metastasis of a gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Intestinal Neoplasms; Liver Neoplasms; Middle Aged; Necrosis; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Time Factors; Treatment Outcome; Tumor Burden | 2017 |
[A Case of Resected Giant Gastrointestinal Stromal Tumor Associated with Intraperitoneal Bleeding Following Imatinib Administration].
Topics: Aged; Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Gastroscopy; Hemorrhage; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Stomach Neoplasms | 2016 |
miRNA-21 sensitizes gastrointestinal stromal tumors (GISTs) cells to Imatinib via targeting B-cell lymphoma 2 (Bcl-2).
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lymphoma, B-Cell; MicroRNAs; Piperazines; Pyrimidines | 2016 |
Clinicopathologic features and prognosis of primary gastrointestinal stromal tumor patients under 35 years of age: A 10-year retrospective study.
Topics: Adolescent; Adult; Antineoplastic Agents; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestine, Small; Male; Prognosis; Retrospective Studies; Young Adult | 2016 |
Proteogenomics for the Study of Gastrointestinal Stromal Tumors.
Topics: Antineoplastic Agents; Culture Media, Conditioned; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Protein Kinase Inhibitors; Proteogenomics; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha; Tumor Cells, Cultured | 2016 |
Detection and Quantification of KIT Mutations in ctDNA by Plasma Safe-SeqS.
Topics: Antineoplastic Agents; DNA Mutational Analysis; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Outcome Assessment, Health Care; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Pyridines; Pyrroles; Reproducibility of Results; Sunitinib | 2016 |
Computed tomography features and predictive findings of ruptured gastrointestinal stromal tumours.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Ascites; Disease Progression; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hematoma; Hemoperitoneum; Humans; Imatinib Mesylate; Indoles; Intestine, Small; Male; Middle Aged; Necrosis; Peritonitis; Pyrroles; Rupture, Spontaneous; Sensitivity and Specificity; Sunitinib; Tomography, X-Ray Computed; Young Adult | 2017 |
A case of multiple gastrointestinal stromal tumors caused by a germline KIT gene mutation (p.Leu576Pro).
Topics: Adult; Antineoplastic Agents; Asthenia; Biopsy; DNA Mutational Analysis; Endoscopy, Gastrointestinal; Exons; Female; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Germ-Line Mutation; Humans; Imatinib Mesylate; Interstitial Cells of Cajal; Intestine, Small; Neoadjuvant Therapy; Neoplasms, Multiple Primary; Proto-Oncogene Proteins c-kit; Rare Diseases; Stomach; Tomography, X-Ray Computed; Young Adult | 2017 |
Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations.
Topics: Anilides; Animals; Antineoplastic Agents; Apoptosis; Biopsy; Cell Line, Tumor; Disease Models, Animal; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mice; Mutation; Necrosis; Neoplasm Grading; Neovascularization, Pathologic; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Rectal GIST-Outcomes and viewpoint from a tertiary cancer center.
Topics: Adult; Aged; Anal Canal; Antineoplastic Agents; Chemotherapy, Adjuvant; Cohort Studies; Digestive System Surgical Procedures; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Organ Sparing Treatments; Rectal Neoplasms; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome | 2016 |
Slow desensitization of imatinib-induced nonimmediate reactions and dynamic changes of drug-specific CD4
Topics: Adult; Aged; Antineoplastic Agents; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Drug Hypersensitivity; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Prednisolone; Protein Kinase Inhibitors; T-Lymphocyte Subsets | 2016 |
Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Binding Sites; Cell Line, Tumor; Cell Survival; Cilia; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Interstitial Cells of Cajal; Mutation; Nerve Tissue Proteins; Nuclear Proteins; Oxides; Promoter Regions, Genetic; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha; RNA Interference; RNA, Messenger; Signal Transduction; Transfection; Zinc Finger Protein GLI1; Zinc Finger Protein Gli2; Zinc Finger Protein Gli3 | 2016 |
New Drug and Possible New Toxicity - Squamous Cell Carcinoma Following Imatinib in Patients with Gastrointestinal Stromal Tumors.
Topics: Aged; Carcinoma, Squamous Cell; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasms, Second Primary; Proto-Oncogene Mas; Skin Neoplasms | 2016 |
Primary Extragastrointestinal Stromal Tumours in the Hepatobiliary Tree and Telocytes.
Topics: Actins; Adult; Aged; Antigens, CD34; Antineoplastic Agents; Biomarkers, Tumor; Female; Gallbladder; Gallstones; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver; Male; Middle Aged; Pancreas; Proto-Oncogene Proteins c-kit; Telocytes; Treatment Outcome; Vimentin | 2016 |
Diagnosis and treatment of gastrointestinal stromal tumor extending to prostate: A case report and literature review.
Topics: Aged; Antineoplastic Agents; Colonoscopy; Dysuria; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Neoadjuvant Therapy; Neoplasm Invasiveness; Preoperative Period; Prostate; Prostatectomy; Rectal Neoplasms; Treatment Outcome; Ultrasonography; Urinary Bladder | 2016 |
An exploratory association of polymorphisms in angiogenesis-related genes with susceptibility, clinical response and toxicity in gastrointestinal stromal tumors receiving sunitinib after imatinib failure.
Topics: Adult; Aged; Aged, 80 and over; Demography; Disease Progression; Female; Gastrointestinal Stromal Tumors; Genetic Association Studies; Genetic Predisposition to Disease; Haplotypes; Humans; Imatinib Mesylate; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neovascularization, Pathologic; Polymorphism, Single Nucleotide; Pyrroles; Sunitinib; Time Factors; Treatment Failure; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-3; Young Adult | 2017 |
The Therapeutic Response of Gastrointestinal Stromal Tumors to Imatinib Treatment Assessed by Intravoxel Incoherent Motion Diffusion-Weighted Magnetic Resonance Imaging with Histopathological Correlation.
Topics: Animals; Cell Line, Tumor; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Mice; Mice, Inbred BALB C; Mice, Nude; Xenograft Model Antitumor Assays | 2016 |
[Lancet in the era of targeted drug therapy: the role of surgery in the management of advanced gastrointestinal stromal tumor].
Topics: Antineoplastic Agents; Disease Progression; Disease-Free Survival; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Prognosis; Pyrimidines | 2016 |
[Preliminary understanding of gastrointestinal stromal tumor with the highest risk].
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Prognosis; Pyrimidines; Risk | 2016 |
[Changes of diagnosis and treatment for gastrointestinal stromal tumors during a 18-year period in four medical centers of China].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; China; Combined Modality Therapy; Exons; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Proto-Oncogene Proteins c-kit; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Young Adult | 2016 |
[Current status of surgical treatment of gastric gastrointestinal tumors: a national multi-center retrospective study].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; China; Combined Modality Therapy; Female; Gastrectomy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Laparoscopy; Laparotomy; Male; Middle Aged; Postoperative Period; Prognosis; Retrospective Studies; Splenectomy; Stomach Neoplasms; Survival Rate; Young Adult | 2016 |
[A Chinese multi-center study on the significance of monitoring imatinib plasma concentration in patients with gastrointestinal stromal tumor before and after administration].
Topics: Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Cross-Sectional Studies; Female; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Tandem Mass Spectrometry | 2016 |
[Clinical characteristics and prognosis analysis of 119 cases with giant gastrointestinal stromal tumor].
Topics: Abdominal Cavity; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestine, Small; Lymph Node Excision; Male; Middle Aged; Multivariate Analysis; Prognosis; Retrospective Studies; Risk Factors; Survival Rate; Young Adult | 2016 |
[Efficacy analysis of targeted therapy combined with surgery in the treatment of recurrent and metastatic gastrointestinal stromal tumor].
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies | 2016 |
[Efficacy observation on imatinib reintroduction in gastrointestinal stromal tumor with high recurrence risk after imatinib adjuvant therapy failure].
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Exons; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Retrospective Studies | 2016 |
[Molecular mechanism of gastrointestinal stromal tumors and progress in drug research].
Topics: Benzimidazoles; Exons; Gastrointestinal Stromal Tumors; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Indazoles; Mutation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines; Quinolones; Succinate Dehydrogenase; Sulfonamides | 2016 |
[Treatment and prognosis of 108 patients with high-risk gastrointestinal stromal tumor].
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Disease Progression; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Postoperative Period; Prognosis; Retrospective Studies; Risk Factors; Survival Rate | 2016 |
A lower dosage of imatinib in patients with gastrointestinal stromal tumors with toxicity of the treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Postoperative Period; Retrospective Studies; Treatment Outcome | 2016 |
Gastrointestinal stromal tumours (GISTs): A descriptive study on 29 cases.
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Intestinal Neoplasms; Intestine, Small; Male; Middle Aged; Proto-Oncogene Proteins c-kit; Pyrroles; Retrospective Studies; Stomach Neoplasms; Sunitinib; Survival Rate; Tumor Burden; Weight Loss | 2016 |
Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate.
Topics: Adult; Aged; Aged, 80 and over; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Male; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-kit; RNA, Small Interfering; Tissue Array Analysis | 2017 |
Assessing tumor vascularization as a potential biomarker of imatinib resistance in gastrointestinal stromal tumors by dynamic contrast-enhanced magnetic resonance imaging.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Contrast Media; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Heterografts; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Mice; Neovascularization, Pathologic | 2017 |
Genomic and transcriptomic analysis of imatinib resistance in gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genomics; Humans; Imatinib Mesylate; Mutation; Prognosis; Proto-Oncogene Proteins c-kit; Tumor Cells, Cultured | 2017 |
Gain of TP53 Mutation in Imatinib-treated SDH-Deficient Gastrointestinal Stromal Tumor and Clinical Utilization of Targeted Next-generation Sequencing Panel for Therapeutic Decision Support.
Topics: Adult; Clinical Decision-Making; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Mutation, Missense; Succinate Dehydrogenase; Tumor Suppressor Protein p53 | 2018 |
Incorporation of NLR into NIH stratification system increases predictive accuracy for surgically resected gastrointestinal stromal tumors.
Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukocyte Count; Lymphocytes; Male; Middle Aged; Multivariate Analysis; National Institutes of Health (U.S.); Neutrophils; Outcome Assessment, Health Care; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Factors; United States | 2017 |
Preoperative Chemotherapy and Survival for Large Anorectal Gastrointestinal Stromal Tumors: A National Analysis of 333 Cases.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Anus Neoplasms; Chemotherapy, Adjuvant; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Rectal Neoplasms; Survival Rate; Tumor Burden; United States; Young Adult | 2017 |
Retrospective analysis of 85 cases of intermediate-risk gastrointestinal stromal tumor.
Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; China; Disease Progression; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2017 |
Familial gastrointestinal stromal tumors, lentigines, and café-au-lait macules associated with germline c-kit mutation treated with imatinib.
Topics: Adult; Antineoplastic Agents; Cafe-au-Lait Spots; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Germ-Line Mutation; Humans; Imatinib Mesylate; Lentigo; Male; Pedigree; Proto-Oncogene Proteins c-kit | 2017 |
Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate | 2017 |
[A Case of Small Intestinal Gastrointestinal Stromal Tumor(GIST)with Synchronous Colonic Cancer and Gastric Cancer at a Different Time].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Appendiceal Neoplasms; Female; Gastrointestinal Stromal Tumors; Humans; Ileal Neoplasms; Imatinib Mesylate; Neoplasms, Multiple Primary; Stomach Neoplasms; Treatment Outcome | 2016 |
[Resection of a Huge Gastrointestinal Stromal Tumor of the Stomach Following Neoadjuvant Chemotherapy with Imatinib].
Topics: Aged; Antineoplastic Agents; Female; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Stomach Neoplasms; Treatment Outcome | 2016 |
[A Case of Gastrointestinal Stromal Tumor(GIST)Originating in the Anal Canal].
Topics: Aged; Antineoplastic Agents; Anus Neoplasms; Chemotherapy, Adjuvant; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Proto-Oncogene Proteins c-kit | 2016 |
Giant gastric gastrointestinal stromal tumor with severe peritoneal dissemination controlled by imatinib therapy following debulking surgery: a case report.
Topics: Abdominal Pain; Anorexia; Antineoplastic Agents; Combined Modality Therapy; Cytoreduction Surgical Procedures; Disease Progression; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Laparotomy; Middle Aged; Peritoneal Neoplasms; Prognosis; Stomach Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
GIST: Institutional Experience at SRMS-IMS, India.
Topics: Antineoplastic Agents; Diagnosis, Differential; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; India; Treatment Outcome | 2016 |
Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.
Topics: Aged; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Prognosis; Proportional Hazards Models; Proto-Oncogene Proteins c-kit; Randomized Controlled Trials as Topic; Receptor, Platelet-Derived Growth Factor alpha; Succinate Dehydrogenase; Survival Rate; Treatment Outcome | 2017 |
[Low-Dose and Interval Administration of Imatinib in a Patient with Liver Metastasis of the Gastrointestinal Stromal Tumor of the Stomach - A Case Report].
Topics: Aged; Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Recurrence; Stomach Neoplasms; Treatment Outcome | 2017 |
Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Cohort Studies; Digestive System Surgical Procedures; Esophageal Neoplasms; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neoadjuvant Therapy; Netherlands; Palliative Care; Prognosis; Receptor, Platelet-Derived Growth Factor alpha; Retrospective Studies; Stomach Neoplasms; Treatment Outcome; United States; Young Adult | 2017 |
Use of imatinib mesylate in gastrointestinal stromal tumours: Pan-Birmingham Cancer Network experience.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Survival Analysis | 2008 |
Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor.
Topics: Adult; Agammaglobulinemia; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Female; gamma-Globulins; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunoglobulins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies | 2008 |
Protein kinase C-theta regulates KIT expression and proliferation in gastrointestinal stromal tumors.
Topics: Apoptosis; Base Sequence; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Isoenzymes; Molecular Sequence Data; Phosphorylation; Piperazines; Protein Kinase C; Protein Kinase C-theta; Proto-Oncogene Proteins c-kit; Pyrimidines; RNA, Small Interfering; Signal Transduction | 2008 |
Verification of imatinib cost-effectiveness in advanced gastrointestinal stromal tumor in British Columbia (VINCE-BC study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; British Columbia; Cost-Benefit Analysis; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Life Expectancy; Male; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies | 2008 |
Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Combined Modality Therapy; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines | 2008 |
Surgical outcomes of patients with gastrointestinal stromal tumors in the era of targeted drug therapy.
Topics: Aged; Benzamides; Chemotherapy, Adjuvant; Cohort Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Neoplasm Staging; Piperazines; Probability; Proportional Hazards Models; Proto-Oncogene Proteins c-kit; Pyrimidines; Retrospective Studies; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2008 |
Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; DNA Mutational Analysis; Gastrointestinal Stromal Tumors; Gene Amplification; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Imatinib Mesylate; Mitogen-Activated Protein Kinase Kinases; Mutation; Piperazines; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Receptor, Platelet-Derived Growth Factor alpha; RNA, Small Interfering; Signal Transduction | 2008 |
Disease progression in some cancers may be due to low blood levels of targeted therapies.
Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Biological Availability; Dasatinib; Disease Progression; Drug Administration Schedule; Drug Interactions; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Patient Compliance; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2008 |
Early response assessment in gastrointestinal stromal tumors with FDG PET scan 24 hours after a single dose of imatinib.
Topics: Antineoplastic Agents; Benzamides; Biopsy, Fine-Needle; Diagnostic Imaging; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Positron-Emission Tomography; Proto-Oncogene Proteins c-kit; Pyrimidines; Radiopharmaceuticals; Time Factors; Tomography, X-Ray Computed | 2008 |
Pathologic complete response confirmed by surgical resection for liver metastases of gastrointestinal stromal tumor after treatment with imatinib mesylate.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrectomy; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Liver Neoplasms; Magnetic Resonance Imaging; Male; Neoadjuvant Therapy; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.
Topics: Adult; Aged; Benzamides; Child; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Genes, ras; Genotype; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Piperazines; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2008 |
Heterogeneity of kinase inhibitor resistance mechanisms in GIST.
Topics: Aged; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib | 2008 |
Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Molecular Biology; Mutation; Neurofibromatosis 1; Patient Selection; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2008 |
Management of gastrointestinal stromal tumours in the Imatinib era: a surgeon's perspective.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Physicians; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome | 2008 |
Metastatic gastrointestinal stromal tumors in the era of imatinib: improved survival and elimination of socioeconomic survival disparities.
Topics: Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Healthcare Disparities; Humans; Imatinib Mesylate; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Piperazines; Proportional Hazards Models; Pyrimidines; SEER Program; Socioeconomic Factors; Survival Rate; United States | 2008 |
Persistent cutaneous hyperpigmentation after tyrosine kinase inhibition with imatinib for GIST.
Topics: Benzamides; Biopsy, Needle; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Hyperpigmentation; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Neoplasm Staging; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Risk Assessment | 2008 |
Chronic myeloid leukemia in two patients with gastrointestinal stromal tumor.
Topics: Aged; Benzamides; Female; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasms, Second Primary; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines | 2008 |
Gastrointestinal stromal tumor of the stomach with lymph node metastasis.
Topics: Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Female; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lymph Node Excision; Lymphatic Metastasis; Piperazines; Pyrimidines; Stomach Neoplasms | 2008 |
Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression.
Topics: Adult; Aged; Benzamides; Cell Differentiation; Disease Progression; DNA Mutational Analysis; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Stem Cell Factor | 2009 |
Education and imaging. Gastrointestinal: Sister Mary Joseph nodule.
Topics: Abdominal Neoplasms; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Stomach Neoplasms; Tomography, X-Ray Computed; Treatment Outcome; Umbilicus | 2008 |
'Please, desist RECIST criteria in GIST, at least in me'.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Outcome Assessment, Health Care; Piperazines; Pyrimidines; Treatment Outcome | 2008 |
[A case of gastric gastrointestinal stromal tumor operated after low-dose chemotherapy with imatinib mesylate].
Topics: Aged; Antineoplastic Agents; Benzamides; Biopsy; Gastrointestinal Stromal Tumors; Gastroscopy; Humans; Imatinib Mesylate; Male; Piperazines; Positron-Emission Tomography; Pyrimidines; Tomography, X-Ray Computed | 2008 |
Perforation of the colon by invading recurrent gastrointestinal stromal tumors during sunitinib treatment.
Topics: Aged; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Intestinal Perforation; Male; Neoplasm Recurrence, Local; Peritonitis; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2008 |
Imatinib-induced hand-foot syndrome in a patient with metastatic gastrointestinal stromal tumor.
Topics: Benzamides; Biopsy, Needle; Drug Eruptions; Erythema; Follow-Up Studies; Foot Dermatoses; Gastrointestinal Stromal Tumors; Hand Dermatoses; Humans; Imatinib Mesylate; Immunohistochemistry; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Piperazines; Protein Kinase Inhibitors; Pyloric Antrum; Pyrimidines; Risk Assessment; Stomach Neoplasms; Syndrome | 2008 |
Abundant Fas expression by gastrointestinal stromal tumours may serve as a therapeutic target for MegaFasL.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Fas Ligand Protein; fas Receptor; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines | 2008 |
Clinical practice guidelines for gastrointestinal stromal tumor (GIST) in Japan: English version.
Topics: Algorithms; Antineoplastic Agents; Benzamides; Diagnostic Imaging; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines | 2008 |
A case of huge GIST of the stomach successfully resected following effective neoadjuvant chemotherapy.
Topics: Aged; Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoadjuvant Therapy; Piperazines; Pyrimidines; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Prognosis, imatinib dose, and benefit of sunitinib in GIST: knowing the genotype.
Topics: Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2008 |
Oncogenic and ligand-dependent activation of KIT/PDGFRA in surgical samples of imatinib-treated gastrointestinal stromal tumours (GISTs).
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Piperazines; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Signal Transduction; Stem Cell Factor | 2009 |
Imatinib mesylate induces quiescence in gastrointestinal stromal tumor cells through the CDH1-SKP2-p27Kip1 signaling axis.
Topics: Antigens, CD; Antineoplastic Agents; Benzamides; Cadherins; Cell Cycle; Cell Division; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Down-Regulation; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Intracellular Signaling Peptides and Proteins; Microscopy, Fluorescence; Piperazines; Pyrimidines; S-Phase Kinase-Associated Proteins; Signal Transduction; Tissue Array Analysis; Up-Regulation | 2008 |
'Time is a GIFT in GIST'--the medical and paramedical perspective of a case with metastatic gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leiomyosarcoma; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms, Muscle Tissue; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Tomography, X-Ray Computed | 2009 |
Population pharmacokinetics and pharmacogenetics of imatinib in children and adults.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Benzamides; Blood Proteins; Body Weight; Child; Child, Preschool; Gastrointestinal Stromal Tumors; Glycoproteins; Humans; Imatinib Mesylate; Metabolic Clearance Rate; Middle Aged; Pharmacogenetics; Piperazines; Polymorphism, Genetic; Population Groups; Pyrimidines; Serum Albumin; Sex Factors; Young Adult | 2008 |
[A resected case of postoperative liver metastasis of a gastrointestinal stromal tumor showing complete response after imatinib treatment].
Topics: Aged; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Piperazines; Positron-Emission Tomography; Pyrimidines; Tomography, X-Ray Computed | 2008 |
Synchronous small-cell lung cancer and gastrointestinal stromal tumor: a case report.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Doxorubicin; Etoposide; Fatal Outcome; Gastrointestinal Stromal Tumors; Humans; Ifosfamide; Imatinib Mesylate; Lung Neoplasms; Male; Middle Aged; Neoplasms, Multiple Primary; Palliative Care; Piperazines; Pyrimidines; Small Cell Lung Carcinoma; Stomach Neoplasms | 2009 |
PET/CT imaging of gastrointestinal stromal tumor with calcified peritoneal implants after imatinib therapy.
Topics: Antineoplastic Agents; Benzamides; Calcinosis; Female; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Peritoneum; Piperazines; Positron-Emission Tomography; Prostheses and Implants; Pyrimidines; Tomography, X-Ray Computed | 2008 |
Dose escalation of imatinib after failure of standard dose in Korean patients with metastatic or unresectable gastrointestinal stromal tumor.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Benzamides; Disease Progression; DNA Mutational Analysis; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Korea; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Retrospective Studies; Survival Rate; Treatment Failure | 2009 |
Imatinib-induced interstitial lung disease and sunitinib-associated intra-tumour haemorrhage.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Hemorrhage; Humans; Imatinib Mesylate; Indoles; Lung Diseases, Interstitial; Male; Middle Aged; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2008 |
[An update of the surgical indications for gastrointestinal stromal tumors].
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Piperazines; Pyrimidines | 2008 |
Sonography of multifocal Brucella orchitis.
Topics: Adult; Antineoplastic Agents; Benzamides; Brucellosis; Contrast Media; Female; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Hemangioma; Humans; Imatinib Mesylate; Liver Neoplasms; Magnetic Resonance Imaging; Piperazines; Pyrimidines; Radiopharmaceuticals; Tomography, X-Ray Computed; Ultrasonography | 2008 |
[Clinical practice guidelines in gastrointestinal stromal tumours (GEIS): update 2008].
Topics: Antineoplastic Agents; Benzamides; Consensus; Diagnosis, Differential; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Neoadjuvant Therapy; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Risk Factors; Time Factors; Tomography, X-Ray Computed | 2008 |
Secondary C-kit mutation is a cause of acquired resistance to imatinib in gastrointestinal stromal tumor.
Topics: Aged; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines | 2009 |
[A case of gastrointestinal stromal tumor of the stomach with rapid growth in a short term].
Topics: Aged; Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Gastroscopy; Humans; Imatinib Mesylate; Male; Piperazines; Pyrimidines; Stomach Neoplasms; Time Factors; Tomography, X-Ray Computed | 2008 |
Imaging characteristics of liver metastasis from gastrointestinal stromal tumor before and after imatinib mesylate treatment.
Topics: Aged; Antineoplastic Agents; Benzamides; Colon; Fatal Outcome; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestinal Neoplasms; Intestine, Small; Liver; Liver Neoplasms; Male; Neoplasm Invasiveness; Piperazines; Pyrimidines; Stomach; Stomach Neoplasms; Ultrasonography | 2008 |
Imatinib mesylate-induced repigmentation of vitiligo lesions in a patient with recurrent gastrointestinal stromal tumors.
Topics: Aged; Benzamides; Gastrointestinal Stromal Tumors; Humans; Hypopigmentation; Imatinib Mesylate; Male; Melanins; Neoplasm Recurrence, Local; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Vitiligo | 2008 |
Inhibition of focal adhesion kinase as a potential therapeutic strategy for imatinib-resistant gastrointestinal stromal tumor.
Topics: Administration, Oral; Animals; Benzamides; Cell Line; Cell Proliferation; Drug Resistance, Neoplasm; Female; Focal Adhesion Protein-Tyrosine Kinases; Gastrointestinal Stromal Tumors; Imatinib Mesylate; Mice; Mice, Nude; Morpholines; Mutation; Piperazines; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Pyrimidines; Substrate Specificity | 2009 |
Response of Imitanib Meysylate in patients with gastrointestinal stromal cell tumour.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Prospective Studies; Pyrimidines | 2008 |
KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Phosphorylation; Piperazines; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; Spectrometry, Fluorescence; Sunitinib | 2009 |
Nanoneoadjuvant therapy of gastrointestinal stromal tumor (GIST).
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Piperazines; Pyrimidines; Randomized Controlled Trials as Topic | 2009 |
T670X KIT mutations in gastrointestinal stromal tumors: making sense of missense.
Topics: Antineoplastic Agents; Benzamides; Computer Simulation; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Immunoblotting; Immunoprecipitation; In Vitro Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Mutation, Missense; Piperazines; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Reproducibility of Results; Research Design; Threonine | 2009 |
The use of contrast-enhanced ultrasound in patients with GIST metastases that are negative in CT and PET.
Topics: Adult; Antineoplastic Agents; Benzamides; Contrast Media; Female; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Metastasis; Piperazines; Positron-Emission Tomography; Pyrimidines; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed; Ultrasonography | 2008 |
Management of imatinib-related exacerbation of psoriasis in a patient with a gastrointestinal stromal tumour.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Eruptions; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Methotrexate; Middle Aged; Peritoneal Neoplasms; Piperazines; Psoriasis; Pyrimidines; Treatment Outcome | 2009 |
Upper abdominal mass with diagnostic dilemma.
Topics: Adult; Antineoplastic Agents; Benzamides; Biopsy, Fine-Needle; Diagnosis, Differential; Gastric Fundus; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Piperazines; Pyrimidines | 2009 |
Hits and misses in targeting pediatric cancers.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Infant; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib | 2009 |
Activity of nilotinib (AMN-107) alone in advanced gastrointestinal stromal tumors progressing on imatinib and sunitinib. Case report.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Positron-Emission Tomography; Pyrimidines; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2009 |
Is anticancer drug development heading in the right direction?
Topics: Antineoplastic Agents; Benzamides; Drug Delivery Systems; Drug Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2009 |
A gastrointestinal stromal tumor of the jejunum associated with intrahepatic cholangiocarcinoma and pulmonary hamartoma: a case report.
Topics: Antineoplastic Agents; Benzamides; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Gastrointestinal Stromal Tumors; Hamartoma; Humans; Imatinib Mesylate; Jejunal Neoplasms; Lung Diseases; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2009 |
Diagnosing gastrointestinal stromal tumors before the year 2000.
Topics: Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Healthcare Disparities; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Pyrimidines; SEER Program; Socioeconomic Factors; Survival Rate; United States | 2009 |
Perioperative tyrosine kinase inhibitors for GIST: standard ... or an idea that needs further investigation?
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoadjuvant Therapy; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib | 2009 |
Controversies in the surgical management of GIST in the era of imatinib.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoadjuvant Therapy; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib | 2009 |
Adjuvant treatment of GIST with imatinib: solid ground or still quicksand? A comment on behalf of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, the NCRI Sarcoma Clinical Studies Group (UK), the Japanese Study Group on GIST, the
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Societies, Medical; Treatment Outcome | 2009 |
Dramatic response of a gastrointestinal stromal tumor to neadjuvant imatinib therapy.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Tomography, X-Ray Computed | 2009 |
[Surgical treatment for patients with advanced gastrointestinal stromal tumor after targeted therapy].
Topics: Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Retrospective Studies; Treatment Outcome | 2009 |
Adjuvant imatinib in GIST: a self-fulfilling prophecy, or more?
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines | 2009 |
Severe esophagitis in a patient with gastrointestinal stromal tumor treated with imatinib.
Topics: Benzamides; Biopsy, Needle; Chemotherapy, Adjuvant; Esophagitis; Esophagoscopy; Follow-Up Studies; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Piperazines; Pyrimidines; Risk Assessment; Severity of Illness Index; Stomach Neoplasms; Tomography, X-Ray Computed | 2009 |
Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Piperazines; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib; Survival Rate; Treatment Failure; Treatment Outcome | 2009 |
Cystic hepatic metastasis from gastrointestinal stromal tumor prior to imatinib mimicking a liver abscess.
Topics: Antineoplastic Agents; Benzamides; Biopsy; Cysts; Diagnosis, Differential; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Abscess; Liver Neoplasms; Male; Middle Aged; Piperazines; Pyrimidines; Tomography, X-Ray Computed | 2009 |
Usefulness of positron emission and computed tomography scan in early evaluation of treatment response in gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Benzamides; Drug Monitoring; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Piperazines; Positron-Emission Tomography; Pyrimidines; Radiography, Abdominal | 2010 |
Does imatinib turn recurrent and/or metastasized gastrointestinal stromal tumors into a chronic disease? - single center experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chronic Disease; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Receptors, Amino Acid; Receptors, Platelet-Derived Growth Factor; Survival Analysis; Treatment Outcome | 2009 |
Imatinib mesylate neoadjuvant treatment for rectal malignant gastrointestinal stromal tumor.
Topics: Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoadjuvant Therapy; Piperazines; Pyrimidines; Rectal Neoplasms | 2009 |
Surgical resection of esophageal gastrointestinal stromal tumors.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Deglutition Disorders; Esophageal Neoplasms; Esophagectomy; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Retrospective Studies; Thoracotomy; Treatment Outcome | 2009 |
Invited commentary.
Topics: Antineoplastic Agents; Benzamides; Esophageal Neoplasms; Esophagectomy; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Time Factors | 2009 |
[Strategy for patients with GIST after failure of imatinib].
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Failure | 2009 |
Unlucky number 13? Differential effects of KIT exon 13 mutation in gastrointestinal stromal tumors.
Topics: Benzamides; Drug Resistance, Neoplasm; Exons; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Mutation, Missense; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines | 2008 |
Therapeutic monitoring of drug plasma concentrations and improved clinical outcomes in GIST.
Topics: Benzamides; Drug Monitoring; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Survival Analysis | 2009 |
Kinase mutations and efficacy of imatinib in Korean patients with advanced gastrointestinal stromal tumors.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Exons; Female; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Piperazines; Proto-Oncogene Proteins c-akt; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2009 |
Cas-L was overexpressed in imatinib-resistant gastrointestinal stromal tumor cells.
Topics: Adaptor Proteins, Signal Transducing; Benzamides; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Gene Expression Profiling; Humans; Imatinib Mesylate; Isoenzymes; Janus Kinase 2; Oligonucleotide Array Sequence Analysis; Phosphoproteins; Phosphorylation; Piperazines; Protein Kinase C; Protein Kinase C-theta; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; RNA, Small Interfering; src-Family Kinases | 2009 |
New paradigms in gastrointestinal stromal tumour management.
Topics: Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2009 |
Myelodysplastic syndrome appearing during imatinib mesylate therapy in a patient with GIST.
Topics: Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Karyotyping; Middle Aged; Myelodysplastic Syndromes; Piperazines; Pyrimidines | 2009 |
Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Patient Selection; Piperazines; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome; Young Adult | 2009 |
Repeated surgery improves survival in recurrent gastrointestinal stromal tumors: a retrospective analysis of 144 patients.
Topics: Antineoplastic Agents; Benzamides; Clinical Protocols; Combined Modality Therapy; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leiomyoma; Leiomyosarcoma; Longitudinal Studies; Male; Middle Aged; Neoplasm Recurrence, Local; Neurilemmoma; Piperazines; Pyrimidines; Reoperation; Retrospective Studies; Treatment Outcome | 2009 |
Gastrointestinal stromal tumor of the esophagus.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Esophageal Neoplasms; Esophagoscopy; Esophagus; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2009 |
[Imaging of gastrointestinal stromal tumors].
Topics: Adult; Aged; Angiography; Antineoplastic Agents; Benzamides; Biopsy; Capsule Endoscopy; Contrast Media; Diagnosis, Differential; Endosonography; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Piperazines; Positron-Emission Tomography; Pyrimidines; Recurrence; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Cell cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Benzamides; Cell Cycle; Cell Cycle Proteins; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Multivariate Analysis; Mutation; Piperazines; Proportional Hazards Models; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Survival Rate | 2009 |
High efficacy of panobinostat towards human gastrointestinal stromal tumors in a xenograft mouse model.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Enzyme Inhibitors; Exons; Gastrointestinal Stromal Tumors; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Imatinib Mesylate; Indoles; Mice; Panobinostat; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction; Xenograft Model Antitumor Assays | 2009 |
Successes and challenges in translational research: the development of targeted therapy for gastrointestinal stromal tumours.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines | 2009 |
[Review of 32 gastro-intestinal stromal tumours with CD117 antigen].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Duodenal Neoplasms; Female; Gastrointestinal Stromal Tumors; Humans; Ileal Neoplasms; Imatinib Mesylate; Jejunal Neoplasms; Male; Middle Aged; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Retrospective Studies; Stomach Neoplasms; Treatment Outcome | 2009 |
Prognosis and predictive value of KIT exon 11 deletion in GISTs.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Exons; Female; Gastrointestinal Stromal Tumors; Gene Deletion; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Retrospective Studies; Survival Rate; Young Adult | 2009 |
[A case of recurrent gastrointestinal stromal tumor of the stomach with complete response to imatinib mesilate].
Topics: Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Remission Induction; Stomach Neoplasms | 2009 |
Incomplete Carney triad--a review of two cases.
Topics: Adult; Anti-Bacterial Agents; Antineoplastic Agents; Benzamides; Bronchial Diseases; Chondroma; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Lung Neoplasms; Neoplasms, Multiple Primary; Paraganglioma, Extra-Adrenal; Piperazines; Pyrimidines; Tomography, X-Ray Computed | 2009 |
Primary large gastrointestinal stromal tumor of the liver: report of a case.
Topics: Adult; Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Reoperation; Skin Neoplasms; Stomach Neoplasms | 2009 |
Long-surviving patients with recurrent GIST after receiving cytoreductive surgery with imatinib therapy.
Topics: Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2009 |
Gastrointestinal stromal tumor of the stomach with extremely slow-growing hematogenous metastasis.
Topics: Aged; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Lung Neoplasms; Piperazines; Pyrimidines; Stomach Neoplasms | 2009 |
Residual and recurrent gastrointestinal stromal tumors with KIT mutations: findings at first follow-up CT after imatinib treatment.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Seeding; Neoplasm, Residual; Peptide Fragments; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Retrospective Studies; Splenic Neoplasms; Tomography, X-Ray Computed | 2009 |
[Imaging follow-up of gastrointestinal stromal tumors (GIST) during therapy: a case report].
Topics: Aged, 80 and over; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Contrast Media; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Gastrointestinal Stromal Tumors; Humans; Ileal Neoplasms; Ileum; Imatinib Mesylate; Liver Neoplasms; Piperazines; Pyrimidines; Tomography, X-Ray Computed | 2009 |
Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients?
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Medical Futility; Middle Aged; Neoplasm Metastasis; Piperazines; Pyrimidines; Retrospective Studies; Treatment Outcome | 2010 |
Hepatic arterial embolization and chemoembolization for imatinib-resistant gastrointestinal stromal tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Embolization, Therapeutic; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hepatic Artery; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Survival Rate; Treatment Outcome | 2009 |
In vivo effect of imatinib on progression of cecal GIST-like tumors in exon 17-type c-kit knock-in mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cecal Neoplasms; Cell Proliferation; Disease Progression; Exons; Female; Gastrointestinal Stromal Tumors; Gene Knock-In Techniques; Heterozygote; Imatinib Mesylate; Ki-67 Antigen; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutation; Phosphorylation; Piperazines; Polymerase Chain Reaction; Proto-Oncogene Proteins c-kit; Pyrimidines; RNA, Messenger; Signal Transduction | 2009 |
Congestive heart failure during imatinib mesylate treatment.
Topics: Aged; Benzamides; Female; Gastrointestinal Stromal Tumors; Heart Failure; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Treatment Outcome; Ultrasonography | 2010 |
Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors.
Topics: Acute Disease; Anti-Inflammatory Agents; Antineoplastic Agents; Benzamides; Chemical and Drug Induced Liver Injury; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Intestinal Neoplasms; Liver; Liver Failure; Middle Aged; Peritoneal Neoplasms; Piperazines; Prednisolone; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib | 2010 |
Gastrointestinal stromal tumors II: medical oncology and tumor response assessment.
Topics: Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2009 |
Downstaging of a rectal gastrointestinal stromal tumor by neoadjuvant imatinib therapy allowing for a conservative surgical approach.
Topics: Adult; Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoadjuvant Therapy; Neoplasm Staging; Piperazines; Pyrimidines; Rectal Neoplasms | 2009 |
[GIST: Imaging diagnosis, staging, and response assessment].
Topics: Antineoplastic Agents; Benzamides; Biopsy; Colonic Neoplasms; Contrast Media; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Image Processing, Computer-Assisted; Imatinib Mesylate; Liver Neoplasms; Neoplasm Staging; Piperazines; Positron-Emission Tomography; Pyrimidines; Sensitivity and Specificity; Stomach Neoplasms; Tomography, Spiral Computed | 2009 |
Perfusion patterns of metastatic gastrointestinal stromal tumor lesions under specific molecular therapy.
Topics: Adult; Aged; Aged, 80 and over; Angiography; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Molecular Targeted Therapy; Perfusion Imaging; Pilot Projects; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Activate and resist: L576P-KIT in GIST.
Topics: Aged; Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Genes, ras; Humans; Imatinib Mesylate; Immunohistochemistry; In Situ Hybridization, Fluorescence; Male; Middle Aged; Mutation; Piperazines; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2009 |
Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Biomarkers, Tumor; Clinical Trials, Phase III as Topic; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Solubility; Sunitinib; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Green tea (-)-epigalocatechin-3-gallate inhibits KIT activity and causes caspase-dependent cell death in gastrointestinal stromal tumor including imatinib-resistant cells.
Topics: Animals; Apoptosis; Benzamides; Blotting, Western; Caspase 3; Caspase 8; Caspase 9; Caspases; Catechin; Cell Line; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Tea; Time Factors | 2009 |
Biochemical and pathological response of prostate cancer in a patient with metastatic renal cell carcinoma on sunitinib treatment.
Topics: Benzamides; Carcinoma, Renal Cell; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Kidney Neoplasms; Male; Middle Aged; Piperazines; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrimidines; Pyrroles; Sunitinib | 2009 |
Predicting recurrence-free survival after surgery for GIST.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Digestive System Surgical Procedures; Disease-Free Survival; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mitotic Index; Neoplasm Invasiveness; Neoplasm Staging; Nomograms; Patient Selection; Piperazines; Predictive Value of Tests; Protein Kinase Inhibitors; Pyrimidines; Reproducibility of Results; Risk Assessment; Time Factors; Treatment Outcome | 2009 |
Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Child; Digestive System Surgical Procedures; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Middle Aged; Mitotic Index; Neoplasm Invasiveness; Neoplasm Staging; Nomograms; Patient Selection; Piperazines; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Registries; Reproducibility of Results; Retrospective Studies; Risk Assessment; Spain; Time Factors; Treatment Outcome; United States; Young Adult | 2009 |
[A successfully resected case of liver metastasis of gastrointestinal stromal tumor responding to neoadjuvant chemotherapy with imatinib mesylate and interventional radiology].
Topics: Aged; Antineoplastic Agents; Benzamides; Catheter Ablation; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Neoadjuvant Therapy; Piperazines; Pyrimidines; Radiology, Interventional | 2009 |
Esophageal gastrointestinal stromal tumor with pulmonary and bone metastases.
Topics: Antineoplastic Agents; Benzamides; Bone Neoplasms; Esophageal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Pyrimidines; Tomography, X-Ray Computed | 2010 |
[Successful reintroduction of mesylate imatinib after pneumonitis in two patients with gastrointestinal stromal tumor (GIST)].
Topics: Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Piperazines; Pneumonia; Pyrimidines | 2009 |
Acute myeloid leukemia in patients with gastrointestinal stromal tumors treated with Gleevec.
Topics: Acute Disease; Aged; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myeloid; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2009 |
Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Cells, Cultured; Echocardiography; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Heart Failure; Humans; Imatinib Mesylate; Incidence; Male; Middle Aged; Myocytes, Cardiac; Piperazines; Pyrimidines; Young Adult | 2010 |
Insulin-like growth factor binding protein-3 has dual effects on gastrointestinal stromal tumor cell viability and sensitivity to the anti-tumor effects of imatinib mesylate in vitro.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Gastrointestinal Stromal Tumors; Gene Knockdown Techniques; Humans; Imatinib Mesylate; Insulin-Like Growth Factor Binding Protein 3; Neutralization Tests; Organ Specificity; Piperazines; Pyrimidines | 2009 |
Detection of treatment-induced changes in signaling pathways in gastrointestinal stromal tumors using transcriptomic data.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; DNA Damage; ets-Domain Protein Elk-1; Gastrointestinal Stromal Tumors; Gene Expression Profiling; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; RNA, Messenger; Signal Transduction; STAT3 Transcription Factor; Tumor Suppressor Protein p53 | 2009 |
Disappearance of lentigines in a patient receiving imatinib treatment for familial gastrointestinal stromal tumor syndrome.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Colectomy; Dysplastic Nevus Syndrome; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lentigo; Middle Aged; Piperazines; Pyrimidines; Risk Assessment; Treatment Outcome | 2009 |
Six months neoadjuvant imatinib improves resectability potential of gastric stromal tumors in Egyptian patients.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Benzamides; Biopsy, Needle; Chi-Square Distribution; Egypt; Female; Follow-Up Studies; Gastrectomy; Gastrointestinal Stromal Tumors; Gastroscopy; Hospitals, University; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Piperazines; Prospective Studies; Pyrimidines; Risk Assessment; Saudi Arabia; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2010 |
Evaluation of self-reported progression and correlation of imatinib dose to survival in patients with metastatic gastrointestinal stromal tumors: an open cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cohort Studies; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Surveys and Questionnaires; Treatment Outcome; Young Adult | 2010 |
An acute hepatitis resembling autoimmune hepatitis occurring during imatinib therapy in a gastrointestinal stromal tumor patient.
Topics: Acute Disease; Aged; Antineoplastic Agents; Benzamides; Chemical and Drug Induced Liver Injury; Diagnosis, Differential; Gastrointestinal Stromal Tumors; Hepatitis, Autoimmune; Humans; Imatinib Mesylate; Male; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2009 |
Elevations of creatine kinase in patients treated with imatinib mesylate (Gleevec).
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Case-Control Studies; Cohort Studies; Creatine Kinase; Edema; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Muscular Diseases; Piperazines; Pyrimidines; Up-Regulation; Young Adult | 2010 |
[Successful resection of an advanced gastrointestinal stromal tumor by neoadjuvant chemotherapy with imatinib- a case report].
Topics: Antineoplastic Agents; Benzamides; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Pancreatectomy; Piperazines; Pyrimidines; Splenectomy | 2009 |
Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors.
Topics: Antigens, CD; Antigens, Differentiation, Myelomonocytic; Benzamides; Female; Forkhead Transcription Factors; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Indoles; Interleukin-10; Intestinal Neoplasms; Macrophages; Male; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Receptors, Cell Surface; Sunitinib; T-Lymphocytes, Regulatory | 2010 |
[Study on the mechanism of imatinib-induced resistance in gastrointestinal stromal tumors].
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Codon; Drug Resistance, Neoplasm; Exons; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2009 |
Establishment and characterization of a human gastrointestinal stromal tumour (GIST) xenograft in athymic nude mice.
Topics: Adult; Animals; Benzamides; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Karyotyping; Male; Mice; Mice, Nude; Middle Aged; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Xenograft Model Antitumor Assays | 2009 |
A study of the postoperative course in cases of GIST of the stomach. The efficacy of imatinib in cases of recurrence.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines | 2009 |
Emergence of imatinib resistance associated with downregulation of c-kit expression in recurrent gastrointestinal stromal tumor (GIST): optimal timing of resection.
Topics: Aged, 80 and over; Benzamides; Biopsy, Needle; Combined Modality Therapy; Down-Regulation; Drug Resistance, Neoplasm; Follow-Up Studies; Gastrectomy; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines; Risk Assessment; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
[Long-term survival after surgery and adjuvant imatinib in a patient with rectal GIST, local recurrence, liver metastases and mediastinal pleural metastasis].
Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Mediastinum; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pleural Neoplasms; Pyrimidines; Rectal Neoplasms | 2009 |
[A case of rapid growth GIST successfully treated with resection after long-term use of imatinib].
Topics: Abdominal Neoplasms; Aged; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Hemorrhage; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines | 2009 |
Molecular mechanisms of secondary imatinib resistance in patients with gastrointestinal stromal tumors.
Topics: Adult; Aged; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Signal Transduction | 2010 |
Pyogenic liver abscess associated with a gastrointestinal stromal tumor of the stomach.
Topics: Aged; Anti-Bacterial Agents; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Diagnosis, Differential; Drainage; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Imipenem; Liver Abscess, Pyogenic; Male; Piperazines; Pyrimidines; Streptococcal Infections; Tomography, X-Ray Computed; Vancomycin | 2010 |
[Chinese consensus in diagnosis and treatment of gastrointestinal stromal tumor].
Topics: Actins; Antigens, CD34; Antineoplastic Agents; Benzamides; Follow-Up Studies; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Neoadjuvant Therapy; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Tomography, X-Ray Computed | 2009 |
[Carney triad: clinicopathologic study of 2 cases with molecular analysis].
Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Agents; Benzamides; Chondroma; Female; Follow-Up Studies; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lung Neoplasms; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Piperazines; Pneumonectomy; Proto-Oncogene Proteins c-kit; Pyrimidines | 2009 |
Gastrointestinal stromal tumour of the omentum: a case report.
Topics: Adult; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Omentum; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Tomography, X-Ray Computed | 2008 |
Drug plasma monitoring in CML and GIST: A case-based discussion.
Topics: Adult; Benzamides; Drug Monitoring; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Patient Compliance; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Survival Rate; Treatment Outcome | 2009 |
T-cell lymphoproliferative disorder potentially induced by imatinib in a patient with GIST.
Topics: Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Piperazines; Pyrimidines; T-Lymphocytes; Treatment Outcome | 2010 |
Prognostic analysis of patients with gastrointestinal stromal tumors: a single unit experience with surgical treatment of primary disease.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Survival Analysis; Treatment Outcome; Young Adult | 2010 |
Exploring the cause of drug resistance by the detrimental missense mutations in KIT receptor: computational approach.
Topics: Benzamides; Binding Sites; Computational Biology; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Molecular Conformation; Mutation, Missense; Piperazines; Protein Binding; Proto-Oncogene Proteins c-kit; Pyrimidines | 2010 |
Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Cross-Sectional Studies; Female; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome | 2010 |
Imatinib plasma levels: correlation with clinical benefit in GIST patients.
Topics: Albumins; Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Gastrointestinal Stromal Tumors; Genotype; Glycoproteins; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Treatment Outcome | 2010 |
Complete resection after imatinib treatment of a gastrointestinal stromal tumor of the ileum with peritoneal metastases: report of a case.
Topics: Aged; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Ileal Neoplasms; Imatinib Mesylate; Neoadjuvant Therapy; Peritoneal Neoplasms; Piperazines; Pyrimidines | 2010 |
Pleomorphic phenotypes of gastrointestinal stromal tumors at metastatic sites with or without imatinib treatment.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Agents; Benzamides; ErbB Receptors; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta | 2010 |
[Successful treatment of a gastrointestinal stromal tumor with liver metastases in a case that tolerated imatinib administration, by radiofrequency ablation using contrast-enhanced ultrasonography].
Topics: Adult; Antineoplastic Agents; Benzamides; Catheter Ablation; Contrast Media; Drug Tolerance; Female; Ferric Compounds; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Iron; Liver Neoplasms; Oxides; Piperazines; Pyrimidines; Ultrasonography | 2010 |
Role for the proapoptotic factor BIM in mediating imatinib-induced apoptosis in a c-KIT-dependent gastrointestinal stromal tumor cell line.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Benzamides; Blotting, Western; Butadienes; Cell Proliferation; Chromatin Immunoprecipitation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Forkhead Box Protein O3; Forkhead Transcription Factors; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunoprecipitation; Membrane Proteins; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-kit; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2010 |
Gastrointestinal stromal tumor of stomach with inguinal lymph nodes metastasis: a case report.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Inguinal Canal; Lymphatic Metastasis; Male; Middle Aged; Piperazines; Pyrimidines; Stomach Neoplasms | 2010 |
Primary thoracic cavity gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; DNA Mutational Analysis; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Reoperation; Thoracic Neoplasms; Thoracotomy; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Role of surgery combined with kinase inhibition in the management of gastrointestinal stromal tumor (GIST).
Topics: Benzamides; Clinical Trials as Topic; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Survival Rate; Treatment Outcome | 2010 |
Primary extragastrointestinal stromal tumor of the pleura: report of a unique case with genetic confirmation.
Topics: Anoctamin-1; Antineoplastic Agents; Atrial Fibrillation; Benzamides; Chloride Channels; Depression; Gastrointestinal Stromal Tumors; Humans; Hypercholesterolemia; Hypertension; Imatinib Mesylate; Immunohistochemistry; Male; Membrane Proteins; Middle Aged; Mutation; Neoplasm Proteins; Neoplasm Recurrence, Local; Piperazines; Pleural Neoplasms; Polymerase Chain Reaction; Proto-Oncogene Proteins c-kit; Pyrimidines | 2010 |
A case of imatinib-naive ileal fibrous stromal tumor with unusual morphology and double PDGFRA mutation.
Topics: Aged, 80 and over; Benzamides; DNA Mutational Analysis; Exons; Fatal Outcome; Gastrointestinal Stromal Tumors; Humans; Ileal Neoplasms; Imatinib Mesylate; Male; Mutation; Neoplasms, Fibrous Tissue; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2010 |
Prompt lightening of acral lentiginosis in a GIST patient after treatment with imatinib mesylate.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Skin Diseases | 2010 |
NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Diagnostic Imaging; DNA Mutational Analysis; Gastrointestinal Stromal Tumors; Gene Expression Profiling; Humans; Imatinib Mesylate; Indoles; Piperazines; Prognosis; Pyrimidines; Pyrroles; Sunitinib | 2010 |
A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chi-Square Distribution; Disease Progression; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Time Factors; Treatment Outcome; Young Adult | 2010 |
Imatinib response in two GIST patients carrying two hitherto functionally uncharacterized PDGFRA mutations: an imaging, biochemical and molecular modeling study.
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Male; Middle Aged; Models, Molecular; Mutation; Piperazines; Positron-Emission Tomography; Prognosis; Protein Conformation; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Tomography, X-Ray Computed | 2011 |
Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Benzamides; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Double-Blind Method; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lung Neoplasms; Male; Middle Aged; Piperazines; Placebos; Pyrimidines; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Treatment Outcome; Triazoles; Young Adult | 2010 |
[Oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor].
Topics: Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction | 2010 |
Downsizing treatment with tyrosine kinase inhibitors in patients with advanced gastrointestinal stromal tumors improved resectability.
Topics: Aged; Benzamides; Chemotherapy, Adjuvant; Disease Progression; DNA Mutational Analysis; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation, Missense; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sequence Deletion; Sunitinib; Survival Analysis; Tomography, X-Ray Computed | 2010 |
Dramatic regression and bleeding of a duodenal GIST during preoperative imatinib therapy: case report and review.
Topics: Benzamides; Duodenal Neoplasms; Female; Gastrointestinal Hemorrhage; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Neoadjuvant Therapy; Piperazines; Preoperative Care; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2010 |
Gastrointestinal stromal tumor with primary resistance to imatinib and extensive bone metastases.
Topics: Antineoplastic Agents; Benzamides; Bone Neoplasms; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2011 |
The GIST of a tumor's transformation.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines | 2010 |
Acne rosacea associated imatinib mesylate in a gastrointestinal stromal tumor patient.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzamides; Biopsy; Gastrointestinal Stromal Tumors; Histamine Antagonists; Humans; Hyperpigmentation; Imatinib Mesylate; Indoles; Intestinal Neoplasms; Keratoderma, Palmoplantar; Liver Neoplasms; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Rosacea; Skin; Skin Pigmentation; Sunitinib; Treatment Outcome | 2011 |
Current management of GISTs.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib | 2010 |
Serum midkine correlates with tumor progression and imatinib response in gastrointestinal stromal tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Case-Control Studies; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Leiomyoma; Male; Middle Aged; Midkine; Neoplasm Recurrence, Local; Neoplasm Staging; Nerve Growth Factors; Piperazines; Prognosis; Pyrimidines; Survival Rate; Tissue Array Analysis | 2011 |
Pitfalls in mutational testing and reporting of common KIT and PDGFRA mutations in gastrointestinal stromal tumors.
Topics: Benzamides; Disease-Free Survival; DNA Mutational Analysis; Exons; Gastrointestinal Stromal Tumors; Germany; Humans; Imatinib Mesylate; Mutation; Piperazines; Prognosis; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2010 |
Kitlow stem cells cause resistance to Kit/platelet-derived growth factor alpha inhibitors in murine gastrointestinal stromal tumors.
Topics: Animals; Antigens, CD34; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Cell Differentiation; Cell Proliferation; Cell Survival; Cells, Cultured; Clone Cells; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Hyaluronan Receptors; Hyperplasia; Imatinib Mesylate; Interstitial Cells of Cajal; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, Nude; Mutation; Neoplastic Stem Cells; Piperazines; Proto-Oncogene Proteins c-kit; Pyrans; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Time Factors; Tumor Burden | 2010 |
The role of neoadjuvant imatinib mesylate therapy in sphincter-preserving procedures for anorectal gastrointestinal stromal tumor.
Topics: Adult; Aged; Anal Canal; Antineoplastic Agents; Anus Neoplasms; Benzamides; Feasibility Studies; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Rectal Neoplasms; Treatment Outcome | 2011 |
[Association of CT image changes and prognosis in gastrointestinal stromal tumor after targeted therapy].
Topics: Adult; Aged; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
[Efficacy of tyrosine kinase inhibitor therapy combined with surgical resection in patients with metastatic gastrointestinal stromal tumor].
Topics: Adult; Aged; Benzamides; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Intraoperative Period; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Treatment Outcome | 2010 |
[Expression of MDR1 and KIT in imatinib-resistant gastrointestinal stromal tumor cells].
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Cell Adhesion Molecules; Cell Line, Tumor; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines | 2010 |
Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST).
Topics: Antimalarials; Autophagy; Benzamides; Cell Death; Cell Survival; Drug Resistance, Neoplasm; Drug Therapy, Combination; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines | 2010 |
[Successful resection of locally advanced gastrointestinal stromal tumor of the ampulla of Vater after treatment with imatinib].
Topics: Ampulla of Vater; Antineoplastic Agents; Benzamides; Duodenoscopy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Tomography, X-Ray Computed | 2010 |
The neo-adjuvant treatment in gastrointestinal stromal tumor.
Topics: Aged; Benzamides; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoadjuvant Therapy; Piperazines; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrimidines | 2010 |
Emergence of secondary resistance to imatinib in recurrent gastric GIST.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Stomach Neoplasms | 2010 |
Imatinib induced severe skin reactions and neutropenia in a patient with gastrointestinal stromal tumor.
Topics: Aged; Antineoplastic Agents; Benzamides; Exanthema; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neutropenia; Piperazines; Prognosis; Pyrimidines; Tomography, X-Ray Computed | 2010 |
Giant gastrointestinal stromal tumor with remarkable preoperative response to imatinib mesylate.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines | 2010 |
Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Health Care Costs; Humans; Imatinib Mesylate; Markov Chains; Models, Economic; Neoplasm Recurrence, Local; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Time Factors | 2010 |
Imatinib upregulates compensatory integrin signaling in a mouse model of gastrointestinal stromal tumor and is more effective when combined with dasatinib.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Disease Models, Animal; Down-Regulation; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Integrins; Mice; Neoplasm Proteins; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Reproducibility of Results; Signal Transduction; src-Family Kinases; Thiazoles; Up-Regulation | 2010 |
Gastrointestinal stromal tumour in a young adult.
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Stomach Neoplasms | 2010 |
Nonadherence to imatinib during an economic downturn.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Economic Recession; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Patient Compliance; Piperazines; Pyrimidines | 2010 |
Relationship between FDG uptake and the pathological risk category in gastrointestinal stromal tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; In Vitro Techniques; Male; Middle Aged; Piperazines; Positron-Emission Tomography; Pyrimidines; Radiopharmaceuticals; Retrospective Studies; Risk Factors; Tomography, X-Ray Computed | 2010 |
Unusual presentation of gastrointestinal stromal tumor with early cerebral involvement.
Topics: Benzamides; Brain Neoplasms; Disease Progression; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Tomography, X-Ray Computed | 2011 |
A novel primary KIT exon 9 single nucleotide substitution c.1427G>T (p.Ser476Ile) in a gastrointestinal stromal tumor.
Topics: Adult; Antineoplastic Agents; Base Sequence; Benzamides; Combined Modality Therapy; Digestive System Surgical Procedures; Disease Progression; Exons; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Male; Molecular Sequence Data; Peritoneal Neoplasms; Piperazines; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib | 2010 |
Pathologic complete response with neoadjuvant imatinib for locally advanced pelvic GIST.
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Piperazines; Pyrimidines; Rectal Neoplasms; Remission Induction; Treatment Outcome | 2011 |
Response to nilotinib as a first-line treatment for metastatic gastrointestinal stromal tumors.
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Peritoneal Neoplasms; Piperazines; Positron-Emission Tomography; Pyrimidines | 2012 |
ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours.
Topics: Animals; Benzamides; Binding Sites; Biomarkers, Tumor; Cell Line, Tumor; Cell Lineage; Cell Survival; Cell Transformation, Neoplastic; Disease Progression; DNA-Binding Proteins; Enhancer Elements, Genetic; Gastrointestinal Stromal Tumors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Interstitial Cells of Cajal; Mice; Mutant Proteins; Mutation; NIH 3T3 Cells; Oncogenes; Piperazines; Protein Stability; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction; Transcription Factors | 2010 |
Diplopia as a presenting symptom in a gastric gastrointestinal stromal tumor.
Topics: Aged; Benzamides; Combined Modality Therapy; Cranial Fossa, Posterior; Diplopia; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Skull Base Neoplasms | 2011 |
Therapeutic implications of autophagy-mediated cell survival in gastrointestinal stromal tumor after treatment with imatinib mesylate.
Topics: Apoptosis; Autophagy; Benzamides; Cell Survival; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Microtubule-Associated Proteins; Models, Biological; Piperazines; Pyrimidines | 2010 |
Cancer: Oncogenes in context.
Topics: Animals; Benzamides; Cell Survival; Cell Transformation, Neoplastic; DNA-Binding Proteins; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Mutation; Oncogenes; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Transcription Factors | 2010 |
Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Biological Availability; Compassionate Use Trials; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gastrectomy; Gastrointestinal Stromal Tumors; Half-Life; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neoplasm Staging; Piperazines; Protease Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib; Survival Analysis | 2011 |
Surgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesylate treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease Progression; Exons; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome | 2010 |
The effect of neoadjuvant Imatinib therapy on outcome and survival after rectal gastrointestinal stromal tumour.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Piperazines; Pyrimidines; Rectal Neoplasms; Survival Rate | 2011 |
[The role of pathologists in the target therapy of gastrointestinal tumors].
Topics: Anoctamin-1; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Chloride Channels; Drug Delivery Systems; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Membrane Proteins; Neoplasm Proteins; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib; Vascular Endothelial Growth Factor A | 2010 |
Clinical practice guideline for accurate diagnosis and effective treatment of gastrointestinal stromal tumor in Korea.
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Recurrence; Republic of Korea | 2010 |
[Complete response achieved in a case of gastric gastrointestinal stromal tumor by administration of imatinib mesilate with concurrent relatively high-dose steroid therapy to control side effects].
Topics: Benzamides; Drug Eruptions; Drug Therapy, Combination; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Prednisolone; Pruritus; Pyrimidines; Treatment Outcome | 2010 |
Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Benzamides; Chi-Square Distribution; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; Exons; Female; Gastrointestinal Stromal Tumors; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Mutation; Phenotype; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Sunitinib; Time Factors; Treatment Failure | 2012 |
DW MRI for evaluation of treatment response to imatinib in a rectal gastrointestinal stromal tumour.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Piperazines; Positron-Emission Tomography; Pyrimidines; Rectal Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Synergistic induction of apoptosis by the Bcl-2 inhibitor ABT-737 and imatinib mesylate in gastrointestinal stromal tumor cells.
Topics: Apoptosis; Benzamides; Biphenyl Compounds; Cell Line, Tumor; Drug Synergism; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; In Situ Nick-End Labeling; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Sulfonamides | 2011 |
Gastrointestinal Stromal Tumors (GIST) special issue. Preface.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines | 2011 |
Cyclooxygenase-2 expression in gastrointestinal stromal tumours.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chi-Square Distribution; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Progression; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Indoles; Male; Middle Aged; Mitosis; Neoplasm Metastasis; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Tumor Burden | 2010 |
Protein expression of cancer testis antigens predicts tumor recurrence and treatment response to imatinib in gastrointestinal stromal tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Piperazines; Pyrimidines; Recurrence; Testis | 2011 |
Small gastrointestinal stromal tumor of the stomach showing rapid growth and early metastasis to the liver.
Topics: Aged; Antineoplastic Agents; Benzamides; Endoscopy, Gastrointestinal; Fatal Outcome; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Piperazines; Pyrimidines; Stomach Neoplasms | 2010 |
An unusual and potentially misleading phenotypic change in a primary gastrointestinal stromal tumour (GIST) under imatinib mesylate therapy.
Topics: Antigens, CD34; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Combined Modality Therapy; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Phenotype; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Tomography, X-Ray Computed | 2011 |
Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Enzyme Inhibitors; Everolimus; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Mice; Mice, Knockout; Piperazines; Positron-Emission Tomography; Proto-Oncogene Proteins c-kit; Pyrimidines; Radiopharmaceuticals; Receptor, Platelet-Derived Growth Factor alpha; Sirolimus; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2010 |
Gastrointestinal stromal tumors treated with imatinib mesylate: apparent diffusion coefficient in the evaluation of therapy response in patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Diffusion Magnetic Resonance Imaging; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Linear Models; Male; Middle Aged; Piperazines; Prospective Studies; Pyrimidines; Treatment Outcome | 2011 |
[Usefulness of low-dose and long-term administration of imatinib in patients with liver metastases of rectal GIST and GIST of stomach].
Topics: Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Piperazines; Pyrimidines; Rectal Neoplasms; Stomach Neoplasms | 2010 |
[More than 20 years of long-term survival case of intraabdominal GIST by combined therapies with frequent surgeries].
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Piperazines; Pyrimidines; Reoperation | 2010 |
[Curative resection for bulky rectal gastrointestinal stromal tumor after neoadjuvant imatinib mesylate].
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Piperazines; Pyrimidines; Rectal Neoplasms | 2010 |
A sporadic multiple gastrointestinal stromal tumor with unique clinical and molecular features.
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Exons; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestinal Neoplasms; Intestine, Small; Male; Middle Aged; Mutation; Neoplasms, Multiple Primary; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Treatment Outcome | 2011 |
A resectable case of gastrointestinal stromal tumor derived from the rectal wall after oral targeted molecular therapy with imatinib mesylate.
Topics: Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Molecular Targeted Therapy; Pelvic Neoplasms; Piperazines; Pyrimidines; Rectum; Treatment Outcome | 2006 |
Oral pigmentation in the hard palate associated with imatinib mesylate therapy: a report of three cases.
Topics: Aged; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Melanosis; Middle Aged; Palate, Hard; Piperazines; Pyrimidines | 2011 |
[Management of hypothyroidism secondary to tyrosine kinase inhibitors: description of treatment in three distinct clinical settings].
Topics: Adult; Benzamides; Benzenesulfonates; Carcinoma, Renal Cell; Choristoma; Female; Gastrointestinal Stromal Tumors; Humans; Hypothyroidism; Imatinib Mesylate; Indoles; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Piperazines; Pleural Diseases; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thymus Gland; Thyroxine | 2011 |
Mutational spectrum and therapy response of metastasized GIST in Central Switzerland - a population-based study.
Topics: Adult; Aged; Aged, 80 and over; Base Sequence; Benzamides; Disease Progression; DNA Mutational Analysis; DNA Primers; Exons; Female; Gastrointestinal Stromal Tumors; Genetics, Population; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Molecular Sequence Data; Mutation; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Switzerland | 2011 |
Surgical intervention for imatinib and sunitinib-resistant gastrointestinal stromal tumors.
Topics: Aged; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Male; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Radiography; Sunitinib | 2011 |
Fluorescence in situ hybridization analysis and immunophenotyping of c-Kit/PDGFRA and Bcl-2 expression in gastrointestinal stromal tumors.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Biopsy; Drug Resistance; Female; Gastrointestinal Stromal Tumors; Gene Dosage; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunophenotyping; In Situ Hybridization, Fluorescence; Male; Middle Aged; Piperazines; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2010 |
ENDOGLIN/CD105 is expressed in KIT positive cells in the gut and in gastrointestinal stromal tumours.
Topics: Animals; Antigens, CD; Antigens, CD34; Azacitidine; Benzamides; Cell Line, Tumor; Decitabine; DNA Methylation; Endoglin; Endothelium, Vascular; Gastrointestinal Stromal Tumors; Gastrointestinal Tract; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Interstitial Cells of Cajal; Mice; Mice, Transgenic; Piperazines; Platelet Endothelial Cell Adhesion Molecule-1; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Cell Surface; RNA, Messenger; Signal Transduction | 2012 |
Long-term exposure of gastrointestinal stromal tumor cells to sunitinib induces epigenetic silencing of the PTEN gene.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; PTEN Phosphohydrolase; Pyrimidines; Pyrroles; Sunitinib | 2012 |
A case of hepatic metastasis from gastric GIST successfully resected following neoadjuvant targeted therapy.
Topics: Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Female; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Jaundice, Obstructive; Liver Neoplasms; Molecular Targeted Therapy; Neoadjuvant Therapy; Piperazines; Pyrimidines; Stomach Neoplasms | 2011 |
[The giant gastrointestinal tumor of the stomach].
Topics: Abdominal Pain; Aged; Antineoplastic Agents; Benzamides; Duodenum; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Mitotic Index; Neoplasm Recurrence, Local; Patient Care Planning; Piperazines; Preoperative Care; Pyrimidines; Radiography; Risk Assessment; Stomach; Treatment Outcome | 2011 |
Gastrointestinal Stromal Tumor Masquerading as a Spontaneous Rectal Hematoma.
Topics: Aged; Antineoplastic Agents; Colonoscopy; Diagnosis, Differential; Endosonography; Gastrointestinal Stromal Tumors; Hematoma; Humans; Imatinib Mesylate; Male; Prognosis; Rectal Neoplasms; Tomography, X-Ray Computed | 2012 |
Imatinib adjuvant therapy after surgical excision of gastrointestinal stromal tumour.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Survival | 2011 |
Nonadherence to imatinib treatment in patients with gastrointestinal stromal tumors: the ADAGIO study.
Topics: Adolescent; Adult; Benzamides; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Medication Adherence; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Prospective Studies; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Survival Rate; Treatment Outcome; Young Adult | 2011 |
Neoadjuvant treatment of rectal gastrointestinal stromal tumors with imatinib.
Topics: Antineoplastic Agents; Benzamides; Biopsy; Colectomy; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Piperazines; Pyrimidines; Rectal Neoplasms; Tomography, X-Ray Computed | 2010 |
Treatment of gastrointestinal stromal tumor after imatinib and sunitinib.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib; Treatment Failure | 2011 |
Small-intestinal rhabdoid gastrointestinal stromal tumor (GIST): mutation analysis and clinical implications of a rare morphological variant.
Topics: Antineoplastic Agents; Benzamides; DNA Mutational Analysis; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines | 2011 |
Subcutaneous metastasis of a GIST tumour unresponsive to Imatinib.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Electrocoagulation; Esophageal Neoplasms; Esophagectomy; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Piperazines; Pyrimidines; Soft Tissue Neoplasms; Subcutaneous Tissue; Surgical Flaps | 2011 |
[Evidence-based treatment of gastrointestinal stromal tumor (GIST) with tyrosine kinase inhibitors-imatinib and sunitinib].
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Disease Progression; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Recurrence; Sunitinib | 2011 |
[GIST refractory to imatinib treatment].
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2011 |
[A case of imatinib-resistant GIST treated by sunitinib].
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fatal Outcome; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Male; Middle Aged; Piperazines; Pyrimidines; Pyrroles; Quality of Life; Sunitinib; Tomography, X-Ray Computed | 2011 |
[Successful resection of a gastrointestinal stromal tumor in the pelvis with imatinib mesylate as neoadjuvant therapy].
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Pelvic Neoplasms; Piperazines; Pyrimidines; Treatment Outcome | 2011 |
The GLIVEC international patient assistance programme: the Nairobi experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Child; Developing Countries; Female; Gastrointestinal Stromal Tumors; Health Services Accessibility; Humans; Imatinib Mesylate; Kenya; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Young Adult | 2009 |
Role of F-18-FDG-PET/CT in restaging of patients affected by gastrointestinal stromal tumours (GIST).
Topics: Benzamides; Feasibility Studies; Female; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Staging; Piperazines; Positron-Emission Tomography; Pyrimidines; Reproducibility of Results; Retrospective Studies; Tomography, X-Ray Computed | 2010 |
Molecular targeted therapy of gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Disease-Free Survival; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor Protein-Tyrosine Kinases | 2011 |
Biliary excretion of imatinib and its active metabolite CGP74588 during severe hepatic dysfunction.
Topics: Aged; Antineoplastic Agents; Benzamides; Bile; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Diseases; Male; Piperazines; Pyrimidines; Severity of Illness Index | 2012 |
Synchronous gastric adenocarcinoma and gastrointestinal stromal tumor (GIST) of the stomach: a case report.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoplasms, Multiple Primary; Piperazines; Pyrimidines; Stomach Neoplasms | 2011 |
Effective salvage therapy of imatinib-resistant gastrointestinal stromal tumor with combination of imatinib and pegylated liposomal doxorubicin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Doxorubicin; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Polyethylene Glycols; Proto-Oncogene Proteins c-kit; Pyrimidines; Salvage Therapy | 2011 |
Imatinib: as adjuvant therapy for gastrointestinal stromal tumor†: profile report.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2011 |
A metastatic case of gastrointestinal stromal tumor (GIST) treated with imatinib mesylate (Glivec(®)) in Mali.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines | 2011 |
Imatinib and inoperable or metastatic gastrointestinal stromal tumours. Longer follow-up confirms the overall survival benefit.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dose-Response Relationship, Drug; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Survival Rate; Time Factors | 2011 |
[KIT and KIT: from biology to clinical use].
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles | 2012 |
[Sunitinib as a second-line therapy for imatinib-resistant gastrointestinal stromal tumors].
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Pyrimidines; Pyrroles; Salvage Therapy; Sunitinib | 2011 |
[Therapeutic adherence to oral cancer therapy and interdisciplinary management].
Topics: Adenocarcinoma; Administration, Oral; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Capecitabine; Cecal Neoplasms; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Interdisciplinary Communication; Male; Medication Adherence; Neoplasms; Outpatients; Patient-Centered Care; Pharmacists; Physician's Role; Pilot Projects; Piperazines; Prospective Studies; Pyrimidines; Switzerland; Time Factors; Treatment Outcome | 2011 |
Incorporation of adjuvant therapy into the multimodality management of gastrointestinal stromal tumors of the stomach in the United States.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Disease Management; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Piperazines; Prognosis; Pyrimidines; Stomach Neoplasms; Survival Rate | 2012 |
Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - the impact of tumour rupture on patient outcomes.
Topics: Adolescent; Adult; Aged, 80 and over; Benzamides; Chemotherapy, Adjuvant; Child; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Piperazines; Practice Guidelines as Topic; Proportional Hazards Models; Pyrimidines; Registries; Retrospective Studies; Risk Assessment; Rupture, Spontaneous; Statistics, Nonparametric; Survival Analysis; Treatment Outcome; Tumor Burden; Young Adult | 2011 |
The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Benzoquinones; Cell Line, Tumor; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Indoles; Lactams, Macrocyclic; Mice; Mice, Nude; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Stem Cell Factor; Sunitinib; Xenograft Model Antitumor Assays | 2011 |
Abnormal elevated PTEN expression in the mouse antrum of a model of GIST Kit(K641E/K641E).
Topics: Animals; Benzamides; Blotting, Western; Cell Line, Tumor; Cell Nucleus; Disease Models, Animal; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Gene Knock-In Techniques; Homozygote; Humans; Imatinib Mesylate; Inositol Polyphosphate 5-Phosphatases; Mice; Mice, Transgenic; Mutation; Phosphatidylinositol 3-Kinases; Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases; Phosphoric Monoester Hydrolases; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-kit; PTEN Phosphohydrolase; Pyloric Antrum; Pyrimidines; Real-Time Polymerase Chain Reaction; Signal Transduction; Up-Regulation | 2011 |
[A case of gastric gastrointestinal stromal tumor resected after chemotherapy with imatinib].
Topics: Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Piperazines; Pyrimidines; Tomography, X-Ray Computed | 2011 |
Transanal endoscopic microsurgery after neoadjuvant therapy for rectal GIST.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Piperazines; Pyrimidines; Rectal Neoplasms | 2011 |
The heat shock protein 90 inhibitor IPI-504 induces KIT degradation, tumor shrinkage, and cell proliferation arrest in xenograft models of gastrointestinal stromal tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzoquinones; Cell Growth Processes; Cell Line, Tumor; Female; Gastrointestinal Stromal Tumors; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Indoles; Lactams, Macrocyclic; Mice; Mice, Nude; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays | 2011 |
[Treatment strategy for marginally resectable GIST].
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Practice Guidelines as Topic; Prognosis; Pyrimidines | 2011 |
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.
Topics: Animals; Benzamides; Blotting, Western; CD8-Positive T-Lymphocytes; Chromatin Immunoprecipitation; Flow Cytometry; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Mice; Mice, Inbred C57BL; Microarray Analysis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; T-Lymphocytes, Regulatory | 2011 |
Anticancer effects of imatinib via immunostimulation.
Topics: Animals; Benzamides; CD8-Positive T-Lymphocytes; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Piperazines; Pyrimidines; T-Lymphocytes, Regulatory | 2011 |
Use of total and unbound imatinib and metabolite LC-MS/MS assay to understand individual responses in CML and GIST patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chromatography, Liquid; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Tandem Mass Spectrometry; Young Adult | 2011 |
CT scan is not everything in the evaluation of a patient with gastrointestinal tumors (GIST) under imatinib therapy.
Topics: Adult; Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Histocytochemistry; Humans; Imatinib Mesylate; Male; Piperazines; Pyrimidines; Tomography, X-Ray Computed | 2012 |
Proteomic detection of a large amount of SCGFα in the stroma of GISTs after imatinib therapy.
Topics: Benzamides; Blotting, Western; Cell Line, Tumor; Electrophoresis, Polyacrylamide Gel; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Glycosylation; Hematopoietic Cell Growth Factors; Humans; Imatinib Mesylate; Immunohistochemistry; Lectins, C-Type; Piperazines; Proteomics; Pyrimidines; RNA, Messenger; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Stromal Cells | 2011 |
Advances in the surgical management of gastrointestinal stromal tumor.
Topics: Algorithms; Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Nomograms; Piperazines; Prognosis; Pyrimidines; Recurrence; Stem Cell Factor; Tomography, X-Ray Computed | 2011 |
[A case of small intestinal GIST maintained as a long stable disease by imatinib mesylate 400 mg/day, alternate-day administration for 2 weeks followed by a 2 week interval].
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestine, Small; Middle Aged; Piperazines; Pyrimidines; Tomography, X-Ray Computed | 2011 |
Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chi-Square Distribution; Child; Disease Progression; DNA Mutational Analysis; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Mitotic Index; Nomograms; Piperazines; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Risk Assessment; Risk Factors; Survival Rate; Time Factors; Tumor Burden; Young Adult | 2011 |
Bone marrow necrosis secondary to imatinib usage, mimicking spinal metastasis on magnetic resonance imaging and FDG-PET/CT.
Topics: Aged; Antineoplastic Agents; Benzamides; Bone Marrow; Bone Marrow Diseases; Diagnosis, Differential; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Multimodal Imaging; Necrosis; Piperazines; Positron-Emission Tomography; Pyrimidines; Spinal Neoplasms; Tomography, X-Ray Computed | 2012 |
Survivin expression and its potential clinical significance in gastrointestinal stromal sarcoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Inhibitor of Apoptosis Proteins; Male; Middle Aged; Mitosis; Piperazines; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Survivin; Treatment Outcome | 2011 |
Gynecomastia during imatinib mesylate treatment for gastrointestinal stromal tumor: a rare adverse event.
Topics: Adult; Aged; Benzamides; Estradiol; Estrogen Antagonists; Female; Gastrointestinal Stromal Tumors; Gynecomastia; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Tamoxifen; Testosterone | 2011 |
Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Niacinamide; Phenylurea Compounds; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Retrospective Studies; Risk Factors; Serum Albumin; Sorafenib; Sunitinib; Survival Rate; Young Adult | 2012 |
Characterization of novel germline c-kit gene mutation, KIT-Tyr553Cys, observed in a family with multiple gastrointestinal stromal tumors.
Topics: Adult; Aged; Amino Acid Substitution; Animals; Benzamides; Cell Line; Cell Proliferation; DNA Mutational Analysis; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Genetic Predisposition to Disease; Germ-Line Mutation; Humans; Imatinib Mesylate; Male; Mice; Pedigree; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor Protein-Tyrosine Kinases | 2012 |
[Clinical analysis of 79 gastrointestinal tract stromal tumor cases].
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines | 2011 |
Gastrointestinal stromal tumors of the stomach.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Gastroscopy; Humans; Imatinib Mesylate; Indoles; Laparoscopy; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Radiotherapy, Adjuvant; Stomach Neoplasms; Sunitinib | 2012 |
Renal dysfunction in a renal transplant patient treated concurrently with cyclosporine and imatinib.
Topics: Aged; Antineoplastic Agents; Benzamides; Cyclosporine; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunosuppressive Agents; Kidney Diseases; Kidney Transplantation; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2012 |
Resection of focally progressive gastrointestinal stromal tumours resistant to imatinib therapy.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Digestive System Surgical Procedures; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; Treatment Outcome | 2012 |
Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Exons; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Retrospective Studies; Survival Rate; Young Adult | 2012 |
[Three cases of giant rectal gastrointestinal stromal tumor].
Topics: Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Rectal Neoplasms; Tomography, X-Ray Computed | 2011 |
[A case of ruptured gastrointestinal stromal tumor of the duodenum with intraabdominal bleeding].
Topics: Antineoplastic Agents; Benzamides; Duodenal Neoplasms; Gastrointestinal Stromal Tumors; Hemorrhage; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Tomography, X-Ray Computed | 2011 |
[Twenty-one-year survival case of rectal GIST treated with combined therapies].
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Pyrimidines; Pyrroles; Rectal Neoplasms; Recurrence; Sunitinib; Time Factors | 2011 |
[Curative resection for bulky gastrointestinal stromal tumor with conversion therapy by imatinib].
Topics: Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines | 2011 |
[A case report of GIST of the small intestine with multiple liver abscesses].
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Drainage; Female; Gastrointestinal Stromal Tumors; Humans; Ileal Neoplasms; Imatinib Mesylate; Liver Abscess; Middle Aged; Piperazines; Pyrimidines; Tomography, X-Ray Computed | 2011 |
[A case of gastrointestinal stromal tumor (GIST) successfully treated with resection after a long-term control medication by molecular targeted drugs].
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Intestinal Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Piperazines; Pyrimidines; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2011 |
[Hepatic metastasis from gastric GIST radically resected after imatinib mesylate therapy-a case report].
Topics: Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Neoadjuvant Therapy; Piperazines; Pyrimidines; Stomach Neoplasms; Tomography, X-Ray Computed | 2011 |
The combination of surgery and imatinib in GIST: a reality for localized tumors at high risk, an open issue for metastatic ones.
Topics: Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2012 |
Pediatric gastrointestinal stromal tumor.
Topics: Adolescent; Adult; Benzamides; Child; Combined Modality Therapy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Young Adult | 2012 |
[Imatinib in the GIST therapy: ten years later].
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Time Factors | 2011 |
KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors.
Topics: 3T3 Cells; Aged; Animals; Benzamides; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Genes, ras; HEK293 Cells; Humans; Imatinib Mesylate; Male; MAP Kinase Signaling System; Mice; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrimidines | 2012 |
Neoadjuvant and adjuvant therapy with imatinib for locally advanced gastrointestinal stromal tumors in eastern Indian patients.
Topics: Adult; Aged; Asian People; Benzamides; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Piperazines; Prospective Studies; Pyrimidines; Treatment Outcome | 2011 |
Laparoscopic resection of a gastrointestinal stromal tumor of the rectum after treatment with imatinib mesylate: report of a case.
Topics: Antineoplastic Agents; Benzamides; Biopsy, Fine-Needle; Colectomy; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Laparoscopy; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Piperazines; Preoperative Care; Pyrimidines; Rectal Neoplasms; Risk Assessment; Treatment Outcome | 2012 |
Right axillosubclavian vein thrombosis resolved by percutaneous rheolytic thrombectomy in a patient with a recurrent gastrointestinal stromal tumour undergoing imatinib mesylate treatment.
Topics: Angiography; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Phlebography; Piperazines; Pyrimidines; Subclavian Vein; Thrombectomy; Thrombolytic Therapy; Venous Thrombosis; Warfarin | 2012 |
[A case of bleeding giant gastrointestinal stromal tumor of the stomach who achieved partial response by chemotherapy].
Topics: Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Gastrectomy; Gastrointestinal Stromal Tumors; Hemorrhage; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Splenectomy; Stomach Neoplasms; Tomography, X-Ray Computed | 2012 |
Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bayes Theorem; Benzamides; Drug Monitoring; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Linear Models; Male; Middle Aged; Models, Biological; Nonlinear Dynamics; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reproducibility of Results; Young Adult | 2012 |
A multi-centre analysis of the impact of updated risk stratification on follow-up of gastric gastro-intestinal stromal tumours in the post-imatinib era.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Prospective Studies; Pyrimidines; Risk Assessment; Risk Factors; Stomach Neoplasms; Watchful Waiting | 2012 |
FDA updates Gleevec label for GIST patients.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Disease-Free Survival; Drug Administration Schedule; Drug Labeling; Europe; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Neoplasm Recurrence, Local; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Time Factors; Treatment Outcome; United States; United States Food and Drug Administration | 2012 |
Gastrointestinal stromal tumors: case series of 29 patients defining the role of imatinib prior to surgery.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Piperazines; Pyrimidines | 2012 |
Updates on the management of gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pedigree; Piperazines; Pyrimidines; Radiotherapy, Adjuvant; Receptor, Platelet-Derived Growth Factor alpha; Risk Assessment | 2012 |
Intracranial metastasis from pediatric GI stromal tumor.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Brain Neoplasms; Drug Administration Schedule; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Piperazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Stomach Neoplasms; Sunitinib; Treatment Outcome | 2012 |
Gastrointestinal stromal tumor arising in the rectovaginal septum.
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Histocytochemistry; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Piperazines; Pyrimidines; Radiography, Abdominal; Rectal Neoplasms; Vaginal Neoplasms | 2012 |
Neoadjuvant use of sunitinib in locally advanced GIST with intolerance to imatinib.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neoadjuvant Therapy; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2012 |
Survival of gastrointestinal stromal tumor patients in the imatinib era: life raft group observational registry.
Topics: Adolescent; Adult; Age Factors; Age of Onset; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Child; Child, Preschool; DNA Mutational Analysis; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Prognosis; Proportional Hazards Models; Pyrimidines; Retrospective Studies; Sex Factors; Survival Analysis; Young Adult | 2012 |
Aggressive gastrointestinal stromal tumour of the oesophagus with homozygous KIT exon 11 deletion mutation.
Topics: Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Combined Modality Therapy; Esophageal Neoplasms; Exons; Female; Gastrointestinal Stromal Tumors; Gene Deletion; Homozygote; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines | 2012 |
The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Multivariate Analysis; Piperazines; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Young Adult | 2012 |
Gastrointestinal stromal tumors (GIST): a single center experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Disease Progression; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Length of Stay; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies | 2012 |
Serum creatine kinase increase in patients treated with tyrosine kinase inhibitors for solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Creatine Kinase; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasms; Piperazines; Prospective Studies; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2012 |
Optimal duration of adjuvant therapy for patients with resected gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Piperazines; Pyrimidines | 2012 |
[Treatment of recurrent or metastatic gastrointestinal stromal tumor: surgery or not].
Topics: Benzamides; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines | 2012 |
[Clinical analysis of imatinib in patients with advanced gastrointestinal stromal tumor].
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Exons; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Retrospective Studies; Treatment Outcome; Young Adult | 2012 |
[Prognosis analysis of 216 cases of gastrointestinal stromal tumor].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Retrospective Studies; Survival Rate; Young Adult | 2012 |
[Therapeutic effect of in vitro 5-aza-2'-deoxycytidine combined with imatinib on gastrointestinal stromal tumor].
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Decitabine; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines | 2012 |
Gastrointestinal stromal tumors treatment in the Imatinib era. The role of fair indication.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies | 2012 |
Retinal neovascularization and hemorrhage associated with the use of imatinib (Gleevec(®)) in a patient being treated for gastrointestinal stromal tumor (GIST).
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Retinal Hemorrhage; Retinal Neovascularization | 2012 |
Effectiveness of adjuvant imatinib in patients with gastrointestinal stromal tumor: results of a population-based, matched-cohort study.
Topics: Aged; Benzamides; Chemotherapy, Adjuvant; Cohort Studies; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Medication Adherence; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; Treatment Outcome | 2012 |
Involvement of signaling molecules in the prediction of response to imatinib treatment in metastatic GIST patients.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Phosphatidylethanolamine Binding Protein; Piperazines; Predictive Value of Tests; Protein Kinase C; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor Cross-Talk; Receptor, IGF Type 1; Receptor, Platelet-Derived Growth Factor alpha; Retrospective Studies; Signal Transduction | 2012 |
Prospective observational study of imatinib therapy in Japanese patients with advanced gastrointestinal stromal tumors: long-term follow-up and second malignancy.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Drug Administration Schedule; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms, Second Primary; Piperazines; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Time Factors; Treatment Outcome | 2012 |
Esophageal gastrointestinal stromal tumor: report of 7 patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Electronic Health Records; Esophageal Neoplasms; Esophagectomy; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Incidental Findings; Male; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Neoplasms, Second Primary; Piperazines; Positron-Emission Tomography; Pyrimidines; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
FDA grants imatinib (Gleevec) full approval for adjuvant treatment of GIST.
Topics: Antineoplastic Agents; Benzamides; Drug Approval; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; United States; United States Food and Drug Administration | 2012 |
[A case of long survival after resection and treatment with imatinib mesylate against metachronous liver metastases and a lung metastasis of a small intestine gastrointestinal stromal tumor].
Topics: Aged; Antineoplastic Agents; Benzamides; Fatal Outcome; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestinal Neoplasms; Intestine, Small; Liver Neoplasms; Lung Neoplasms; Male; Piperazines; Pyrimidines; Time Factors; Tomography, X-Ray Computed | 2012 |
Chronic therapy in gastrointestinal stromal tumours (GISTs): the big gap between theory and practice.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Gastrointestinal Stromal Tumors; Home Care Services; Humans; Imatinib Mesylate; Medication Adherence; Monitoring, Physiologic; Piperazines; Practice Guidelines as Topic; Precision Medicine; Pyrimidines; Recurrence; Treatment Outcome | 2012 |
Intervention in gastrointestinal stromal tumour with a high risk of malignancy and associated with thalassaemia minor.
Topics: Aged; Antineoplastic Agents; Benzamides; beta-Thalassemia; Chemotherapy, Adjuvant; Diagnosis, Differential; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Treatment Outcome; Vitamin B 12; Vitamin B 12 Deficiency | 2012 |
[Pregnancy and extra-gastrointestinal stromal tumor: an exceptional association].
Topics: Abdominal Neoplasms; Adult; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Neoplasms, Connective Tissue; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Pyrimidines | 2012 |
[A new genetic diagnosis of familiar gastrointestinal stromal tumour].
Topics: Aged; Antineoplastic Agents; Benzamides; Family; Fatal Outcome; Female; Gastrointestinal Stromal Tumors; Genetic Predisposition to Disease; Germ-Line Mutation; Humans; Imatinib Mesylate; Intestinal Neoplasms; Male; Middle Aged; Mutation, Missense; Pigmentation Disorders; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines | 2012 |
Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or -intolerant gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Asian People; Benzamides; China; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib; Survival Analysis; Treatment Outcome | 2012 |
Imatinib resistance and microcytic erythrocytosis in a KitV558Δ;T669I/+ gatekeeper-mutant mouse model of gastrointestinal stromal tumor.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Lineage; Dasatinib; Disease Models, Animal; Drug Resistance; Drug Resistance, Neoplasm; Erythrocytes; Exons; Gastrointestinal Stromal Tumors; Imatinib Mesylate; Mice; Mutation; Phenotype; Piperazines; Polycythemia; Proto-Oncogene Proteins c-kit; Pyrimidines; Thiazoles | 2012 |
Evaluation of malignancy using Ki-67, p53, EGFR and COX-2 expressions in gastrointestinal stromal tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Cyclooxygenase 2; ErbB Receptors; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Ki-67 Antigen; Male; Middle Aged; Mitotic Index; Neoplasm Grading; Piperazines; Prognosis; Proportional Hazards Models; Pyrimidines; Tumor Suppressor Protein p53 | 2012 |
'Big'-insulin-like growth factor-II signaling is an autocrine survival pathway in gastrointestinal stromal tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Autocrine Communication; Benzamides; Cell Death; Cell Survival; Down-Regulation; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Insulin-Like Growth Factor II; Male; Middle Aged; Neoplasm Proteins; Piperazines; Protein Precursors; Pyrimidines; Receptor, IGF Type 1; Receptor, Insulin; Tumor Cells, Cultured; Young Adult | 2012 |
p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; DNA-Binding Proteins; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Heterogeneous-Nuclear Ribonucleoprotein K; Humans; Imatinib Mesylate; Imidazoles; Mutation; Nuclear Proteins; Phosphorylation; Piperazines; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins c-mdm2; Pyrimidines; Sequence Analysis, DNA; Signal Transduction; Transcription Factors; Transcription, Genetic; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2012 |
Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors.
Topics: Benzamides; Benzenesulfonates; Cell Line, Tumor; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Mutation; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Sorafenib | 2012 |
Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Disease Progression; Feasibility Studies; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Young Adult | 2012 |
[Long-term progression-free survival after reduction surgery and postoperative low-dose imatinib administration for multiple liver metastases of duodenal gastrointestinal stromal tumor].
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Disease-Free Survival; Duodenal Neoplasms; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Magnetic Resonance Imaging; Middle Aged; Piperazines; Pyrimidines; Tomography, X-Ray Computed | 2012 |
Resected duodenal gastrointestinal stromal tumour with an affected margin and exon 9 mutation: adjuvant therapy.
Topics: Adult; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; DNA Mutational Analysis; Dose-Response Relationship, Drug; Duodenal Neoplasms; Exons; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Multimodal Imaging; Mutation; Piperazines; Positron-Emission Tomography; Proto-Oncogene Proteins c-kit; Pyrimidines; Tomography, X-Ray Computed | 2012 |
The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Isoindoles; Mice; Mice, SCID; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Exons; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neoplasm Staging; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome; Young Adult | 2012 |
Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Risk Factors; Young Adult | 2012 |
A hemodialysis patient with primary extra-gastrointestinal stromal tumor: favorable outcome with imatinib mesylate.
Topics: Aged; Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Ki-67 Antigen; Male; Peritoneal Neoplasms; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Renal Dialysis | 2012 |
Tumor rupture exposes the patient to an increased risk of relapse, regardless of the size and number of mitoses.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intraoperative Complications; Mitotic Index; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Risk; Rupture, Spontaneous | 2012 |
Haemoperitoneum as an indicator of GIST.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hemoperitoneum; Humans; Imatinib Mesylate; Middle Aged; Piperazines; Pyrimidines; Rupture, Spontaneous; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Congestive heart failure in a 77-year-old woman receiving adjuvant treatment with imatinib for a large gastric gastrointestinal stromal tumour.
Topics: Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Heart Failure; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Rupture; Treatment Outcome | 2012 |
Patient with high-risk GIST not associated with c-KIT mutations: same benefit from adjuvant therapy?
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neurofibromatosis 1; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Risk; Tomography, X-Ray Computed | 2012 |
Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.
Topics: Animals; Antineoplastic Agents; Benzamides; Benzimidazoles; Cell Line, Tumor; CHO Cells; Cricetinae; Drug Resistance, Neoplasm; Enzyme Activation; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Mutation; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2012 |
Personalized therapy: prognostic factors in gastrointestinal stromal tumor (GIST).
Topics: Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Precision Medicine; Prognosis; Protein Kinase Inhibitors; Pyrimidines | 2012 |
Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease-Free Survival; Dose-Response Relationship, Drug; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Markov Chains; Models, Econometric; Piperazines; Pyrimidines; Quality-Adjusted Life Years; Time Factors; United States | 2013 |
A rare case of gastrointestinal stromal tumor presenting with closed perforation of the small intestine.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestinal Perforation; Intestine, Small; Male; Middle Aged; Piperazines; Pyrimidines; Tomography, X-Ray Computed | 2012 |
[Establishment and pathologic analysis of imatinib-resistant gastrointestinal stromal tumor xenografts].
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Differentiation; Cell Line, Tumor; Desmin; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Myogenin; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Rhabdomyosarcoma; Xenograft Model Antitumor Assays | 2012 |
Length of adjuvant imatinib therapy in GIST: weighing benefits, side effects and costs.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Costs; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Medication Adherence; Piperazines; Pyrimidines; Randomized Controlled Trials as Topic; Time Factors | 2012 |
Surgical management of rectal gastrointestinal stromal tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Digestive System Surgical Procedures; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Netherlands; Piperazines; Pyrimidines; Rectal Neoplasms; Retrospective Studies; Treatment Outcome | 2013 |
Treatment response monitoring in patients with gastrointestinal stromal tumor using diffusion-weighted imaging: preliminary results in comparison with positron emission tomography/computed tomography.
Topics: Antineoplastic Agents; Benzamides; Diffusion Magnetic Resonance Imaging; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Multimodal Imaging; Pilot Projects; Piperazines; Positron-Emission Tomography; Prognosis; Pyrimidines; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
C-KIT mutations were closely associated with the response to Imatinib in Chinese advanced gastrointestinal stromal tumor patients.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Benzamides; Biomarkers, Tumor; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Piperazines; Proportional Hazards Models; Proto-Oncogene Proteins c-kit; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction | 2012 |
Role of operative therapy in treatment of metastatic gastrointestinal stromal tumors.
Topics: Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Minnesota; Neoplasm Metastasis; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib | 2012 |
Clinical, pathological and surgical characteristics of duodenal gastrointestinal stromal tumor and their influence on survival: a multi-center study.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Disease-Free Survival; Duodenal Neoplasms; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Middle Aged; Mitotic Index; Pancreaticoduodenectomy; Piperazines; Proportional Hazards Models; Pyrimidines; Retrospective Studies | 2012 |
Choices of surgical approaches for gastrointestinal stromal tumors of the stomach: laparoscopic versus open resection.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Blood Loss, Surgical; Blood Volume; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Laparoscopy; Length of Stay; Male; Middle Aged; Operative Time; Piperazines; Pyrimidines; Stomach Neoplasms; Young Adult | 2012 |
Patterns of extension of gastrointestinal stromal tumors (GIST) treated with imatinib (Gleevec®) by 18F-FDG PET/CT.
Topics: Aged; Antineoplastic Agents; Benzamides; Drug Monitoring; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Piperazines; Positron-Emission Tomography; Pyrimidines; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Piperazines; Prospective Studies; Pyrimidines | 2012 |
Tyrosine-kinase mutations in c-KIT and PDGFR-alpha genes of imatinib naïve adult patients with gastrointestinal stromal tumours (GISTs) of the stomach and small intestine: relation to tumour-biological risk-profile and long-term outcome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; DNA Mutational Analysis; Exons; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestinal Neoplasms; Intestine, Small; Male; Middle Aged; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Risk Assessment; Stomach Neoplasms | 2012 |
Therapeutic drug monitoring of imatinib--new data strengthen the case.
Topics: Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Piperazines; Pyrimidines | 2012 |
Genomic Grade Index predicts postoperative clinical outcome of GIST.
Topics: Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Gene Expression Profiling; Humans; Imatinib Mesylate; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Piperazines; Prognosis; Pyrimidines; Treatment Outcome | 2012 |
[Secondary mutation of c-kit/PDGFRα genotypes after imatinib mesylate therapy and its relationship with efficacy of sunitinib].
Topics: Antineoplastic Agents; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Exons; Female; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2012 |
Molecular alterations and expression of succinate dehydrogenase complex in wild-type KIT/PDGFRA/BRAF gastrointestinal stromal tumors.
Topics: Adult; Aged; Aged, 80 and over; Anoctamin-1; Base Sequence; Benzamides; Chloride Channels; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Mutation; Neoplasm Proteins; Paraganglioma; Piperazines; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Sequence Analysis, DNA; Succinate Dehydrogenase | 2013 |
The lack of CD34 expression in gastrointestinal stromal tumors is related to cystic degeneration following imatinib use.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gastrointestinal Tract; Genotype; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Piperazines; Proportional Hazards Models; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Tomography, X-Ray Computed; Treatment Outcome; Vascular Endothelial Growth Factor A; Young Adult | 2012 |
Imatinib mesylate (Gleevec) induced unilateral optic disc edema.
Topics: Aged; Antineoplastic Agents; Benzamides; Diagnosis, Differential; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Optic Disk; Papilledema; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2012 |
Gastrointestinal stromal tumor of the rectum: results of surgical and multimodality therapy in the era of imatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Prognosis; Prospective Studies; Pyrimidines; Rectal Neoplasms; Survival Rate | 2013 |
Adjuvant therapy for high-risk gastrointestinal stromal tumour: considerations for optimal management.
Topics: Animals; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Disease Management; Disease-Free Survival; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic | 2012 |
[Responses to treatment and switching tyrosine kinase inhibitors in gastrointestinal stromal tumor(GIST)].
Topics: Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib; Treatment Outcome | 2012 |
Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Disease Management; DNA Mutational Analysis; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Staging; Piperazines; Prognosis; Pyrimidines; Risk Assessment; Treatment Outcome | 2012 |
Extra-gastrointestinal stromal tumor of the pelvic cavity: case report.
Topics: Antigens, CD34; Antineoplastic Agents; Benzamides; Exons; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Mutation; Pelvis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Vimentin | 2012 |
Inactivation of Patched1 in mice leads to development of gastrointestinal stromal-like tumors that express Pdgfrα but not kit.
Topics: Animals; Benzamides; Cell Transformation, Neoplastic; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression; Genotype; Hedgehog Proteins; Humans; Imatinib Mesylate; Integrases; Intestinal Mucosa; Kruppel-Like Transcription Factors; Leiomyosarcoma; Mice; Muramidase; Nerve Tissue Proteins; Patched Receptors; Patched-1 Receptor; Piperazines; Promoter Regions, Genetic; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptors, Cell Surface; Signal Transduction; Zinc Finger Protein GLI1; Zinc Finger Protein Gli2; Zinc Finger Protein Gli3 | 2013 |
Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Drug Administration Schedule; Female; Gastrectomy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Netherlands; Piperazines; Pyrimidines; Retrospective Studies; Time Factors; Treatment Outcome | 2013 |
Pancreatic extra-gastrointestinal stromal tumour masquerading as a bleeding duodenal mass.
Topics: Antigens, CD34; Antineoplastic Agents; Benzamides; Diagnosis, Differential; Duodenal Neoplasms; Duodenum; Gastrointestinal Hemorrhage; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mitosis; Pancreas; Pancreatic Neoplasms; Pancreaticoduodenectomy; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines | 2012 |
Collision tumour involving a rectal gastrointestinal stromal tumour with invasion of the prostate and a prostatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Biopsy; Chemotherapy, Adjuvant; Diagnosis, Differential; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasms, Multiple Primary; Piperazines; Predictive Value of Tests; Prostate; Prostatectomy; Prostatic Neoplasms; Pyrimidines; Rectal Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease Progression; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Male; Middle Aged; Organic Cation Transport Proteins; Piperazines; Polymorphism, Genetic; Protein Kinase Inhibitors; Pyrimidines; Solute Carrier Family 22 Member 5; Symporters; Young Adult | 2013 |
Tumor volume as an alternative response measurement for imatinib treated GIST patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Automation; Benzamides; Cohort Studies; Disease Progression; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imaging, Three-Dimensional; Imatinib Mesylate; Male; Medical Oncology; Middle Aged; Neoplasm Metastasis; Observer Variation; Piperazines; Pyrimidines; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chemotherapy, Adjuvant; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Salvage Therapy; Sorafenib; Sunitinib; Treatment Outcome; Young Adult | 2013 |
[A case of recurrent gastrointestinal stromal tumor with complete response from treatment with reduced dose of imatinib mesylate].
Topics: Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Recurrence; Remission Induction; Stomach Neoplasms; Tomography, X-Ray Computed | 2012 |
Evaluation of regorafenib in colorectal cancer and GIST.
Topics: Antineoplastic Agents; Benzamides; Colorectal Neoplasms; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sunitinib | 2013 |
Autophagy is involved in endogenous and NVP-AUY922-induced KIT degradation in gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Autophagy; Benzamides; Benzoquinones; Cell Death; Cell Extracts; Cell Line, Tumor; Down-Regulation; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Isoxazoles; Lactams, Macrocyclic; Models, Biological; Phosphorylation; Piperazines; Proteolysis; Proto-Oncogene Proteins c-kit; Pyrimidines; Resorcinols | 2013 |
Prognostic factors in surgically managed gastrointestinal stromal tumours.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Piperazines; Prognosis; Pyrimidines; Retrospective Studies; Young Adult | 2012 |
Neoadjuvant imatinib for borderline resectable GIST.
Topics: Adult; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Radiography; Treatment Outcome | 2012 |
Pregnancy with metastatic gastrointestinal stromal tumor (GIST) on imatinib chemotherapy: an oncologist's nightmare and obstetrician's dilemma.
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Physician's Role; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Pyrimidines; Remission Induction; Treatment Outcome | 2013 |
Clinicopathological study of 113 gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Retrospective Studies | 2013 |
Comparison of the long-term risk of recurrence and other clinical outcomes in GIST patients receiving imatinib as adjuvant therapy--a retrospective chart extract-based approach.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Practice Patterns, Physicians'; Pyrimidines; Retrospective Studies; Risk Factors; Time; Treatment Outcome | 2013 |
A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Indazoles; Mice; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction; Sulfonamides; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Modern treatment of gastric gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Endoscopy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Minimally Invasive Surgical Procedures; Neoadjuvant Therapy; Piperazines; Prognosis; Pyrimidines; Recurrence; Sarcoma; Stomach Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Treatment of advanced gastrointestinal stromal tumors in patients over 75 years old: clinical and pharmacological implications.
Topics: Age Factors; Aged; Aged, 80 and over; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Piperazines; Pyrimidines; Retrospective Studies; Treatment Outcome | 2013 |
Establishment and characterization of a novel xenograft model of human gastrointestinal stromal tumor in mice.
Topics: Aged; Animals; Benzamides; Disease Models, Animal; Esophageal Neoplasms; Exons; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Indoles; Male; Mice; Molecular Targeted Therapy; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib; Transplantation, Heterologous | 2013 |
[Two cases of surgical resection of rectal gastrointestinal stromal tumor after neoadjuvant therapy with imatinib mesylate].
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Piperazines; Pyrimidines; Rectal Neoplasms | 2012 |
[A case of recurrent intestinal GIST with long-term survival-beneficial effect of multimodality therapy using high-dose imatinib and surgery].
Topics: Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Jejunal Neoplasms; Piperazines; Pyrimidines; Recurrence; Time Factors | 2012 |
[A case of extragastric pedunculated gastrointestinal stromal tumor of the stomach with peritoneal dissemination].
Topics: Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Peritoneal Neoplasms; Piperazines; Pyrimidines; Stomach Neoplasms | 2012 |
[A case of drug resistant recurrent gastrointestinal stromal tumor treated surgically by resection, partial hepatectomy and diaphragmectomy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Diaphragm; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Indoles; Jejunal Neoplasms; Liver Neoplasms; Male; Peritoneal Neoplasms; Piperazines; Pyrimidines; Pyrroles; Recurrence; Sunitinib | 2012 |
Molecular characterization of an Italian series of sporadic GISTs.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Piperazines; Polymerase Chain Reaction; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins p21(ras); Pyrimidines; ras Proteins; Receptor, Platelet-Derived Growth Factor alpha; Retrospective Studies | 2013 |
[A case of multiple metastatic giant rectal GIST successfully treated with surgical intervention after administration of imatinib mesylate].
Topics: Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoplasm Metastasis; Piperazines; Pyrimidines; Rectal Neoplasms | 2013 |
Is exon mutation analysis needed for adjuvant treatment of gastrointestinal stromal tumor?
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Clinical Trials as Topic; DNA Mutational Analysis; Exons; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome | 2013 |
ESMO: regorafenib improved PFS for GIST in post-imatinib/sunitinib setting.
Topics: Antineoplastic Agents; Benzamides; Disease-Free Survival; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sunitinib | 2012 |
The SSG XVIII/AIO trial: results change the current adjuvant treatment recommendations for gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Practice Guidelines as Topic; Pyrimidines; Randomized Controlled Trials as Topic | 2013 |
Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; DNA Mutational Analysis; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2013 |
Dedifferentiation in gastrointestinal stromal tumor to an anaplastic KIT-negative phenotype: a diagnostic pitfall: morphologic and molecular characterization of 8 cases occurring either de novo or after imatinib therapy.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Cell Dedifferentiation; DNA Mutational Analysis; Female; Gastrointestinal Stromal Tumors; Gene Dosage; Genes, p53; Humans; Imatinib Mesylate; Immunohistochemistry; In Situ Hybridization, Fluorescence; Male; Middle Aged; Mutation; Phenotype; Piperazines; Polymerase Chain Reaction; Proto-Oncogene Proteins c-kit; Pyrimidines; Young Adult | 2013 |
Extended adjuvant therapy with imatinib in patients with gastrointestinal stromal tumors : recommendations for patient selection, risk assessment, and molecular response monitoring.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Patient Selection; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Risk Assessment; Risk Factors | 2013 |
A 32-month follow-up study of nanovesicle concentrations in blood from 12 patients with gastrointestinal stromal tumour treated with imatinib.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Microscopy, Electron, Scanning; Piperazines; Pyrimidines | 2013 |
Local excision with adjuvant imatinib therapy for anorectal gastrointestinal stromal tumors.
Topics: Aged; Anus Neoplasms; Benzamides; Chemotherapy, Adjuvant; Colectomy; Combined Modality Therapy; Endosonography; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Piperazines; Positron-Emission Tomography; Pyrimidines; Rectal Neoplasms; Risk Assessment; Sampling Studies; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
ZNF-mediated resistance to imatinib mesylate in gastrointestinal stromal tumor.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Benzamides; Cell Adhesion Molecules; Cell Line, Tumor; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Library; Genetic Loci; Humans; Imatinib Mesylate; Indoles; Phosphoproteins; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; RNA, Small Interfering; Sunitinib; Transforming Growth Factor beta3; Zinc Fingers | 2013 |
When a thymic carcinoma "becomes" a GIST.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib; Thymoma; Thymus Neoplasms; Treatment Failure; Treatment Outcome | 2013 |
Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth.
Topics: Animals; Antibodies, Monoclonal; Benzamides; Cell Line, Tumor; Cell Membrane; Cell Proliferation; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Macrophages; Mice; Mice, Inbred C57BL; Mice, Transgenic; Phagocytosis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Xenograft Model Antitumor Assays | 2013 |
Monitoring of plasma imatinib concentration for the effective treatment of CML patients.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Body Height; Body Weight; Dose-Response Relationship, Drug; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome | 2004 |
Biliary excretion of imatinib mesylate and its metabolite CGP 74588 in humans.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Benzamides; Bile; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Stents | 2004 |
Cerebral relapse of metastatic gastrointestinal stromal tumor during treatment with imatinib mesylate: case report.
Topics: Antineoplastic Agents; Benzamides; Brain Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines | 2004 |
A phenomenal response to treatment by an advanced tumour.
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Stomach Neoplasms | 2004 |
Gastrointestinal stromal tumors arising from the stomach: a report of three children.
Topics: Abdominal Pain; Anemia; Benzamides; Chemotherapy, Adjuvant; Child; Child, Preschool; Female; Follow-Up Studies; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Laparotomy; Liver Neoplasms; Male; Piperazines; Pyrimidines; Radiography; Stomach Neoplasms | 2004 |
KIT gene deletions at the intron 10-exon 11 boundary in GI stromal tumors.
Topics: Amino Acid Sequence; Base Sequence; Benzamides; Binding Sites; Chromatography, High Pressure Liquid; DNA; DNA, Complementary; Exons; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Deletion; Homozygote; Humans; Imatinib Mesylate; Introns; Molecular Sequence Data; Mutation; Piperazines; Polymerase Chain Reaction; Prognosis; Protein Isoforms; Proto-Oncogene Proteins c-kit; Pyrimidines; Sequence Analysis, DNA; Treatment Outcome | 2004 |
Combination treatment of rituximab and imatinib mesylate for simultaneous relapse of MALT lymphoma and a gastrointestinal stromal tumor.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Disease Progression; Doxorubicin; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lymphoma; Lymphoma, B-Cell, Marginal Zone; Middle Aged; Piperazines; Prednisolone; Pyrimidines; Recurrence; Rituximab; Vincristine | 2004 |
Imatinib and gastrointestinal stromal tumor (GIST): a selective targeted therapy.
Topics: Adult; Aged; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Tomography, X-Ray Computed; Treatment Outcome | 2004 |
Prevalence of KIT expression in human tumors.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Gene Expression Profiling; Humans; Imatinib Mesylate; Immunohistochemistry; Neoplasms; Oligonucleotide Array Sequence Analysis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines | 2004 |
Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antineoplastic Agents; Benzamides; Drug Eruptions; Edema; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lansoprazole; Middle Aged; Omeprazole; Piperazines; Proton Pump Inhibitors; Pyrimidines; Stevens-Johnson Syndrome | 2005 |
[A case of metastatic gastrointestinal stromal tumor developing a resistance to STI571 (imatinib mesylate)].
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Exons; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Peritoneal Neoplasms; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2004 |
Secondary resistance to imatinib mesylate in a patient with unresectable duodenal GIST without mutations in exons 9, 11, 13, or 17 of the c-kit protooncogene.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Duodenal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Tomography, X-Ray Computed | 2004 |
Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Agents; Benzamides; Body Weight; Female; Gastrointestinal Stromal Tumors; Granulocytes; Hemoglobins; Humans; Imatinib Mesylate; Leukocyte Count; Male; Piperazines; Pyrimidines; Retrospective Studies; Sarcoma; Time Factors | 2005 |
A treatment using STI571 for jejunal gastrointestinal stromal tumor (GIST) accompanied with liver metastasis and peritoneal dissemination.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Jejunal Neoplasms; Liver Neoplasms; Male; Middle Aged; Peritoneal Neoplasms; Piperazines; Pyrimidines; Tomography, X-Ray Computed | 2004 |
Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden.
Topics: Age Factors; Antineoplastic Agents; Benzamides; Digestive System Surgical Procedures; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Incidence; Ki-67 Antigen; Piperazines; Prevalence; Prognosis; Pyrimidines; Retrospective Studies; Risk Factors; Survival Analysis; Sweden | 2005 |
Imatinib in gastrointestinal stromal tumors.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome | 2004 |
Effect of imatinib (STI571) on metastatic gastrointestinal stromal tumors: report of a case.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Peritoneal Neoplasms; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2005 |
Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Exons; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Staurosporine | 2005 |
Corticosteroid-responsive interstitial pneumonitis related to imantinib mesylate with successful rechallenge, and potential causative mechanisms.
Topics: Aged; Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lung Diseases, Interstitial; Male; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2005 |
KIT/Val654 Ala receptor detected in one imatinib-resistant GIST patient.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines | 2005 |
STI571 (Glivec) inhibits the interaction between c-KIT and heat shock protein 90 of the gastrointestinal stromal tumor cell line, GIST-T1.
Topics: Benzamides; Benzoquinones; Cell Line, Tumor; Cell Membrane; Cell Survival; Drug Interactions; Gastrointestinal Stromal Tumors; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Lactams, Macrocyclic; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Quinones | 2005 |
Gastrointestinal stromal tumor with metastases in an adult woman treated with imatinib mesylate: MDCT findings.
Topics: Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Piperazines; Pyrimidines; Tomography, X-Ray Computed | 2005 |
CASE 3. Pathologic complete remission of metastatic gastrointestinal stromal tumor after imatinib mesylate.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction | 2005 |
Transient respiratory failure possibly associated to imatinib.
Topics: Aged; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Respiratory Insufficiency | 2005 |
Malignant gastrointestinal stromal tumor of the small intestine complicated with pulmonary tuberculosis during treatment with imatinib mesylate.
Topics: Administration, Oral; Antineoplastic Agents; Antitubercular Agents; Benzamides; Combined Modality Therapy; Digestive System Surgical Procedures; Fatal Outcome; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Jejunal Neoplasms; Laparotomy; Leiomyosarcoma; Liver Neoplasms; Male; Middle Aged; Neutropenia; Piperazines; Pyrimidines; Tomography, X-Ray Computed; Tuberculosis, Pulmonary | 2005 |
Expression of c-kit (CD117) in neuroendocrine tumours--a target for therapy?
Topics: Adenosine Triphosphate; Antibodies, Monoclonal; Antineoplastic Agents; Benzamides; Binding Sites; Epitopes; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Neuroendocrine Tumors; Piperazines; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines | 2005 |
Gastrointestinal stromal tumors: CT and MRI findings.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Duodenal Neoplasms; Female; Gastrointestinal Stromal Tumors; Humans; Image Enhancement; Imatinib Mesylate; Intestine, Small; Liver Neoplasms; Magnetic Resonance Imaging; Male; Mesentery; Middle Aged; Peritoneal Neoplasms; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Radiographic Image Enhancement; Rectal Neoplasms; Stomach Neoplasms; Tomography, X-Ray Computed | 2005 |
Oral lichenoid eruption secondary to imatinib (Glivec).
Topics: Antineoplastic Agents; Benzamides; Drug Eruptions; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lichenoid Eruptions; Male; Middle Aged; Mouth Diseases; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2004 |
[GI hemorrhage with fulminant shock induced by jejunal gastrointestinal stromal tumor (GIST) coincident with duodenal neuroendocrine carcinoma (NET) + neurofibromatosis (NF) -- case report and review of the literature].
Topics: Adult; Antineoplastic Agents; Benzamides; Carcinoma, Neuroendocrine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Duodenal Neoplasms; Duodenum; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Jejunal Neoplasms; Neurofibromatosis 1; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Shock, Hemorrhagic; Time Factors; Tomography, Spiral Computed; Treatment Outcome | 2005 |
Staging for CLL-type non-Hodgkin's lymphoma reveals a gastrointestinal stromal tumour.
Topics: Aged; Benzamides; Biopsy, Needle; Diagnosis, Differential; Follow-Up Studies; Gastrointestinal Stromal Tumors; Gastroscopy; Humans; Imatinib Mesylate; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Neoplasm Staging; Piperazines; Pyrimidines; Risk Assessment; Stomach Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2005 |
[Imatinib mesylate alone for refractory advanced gastrointestinal stromal tumor].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Edema; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukopenia; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Peritoneal Neoplasms; Piperazines; Pyrimidines; Remission Induction; Survival Rate | 2004 |
Neoadjuvant imatinib in gastrointestinal stromal tumor of the rectum: report of a case.
Topics: Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Neoadjuvant Therapy; Piperazines; Pyrimidines; Rectal Neoplasms | 2005 |
Role of computed tomography in the follow-up of hepatic and peritoneal metastases of GIST under imatinib mesylate treatment: a prospective study of 54 patients.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Contrast Media; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Iohexol; Liver Neoplasms; Male; Middle Aged; Peritoneal Neoplasms; Piperazines; Prospective Studies; Pyrimidines; Tomography, X-Ray Computed; Treatment Outcome | 2005 |
Pathological changes related to Imatinib treatment in a patient with a metastatic gastrointestinal stromal tumour.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Treatment Outcome | 2005 |
Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations.
Topics: Aged; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines | 2005 |
Neoadjuvant therapy with imatinib mesylate for locally advanced GI stromal tumor.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Piperazines; Pyrimidines | 2005 |
[Treatment of patients with gastrointestinal stromal tumour with imatinib mesylate].
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Esophageal Neoplasms; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestinal Neoplasms; Male; Middle Aged; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Stomach Neoplasms; Treatment Outcome | 2005 |
Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines | 2005 |
Induction of gastric GIST in rat and establishment of GIST cell line.
Topics: Animals; Antigens, CD34; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; Duodenogastric Reflux; Gastrointestinal Stromal Tumors; Imatinib Mesylate; In Vitro Techniques; Male; Mesenchymoma; Mice; Mice, Inbred BALB C; Mice, Nude; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Rats; Rats, Wistar | 2006 |
Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling.
Topics: Adult; Aged; Amino Acid Sequence; Antineoplastic Agents; Benzamides; Cell Transformation, Neoplastic; Crystallography, X-Ray; DNA Mutational Analysis; DNA, Neoplasm; Female; Gastrointestinal Stromal Tumors; Germ-Line Mutation; Humans; Imatinib Mesylate; Male; Middle Aged; Models, Chemical; Molecular Sequence Data; Pedigree; Piperazines; Platelet-Derived Growth Factor; Protein Conformation; Proto-Oncogene Proteins c-kit; Pyrimidines | 2005 |
A rare case of rapid growth of exophytic gastrointestinal stromal tumor of the stomach.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Invasiveness; Piperazines; Pyrimidines; Stomach Neoplasms | 2005 |
Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.
Topics: Adult; Aged; Aged, 80 and over; Amino Acid Sequence; Antineoplastic Agents; Benzamides; Blotting, Western; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Male; Middle Aged; Molecular Sequence Data; Mutation; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2005 |
An omental mass: any hypothesis?
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Digestive System Surgical Procedures; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Omentum; Peritoneal Neoplasms; Piperazines; Pyrimidines; Splenic Neoplasms; Tomography, X-Ray Computed | 2005 |
Concurrent male gynecomastia and testicular hydrocele after imatinib mesylate treatment of a gastrointestinal stromal tumor.
Topics: Adult; Androgens; Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Gynecomastia; Humans; Imatinib Mesylate; Male; Piperazines; Pyrimidines; Testicular Hydrocele; Testis; Ultrasonography | 2005 |
No GIST-type c-kit gain of function mutations in neuroblastic tumours.
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Brain Neoplasms; Child; Child, Preschool; Chromatography, High Pressure Liquid; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Infant; Mutation; Neuroblastoma; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines | 2005 |
Gastrointestinal stromal tumour treated with neoadjuvant imatinib.
Topics: Aged; Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoadjuvant Therapy; Piperazines; Positron-Emission Tomography; Pyrimidines; Stomach Neoplasms; Tomography, X-Ray Computed | 2005 |
Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall.
Topics: Actins; Adult; Aged; Antigens, CD34; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Desmin; Gastrointestinal Stromal Tumors; Gastrointestinal Tract; Humans; Imatinib Mesylate; Immunohistochemistry; Keratins; Middle Aged; Muscle, Smooth; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Reproducibility of Results; Sensitivity and Specificity | 2005 |
Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Caspases; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Phosphorylation; Piperazines; Protein Serine-Threonine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Pyrimidines; Time Factors | 2005 |
Resistance to imatinib, low-grade FDG-avidity on PET, and acquired KIT exon 17 mutation in gastrointestinal stromal tumour.
Topics: Antineoplastic Agents; Benzamides; Diagnostic Errors; Drug Monitoring; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Glucose-6-Phosphate; Humans; Imatinib Mesylate; Middle Aged; Piperazines; Positron-Emission Tomography; Proto-Oncogene Proteins c-kit; Pyrimidines; Sequence Deletion | 2005 |
Effect of angiosonography to monitor response during imatinib treatment in patients with metastatic gastrointestinal stromal tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Tomography, X-Ray Computed; Ultrasonography; Vascular Endothelial Growth Factor A | 2005 |
Primary gastrointestinal stromal tumor of the liver with lung metastases successfully treated with STI-571 (imatinib mesylate).
Topics: Adult; Antineoplastic Agents; Benzamides; Cell Differentiation; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Neoplasm Metastasis; Phenotype; Piperazines; Positron-Emission Tomography; Proto-Oncogene Proteins c-kit; Pyrimidines; Tissue Distribution; Tomography, X-Ray Computed; Treatment Outcome; Vimentin | 2006 |
[Imatinib mesylate STI571 therapy for five patients with advanced gastrointestinal stromal tumors].
Topics: Adult; Aged, 80 and over; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Staging; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Retrospective Studies | 2005 |
Gastrointestinal stromal tumors presenting as gynecological tumors.
Topics: Aged; Benzamides; Diagnosis, Differential; Female; Gastrointestinal Stromal Tumors; Genital Neoplasms, Female; Humans; Imatinib Mesylate; Middle Aged; Piperazines; Pyrimidines | 2006 |
Complete remission with imatinib in metastastic gastrointestinal stromal tumors.
Topics: Benzamides; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Neoplasm Metastasis; Neoplasm Staging; Piperazines; Pyrimidines; Treatment Outcome | 2005 |
Severe hypoglycemia caused by paraneoplastic production of IGF-II in patients with advanced gastrointestinal stromal tumors: a report of two cases.
Topics: Abdominal Pain; Adult; Benzamides; Blood Glucose; Combined Modality Therapy; Digestive System Surgical Procedures; Follow-Up Studies; Gastrointestinal Stromal Tumors; Glucose; Humans; Hypoglycemia; Imatinib Mesylate; Insulin-Like Growth Factor II; Intestine, Small; Male; Middle Aged; Paraneoplastic Syndromes; Piperazines; Pyrimidines; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2005 |
Factors associated with disease progression in patients with gastrointestinal stromal tumors in the pre-imatinib era.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Disease Progression; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2005 |
Current management of metastatic gastrointestinal stromal tumor: a case report.
Topics: Benzamides; Disease Management; Disease-Free Survival; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines | 2003 |
F-18 FDG PET for assessing tyrosine kinase-related signal transduction inhibition in a GIST c-kit-positive tumor patient by imatinib.
Topics: Antineoplastic Agents; Benzamides; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Positron-Emission Tomography; Protein-Tyrosine Kinases; Pyrimidines; Radiopharmaceuticals; Signal Transduction; Treatment Outcome | 2005 |
CT evaluation of gastrointestinal stromal tumors treated with imatinib mesylate.
Topics: Antineoplastic Agents; Benzamides; Data Interpretation, Statistical; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Radionuclide Imaging; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2005 |
[Recommendations for the management of GIST patients].
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; France; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Staging; Piperazines; Pyrimidines | 2005 |
An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle; Female; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Mice; Mice, Inbred DBA; Piperazines; Positron-Emission Tomography; Proto-Oncogene Proteins c-kit; Pyrimidines; Xenograft Model Antitumor Assays | 2005 |
[A case of Giant GIST of the stomach successfully treated with imatinib mesylate neoadjuvant therapy and followed postoperatively].
Topics: Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Drug Administration Schedule; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoadjuvant Therapy; Piperazines; Prognosis; Pyrimidines; Stomach Neoplasms | 2005 |
Advanced-stage gastrointestinal stromal tumor treated with imatinib in a 12-year-old girl with a unique mutation of PDGFRA.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Child; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Piperazines; Prognosis; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2005 |
Gastrointestinal stromal tumours: correlation of F-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment response--an AGITG study.
Topics: Antineoplastic Agents; Benzamides; Fluorodeoxyglucose F18; Gamma Cameras; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Positron-Emission Tomography; Pyrimidines; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2005 |
Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes.
Topics: Antineoplastic Agents; Benzamides; DNA Mutational Analysis; Enzyme Activation; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2005 |
[A long-term survival case with multiple liver metastases from duodenal gastrointestinal stromal tumor that was drastically reduced by the treatment with imatinib].
Topics: Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Duodenal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Pancreaticoduodenectomy; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2005 |
[Peritoneal dissemination from gastrointestinal stromal tumor of small intestine responding completely to imatinib mesylate (STI 571)].
Topics: Antineoplastic Agents; Benzamides; Drug Administration Schedule; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Jejunal Neoplasms; Male; Middle Aged; Peritoneal Neoplasms; Piperazines; Pyrimidines; Remission Induction | 2005 |
Pathological complete response in advanced gastrointestinal stromal tumor after imatinib therapy.
Topics: Antineoplastic Agents; Benzamides; Follow-Up Studies; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Stomach; Tomography, X-Ray Computed | 2005 |
[Gastrointestinal stromal tumor successfully treated with re-administration of STI571 despite of serious skin rash: a case report].
Topics: Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Drug Eruptions; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mesentery; Neoplasm Recurrence, Local; Peritoneal Neoplasms; Piperazines; Pyrimidines | 2005 |
Imatinib binding and cKIT inhibition is abrogated by the cKIT kinase domain I missense mutation Val654Ala.
Topics: Alanine; Alleles; Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Benzamides; Cell Line; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Models, Molecular; Molecular Sequence Data; Mutation, Missense; Piperazines; Pyrimidines; Sequence Homology, Amino Acid; Stem Cell Factor; Valine | 2005 |
[How should patients with completely resected gastrointestinal stromal tumours (GIST) be followed up?].
Topics: Adult; Aftercare; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cost-Benefit Analysis; Endoscopy, Gastrointestinal; Endosonography; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Pyrimidines | 2005 |
BNP as a marker of the heart failure in the treatment of imatinib mesylate.
Topics: Adult; Aged; Alleles; Base Sequence; Benzamides; Biomarkers, Tumor; Diarrhea; DNA Mutational Analysis; Edema; Exanthema; Female; Gastrointestinal Stromal Tumors; Gene Frequency; Genotype; Heart Failure; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Natriuretic Peptide, Brain; Piperazines; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2006 |
Patterns of progression in gastrointestinal stromal tumor treated with imatinib mesylate.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Decision Making; Disease Progression; Drug Administration Schedule; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestinal Neoplasms; Male; Middle Aged; Piperazines; Prognosis; Prospective Studies; Pyrimidines; Remission Induction; Stomach Neoplasms; Survival Analysis; Tomography, Spiral Computed | 2006 |
[Gastrointestinal stromal tumors (GIST). Clinical characteristics, diagnosis, and therapy in five cases].
Topics: Adult; Aged; Benzamides; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Piperazines; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Radionuclide Imaging; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography | 2006 |
MDCT appearance of gastrointestinal stromal tumors after therapy with imatinib mesylate.
Topics: Aged; Aged, 80 and over; Benzamides; Contrast Media; Female; Gastrointestinal Stromal Tumors; Humans; Image Processing, Computer-Assisted; Imatinib Mesylate; Iopamidol; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Immunohistochemical and genetic features of gastric and metastatic liver gastrointestinal stromal tumors: sequential analyses.
Topics: Aged; Amino Acid Sequence; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Liver Neoplasms; Loss of Heterozygosity; Male; Microsatellite Repeats; Middle Aged; Molecular Sequence Data; Neoplasm Proteins; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Sequence Homology, Amino Acid; Stomach Neoplasms | 2006 |
Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Disease Progression; Drug Administration Schedule; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Piperazines; Prognosis; Pyrimidines; Remission Induction | 2006 |
Expression of Bcl-2 in gastrointestinal stromal tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylate.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Biomarkers, Tumor; Disease Progression; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Piperazines; Prognosis; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Retrospective Studies | 2006 |
First report of a complete pathological response of a pelvic GIST treated with imatinib as neoadjuvant therapy.
Topics: Aged; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Rectal Neoplasms; Rectum; Treatment Outcome; Ultrasonography | 2006 |
Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines.
Topics: Antineoplastic Agents; Benzamides; Biological Transport; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2006 |
Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.
Topics: Adult; Aged; Amino Acid Sequence; Base Sequence; Benzamides; DNA Mutational Analysis; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Molecular Sequence Data; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Sequence Homology, Amino Acid | 2006 |
[Gastrointestinal stromal tumors localized in small intestine and diagnosed preoperatively as gynecological neoplasms].
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Diagnosis, Differential; Female; Gastrointestinal Stromal Tumors; Genital Neoplasms, Female; Humans; Imatinib Mesylate; Intestine, Small; Middle Aged; Piperazines; Prognosis; Pyrimidines; Treatment Outcome | 2005 |
Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase II as Topic; Female; Florida; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Incidence; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Registries; SEER Program; Survival Analysis; Treatment Outcome | 2006 |
Is there a role for neoadjuvant treatment with Gleevec for large rectal gastrointestinal stromal tumors?
Topics: Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoadjuvant Therapy; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Rectal Neoplasms; Treatment Outcome | 2007 |
STI571 (Glivec) induces cell death in the gastrointestinal stromal tumor cell line, GIST-T1, via endoplasmic reticulum stress response.
Topics: Antineoplastic Agents; Benzamides; Blotting, Western; Brefeldin A; Caspase 3; Caspase 7; Caspases; Cell Line, Tumor; Cell Survival; Cycloheximide; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Flow Cytometry; Gastrointestinal Stromal Tumors; Heat-Shock Proteins; Humans; Imatinib Mesylate; Molecular Chaperones; Piperazines; Protein Synthesis Inhibitors; Pyrimidines; Tunicamycin | 2006 |
Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Diagnosis, Differential; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Diseases, Interstitial; Male; Middle Aged; Piperazines; Pyrimidines; Risk Factors; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Advanced gastrointestinal stromal tumor patients with complete response after treatment with imatinib mesylate.
Topics: Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Prospective Studies; Pyrimidines; Tomography, X-Ray Computed | 2006 |
Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line; Cell Proliferation; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Indoles; Mutation; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib; Tumor Cells, Cultured | 2006 |
Altered bone and mineral metabolism in patients receiving imatinib mesylate.
Topics: Benzamides; Biomarkers; Bone and Bones; Bone Remodeling; Calcitriol; Calcium; Female; Gastrointestinal Stromal Tumors; Humans; Hypophosphatemia; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Osteocalcin; Parathyroid Hormone; Phosphates; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Vitamin D | 2006 |
[The diagnostic and predictive role of kit (CD117)].
Topics: Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Genetic Markers; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Mutation; Neoplasms; Piperazines; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Sensitivity and Specificity; Signal Transduction | 2006 |
Treatment of gastrointestinal stromal tumor with imatinib mesylate: a retrospective single-center experience in Heidelberg.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Germany; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Severity of Illness Index; Survival Rate; Treatment Outcome | 2006 |
Population-based study of the diagnosis and treatment of gastrointestinal stromal tumours.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Child; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Retrospective Studies; Risk Factors; Statistics, Nonparametric | 2006 |
Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms.
Topics: Apoptosis; Benzamides; Chromones; Gastrointestinal Stromal Tumors; Glucose; Glucose Transporter Type 4; Humans; Imatinib Mesylate; Morpholines; Mutation; Phosphatidylinositol 3-Kinases; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction; Tumor Cells, Cultured | 2006 |
Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Disease Progression; Doxorubicin; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neoplasm Staging; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Survival Analysis; Treatment Outcome | 2006 |
Long-term survival of a case with multiple liver metastases from duodenal gastrointestinal stromal tumor drastically reduced by the treatment with imatinib and hepatectomy.
Topics: Adult; Antineoplastic Agents; Benzamides; Duodenal Neoplasms; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Liver; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Survivors | 2006 |
[Flushing revealing the recurrence of a rectal gastrointestinal stromal tumour. Efficacy of imatinib].
Topics: Aged; Antineoplastic Agents; Benzamides; Flushing; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Piperazines; Pyrimidines; Rectal Neoplasms | 2006 |
Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Down-Regulation; Flavonoids; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Phosphorylation; Piperazines; Piperidines; Promoter Regions, Genetic; Proto-Oncogene Proteins c-kit; Pyrimidines; RNA Polymerase II; Transcription, Genetic | 2006 |
Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Models, Molecular; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines | 2006 |
[Duodenal gastrointestinal stromal tumors. Report of a case].
Topics: Aged; Antineoplastic Agents; Benzamides; Duodenal Neoplasms; Duodenal Ulcer; Gastrointestinal Hemorrhage; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Pancreaticoduodenectomy; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Radiography; Recurrence | 2006 |
Efficacy of imatinib mesylate in patients with liver metastases from gastrointestinal stromal tumor failing intra-arterial hepatic chemotherapy with epirubicin.
Topics: Aged; Antineoplastic Agents; Benzamides; Epirubicin; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Piperazines; Pyrimidines | 2003 |
[A case of recurrent GIST successfully treated with low-dose imatinib mesilate].
Topics: Aged; Antineoplastic Agents; Benzamides; Drug Administration Schedule; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestinal Neoplasms; Intestine, Small; Male; Neoplasm Recurrence, Local; Pelvis; Piperazines; Point Mutation; Proto-Oncogene Proteins c-kit; Pyrimidines | 2006 |
Non-islet-cell tumor induced hypoglycemia in patients with advanced gastrointestinal stromal tumor possibly worsened by imatinib.
Topics: Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Hypoglycemia; Imatinib Mesylate; Insulin-Like Growth Factor II; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein Precursors; Pyrimidines | 2006 |
Gastrointestinal stromal tumor. A study of 158 cases: clinicopathological features and prognostic factors.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Gastrointestinal Tract; Humans; Imatinib Mesylate; Male; Middle Aged; Mitosis; Neoplasm Invasiveness; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Stromal Cells; Survival Analysis | 2006 |
Ongoing challenges of a global international patient assistance program.
Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Developing Countries; Gastrointestinal Stromal Tumors; Global Health; Health Services Accessibility; Humans; Imatinib Mesylate; International Cooperation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Piperazines; Program Development; Program Evaluation; Public Health; Pyrimidines; Thailand | 2006 |
Extragastrointestinal stromal tumors presenting as vulvovaginal/rectovaginal septal masses: a diagnostic pitfall.
Topics: Adult; Antigens, CD34; Antineoplastic Agents; Benzamides; Diagnosis, Differential; DNA, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Leiomyoma; Leiomyosarcoma; Middle Aged; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Rectal Neoplasms; Vaginal Neoplasms; Vulvar Neoplasms | 2006 |
[A gastric stromal tumor (GIST) with a prolonged partial response to a reduced dose of imatinib mesilate].
Topics: Aged; Anemia; Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukopenia; Liver Neoplasms; Piperazines; Pyrimidines; Stomach Neoplasms | 2006 |
KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib.
Topics: Adult; Aged; Aged, 80 and over; Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Benzamides; DNA Primers; DNA, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Molecular Sequence Data; Mutation; Piperazines; Polymerase Chain Reaction; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2006 |
Pathological response of gastrointestinal stromal tumour to imatinib treatment correlates with tumour KIT mutational status in individual tumour clones.
Topics: Antineoplastic Agents; Base Sequence; Benzamides; DNA, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines | 2006 |
Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein.
Topics: Administration, Oral; Adult; Age Factors; Aged; Antineoplastic Agents; Benzamides; Body Weight; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestinal Absorption; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Orosomucoid; Piperazines; Pyrimidines; Sex Factors | 2006 |
Pathologic, radiologic and PET scan response of gastrointestinal stromal tumors after neoadjuvant treatment with imatinib mesylate.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Piperazines; Positron-Emission Tomography; Pyrimidines; Radiography; Treatment Outcome | 2006 |
[Gastro-intestinal stromal tumours (GISTs): prognostic and therapeutic features].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Mitotic Index; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Time Factors | 2006 |
[Gastrointestinal stromal tumors: report of three cases and review of the literature].
Topics: Aged; Antineoplastic Agents; Benzamides; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Radiography, Abdominal; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Response evaluation in gastrointestinal stromal tumours treated with imatinib: misdiagnosis of disease progression on CT due to cystic change in liver metastases.
Topics: Aged; Antineoplastic Agents; Benzamides; Cysts; Diagnostic Errors; Disease Progression; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Piperazines; Pyrimidines; Tomography, X-Ray Computed | 2006 |
Response to imatinib in KIT- and PDGFRA-wild type gastrointestinal stromal associated with neurofibromatosis type 1.
Topics: Abdominal Pain; Aged; Antineoplastic Agents; Benzamides; Diagnosis, Differential; DNA; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Jejunal Neoplasms; Mutation; Neurofibromatosis 1; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Tomography, X-Ray Computed | 2006 |
[STI571 for gastrointestinal stromal tumors].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Drug Administration Schedule; Female; Gastrectomy; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Stomach Neoplasms | 2006 |
Everolimus alters imatinib blood partition in favour of the erythrocyte.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Erythrocytes; Everolimus; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunosuppressive Agents; In Vitro Techniques; Mass Spectrometry; Piperazines; Plasma; Pyrimidines; Sirolimus; Stomach Neoplasms | 2006 |
Could imatinib replace surgery in esophageal gastrointestinal stromal tumor.
Topics: Antigens, CD34; Antineoplastic Agents; Benzamides; Esophageal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines | 2006 |
Imatinib and altered bone and mineral metabolism.
Topics: Benzamides; Calcium; Chemotherapy, Adjuvant; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Hypophosphatemia; Imatinib Mesylate; Phosphates; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2006 |
Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor.
Topics: Animals; Benzamides; Cell Proliferation; Disease Models, Animal; Down-Regulation; Everolimus; Gastrointestinal Stromal Tumors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Imatinib Mesylate; Mice; Mice, Inbred C57BL; Mice, Transgenic; Phosphorylation; Piperazines; Protein Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2006 |
Recurrent gastrointestinal stromal tumor (GIST) of the stomach associated with a novel c-kit mutation after imatinib treatment.
Topics: Antineoplastic Agents; Base Sequence; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Molecular Sequence Data; Neoplasm Recurrence, Local; Piperazines; Point Mutation; Proto-Oncogene Proteins c-kit; Pyrimidines | 2006 |
Treatment of advanced gastrointestinal stromal tumor: a marriage of targeted therapy and surgery?
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2007 |
Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; Feasibility Studies; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Medical Records; Middle Aged; Necrosis; Peritoneal Neoplasms; Piperazines; Preoperative Care; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Survival Rate | 2006 |
Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor.
Topics: Benzamides; Benzoquinones; Cell Cycle; Cell Line, Tumor; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Lactams, Macrocyclic; Phosphatidylinositol 3-Kinases; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction | 2006 |
Early effects of imatinib mesylate on the expression of insulin-like growth factor binding protein-3 and positron emission tomography in patients with gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Survival; Gastrointestinal Stromal Tumors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor Binding Proteins; Piperazines; Positron-Emission Tomography; Pyrimidines; Radiography; Sarcoma; Up-Regulation | 2006 |
Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Demography; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Multivariate Analysis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Treatment Outcome | 2006 |
Metastatic gastrointestinal stromal tumor and hypercalcemia in a patient with ulcerative colitis.
Topics: Antineoplastic Agents; Benzamides; Colitis, Ulcerative; Gastrointestinal Stromal Tumors; Humans; Hypercalcemia; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Peritoneal Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Rectum; Treatment Outcome | 2006 |
[Etiology of and therapy for gastrointestinal stromal tumor].
Topics: Antineoplastic Agents; Benzamides; Digestive System Surgical Procedures; Drug Design; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2006 |
Image of the month. Cecal gastrointestinal stromal tumor.
Topics: Adult; Benzamides; Cecal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Tomography, X-Ray Computed | 2006 |
[Efficacy and safety of adjuvant post-surgical therapy with imatinib in gastrointestinal stromal tumor patients with high risk of recurrence: interim analysis from a multicenter prospective clinical trial].
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Chemotherapy, Adjuvant; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Postoperative Period; Prospective Studies; Pyrimidines; Young Adult | 2006 |
[Clinical analysis of 60 cases with malignant gastrointestinal stromal tumors].
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Retrospective Studies | 2006 |
Sunitinib for imatinib-resistant GIST.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Multicenter Studies as Topic; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib | 2006 |
Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Follow-Up Studies; Gastroenterology; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Intestine, Small; Ki-67 Antigen; Male; Middle Aged; Mitosis; Piperazines; Predictive Value of Tests; Prognosis; Pyrimidines; Retrospective Studies; Risk Assessment; Survival Analysis | 2006 |
Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Metabolic Clearance Rate; Middle Aged; Patient Selection; Piperazines; Pyrimidines; Reproducibility of Results | 2006 |
Polyclonal resistance in gastrointestinal stromal tumor treated with sequential kinase inhibitors.
Topics: Benzamides; DNA Mutational Analysis; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines | 2006 |
Gastrointestinal stromal tumors (GISTs) on prostate needle biopsy: A clinicopathologic study of 8 cases.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Biopsy, Needle; Combined Modality Therapy; Diagnosis, Differential; Digestive System Surgical Procedures; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Piperazines; Prostate; Prostatic Neoplasms; Pyrimidines | 2006 |
Clinical outcome in gastrointestinal stromal tumor patients who interrupted imatinib after achieving stable disease or better response.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; Drug Administration Schedule; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Prospective Studies; Pyrimidines; Treatment Outcome | 2006 |
Surgical resection of gastrointestinal stromal tumors after treatment with imatinib.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome | 2007 |
Predicting the antitumor effects of STI571 by analysis of c-kit gene mutations in gastrointestinal stromal tumors of the stomach: Report of a case.
Topics: Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; DNA, Neoplasm; Exons; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Mutation; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Stomach Neoplasms | 2006 |
Outcome of metastatic GIST in the era before tyrosine kinase inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Survival Rate | 2007 |
Malignant gastrointestinal stromal neoplasm.
Topics: Adult; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Piperazines; Pyrimidines; Sarcoma | 2006 |
[A case of gastrointestinal stromal tumor with liver and bone metastases effectively treated with radiofrequency ablation and imatinib mesylate].
Topics: Antineoplastic Agents; Benzamides; Bone Neoplasms; Catheter Ablation; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestine, Small; Liver Neoplasms; Male; Middle Aged; Piperazines; Pyrimidines | 2006 |
Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Imatinib Mesylate; Male; Mice; Mice, Nude; Phosphorylation; Piperazines; Point Mutation; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Staurosporine; Tyrosine; Xenograft Model Antitumor Assays | 2006 |
Current and future management of GIST.
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Benzoquinones; Disease Progression; Dose-Response Relationship, Drug; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Lactams, Macrocyclic; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2006 |
Central nervous system metastases from imatinib mesylate resistant gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Benzamides; Brain Neoplasms; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Middle Aged; Piperazines; Pyrimidines | 2007 |
Imatinib mesylate therapy in advanced gastrointestinal stromal tumors: experience from a single institute.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Survival Rate | 2006 |
Development and validation of a liquid chromatography method for the simultaneous determination of alpha-tocopherol, retinol and retinyl esters in human serum using a monolithic column for the monitoring of anticancer therapy side effects.
Topics: Absorption; alpha-Tocopherol; Antineoplastic Agents; Benzamides; Calibration; Chromatography; Chromatography, High Pressure Liquid; Diarrhea; Drug Monitoring; Esters; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Reproducibility of Results; Time Factors; Vitamin A | 2006 |
Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors.
Topics: Benzamides; Cell Proliferation; Cluster Analysis; DNA Mutational Analysis; Drug Resistance, Neoplasm; Exons; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Microscopy, Electron; Mutation; Oligonucleotide Array Sequence Analysis; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Sequence Analysis, DNA; Treatment Outcome | 2007 |
Hypercalcaemia in a patient with a gastrointestinal stromal tumour.
Topics: Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Diphosphonates; Drug Therapy, Combination; Female; Gastrointestinal Stromal Tumors; Humans; Hypercalcemia; Imatinib Mesylate; Middle Aged; Pamidronate; Peritoneal Neoplasms; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines | 2007 |
Expression of c-KIT oncoprotein in gastrointestinal stromal tumors in adults and children: guideline for diagnosis and treatment.
Topics: Benzamides; Child; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor Protein-Tyrosine Kinases | 2006 |
[Neoadjuvant therapy with imatinib mesilate for gastrointestinal stromal tumor of the stomach before subsequent successful surgical resection].
Topics: Aged; Antineoplastic Agents; Benzamides; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoadjuvant Therapy; Piperazines; Pyrimidines; Stomach Neoplasms | 2006 |
Hypoglycemia in the setting of advanced gastrointestinal stromal tumor.
Topics: Abdominal Neoplasms; Aged; Antineoplastic Agents; Benzamides; Blood Glucose; Diagnosis, Differential; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Hypoglycemia; Imatinib Mesylate; Leiomyosarcoma; Neoplasm Recurrence, Local; Palliative Care; Paraneoplastic Syndromes; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2006 |
Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase II as Topic; Cost-Benefit Analysis; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Models, Economic; Piperazines; Pyrimidines; Survival Analysis; United States | 2007 |
Effects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: implications for treatment of fibrotic diseases.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Benzamides; Bleomycin; Blotting, Western; Bromodeoxyuridine; Caspase 3; Cell Line, Tumor; Cells, Cultured; Collagen; DNA, Single-Stranded; Dose-Response Relationship, Drug; Epithelial Cells; Fibroblasts; Fibrosis; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Indicators and Reagents; Injections, Intraperitoneal; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Diseases; Mesenchymal Stem Cells; Mice; Phenotype; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction | 2007 |
Herpes zoster complicating imatinib mesylate for gastrointestinal stromal tumour.
Topics: Acyclovir; Antiviral Agents; Bandages; Benzamides; Diagnosis, Differential; Gastrointestinal Stromal Tumors; Herpes Zoster; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2007 |
Lymphomatoid granulomatosis in a patient previously diagnosed with a gastrointestinal stromal tumour and treated with imatinib.
Topics: Adult; Antineoplastic Agents; Benzamides; Fatal Outcome; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lung Neoplasms; Lymphomatoid Granulomatosis; Lymphopenia; Male; Neoplasms, Multiple Primary; Piperazines; Pyrimidines; Tomography, X-Ray Computed | 2007 |
Neoadjuvant therapy for gastrointestinal stromal tumor (GIST): racing against resistance.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Piperazines; Pyrimidines; Stomach Neoplasms | 2007 |
Is rectal administration an alternative route for imatinib?
Topics: Administration, Rectal; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestinal Obstruction; Middle Aged; Neoplasm Metastasis; Piperazines; Pyrimidines | 2007 |
[Imatinib mesylate in the treatment of advanced gastrointestinal stromal tumors].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Middle Aged; Piperazines; Premedication; Preoperative Care; Pyrimidines; Retrospective Studies | 2006 |
[A case of recurrent GIST of the esophagus which completely responded to imatinib mesilate].
Topics: Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Piperazines; Pyrimidines; Remission Induction; Skin Neoplasms | 2007 |
Fatal venous thrombembolism complicating imatinib therapy in a patient with metastatic gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Autopsy; Benzamides; Fatal Outcome; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Thromboembolism | 2006 |
A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Benzamides; Blotting, Western; Cell Line, Tumor; Cell Shape; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Green Fluorescent Proteins; Humans; Imatinib Mesylate; Models, Molecular; Mutation; Oligonucleotide Array Sequence Analysis; Oncogene Proteins; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor Protein-Tyrosine Kinases; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Thiourea | 2007 |
Should surgical resection be combined with imatinib therapy for locally advanced or metastatic gastrointestinal stromal tumors?
Topics: Antineoplastic Agents; Benzamides; Drug Administration Schedule; Elective Surgical Procedures; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome | 2007 |
Resistance to c-KIT kinase inhibitors conferred by V654A mutation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Proliferation; Cells, Cultured; Drug Resistance, Neoplasm; Exons; Fluorescent Antibody Technique; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunoprecipitation; Mice; Mutation; Myeloid Progenitor Cells; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Staurosporine | 2007 |
Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylate.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Disease Models, Animal; Down-Regulation; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; HeLa Cells; Histones; Humans; Imatinib Mesylate; Mice; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Transcription, Genetic; Up-Regulation | 2007 |
KIT mutations and imatinib dose effects in patients with gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Exons; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Randomized Controlled Trials as Topic; Research Design; Treatment Failure | 2007 |
An in vitro cytologic assay for evaluation of the KIT signaling pathway in gastrointestinal stromal tumors.
Topics: Benzamides; Cell Line, Tumor; Cytological Techniques; Drug Resistance, Neoplasm; Evaluation Studies as Topic; Everolimus; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Immunosuppressive Agents; In Vitro Techniques; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Sensitivity and Specificity; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2007 |
Gastric GIST: a single institutional retrospective experience with surgical treatment for primary disease.
Topics: Benzamides; Chemotherapy, Adjuvant; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Staging; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Treatment Outcome | 2007 |
Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST.
Topics: Benzamides; Combined Modality Therapy; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Retrospective Studies; Survival Analysis | 2007 |
Effective neoadjuvant therapy prior to metastasectomy: a new paradigm.
Topics: Benzamides; Disease Progression; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2007 |
c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Drug Resistance, Neoplasm; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunophenotyping; In Situ Hybridization, Fluorescence; Mitosis; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2007 |
Update on gastrointestinal stromal tumor [GIST].
Topics: Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Risk Factors | 2006 |
Coexistence of papillary renal cell carcinoma and gastrointestinal stromal tumor in a case.
Topics: Antineoplastic Agents; Benzamides; Carcinoma, Papillary; Carcinoma, Renal Cell; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kidney Neoplasms; Male; Middle Aged; Neoplasms, Multiple Primary; Nephrectomy; Piperazines; Pyrimidines | 2007 |
Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Child; Disease-Free Survival; DNA Mutational Analysis; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Stem Cell Factor; Survival Analysis; Time Factors; Treatment Outcome | 2007 |
Development of multiple myeloma in a patient with gastrointestinal stromal tumor treated with imatinib mesylate: a case report.
Topics: Aged; Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Multiple Myeloma; Neoplasms, Multiple Primary; Piperazines; Pyrimidines | 2007 |
Early detection of response to imatinib therapy for gastrointestinal stromal tumor by using 18F-FDG-positron emission tomography and computed tomography imaging.
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Positron-Emission Tomography; Pyrimidines; Radiopharmaceuticals; Tomography, Emission-Computed; Treatment Outcome | 2007 |
Downstaging of a gastric GIST by neoadjuvant imatinib and endoscopic assisted laparoscopic resection.
Topics: Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Laparoscopy; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Stomach Neoplasms; Treatment Outcome | 2007 |
Disease progression following imatinib failure in gastrointestinal stromal tumors: role of surgical therapy.
Topics: Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Disease Progression; Fatal Outcome; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Neoplasm Metastasis; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Tomography, X-Ray Computed | 2007 |
Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Multivariate Analysis; Neoplasm Metastasis; Piperazines; Positron-Emission Tomography; Protein-Tyrosine Kinases; Pyrimidines; Sensitivity and Specificity; Tomography, X-Ray Computed | 2007 |
We should desist using RECIST, at least in GIST.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Metastasis; Piperazines; Pyrimidines; Recurrence; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome | 2007 |
Rational drug redesign to overcome drug resistance in cancer therapy: imatinib moving target.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Design; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kinetics; Models, Molecular; Mutation; Phosphorylation; Piperazines; Protein Conformation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Structure-Activity Relationship | 2007 |
Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Staging; Piperazines; Pyrimidines; Risk Assessment; Treatment Outcome | 2007 |
KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway.
Topics: Antineoplastic Agents; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Enzyme Activation; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kinetics; Phosphatidylinositol 3-Kinases; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction; TOR Serine-Threonine Kinases | 2007 |
Effect of imatinib mesylate in a patient with a metastatic gastrointestinal stromal tumor with a c-kit mutation in exon 11.
Topics: Adult; Antineoplastic Agents; Benzamides; Exons; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Sequence Deletion | 2007 |
[Two cases of gastrointestinal stromal tumor (GIST) of the stomach and a consideration of its malignancy potential and treatment strategy - report of two cases].
Topics: Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Stomach Neoplasms | 2007 |
Double resistance to imatinib and AMG 706 caused by multiple acquired KIT exon 17 mutations in a gastrointestinal stromal tumour.
Topics: Base Sequence; Benzamides; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Middle Aged; Niacinamide; Oligonucleotides; Piperazines; Point Mutation; Proto-Oncogene Proteins c-kit; Pyrimidines | 2007 |
Surgical interventions for focal progression of advanced gastrointestinal stromal tumors during imatinib therapy.
Topics: Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Pyrimidines; Retrospective Studies; Survival Analysis | 2007 |
Gastrointestinal stromal tumors involving the prostate: presentation, course, and therapeutic approach.
Topics: Antineoplastic Agents; Benzamides; Biopsy, Needle; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasms, Unknown Primary; Piperazines; Prostatic Neoplasms; Pyrimidines; Treatment Outcome | 2007 |
Proposals for the management of gastrointestinal stromal tumours of the stomach.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Disease-Free Survival; Female; Follow-Up Studies; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Piperazines; Population Surveillance; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines; Splenectomy; Stomach Neoplasms; Thoracic Neoplasms; Thoracic Wall; Treatment Outcome | 2007 |
Massive intraperitoneal stromal tumour: two-year follow-up.
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Peritoneal Neoplasms; Piperazines; Pyrimidines; Tomography, X-Ray Computed | 2007 |
Follow up of three cases after adjuvant treatment of high risk gastrointestinal stromal tumors with Imatinib.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome | 2007 |
Imatimid-induced bone marrow necrosis detected on MRI examination and mimicking bone metastases.
Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow Diseases; Bone Neoplasms; Diagnosis, Differential; Fatal Outcome; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Necrosis; Pelvic Bones; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction | 2007 |
Management of gastrointestinal stromal tumours: a single-centre experience.
Topics: Antineoplastic Agents; Benzamides; Female; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Ireland; Laparoscopy; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Survival Analysis; Treatment Outcome | 2007 |
Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2007 |
Neoadjuvant imatinib in a locally advanced gastrointestinal stromal tumour (GIST) of the rectum: a rare case of two GISTs within a family without a familial GIST syndrome.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Family Health; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Piperazines; Positron-Emission Tomography; Pyrimidines; Rectal Neoplasms | 2007 |
Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Exons; Female; Gastrointestinal Stromal Tumors; Homozygote; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Loss of Heterozygosity; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Risk Assessment | 2007 |
Multiple malignant extragastrointestinal stromal tumors of the greater omentum and results of immunohistochemistry and mutation analysis: a case report.
Topics: Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Ki-67 Antigen; Male; Middle Aged; Mutation; Omentum; Peritoneal Neoplasms; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2007 |
New strategies for treating GIST when imatinib fails.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Sarcoma; Tomography, X-Ray Computed; Treatment Failure | 2007 |
Metastatic gastrointestinal stromal tumor with long-term response after treatment with concomitant radiotherapy and imatinib mesylate.
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Liver Neoplasms; Male; Middle Aged; Piperazines; Pyrimidines; Tomography, X-Ray Computed | 2007 |
Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD.
Topics: Adolescent; Adult; Alleles; Antineoplastic Agents; Base Sequence; Benzamides; Child; DNA Primers; DNA, Neoplasm; Female; Gastrointestinal Stromal Tumors; Genes, Dominant; Germ-Line Mutation; Heterozygote; Humans; Imatinib Mesylate; Iron-Sulfur Proteins; Loss of Heterozygosity; Male; Membrane Proteins; Neoplastic Syndromes, Hereditary; Paraganglioma; Piperazines; Pyrimidines; Succinate Dehydrogenase | 2008 |
[Imatinib mesylate (glivec) as a treatment for gastrointestinal stromal tumor (GIST)--long term follow-up].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Positron-Emission Tomography; Pyrimidines; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2007 |
Dermatitis after suspected imatinib-levothyroxine interaction in a patient with gastrointestinal stromal tumor.
Topics: Aged; Antineoplastic Agents; Benzamides; Drug Eruptions; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Skin; Thyroxine | 2008 |
Current management of GIST.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Disease Management; Drug Delivery Systems; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Proteins; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor | 2004 |
[Drug-induced pneumonia that may have been caused by imatinib mesylate administered for gastrointestinal stromal tumor].
Topics: Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Piperazines; Pneumonia; Pyrimidines | 2007 |
[Imatinib . Sunitinib].
Topics: Angiogenesis Inhibitors; Benzamides; Carcinoma, Renal Cell; Dermatofibrosarcoma; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Kidney Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Skin Neoplasms; Sunitinib; Survival Rate | 2007 |
Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Benzenesulfonates; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mice; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Sorafenib; Thiazoles | 2007 |
[Gastrointestinal stromal tumors (GIST)].
Topics: Aged; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Sarcoma; Treatment Outcome | 2007 |
Treatment of wild-type gastrointestinal stromal tumor (WT-GIST) with imatinib and sunitinib.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2008 |
Imatinib in the management of multiple gastrointestinal stromal tumors associated with a germline KIT K642E mutation.
Topics: Antineoplastic Agents; Benzamides; Duodenal Neoplasms; Esophageal Neoplasms; Exons; Gastrointestinal Stromal Tumors; Germ-Line Mutation; Humans; Imatinib Mesylate; Male; Middle Aged; Pedigree; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Rectal Neoplasms; Stomach Neoplasms | 2007 |
[Chemotherapy and target-therapy of gastrointestinal tumors call for development of pathology].
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; ErbB Receptors; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Staging; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Clone Cells; Drug Resistance, Neoplasm; Evolution, Molecular; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Radiography; Receptor, Platelet-Derived Growth Factor alpha; Sequence Deletion; Survival Analysis | 2007 |
[Is positron emission tomography (PET) scan useful for studying the extent of gastrointestinal stromal tumors].
Topics: Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Combined Modality Therapy; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Ileal Neoplasms; Imatinib Mesylate; Neoplasm Proteins; Neoplasm Staging; Piperazines; Positron-Emission Tomography; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Remission Induction | 2007 |
Mutations in gastrointestinal stromal tumors diagnosed by endoscopic ultrasound-guided fine needle aspiration.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biopsy, Fine-Needle; Endosonography; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines | 2007 |
Focal progression in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: a three-center-based study of 38 patients.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2007 |
Symptomatic hypoglycemia during imatinib mesylate in a non-diabetic female patient with gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Benzamides; Blood Glucose; Female; Gastrointestinal Stromal Tumors; Humans; Hypoglycemia; Imatinib Mesylate; Insulin Resistance; Middle Aged; Piperazines; Pyrimidines; Stomach Neoplasms | 2007 |
Chronic myeloid leukemia and gastrointestinal stromal tumor: simultaneous presentation.
Topics: Antineoplastic Agents; Benzamides; DNA Mutational Analysis; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasms, Second Primary; Piperazines; Pyrimidines; Stomach Neoplasms; Treatment Outcome | 2007 |
An enhanced risk-group stratification system for more practical prognostication of clinically malignant gastrointestinal stromal tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Staging; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Risk Factors; Survival Rate; Treatment Outcome | 2007 |
Clinical, histopathologic, molecular and therapeutic findings in a large kindred with gastrointestinal stromal tumor.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2008 |
Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity.
Topics: Administration, Oral; Adult; Aged; Benzamides; Biomarkers; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Heart Failure; Humans; Imatinib Mesylate; Male; Middle Aged; Natriuretic Peptide, Brain; Neoplasm Staging; Peptide Fragments; Piperazines; Probability; Prospective Studies; Pyrimidines; Risk Assessment; Sensitivity and Specificity; Severity of Illness Index; Statistics, Nonparametric; Troponin T | 2008 |
Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Child; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Multivariate Analysis; Mutation; Piperazines; Prognosis; Prospective Studies; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome | 2007 |
Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cohort Studies; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Tissue Array Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2007 |
Simple segmental resection of the second portion of the duodenum for the treatment of gastrointestinal stromal tumors.
Topics: Aged; Anastomosis, Roux-en-Y; Benzamides; Duodenal Neoplasms; Duodenum; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Minimally Invasive Surgical Procedures; Neoadjuvant Therapy; Piperazines; Pyrimidines; Tomography, X-Ray Computed | 2008 |
Successful resection of an advanced duodenal gastrointestinal stromal tumor after down-staging with imatinib: report of a case.
Topics: Adult; Antineoplastic Agents; Benzamides; Diagnosis, Differential; Dose-Response Relationship, Drug; Duodenal Neoplasms; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreaticoduodenectomy; Piperazines; Positron-Emission Tomography; Protein-Tyrosine Kinases; Pyrimidines; Tomography, X-Ray Computed | 2007 |
Structural reengineering of imatinib to decrease cardiac risk in cancer therapy.
Topics: Animals; Benzamides; Cardiotoxins; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Heart Diseases; Humans; Imatinib Mesylate; K562 Cells; MAP Kinase Kinase 4; Neoplasms, Experimental; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Rats; Rats, Sprague-Dawley | 2007 |
An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.
Topics: Animals; Benzamides; Cardiotoxins; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Heart Diseases; Humans; Imatinib Mesylate; K562 Cells; MAP Kinase Kinase 4; Neoplasms, Experimental; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Rats; Rats, Sprague-Dawley | 2007 |
Targeting c-KIT, PDGFR in cancer of unknown primary: a screening study for molecular markers of benefit.
Topics: Aged; Aged, 80 and over; Benzamides; Exons; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Indoles; Male; Middle Aged; Mutation; Neoplasms, Unknown Primary; Piperazines; Polymorphism, Genetic; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptors, Platelet-Derived Growth Factor; Sunitinib | 2008 |
Unusually large extraintestinal GIST presenting as an abdomino-pelvic tumor.
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; CA-125 Antigen; Diagnosis, Differential; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Ovarian Neoplasms; Piperazines; Pyrimidines | 2008 |
Secondary c-kit mutation in a recurrent gastrointestinal stromal tumor under long-term treatment with imatinib mesylate: report of a case.
Topics: Aged; Antineoplastic Agents; Benzamides; DNA, Neoplasm; Exons; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoplasm Recurrence, Local; Piperazines; Point Mutation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Time Factors; Tomography, X-Ray Computed | 2008 |
Rectal GI stromal tumor mimicking a prostate mass.
Topics: Antineoplastic Agents; Benzamides; Diagnosis, Differential; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Pelvic Exenteration; Piperazines; Prostatic Neoplasms; Pyrimidines; Rectal Neoplasms | 2007 |
Choroidal metastasis from gastrointestinal stromal tumour: a case report.
Topics: Antineoplastic Agents; Benzamides; Choroid Neoplasms; Fatal Outcome; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leiomyosarcoma; Middle Aged; Piperazines; Pyrimidines | 2008 |
[Treatment of metastatic gastrointestinal stromal tumors with Imatinib: report of four cases].
Topics: Aged; Antineoplastic Agents; Benzamides; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2007 |
Rectal gastrointestinal stromal tumors associated with a novel germline KIT mutation.
Topics: Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 4; Exons; Gastrointestinal Stromal Tumors; Germ-Line Mutation; Haplotypes; Humans; Imatinib Mesylate; Male; Microsatellite Repeats; Middle Aged; Pedigree; Piperazines; Polymorphism, Genetic; Proto-Oncogene Proteins c-kit; Pyrimidines; Rectal Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Conjunctival hemorrhagic events associated with imatinib mesylate.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Conjunctival Diseases; Drug Hypersensitivity; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Hemorrhage; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines | 2007 |
Surgical debulking of gastrointestinal stromal tumors: is it a reasonable option after second-line treatment with sunitinib?
Topics: Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Digestive System Surgical Procedures; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2008 |
[Successful treatment of huge peritoneal metastasis from duodenal gastrointestinal stromal tumor resistant for imatinib mesylate].
Topics: Adult; Benzamides; Drug Resistance, Neoplasm; Duodenal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Peritoneal Neoplasms; Piperazines; Pyrimidines; Tomography, X-Ray Computed | 2007 |
Multiple bowel perforations complicating imatinib treatment for advanced gastrointestinal stromal tumor.
Topics: Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestinal Perforation; Piperazines; Pyrimidines | 2008 |
Neoadjuvant imatinib in a gastrointestinal stromal tumor of the rectum: report of a case.
Topics: Antineoplastic Agents; Benzamides; Colectomy; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Laparoscopy; Middle Aged; Neoadjuvant Therapy; Piperazines; Pyrimidines; Rectal Neoplasms | 2008 |
Assessment of gastrointestinal stromal tumors with computed tomography following treatment with imatinib mesylate.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease Progression; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Pyrimidines; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Highlighting the role of FDG PET scan in early response assessment of gastrointestinal stromal tumor treated with imatinib mesylate.
Topics: Antineoplastic Agents; Benzamides; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Positron-Emission Tomography; Pyrimidines; Radiopharmaceuticals | 2008 |
Surgical resection of residual disease in initially inoperable imatinib-resistant/intolerant gastrointestinal stromal tumor treated with sunitinib.
Topics: Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Disease Progression; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Middle Aged; Neoplasm, Residual; Piperazines; Pyrimidines; Pyrroles; Sunitinib; Treatment Outcome | 2009 |
Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor.
Topics: Aged; Antineoplastic Agents; Asian People; Benzamides; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Japan; Male; Middle Aged; Mutation, Missense; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-kit; Pyrimidines | 2008 |
Gastrointestinal stromal tumour of the rectum: report of a case and review of literature.
Topics: Aged; Antigens, CD34; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Rectal Neoplasms; Treatment Outcome | 2008 |
[Activating mutations in receptor tyrosine kinases with relevance for treatment of gastrointestinal stromal tumors].
Topics: Antineoplastic Agents; Benzamides; DNA, Neoplasm; Exons; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor alpha | 2007 |
Transporter pumps and imatinib: a cause of pharmacokinetic resistance?
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Binding; Pyrimidines | 2008 |
Should adjuvant imatinib be used as primary treatment for gastrointestinal stromal tumors?
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Randomized Controlled Trials as Topic | 2008 |
Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Biopsy, Needle; Chi-Square Distribution; DNA Mutational Analysis; DNA, Neoplasm; Female; Gastrointestinal Stromal Tumors; Gene Expression Profiling; Humans; Imatinib Mesylate; Immunohistochemistry; Isoenzymes; Male; Middle Aged; Mitotic Index; Oligonucleotide Array Sequence Analysis; Piperazines; Proportional Hazards Models; Protein Kinase C; Protein Kinase C-theta; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Risk Assessment; Sensitivity and Specificity; Survival Analysis | 2008 |
The Merendino procedure following preoperative imatinib mesylate for locally advanced gastrointestinal stromal tumor of the esophagogastric junction.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Esophagogastric Junction; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2008 |
[Consensus on the medical treatment of gastrointestinal stromal tumors].
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib | 2007 |
[Gastrointestinal stromal tumors (GIST) - clinical experience and current therapeutical aspects].
Topics: Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2007 |
Adjuvant and down-staging treatment with imatinib in gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Staging; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2008 |
A multidisciplinary approach for the treatment of GIST liver metastasis.
Topics: Aged; Benzamides; Combined Modality Therapy; Embolization, Therapeutic; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Piperazines; Pyrimidines | 2008 |
Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Benzamides; Female; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome | 2008 |
[Expert consensus on surgical treatment for gastrointestinal stromal tumors].
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Digestive System Surgical Procedures; Follow-Up Studies; Gastrointestinal Stromal Tumors; Gastrointestinal Tract; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Piperazines; Pyrimidines | 2007 |
A malignant omental extra-gastrointestinal stromal tumor on a young man: a case report and review of the literature.
Topics: Adult; Antigens, CD34; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Omentum; Peritoneal Neoplasms; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines | 2008 |
Interaction of imatinib with human organic ion carriers.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Gene Expression; Humans; Imatinib Mesylate; Organic Cation Transporter 1; Piperazines; Polymerase Chain Reaction; Pyrimidines; Xenopus laevis | 2008 |
Electronic clinical challenges and images in GI. Cystic GIST of the lesser omentum.
Topics: Antineoplastic Agents; Benzamides; Biopsy, Needle; Chemotherapy, Adjuvant; Cysts; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Laparoscopy; Middle Aged; Omentum; Peritoneal Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2008 |
Imatinib mesylate treatment for advanced gastrointestinal stromal tumor: a pilot study focusing on patients experiencing sole liver metastasis after a prior radical resection.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pilot Projects; Piperazines; Postoperative Complications; Pyrimidines | 2007 |
A pharmaco-economic analysis of second-line treatment with imatinib or sunitinib in patients with advanced gastrointestinal stromal tumours.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Cost-Benefit Analysis; Female; Gastrointestinal Stromal Tumors; Health Care Costs; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2008 |